39TH ANNUAL REPORT 2025-26

Quality Excellence

BAL PHARMA



BUILDING A HEALTHIER TODAY FOR A BETTER TOMORROW

Progress in Action

COMMITTED TO QUALITY HEALTH CARE

WWW.BALPHARMA.COM

Quality Excellence

BAL PHARMA

BAL PHARMA LIMITED

COMPANY PROFILE

CIN : L85110KA1987PLC008368

Registered Office : 21-22, Bommasandra, Industrial Area, Bommasandra Industrial Estate, Bangalore, Bangalore South, Karnataka, India, 560099

Corporate Office : 5th Floor Lakshmi Narayan Complex, 10/1 Palace Road Bengaluru, Chickpet, Bangalore, Bangalore South, Karnataka, India, 560053

Equity Shares Listed at : BSE and NSE

Email ID : investors@balpharma.com

Website : www.balpharma.com

BOARD OF DIRECTORS AND KMPs

1. Shailesh Siroya – Chairman and Managing Director
2. Virupakshaya Himesh – Whole Time Director
3. Ravindrakumar Kothari - Non Executive Director
4. Mr. Jatish Sheth - Independent Director
5. Ms. Nicola Neeladri - Independent Director
6. Mr. Bheekamchand Mukesh - Independent Director

Mr. Bharath Bhushan DV – Chief Financial Officer

Mr. Shreepada ML – Company Secretary and Compliance officer (w.e.f June 23 ,2026)

Audit Committee	Nomination & Remuneration Committee	Stakeholders Relationship Committee
Mr. Jatish Sheth - Chairman Ms. Nicola Neeladri - Member Bheekamchand Mukesh - Member	Mr. Jatish Sheth - Chairman Ms. Nicola Neeladri - Member Bheekamchand Mukesh - Member Ravindrakumar Kothari -Member	Mr. Jatish Sheth - Chairman Ms. Nicola Neeladri - Member Bheekamchand Mukesh - Member Ravindrakumar Kothari -Member Shailesh Siroya -Member

STATUTORY AUDITORS	SECRETARIAL AUDITORS	INTERNAL AUDITORS	COST AUDITORS
Messrs SSJNB & Co, Chartered Accountants , Bangalore	Mr. Parameshwar G Bhat Practicing Company Secretary Bangalore	Messrs Murugesh & Company Chartered Accountant , Bangalore	GNV & Associates, Cost Auditors Bangalore

REGISTRAR & TRANSFER AGENTS	BANKERS
MUFG INTIME INDIA PRIVATE LIMITED (Registrar & Transfer Agents) C 101, Embassy 247, L.B.S.Marg, Vikhroli (West) MUMBAI - 400 083	HDFC Bank Canara Bank Federal Bank

PLANT LOCATION

Formulations	API's and Intermediates
Unit I – Formulations # 21 & 22, Bommasandra Industrial Area, Bangalore-560099. Karnataka. **Unit 4 – Formulations** Plot # 1,2,3&69, Sector 4, IIE-Pantnagar Rudrapur, Udham Singh Nagar – 263153, Uttarakhand.	**Unit 2 - API's** # 61/B, Bommasandra Industrial Area Bangalore-560099. Karnataka. **Unit 5 – Intermediates** Thabadewadi Post, Kavatha Mahankal , Sangli-416405, Maharashtra. **Unit 6 – API's and Intermediates** # C-155, Mewar Industrial Area Madri, Udaipur 313001, Rajasthan.

SUBSIDIARY COMPANIES

Lifezen Healthcare Private Limited CIN : U24230KA2014PTC077114 Registered Office : 5th Floor Lakshmi Narayan Complex, Bengaluru, Chickpet, Bangalore, Bangalore South, 560053 Board of Directors: Shailesh Siroya - Director Ravindrakumar Kothari - Director	**Aurum Research & Analytical Solutions Private Limited** CIN : U72100KA2023PTC177577 Registered Office : #21 & 22, Bommasandra, Indl Estate, Hosur Rd, Bommasandra Industrial Estate, Bangalore, Bangalore South, 560099 Board of Directors: Shailesh Siroya - Director Ravindrakumar Kothari - Director
Bal Research Foundation CIN : U73100KA2014NPL076995 Registered Office : # 61-B, Bommasandra Industrial Area, Anekal Taluk, Bangalore, 560099 Board of Directors: Shailesh Siroya - Director Ravindrakumar Kothari - Director	**Balance Clinics LLP** LLPIN : AAC-3012 Registered Office : 22/1, 5th cross BBMP Ward No. 78, Vasanth Nagar, Bangalore, Chickpet, Bangalore 560053 Designated Partners : Shailesh Siroya - Designated Partner Ravindrakumar Kothari - Designated Partner

BAL PHARMA LIMITED

ANNUAL REPORT INDEX

39th Annual General Meeting of Bal Pharma Limited - Information at a Glance

Sl No	Particulars	Details
01	Day, Date and Time of the AGM	Thursday, 24th September, 2026, 11:30 A.M
02	Mode	Video Conference ('VC') and Other Audio-Visual Means ('OAVM')
03	Link for e- voting & participation in the AGM through VC/OAVM	Members may access the same at www.evoting.nsdl.com under Shareholders/Members login by using the remote e-voting credentials
04	Helpline number for VC participation and e-voting	NSDL: 022 - 4886 7000 CDSL: 1800-21-09911
05	Email IDs for any assistance or support for VC participation and e-voting	NSDL: evoting@nsdl.co.in CDSL: evoting@cdslindia.com
06	Record Date / Cut-off date for e-voting	17th September, 2026
07	Book closure	Friday, 18th September, 2026 to Thursday, 24th September, 2026 (both days inclusive)
08	E-voting start time and date	21st September, 2026 (9:00 am IST)
09	E-voting end time and date	23rd September, 2026 (5:00 pm IST)
10	E-Voting website	NSDL : www.evoting.nsdl.com CDSL : www.evoting.cdslindia.com/Evoting/EvotingLogin
11	Record date for Final dividend for Financial Year 2025-26	17th September, 2026
12	Company Contact details for Speaker registration and any other matters	investor@balpharma.com
13	Company Website for download AGM Notice & Annual report	www.balpharma.com

NOTICE is hereby given that the 39th (Thirty Ninth) Annual General Meeting (AGM) of the Members of Bal Pharma Limited will be held on Thursday, 24th September, 2026 at 11:30 A.M through Video Conference ("VC") / Other Audio Visual Means ("OAVM"), to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31, 2026, the Statement of Profit and Loss for the financial year ended as on that date and the Cash Flow Statement together with the Reports of the Board of Directors and the Auditors thereon.

   To consider and if thought fit, to adopt the following resolution as an Ordinary Resolution:

   "RESOLVED THAT the Audited Annual Financial Statements (including the balance sheet of the Company as at March 31, 2026 and the statement of profit and loss together with the notes on accounts, schedules, statement of cash flow, etc.), in the prescribed format, annexed to and forming part of the accounts for the year ended March 31, 2026, including the consolidated financial statements for the year ended as on that date, together with the reports of the Board of Directors' and Auditors' thereon, be and are hereby approved and adopted."

2. **To declare dividend of Rs. 1.20 per Equity Share of Rs 10/- each.**

   To consider and if thought fit, to adopt the following resolution as an Ordinary Resolution:

   "RESOLVED THAT pursuant to the provisions of Section 123 and other applicable provisions, if any, of the Companies Act, 2013, read with the Companies (Declaration and Payment of Dividend) Rules, 2014, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the Articles of Association of the Company, a dividend of Rs. 1.20 (Rupees One and Twenty Paise only) per Equity Share of Rs. 10/- each (i.e., 12% on the face value of the Equity Shares) for the Financial Year ended March 31, 2026, as recommended by the Board of Directors, be and is hereby declared and the same be paid to those Members whose names appear in the Register of Members / List of Beneficial Owners maintained by the Depositories as on the Record Date fixed for this purpose, subject to deduction of tax at source, as applicable."

3. **To re-appoint Mr. Ravindra Kumar Kothari, (DIN : 03418320), who retires by rotation, as a Director of the Company.**

   To consider and if thought fit, to adopt the following resolution as an Ordinary Resolution:

   "RESOLVED THAT pursuant to the provisions of Section 152 and other applicable provisions, if any, of the Companies Act, 2013, the Companies (Appointment and Qualification of Directors) Rules, 2014, Regulation 17 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the Articles of Association of the Company, Mr. Ravindra Kumar Kothari (DIN : 03418320), who retires by rotation at this meeting, being eligible and having offered himself for re-appointment, be and is hereby re-appointed as a Director of the Company.

SPECIAL BUSINESS:

4. **To ratify the remuneration payable to Cost Auditors for the Financial Year 2026-27.**

   To consider and if thought fit, to adopt the following resolution as an Ordinary Resolution:

   "RESOLVED THAT pursuant to the provisions of Section 148 and other applicable provisions, if any, of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014 (including any statutory modifications or re-enactment thereof), the remuneration payable to Messrs. GNV & Associates, Cost Auditors (Firm Registration No.000150), appointed by the Board of Directors based on the recommendation of the Audit Committee of the Company to conduct the audit of the Cost records of the Company for the Financial Year 2026-27, amounting to Rs. 75,000/- (Rupees Seventy Five Thousand only) or such other amount(s) as may be decided by the Board including applicable taxes and excluding out of pocket expenses incurred by them in connection with the audit of cost records, be and is hereby ratified and approved.

   RESOLVED FURTHER THAT any of the Board of Directors or Company Secretary of the Company be and are hereby authorized to do all such acts, deeds, matters and things as may be considered necessary and expedient in order to give effect to the above said Resolution."

5. **To renew contract with Messrs. Desa Marketing International.**

   To consider and if thought fit to adopt the following Resolution as Ordinary Resolution:

   "RESOLVED THAT pursuant to Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 [Listing Regulations, 2015], (including any statutory modification(s) or amendments(s) or re-enactments(s) thereof, for the time being in force), and provisions of Section 188 of the Companies Act, 2013 other applicable provisions, if any, of the Companies Act, 2013 read with Companies (Meetings of Board and its powers) Rules, 2014 and the Company's policy on related party transactions, based on the approval of the Audit Committee and recommendation of the Board of Directors, approval of the Members be and is hereby accorded to enter into and/or continue the related party transaction(s) / contract(s) / arrangement(s) / between the Company and Desa Marketing International, on such terms and conditions as more specifically set out in the explanatory statement to this resolution, which will not exceed / exceeds the materiality threshold limit as prescribed under the Listing Regulations, 2015 or the Company's policy on related party transactions and materiality.

RESOLVED FURTHER THAT the said contract(s)/ arrangement(s)/ transaction(s) shall be carried out at arm's length basis and in the ordinary course of business of the Company and the aggregate amount/value of all such arrangements/ transactions/ contracts shall not exceed Rs.30 Crore (Rupees Thirty Crores only) in one Financial Year.

RESOLVED FURTHER THAT the Board of Directors of the Company (hereinafter referred to as 'Board' which term shall be deemed to include the Audit Committee of the Board and any duly constituted committee empowered to exercise its powers including powers conferred under this resolution) be and is hereby authorised to do all such acts, deeds, matters and things as it may deem fit in its absolute discretion and to take all such steps as may be required in this connection including finalizing and executing necessary contract(s), arrangement(s), agreement(s) and such other documents as may be required, seeking all necessary approvals to give effect to this resolution, for and on behalf of the Company, to delegate all or any of its powers conferred under this resolution to any Director or Key Managerial Personnel or any officer / executive of the Company and to resolve all such issues, questions, difficulties or doubts whatsoever that may arise in this regard and all action(s) taken by the Company in connection with any matter referred to or contemplated in this resolution, be and are hereby approved, ratified and confirmed in all respects."

6. **Change in designation of Mr. Ravindra Kumar Kothari (DIN – 03418320) from Non-Executive Director to Whole-Time Director .**

To consider and if thought fit to adopt the following Resolution as Special Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198, 203 read with the Schedule V of the Companies Act, 2013, Rule 3 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, Rule 8 of the Companies (Meetings of Board and its Powers) Rules, 2014 and other applicable provisions of the Companies Act, 2013 (including the rules, notifications, circulars, guidelines etc. issued thereunder) ("Companies Act") read with applicable guidelines issued by the Central Government, from time to time, Listing Regulations, 2015 and all other applicable statutes, laws, rules, regulations, guidelines, circulars etc. issued by other appropriate authority(ies), if any, (including any statutory amendment or modification or re-enactment thereof, for the time being in force) with provisions of the applicable laws and in line with the memorandum and articles of association, based on the recommendation of the Nomination and Remuneration Committee and the Board, approval of the shareholders be and is hereby accorded for change in designation of Mr. Ravindra Kumar Kothari (DIN:03418320) from Non-Executive Director to Whole-Time Director of the Company (in Executive category), effective from October 01, 2026 till July 30, 2030 and liable to retire by rotation.

RESOLVED FURTHER THAT based on the recommendation of the Nomination and Remuneration Committee and Board of Directors of the Company, approval of the Shareholders be and is hereby accorded for payment of remuneration to Mr. Ravindra Kumar Kothari at Gross amount of Rs 22,50,000/-per annum (Rupees Twenty-two Lakh Fifty Thousand only) for the period of 03 (three) years effective from October 01, 2026.

RESOLVED FURTHER THAT in the event of any inadequacy or absence of profits in any financial year or years, the aforementioned remuneration comprising of the afore-mentioned components as approved herein be continued to be paid as minimum remuneration to Mr. Ravindra Kumar Kothari, subject to such revisions as may be approved by the Board from time to time.

RESOLVED FURTHER THAT Annual revision in the salary if any shall be decided by the Nomination and Remuneration Committee and Board of directors based upon Company's performance and personal performance measured against agreed objectives for the year as decided by the board from time to time.

RESOLVED FURTHER THAT the Board of Directors or the Company Secretary of the Company be and are hereby severally authorized to do all such acts, deeds, matters and things as may be considered necessary, expedient, usual or proper to give full effect to this resolution."

7. **Change in designation of Mr. Virupakshaya Himesh (DIN: 08554422) from Whole-Time Director to Non-Executive Director.**

To consider and if thought fit to adopt the following Resolution as Special Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 152, 160, 197 and other applicable provisions of the Companies Act, 2013, read with relevant rules thereunder (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), the Listing Regulations, 2015 , and other applicable laws, regulations, and guidelines as may be prescribed by the SEBI and the Ministry of Corporate Affairs (MCA), and based on the request received from Mr. Virupakshaya Himesh (DIN: 08554422), recommendation of the Nomination and Remuneration Committee and Board of Directors, approval of the shareholders of the Company be and is hereby accorded to change the designation of Mr. Virupakshaya Himesh from Whole-Time Director (in Executive category) to Director of the Company (Non-Executive category), effective from October 01, 2026 till 31st July 2029.

RESOLVED FURTHER THAT based on the recommendation of the Nomination and Remuneration Committee and Board of Directors of the Company, approval of the Shareholders be and is hereby accorded for payment of honor remuneration to Mr. Virupakshaya Himesh for an amount of Rs. 2,40,000/- per annum (Rupees Two lakh Forty Thousand only) as more specifically set out in the explanatory statement to this resolution, from October 01, 2026 till 31st July 2029.

RESOLVED FURTHER THAT in the event of any inadequacy or absence of profits in any financial year or years, the aforementioned remuneration as approved herein be continued to be paid as minimum remuneration to Mr. Virupakshaya Himesh, subject to such revisions as may be approved by the Board from time to time.

RESOLVED FURTHER THAT Annual revision in the salary if any shall be decided by the Nomination and Remuneration Committee and Board of directors based upon Company's performance and personal performance measured against agreed objectives for the year as decided by the board from time to time.

RESOLVED FURTHER THAT the office of Mr. Virupakshaya Himesh (DIN:08554422) shall be liable to retire by rotation.

RESOLVED FURTHER THAT any of the Directors and Company Secretary of the Company be and is hereby severally authorized to do all acts, deeds, matters, and things necessary to give effect to this resolution, including but not limited to filing the requisite forms with the Registrar of Companies, notifying stock exchanges in compliance with SEBI regulations, and making any other disclosures as may be required under applicable laws."

By the order of the Board of Directors
For Bal Pharma Limited

Place: Bengaluru
Date: 12.08.2026

Shreepada ML
Company Secretary and Compliance officer
ICSI M No:A66681

NOTES:-

1. 1.Explanatory Statement pursuant to Section 102 of the Act setting out material facts relating to business under item numbers 4 to 7 to be transacted at the meeting is annexed hereto and forms part of this Notice.

2. The Ministry of Corporate Affairs ("MCA") vide its Circular No. 9/2025 dated September 22, 2025 has allowed the Companies to conduct its Annual General Meeting through video conferencing ("VC") or other audio-visual means ("OAVM") till further orders, in accordance with the requirements laid down in Para 3 and Para 4 of the General Circular No. 20/2020 dated 05.05.2020. In compliance with the applicable provisions of the Companies Act 2013 ("Act"), and foresaid circulars and guidelines issued in this regard, the Board of Directors has approved conducting of the 39th Annual General Meeting (AGM) of the Company through VC / OAVM, without physical presence of the Members.

3. In compliance with applicable provisions of the Companies Act, 2013 ("the Act") read with the MCA Circulars and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations, 2015"), the 39th Annual General Meeting of the Company is being conducted through Video Conferencing ("VC") (hereinafter referred to as "AGM' or "e AGM"). In accordance with the Secretarial Standard -2 on General Meeting issued by the Institute of Company Secretaries of India (ICSI) read with Guidance/Clarification dated April, 15, 2020 issued by ICSI, the proceedings of the AGM shall be deemed to be conducted at the Registered Office of the Company which shall be the deemed Venue of the e-AGM. Since the AGM will be held through VC/OAVM means, the Route Map is not annexed in this Notice.

4. In case of joint holders attending the Meeting, only such joint holder who is higher in the order of names will be entitled to vote.

5. The Register of Members and Share Transfer Books of the Company will remain closed from Friday, 18th September, 2026 to Thursday, 24th September, 2026 (both days inclusive).

6. Members holding more than one Share Certificate in different folios are requested to apply for consolidation of the folios and send the relative Share Certificates to the Company's Registrar and Share Transfer Agent, MUFG Intime India Private Ltd, # C-101, 1ST Floor, 247 Park, Lal Bahadur Shastry Marg, Vikhroli (West) Mumbai-400083.

7. Institutional Shareholders / Corporate Members (i.e. other than individuals / HUF, NRI, etc.) are required to send a certified true copy (PDF/JPG Format) of its Board or governing body Resolution/Authorization etc., authorizing its representative to attend the AGM through VC / OAVM on its behalf and to vote through remote e-voting to the Scrutinizer by email through its registered email address to parameshwar@vjkt.in with a copy marked to evoting@nsdl.co.in

8. Dividend, if any, that may be declared at the Meeting will be paid on or before 24th October, 2026 to those Members entitled there to, whose names appear in the Register of Members of the Company at the close of business hours on 17th September, 2026 and for those holding the Shares in demat mode, the dividend will be paid to the Members whose names are furnished by National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) as beneficial owners on that date and the bank particulars registered with the respective Depository Accounts will be used for this purpose.

9. Members holding shares in electronic form may please note that as per the regulations of National Securities Depository Ltd (NSDL) and Central Depository Services (India) Limited (CDSL), the Company is obliged to print the bank details on the dividend warrants as furnished by these Depositories to the Company and the Company cannot entertain any request for deletion/change of bank details already printed on dividend warrants as per information received from the concerned Depositories. In this regard, Members should contact their Depository Participant (DP) and furnish particulars of any changes desired by them.

10. Pursuant to Section 124 of the Companies Act, 2013 any money transferred to Unpaid Dividend Account and remaining unclaimed for a period of 7 (Seven) years from the date of such transfer to the Unpaid Dividend Account shall be transferred by the Company to the Investor Education and Protection Fund (IEPF) established by the Central Government, and thereafter, the Shareholders shall not be able to claim any Unpaid Dividend amount from the Company.

    The Company has transferred Rs.2,01,842/- being the amount lying in the credit of Unpaid Dividend Account for the financial year 2017-2018, to Investor Education and Protection Fund as stipulated under Section 125 of the Companies Act, 2013 read with Investor Education and Protection Fund (Awareness and Protection of Investors) Rules, 2001. The Members who have not en-cashed the Dividend Warrants for the financial years 2018-19 onwards are requested to write to the Company directly or to MUFG Intime India Pvt Ltd, the Registrar and Share Transfer Agents of the Company.

11. The Members may now avail of the facility of nomination, by nominating in the prescribed form, a person to whom your Shares in the Company shall vest in the event of death of the Member. Interested Members may write to the Company's Registrar & Share Transfer Agent for the prescribed form.

12. Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) by every participant in Securities market. Members holding Shares in electronic form are, therefore, requested to submit the PAN to their Depository Participants with whom they are maintaining their demat accounts. Members holding shares in physical form can submit their PAN details to the Company / Registrar and Transfer Agents, MUFG Intime India Pvt Ltd, Mumbai.

13. In compliance with the aforesaid MCA Circulars and SEBI Circular, Notice of the AGM along with the Annual Report for F.Y 2025-26 is being sent only through electronic mode to those Members whose email addresses are registered with the Company/Depositories. Members may note that the Notice and Annual Report for F.Y 2025-26 will also be available on the Company's website www.balpharma.com & websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively, and on the website of NSDL https://www.evoting.nsdl.com

14. As per Regulation 40 of SEBI Listing Regulations, as amended, Securities of listed Companies can be transferred only in dematerialized form with effect from, April 1, 2019, except in case of request received for transmission or transposition of Securities. In view of this and to eliminate all risks associated with physical shares and for ease of portfolio management, Members holding shares in physical form are requested to consider converting their holdings to

dematerialized form. Members can contact the Company or Company's Registrars and Transfer Agents (RTA), MUFG Intime India Pvt Ltd for assistance in this regard.

15. Relevant documents referred to in the accompanying Notice and the Explanatory Statement, Registers and all other documents will be available for inspection in electronic mode. Members can inspect the same by sending an email to the Company at investor@balpharma.com

16. Members seeking any information/desirous of asking any questions with regard to the accounts, operations or any matter of the Company are requested to send email to the Company at investor@balpharma.com at least 7 days before the Meeting. The same will be replied by the Company suitably.

17. The Company has designated an exclusive email id called investor@balpharma.com to redress Members' complaints/ grievances. In case you have any queries/ complaints or grievances, then please write to us at investor@balpharma.com

18. To support the 'Green Initiative', Members who have not yet registered their email addresses are requested to register the same with their DPs in case the shares are held by them in electronic form and with MUFG Intime India Pvt Ltd, in case the Shares are held by them in physical form.

19. The business set out in the Notice will be transacted through electronic voting system and the Company is providing facility for voting by electronic means. Instructions and other information relating to e-voting are given in this Notice.

20. In terms of provisions of Section 107 of the Act, the resolutions as set out in the notice are being conducted through e-voting, and therefore the said resolutions will not be decided on a show of hands at the AGM & Members attending the AGM through VC / OAVM shall be counted for the purpose of reckoning the quorum of the meeting under Section 103 of the Act.

21. E-AGM: Company has appointed NSDL to provide Video Conferencing facility for the e-AGM and the attendant enablers for conducting the e-AGM.

INFORMATION FOR MEMBERS RELATING TO E-VOTING ARE AS UNDER:

1. Pursuant to the General Circular No. 09/2024 dated September 19, 2024, issued by the Ministry of Corporate Affairs (MCA) and circular issued by SEBI vide circular no. SEBI/ HO/ CFD/ CFDPoD-2/ P/ CIR/ 2024/ 133 dated October 3, 2024 ("SEBI Circular") and other applicable circulars and notifications issued (including any statutory modifications or re-enactment thereof for the time being in force and as amended from time to time, companies are allowed to hold EGM/AGM through Video Conferencing (VC) or other audio visual means (OAVM), without the physical presence of members at a common venue. In compliance with the said Circulars, EGM/AGM shall be conducted through VC / OAVM.

2. Pursuant to the Circular No. 14/2020 dated April 08, 2020, issued by the Ministry of Corporate Affairs, the facility to appoint proxy to attend and cast vote for the members is not available for this AGM. However, the Body Corporates are entitled to appoint authorised representatives to attend the AGM through VC/OAVM and participate there at and cast their votes through e-voting.

3. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.

4. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.

5. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) the Secret arial Standard on General Meetings (SS-2) issued by the ICSI and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs from time to time the Company is providing facility of remote e-Voting to its Members in respect of the business to be transacted at the EGM/AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-Voting system as well as e-voting on the date of the EGM/AGM will be provided by NSDL.

6. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM has been uploaded on the website of the Company at www.balpharma.com The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and the AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. www.evoting.nsdl.com

7. AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular issued from time to time

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING ARE AS UNDER:-

The remote e-voting period begins on 21st September, 2026 (9:00 am IST) and ends on 23rd September, 2026 (5:00 pm IST). The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e.-17th September, 2026, may cast their vote electronically. The voting right of shareholders shall be in proportion to their shares in the paid-up equity share capital of the Company as on the cut-off date, being 17th September, 2026. Once the vote on resolution is cast by the shareholder the shareholder shall not be allowed to change it subsequently. The members who have cast their vote by remote e-voting prior to the meeting may also attend the meeting, but shall not be allowed to cast the vote again.

How do I vote electronically using NSDL e-Voting system?

To vote electronically on NSDL e-Voting system consists of "Two Steps", which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with **NSDL.**	1. For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2. Existing IDeAS user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section , this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 3. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS Portal" or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 4. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 5. Shareholders/Members can also download NSDL Mobile App "NSDL Speede" facility by scanning the QR code mentioned below for seamless voting experience. NSDL Mobile App is available on App Store Google Play

Individual Shareholders holding securities in demat mode with **CDSL**	1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password. 2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the e-voting is in progress as per the information provided by company. On clicking the e-voting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders (holding securities in demat mode) login through their **depository participants**	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at above mentioned website.

Help desk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login Type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800-21-09911

B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.
   Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
4. Your User ID details are given below :

Manner of holding Shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold Shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is In300*** and Client ID is 12****** then your user ID is IN300***12******.
b) For Members who hold Shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12************** then your user ID is 12**************
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5) Password details for shareholders other than Individual shareholders are given below:

a) If you are already registered for e-Voting, then you can user your existing password to login and cast your vote.

b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.

c) How to retrieve your 'initial password'?
   (I) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
   (ii) If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered.

6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:

a) Click on "Forgot User Details/Password?"(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
b) Physical User Reset Password?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.

7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
8. Now, you will have to click on "Login" button.
9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join Meeting".
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
5. Upon confirmation, the message "Vote cast successfully" will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to parameshwar@vjkt.in with a copy marked to evoting@nsdl.com Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.

2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password

confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.

3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on.: 022 - 4886 7000 or send a request to NSDL at evoting@nsdl.com

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to investor@balpharma.com.

2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) to (investor@balpharma.com). If you are an Individual shareholder holding securities in demat mode, you are requested to refer to the login method explained at step 1 (A) i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.

3. Alternatively, shareholder/members may send a request to evoting@nsdl.co.in for procuring user id and password for e-voting by providing above mentioned documents.

4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

THE INSTRUCTIONS FOR MEMBERS FOR E-VOTING ON THE DAY OF THE ANNUAL GENERAL MEETING ARE AS UNDER:-

1. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.

2. Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.

3. Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.

4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:

1. Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access the same at https://www.evoting.nsdl.com under Shareholders/Members login by using the remote e-voting credentials. The link for VC/OAVM will be available in Shareholder/Members login where the EVEN of Company will be displayed. Please note that the Members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush. Further Members can also use the OTP based login for logging into the e-Voting system of NSDL.

2. Members are encouraged to join the Meeting through Laptops for better experience.

3. Further Members will be required to allow Camera and use Internet with good speed to avoid any disturbance during the meeting.

4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.

5. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at Company email id.The same will be replied by the Company suitably.

6. Shareholders who would like to express their views/ask questions during the Meeting may register themselves as a speaker and may send their request mentioning their name, demat account number/folio number, email id, mobile number at investor@balpharma.com

7. Those Shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the Meeting.

Other Instructions:

(I) This AGM Notice is being sent to all the Members, whose names appear in the Register of Members/ List of Beneficial Owners as received from National Securities Depository Limited (NSDL) / Central Depository Services (India) Limited (CDSL) as on the date determined in accordance with applicable provisions of law . Any person, who acquires Shares of the Company and becomes a Member of the Company after sending of the Notice and holding Shares as of the cut-off date of 17th September, 2026, may obtain the login ID and password by sending a request at evoting@nsdl.co.in However, if he/she is already registered with NSDL for remote e-voting then he/she can use his/her existing User ID and password for casting the vote.

(ii) You can also update your mobile number and e-mail id in the user profile details of the folio which may be used for sending future communication(s).

(iii) The Board of Directors has appointed Mr. Parameshwar G Bhat, Practicing Company Secretary (Membership No. FCS 8860) as the Scrutinizer to scrutinize the e-voting process in a fair and transparent manner.

(iv) The Scrutinizer shall within a period not exceeding twenty-four (24) hours from the conclusion of the e-voting period unlock the votes in the presence of at least two (2) witnesses not in the employment of the Company and make a Scrutinizer's Report of the votes cast in favor or against, if any, forthwith to the Managing Director or designated Director of the Company.

(v) The Results shall be declared within 2 working days from the conclusion of the Annual General Meeting. The results declared along with the Scrutinizer's Report shall be placed on the Company's website www.balpharma.com and on the website of NSDL within two (2) working days of passing of the resolutions at the AGM of the Company and also be communicated to BSE and NSE.

(vi) Subject to receipt of requisite number of votes, the Resolutions shall be deemed to be passed on the date of the Meeting, i.e. Thursday, 24th September, 2026.

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 (1) OF THE COMPANIES ACT, 2013:

Item No. 4:

To ratify the remuneration payable to Cost Auditors for the Financial Year 2026-27:

Based on the recommendation of the Audit Committee, the Board of Directors of the Company at its Meeting held on 27.05.2026, , approved the appointment of Messrs. GNV & Associates, Cost Auditors (Firm Registration No.000150) as Cost Auditors to conduct the audit of the cost records of the Company for the Financial Year 2026-27 in accordance with the Companies (Cost Records and Audit) Rules, 2014, at a remuneration of Rs. 75,000/- (Rupees Seventy-Five Thousand only) or such other amount(s) as may be decided by the Board including applicable taxes and excluding out of pocket expenses at actuals.

In terms of the provisions of Section 148(3) of the Companies Act, 2013 read with Rule 14(a) (ii) of the Companies (Audit and Auditors) Rules, 2014, the remuneration payable to the Cost Auditor must be ratified by the Members of the Company. Accordingly, the Members are requested to ratify the remuneration payable to the Cost Auditors as set out in the Resolution for the aforesaid services to be rendered by them.

None of the Directors, Key Managerial Personnel of the Company, and their relatives isin any way, concerned or interested, financial or otherwise, in the said Resolution.

The Board recommends the Resolution set forth in Item No. 4 of the Notice for approval of the Members.

Item No.5:

To renew contract with Messrs. Desa Marketing International:

The Companies Act, 2013 aims to ensure transparency in the transactions and dealings with the related parties of the Company. The provisions of Section 188(1) of the Companies Act, 2013 read with Regulation 23 of the Listing Regulations, 2015, govern the Related Party Transactions for entering into any contract, transactions or arrangement with the related party (ies).

Pursuant to Section 188 of the Companies Act 2013 and the applicable Rules framed thereunder state that any related party transaction in relation to sale, purchase or supply of any goods or materials or services, unsecured loans, other loans and Advances, directly or through appointment of agent amounting to or exceeding 10% or more of the turnover of the Company as per the last audited financial statement for the preceding financial year shall not be entered into by the company except with the prior approval of the Shareholders of the Company by a resolution.

The Company proposes to enter into related party transaction(s) with Messrs. Desa Marketing International on mutually agreed terms and conditions for the term of 3 years.

Messrs. Desa Marketing International is a proprietary concern of Mr. Shailesh Siroya, Managing Director of the Company and is therefore a Related Party within the meaning of Section 2(76) of the Companies Act, 2013 and Regulation 2(1)(zc) of the Listing Regulations, 2015. Accordingly, transaction(s) so entered will be considered as Related Party Transaction(s) under Section 188(1) of the Companies Act, 2013 read with Regulation 23 of the Listing Regulations, 2015.

The Company has been availing the services of Messrs. Desa Marketing International for approximately nineteen years for

- vendor identification and development;
- marketing and promotion of the Company's pharmaceutical products in India and overseas;
- facilitating export business; and
- providing market intelligence and business development support.

The existing agreement dated 20 May 2023 expired on 19th May 2026.

Considering the satisfactory services rendered by M/s. Desa Marketing International, its long-standing business association with the Company and its expertise in procurement and marketing activities, the Board of Directors, based on the recommendation of the Audit Committee, renewed the agreement for a further period of three (3) years, commencing from 20 May 2026 and ending on 19 May 2029, on substantially similar commercial terms.

The remuneration payable shall continue to be:

a. 2% of the value of domestic sourcing and domestic marketing promotion; and
b. 3% of the value of international sourcing and overseas marketing promotion, exclusive of applicable taxes, subject to the terms and conditions contained in the agreement.

The Audit Committee, after evaluating the commercial rationale, pricing methodology and benchmarking of the proposed transaction, has noted that the proposed transaction is:

- in the ordinary course of business;
- on an arm's length basis;
- commercially beneficial to the Company; and
- in the best interest of the Company and its shareholders.

Accordingly, the Audit Committee has recommended the transaction to the Board for approval and further recommended seeking approval of the shareholders in accordance with Regulation 23 of the SEBI LODR Regulations & Sec 188 of Companies act 2013.

Mr. Shailesh Siroya, Managing Director of the Company, being the sole proprietor of Messrs. Desa Marketing International, is interested in the proposed resolution.

The proposed transactions are in the interest of the Company as these Companies are regularly engaged in providing services to the Companies. Based on the recommendation of the Audit Committee in the meeting held on 27th May 2026, and the Board of directors in its meeting held on 27th May 2026, subject to approval of members of the Company, approved an aggregate limit of transaction in excess of 10% of annual consolidated turnover, collectively for transactions involving sale, purchase or supply of any goods or materials or services, unsecured loans, other loans and Advances for the any financial year, with above mentioned related parties within the definition of Section 2(76) of the Act.

Except Mr. Shailesh Siroya, Managing Director of the Company, none of the other Directors, Key Managerial Personnel or their relatives is concerned or interested, financially or otherwise, in the proposed resolution except to the extent of their shareholding, if any.

Minimum information to be provided to the Shareholders for approval of Related Party Transactions tabled below as Annexure I to the notice.

The Board of Directors recommends the resolution set out at Item No. 5 of the Notice for approval of the Members.

Item No. 6:

Change in designation of Mr. Ravindra Kumar Kothari (DIN:03418320) from Non-Executive Director to Whole-Time Director.

The Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee at their respective meetings held on 12th August 2026 and subject to the approval of the Members of the Company, approved the change in designation of Mr. Ravindra Kumar Kothari (DIN: 03418320) from Non-Executive Director to Whole-Time Director (in Executive category), for the remaining period of five (5) years, with effect from October 01, 2026 till July 30 , 2030 for the remuneration as mentioned in the resolution for the period of three year effective from 01st October 2026.

Mr. Ravindra Kumar Kothari is a graduate in commerce and is a person of integrity, possess relevant expertise and vast experience. He has very good understanding on the functioning of the meetings of the Board and committee (Nomination and Remuneration Committee, Stakeholder, Audit etc.) as per the applicable laws and corporate governance practices. He satisfies all the conditions specified under Section 196 read with Schedule V of the Companies Act, 2013, and is not disqualified from being appointed as a Director in terms of Section 164 of the Companies Act, 2013.

His office shall be liable to retire by rotation.

Mr. Ravindra Kumar Kothari was appointed as an Additional Director (Non-Executive category) of the Company on May 05, 2025 and as a Director on July 25, 2025 by the Members of the Company.

He had been providing valuable strategic guidance and contributing significantly to the growth and development of the Company.

Considering the operational requirements of the Company and the need for dedicated executive oversight and active involvement in the day-to-day management and operations of the Company, the Board of Directors, based on the recommendation of the Nomination and Remuneration Committee and subject to the approval of the Members of the Company, changed his designation from Non-Executive Director to Whole-time Director of the Company wef 01st October 2026.

The proposed change in designation is intended to leverage his experience, strategic insight and knowledge of the Company's affairs, while enabling him to assume a more active and executive role in overseeing the operations and affairs of the Company. The Board has taken on record the declarations submitted by him and after undertaking due veracity of the same is of the opinion that Mr. Ravindra Kumar Kothari possesses requisite skills, experience and knowledge relevant to the Company's business and it would be beneficial to have his association with the Company as Whole-Time Director of the Company (in Executive Category).

He does not hold any substantial interest of shares in the Company and is not related to any other Director of the Company.

Additional information as required in Schedule V of the Companies Act 2013 and brief profile and other requisite information of Mr. Ravindra Kumar Kothari, pursuant to Regulation 36(3) of the SEBI Listing Regulations and SS-2, as on date of Notice, are given in Annexure II.

None of the Directors or Key Managerial Personnel or their relatives, except Mr. Ravindra Kumar Kothari is directly or indirectly concerned or interested, financially or otherwise, in the resolution set out at Item No. 6 of the Notice.

The Board recommends the Resolution set forth in Item No 6 of the Notice for approval of the Members by way of a Special Resolution.

Item No.7:

Change in designation of Mr. Virupakshaya Himesh (DIN: 08554422) from Whole-Time Director to Non-Executive Director

Based on a request received from Mr. Virupakshaya Himesh, the Nomination and Remuneration Committee and the Board of Directors, subject to approval of the members, in their respective meetings held on August 12, 2026, approved the change in designation of Mr. Virupakshaya Himesh from Whole-time Director (Executive Director) to Non-Executive Director of the Company w.e.f October 01, 2026. Also, Mr. Virupakshaya Himesh furnished his consent for change in designation from Whole-Time Director (Executive Director) to Non-Executive Director of the Company. In his role as a Director of the Company, Mr. Virupakshaya Himesh will continue to manage the business of Company and receive honor remuneration in place of the remuneration as approved by the shareholders earlier.

Mr. Virupakshaya Himesh was appointed as the Whole-time Director of the Company for a term of five (5) consecutive years commencing from August 1, 2024 and ending on July 31, 2029, pursuant to the approval of the Members at the 37th Annual General Meeting held on September 25, 2024.

The change in designation from Whole-time Director to Non-Executive Director of the Company will take effect from October 01, 2026 till July 31, 2029 (upto the remaining term of his appointment).

Except the afore-mentioned changes, all other terms and conditions of appointment, as approved by the Members, shall continue to remain unchanged.

Additional information as required in Schedule V of the Companies Act 2013 and brief profile and other requisite information of Mr. Virupakshaya Himesh, pursuant to Regulation 36(3) of the SEBI Listing Regulations and SS-2, as on date of Notice, are given in Annexure II.

Except Mr. Virupakshaya Himesh and his relatives, none of the Directors or Key Managerial Personnel and their immediate relatives is concerned or interested, financially or otherwise, in the aforesaid resolution.

The Board recommends the matter and the resolution set out under Item No. 07 for the approval of the Members by way of passing Special Resolution.

By the order of the Board of Directors
For Bal Pharma Limited

Shreepada ML
Company Secretary and Compliance officer
ICSI M No: A66681

Place: Bengaluru
Date: 12.08.2026

Annexure-1 to the Notice

Information required under Regulation 23 of the Listing Regulations, 2015

As per SEBI Master Circular dated November 11, 2024, and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2025/93 dated June 26, 2025, listed entities to follow Minimum information to be provided to the Shareholders for approval of Related Party Transactions, formulated by Industry Standards Forum. Further, the information required under Regulation 23 of Listing Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/P/CIR/2025/18 dated October 13, 2025 is provided herewith:

Particulars	Details
Name of the Related Party	Desa Marketing International
Country of incorporation of the related party	India
Nature of relationship	Proprietary concern of Mr. Shailesh Siroya, Managing Director
Nature, material terms and particulars of the transaction	Renewal of agreement for sourcing raw materials, marketing promotion, export promotion and related business support services
Material terms and particulars of the transaction	Material terms and conditions are based on the contracts which inter alia include the rates which are based on prevailing market price and commercial terms as on the date of entering into the contract.
Tenure	Three years (20 May 2026 to 19 May 2029)
Value/Consideration	2% of domestic sourcing and domestic marketing promotion value and 3% of international sourcing and overseas marketing promotion value, plus applicable taxes
Purpose and benefit of the transaction	To ensure continuity in sourcing of raw materials, vendor identification, domestic and international marketing support, export promotion and business development activities
Whether in ordinary course of business	Yes
Whether on arm's length basis	Yes
Justification	The related party possesses extensive experience and has successfully rendered similar services for the Company for nearly nineteen years. Continuation of the arrangement is expected to ensure uninterrupted procurement support, business development and export promotion.
Audit Committee recommendation	Recommended for approval after reviewing the commercial terms and confirming that the transaction is in the ordinary course of business and on an arm's length basis.
Any advance paid	Nil
Estimated Value of Approval being sought	Aggregate value of transactions shall not exceeds 30 Crore in one financial year during the tenure of the agreement.
Percentage of Company's annual consolidated turnover represented by the transaction	10% of Consolidated turnover
If the transaction relates to any loans, intercorporate deposits, advances or investments made or given by the listed entity or its subsidiary: i) details of the source of funds in connection with the proposed transaction; ii) where any financial indebtedness is incurred to make or give loans, intercorporate deposits, advances or investments, nature of indebtedness; cost of funds; and tenure;	Not Applicable

Particulars	Details
iii) applicable terms, including covenants, tenure, interest rate and repayment schedule, whether secured or unsecured; if secured, the nature of security; and iv) the purpose for which the funds will be utilized by the ultimate beneficiary of such funds pursuant to the RPT	
Valuation / Pricing methodology	Commission based on the value of sourcing and marketing activities undertaken, determined on commercial terms comparable with prevailing market practices
Details of the Audit Committee approval	Approved by the Audit Committee at its meeting held on 27th May 2026 subject to approval of the Members
Details of the Board approval	Approved by the Board of Directors at its meeting held on 27th May 2026 subject to approval of the Members
Any other information relevant for shareholders	The transaction is proposed in the interest of the Company and is expected to facilitate efficient sourcing and expansion of domestic and international business.

Annexure-II to the Notice

Statement containing additional information as required in Schedule V of the Companies Act, 2013

I. General information:

1	Nature of industry	Pharmaceutical Industry
2	Date or expected date of commencement of commercial production	The Company has already commenced its business activities.
3	In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus	Not Applicable
4	Financial performance based on given indicators	Details are provided in the quarterly results/ latest audited financials that are available on the website of the company at www.balpharma.com
5	Foreign investments or collaborations, if any	Not Applicable

II. Information about the Appointee

	Mr. Ravindrakumar Kothari	Mr.Virupakshaya Himesh
Background Details	Mr. Ravindrakumar Kothari is a bachelor of commerce having 12 years experience in pharma industry with overall experience of 45 years.	Mr. Himesh Virupakshaya is a qualified Chemical Engineer (BE - Chemical Engineering) with over 34 years of experience in the field of manufacturing of Active Pharma Ingredients (API) and has served several reputed pharmaceutical Companies including Bal Pharma Ltd.for over 10 years.
Past Remuneration	Rs.20.42 Lakhs per Annum which is inclusive of salary and perquisites,	Rs. 3,01,280/-(Rupees Three Lakhs One Thousand Two Hundred and Eighty Only) per month which is inclusive of salary and perquisites,
Remuneration Proposed	Rs.22.50 Lakhs per Annum which is inclusive of salary and perquisites, (For the period of 3-year w.e.f 01.10.2026)	Rs.2,40,000/- (Rupees Two lakh Forty Thousand only) honor Remuneration Sitting fee (if any) as decided by board / Committee.
Recognitions or awards	His distinguished experience in the field of Pharma and his experience of more than four decades is well recognized in the industry.	Rich experience in manufacturing operations of Pharma and instrumental in driving qualitative and regulatory practices
Job Profile and his suitability	Mr. Ravindrakumar Kothari has been associated with the Company as non-executive director since May 05 ,2025 providing strategic guidance to the Company.The role of Whole-Time Director, designated as Executive Director, would form part of the core management team of the company and would involve such roles as assigned to him by the board/Chairman & Managing Director of the company from time to time. Considering his qualifications, experience and understanding of the Company's operations, the Board believes that his appointment will be beneficial to the Company.	Mr. Virupakshaya Himesh was appointed as the Whole-time Director of the Company for a term of five (5) consecutive years commencing from August 1, 2024 and ending on July 31, 2029, pursuant to the approval of the Members at the 37th Annual General Meeting held on September 25, 2024.
Comparative remuneration profile with respect to industry, size of the Company, profile of the position and person	The Remuneration proposed is commensurate with the industry and keeping in mind the rich experience he is having and future responsibilities of the job, the salary proposed is justified.	Company is paying honor remuneration for performing the role as non-executive director. Hence salary proposed is justified.
Pecuniary relationship directly or indirectly with the Company or relationship with the managerial personnel, if any	Besides the remuneration, Mr. Ravindrakumar Kothari does not have any other pecuniary relationship with the company	Besides the remuneration, Mr. Virupakshaya Himesh does not have any other pecuniary relationship with the company

III. Other informations

Reasons of loss or inadequate profits	Not Applicable.
Steps taken or proposed to be taken for improvement	The Company shall not be in a loss-making position as on the date of seeking approval for the aforesaid resolutions
Expected increase in productivity and profits in measurable terms	

Additional information of Director seeking appointment / reappointment as Director, pursuant to Regulation 36 of SEBI(LODR) Regulations,2015 and Secretarial Standards

Name of the Director	Mr. Ravindra Kumar Kothari	Mr. Himesh Virupakshya
DIN	03418320	08554422
Designation (Proposed)	Whole Time Director	Non-Executive Director
Date of Birth/Age (years)	01/10/1955	09/08/1961
Original Date of Appointment/ Re-appointment	05/05/2025	28/09/2019
Educational Qualifications	Bachelor of Commerce.	BE - Chemical engineering
Brief Profile	Mr. Ravindra Kumar Kothari having experience in day to day administration and management of Pharma business	Mr. Virupakshaya Himesh having rich experience in Operations, Administration, Quality Assurance and Projects management
Expertise in functional areas	12 years in Pharma industry with overall experience of 45 years.	Total 36 Years experience in Pharma
Nature of expertise in specific functional areas	Pharma industry strategy, financial management, operations oversight and business expansion	Experts in Manufacturing operation of Pharma
Terms and Conditions of Appointment/ Re-Appointment and Remuneration	As per the Nomination and Remuneration Policy of the Company. Appointment as Whole-Time Director, designated as Executive Director, Liable to retire by rotation for remaining period of 5 (five) consecutive years. For further details, refer Notice and Explanatory Statement.	As per the Nomination and Remuneration Policy of the Company. Appointment as Director, designated as Non-Executive Director, Liable to retire by rotation for remaining period of 5 (five) consecutive years. For further details, refer Notice and Explanatory Statement.
Directorship in other Companies/ LLP's	1.Bal Research Foundation - Director 2.Lifezen Healthcare Private Limited- Director 3.Balance Clinics LLP - Designated Partner 4.Aurum Research & Analytical Solutions Private Limited – Director	Nil
Directorship in other Listed Companies & Listed entities from which the Director has resigned in last 3 (three) years	Nil	Nil
Membership/ Chairmanship of Committees in other Public Limited Companies	Nil	Nil
Shareholding in the Company, including shareholding as a beneficial owner (as on the date of this Notice)	2,437	28,420
Inter-se relationship with other Directors and Key Managerial Personnel of the Company	No any inter-se relationship with other directors & KMPs	No any inter-se relationship with other directors & KMPs
No. of Board Meetings attended during FY 2025-26 (upto the date of this Notice)	7 (Seven)	7 (Seven)

Annexure-III to the Notice

Clarification

Disclosure regarding Valuation Method and Accounting Policies under Bal Pharma Limited – Employee Stock Option Plan – 2025

The Members are hereby informed that pursuant to the clarification provided by the Company to the Stock Exchanges, the Company has adopted the Fair Value Method for valuation of stock options granted under the Bal Pharma Limited – Employee Stock Option Plan – 2025.

Accordingly, the Company hereby notifies the Members that the Fair Value Method shall be followed for valuation of stock options under the said ESOP Scheme, in accordance with the applicable provisions of the SEBI regulations and accounting standards.

Further, with respect to Item No. 7 of the Explanatory Statement to the Notice of the 2025 Annual General Meeting, wherein it was stated that the ESOP Scheme "shall conform to the accounting policies specified in the SEBI Regulations, as may be applicable", the Company clarifies that the said wording was intended to align with and comply with the requirements prescribed under the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, as amended from time to time.

The above disclosure is being made for the information and knowledge of the Members and does not constitute any amendment or modification to the Bal Pharma Limited – Employee Stock Option Plan – 2025, and accordingly, no separate approval or Special Resolution of the Members is required in this regard.

By the order of the Board of Directors
For Bal Pharma Limited

Place: Bengaluru
Date: 12.08.2026

Shreepada ML
Company Secretary and Compliance officer
ICSI M No: A66681

Your Directors are pleased to present the Thirty-Nineth (39th) Annual Report and the audited financial statements of the Company, for the financial year ended 31.03.2026

HIGHLIGHTS OF FINANCIAL PERFORMANCE

(Amount in Rs lakhs)

Description	Standalone		Consolidated	
	March 31 , 2026	March 31 , 2025	March 31 , 2026	March 31 , 2025
Revenue from Operations	31,079.70	30,249.64	31,166.13	30,308.33
Other Income	200.29	214.93	192.78	220.29
Total Income	31,279.99	30,464.57	31,358.91	30,528.62
Employee benefits expense	6,592.41	6,182.88	6,646.48	6,240.05
Depreciation and amortization	1,105.91	964.87	1,107.93	977.10
Finance cost	1,681.03	1,684.51	1,681.77	1,685.45
Other expense (Including Material & Purchase costs)	21,264.17	21,059.04	21,329.36	21,112.32
Total expenses	**30,643.48**	**29,891.34**	**30,765.52**	**30,014.88**
Profit / (Loss) before Exceptional Items and Tax	**636.51**	**573.23**	**593.39**	**513.74**
Exceptional (Income) / Expense	0	0	0	0
Profit / (Loss) before Tax	**636.51**	**573.23**	**593.39**	**513.74**
Tax expense (Written back & credits)	-38.61	-206.72	-38.62	-209.92
Profit / (Loss) after Tax	**675.12**	**779.95**	**632.01**	**723.67**
Other Comprehensive Income	43.37	-04.33	43.85	-3.46
Total Comprehensive Income for the year	**718.50**	**775.62**	**675.86**	**720.21**
Earnings per share (Basic)	4.51	4.89	3.95	4.56
Earnings per share (Diluted)	4.51	4.89	3.95	4.56
Net Worth as per Section 2(57) of the Companies Act, 2013	10,409.89	9,882.46	8,225.24	7,740.44

Note: Previous year's figures have been regrouped/reclassified wherever necessary to correspond with the current year's classification/disclosure.

STATE OF COMPANY'S AFFAIRS:

Financial Statements: The Company has complied with the applicable provisions of the Companies Act, 2013 (the Act) and the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements), Regulations, 2015 ('the Listing Regulations') in preparation of Standalone and Consolidated financial statements. The audited consolidated Balance Sheet as at 31st March, 2026, consolidated statement of Profit and Loss for the year ended as on that date together with the Notes and Reports of Auditors along with the Cash flow Statement, Management Discussion and Analysis Report forms part of the Annual Report. The financial figures have been regrouped, wherever required, in line with disclosure requirements under Schedule III of the Act.

a. Standalone:

During the financial year under review, the Company recorded a total income of Rs. 31,279.99 lakhs as against Rs. 30,464.57 lakhs in the previous financial year, reflecting a steady growth in income. Total expenses for the year stood at Rs. 30,643.48 lakhs, compared to Rs.29,891.34 lakhs in the previous year.

The Company reported a net profit of Rs. 675.12 lakhs for the financial year 2025-26 as against Rs. 779.95 lakhs in the previous financial year. While the Company achieved growth in its total income, the marginal decline in net profit was primarily attributable to the increase in operating and other expenses during the year.

b. Consolidated:

On a consolidated basis, the Company recorded a total income of Rs. 31,358.91 lakhs during the financial year 2025-26 as compared to Rs. 30,528.62 lakhs in the previous financial year. Total expenses stood at Rs. 30,765.52 lakhs, as against Rs. 30,014.88 lakhs in the previous year. The consolidated net profit for the year amounted to Rs. 632.01 lakhs, compared to Rs. 723.67 lakhs in the previous financial year.

Brief Summary :

During the year under review, the Company's Revenue from Operations increased by approximately 2.6 % over the previous year, with Profit Before Tax (PBT) amounting to Rs. 636.51 lakhs. The Profit After Tax (PAT) stood at Rs. 675.12 lakhs, which was marginally lower than the previous year's level.

The Company continued to maintain a healthy revenue mix, with exports contributing approximately 60% of the total revenue, while domestic sales accounted for the remaining 40%, reflecting the Company's strong presence in both international and domestic markets. Highlights of Company's performance are covered in detail in the Management Discussion and Analysis Report (MDA), included in this Annual Report as required under Schedule V of the Listing Regulations.

EPS

a. Standalone:

The Basic Earnings per Share has decreased from Rs. 4.89 of previous year to Rs. 4.51 in the current year 2025-26.

b. Consolidated:

The Basic Earnings per Share has decreased from Rs. 4.56 of previous year to Rs. 3.95 in the current year 2025-26.

FINANCE AND ACCOUNTS

As mandated by the Ministry of Corporate Affairs, the Financial Statements for the year ended March 31, 2026 have been prepared in accordance with the Ind AS, notified under Section 133 of the Companies Act, 2013 read with The Companies (Accounts) Rules, 2014, as amended from time to time. The estimates and judgments relating to the Financial Statements are made on a prudent basis, so as to give a true and fair view of the state of affairs and profits and cash flows of your Company for the year ended March 31, 2026.

CONSOLIDATED FINANCIAL STATEMENTS

As per Regulation 33 of the Listing Regulations and Section 129 of the Act read with Schedule III to the Act, the Consolidated Financial Statements of your Company for the financial year ended March 31, 2026 have been prepared in accordance with the relevant Ind AS issued by the Institute of Chartered Accountants of India and on the basis of the audited financial statements of your Company and the last Audited Financial Statements of your Company's subsidiaries as approved by their respective Board of Directors.

NATURE OF BUSINESS

The Company continues to be engaged in development, manufacturing and sale of specialty pharmaceutical formulations and bulk drugs with specific emphasis on branded generics in various therapeutic segments in India and more than 30 countries worldwide.

CHANGE IN THE NATURE OF BUSINESS, IF ANY

During the year under review, there has been no change in the nature of business.

SIGNIFICANT OR MATERIAL ORDERS PASSED BY THE REGULATORS/ COURTS:

During the year under review, there were no significant or material orders passed by the Regulators or Courts or Tribunals against the Company, impacting the Company's operations in future.

SIGNIFICANT EVENTS/ACTIONS, HAVING A MAJOR BEARING ON THE COMPANY'S AFFAIRS:

There are no significant events/actions during the year that may have a major bearing on the Company's affairs.

DIVIDEND

The Board of Directors is pleased to recommend a dividend of Rs. 1.20 per equity share of face value Rs. 10/- each (i.e., 12%), for the financial year ended March 31, 2026. The proposed dividend, if approved by the Members at the ensuing Annual General Meeting, will involve an outflow of approximately Rs. 1.91 crores towards dividend distribution (excluding applicable taxes).

Dividend Distribution Policy

The provisions relating to formulation of a Dividend Distribution Policy under Regulation 43A of the Listing Regulations are not applicable to the Company. Accordingly, the Company has not formulated a Dividend Distribution Policy.

TRANSFER OF UNCLAIMED DIVIDEND AND SHARES TO THE INVESTOR EDUCATION AND PROTECTION FUND (IEPF)

Pursuant to the provisions of Section 124 of the Companies Act, 2013 read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended ("IEPF Rules"), any dividend remaining unpaid or unclaimed for a period of seven years is required to be transferred to the IEPF. Further, all equity shares in respect of which dividend has remained unclaimed for seven consecutive years are also required to be transferred to the demat account of the IEPF Authority.

During the year under review, the Company transferred 10,915 equity shares (having an aggregate nominal value of Rs. 1,09,150/-) to the demat account of the IEPF Authority in respect of shareholders whose dividends had remained unclaimed in accordance with the said provisions. The Company also transferred an amount of Rs. 2,01,842.00 pertaining to the unpaid/unclaimed dividend for the Financial Year 2017-18 to the IEPF, in accordance with the applicable provisions of the Act and the IEPF Rules.

Further, the dividend declared for the Financial Year 2024-25 at the 38th Annual General Meeting held on September 25, 2025, in respect of 1,30,124 equity shares already held by the IEPF Authority, amounting to ₹.1,56,148.80, was remitted to the IEPF Authority during the year under review, in accordance with the applicable provisions of the Act and the IEPF Rules.

The details of the shareholders whose unpaid dividend and corresponding equity shares have been transferred to the IEPF Authority are available on the Company's website at www.balpharma.com

Shareholders holding shares in physical form are advised to encash their dividend warrants promptly and claim their dividends within the prescribed period to avoid transfer of the unpaid dividend and the corresponding shares to the IEPF Authority in accordance with the provisions of the Act and the IEPF Rules.

TRANSFER TO RESERVES

The Board of Directors does not propose to transfer any amounts to the general reserves.

SHARE CAPITAL AND DEBENTURES

Pursuant to the Scheme of Amalgamation of Golden Drugs Private Limited ("Transferor Company") with Bal Pharma Limited ("Transferee Company"), sanctioned by the Hon'ble National Company Law Tribunal, Bengaluru Bench, vide Order in C.P. (CAA) No. 13/BB/2024 dated 26th March, 2025, under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, the Authorised Share Capital of the Company stands revised in accordance with the approved Scheme.

Prior to the amalgamation, the Authorised Share Capital of the Company was ₹.20,00,00,000 (Rupees Twenty Crores only) divided into 2,00,00,000 (Two crores only) equity shares of ₹.10/- (Rupees Ten only) each. The Authorised Share Capital of the Transferor Company was ₹.4,50,00,000 (Rupees Four Crores Fifty Lakhs only) divided into 45,00,000 (Forty-five lakhs only) equity shares of ₹.10/- (Rupees Ten only) each.

Consequent upon the Scheme becoming effective, the Authorised Share Capital of the Company stands revised to ₹.24,50,00,000 (Rupees Twenty-Four Crores Fifty Lakhs only) divided into 2,45,00,000 (Two crore forty-five lakhs only) equity shares of ₹.10/- (Rupees Ten only) each, in accordance with the terms of the Scheme sanctioned by the Hon'ble NCLT.

During the Financial Year 2025-26, your Company did not affect any change in Paid up Share Capital and paid up Equity Share Capital of the Company stood at ₹.. 15,92,08,720/- (Fifteen crores ninety-two lakhs eight thousand seven hundred and twenty only) comprising of ₹.1,59,20,872 (One crore fifty-nine lakhs twenty thousand eight hundred and seventy-two only) Equity Shares of Rs.10 (Rupees Ten only) each.

During the financial year 2025-26 the Company has not issued any Equity Shares with differential voting rights, nor issued any sweat Equity Shares.

During the year under review, your Company did not issue any Debentures.

<u>Event subsequent to financial year-end</u>

The Board of Directors, at its meeting held on 27th May, 2026, approved the issuance of 10,00,000 (Ten Lakh) fully convertible warrants on a preferential basis to Mr. Shailesh Siroya, Promoter of the Company, at an issue price determined in accordance with the applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Each warrant shall be convertible into one equity share of face value ₹.10/- each, subject to the terms and conditions governing the issue.

The Board also approved seeking the approval of the Members of the Company by way of a Special Resolution through Postal Ballot for the proposed preferential issue of warrants. The issue is subject to receipt of the requisite statutory and regulatory approvals, including the approval of the shareholders and the Stock Exchanges, as applicable.

DEPOSITS

Your Company has not accepted any deposits from the public falling within the purview of Section 73 of the Act read with Companies (Acceptance of Deposit) Rules, 2014 and as such, no amount on account of principal or interest on deposits from public was outstanding as on the date of the balance sheet.

Disclosure as per the Companies (Acceptance of Deposits) Second Amendment Rules, 2015 are as under:

The total amount of fixed deposits (excluding interest on Cumulative Deposits) from public, outstanding and unclaimed as at 31st March, 2026, was NIL.

The Company has not accepted any fresh deposits as per the provisions of Section 73 of the Act during the current financial year.

(a) Accepted during the Year	Nil
(b) Remained unpaid or unclaimed as at the end of the year. (Including interest thereon)	Nil
(c) Whether there has been any default in repayment of deposits or payment of interest thereon during the year and if so, number of such cases and the total amount involved:	No deposit has been accepted by the Company during the year and no default arose during the year.
i. As at 1st April 2025	Nil
ii. Maximum during April 2025 to March 2026.	Nil
iii. As at 31st March 2026	Nil
(d) Details of deposits which are not in compliance with the requirements of Chapter V of the Act	Nil

The Company has not accepted any unsecured loan(s) from the Directors of the Company and/or relatives of the Directors, during the year under consideration.

Sl. No.	Name of the Director/Relative of Director	Amount in Rs.
	Nill	

AMENDMENT OF MOA AND AOA

During the financial year under review, there were no amendments made to the Memorandum of Association ("MOA") and/or the Articles of Association ("AOA") of the Company.

However, pursuant to the Scheme of Amalgamation of Golden Drugs Private Limited with the Company, as sanctioned by the Hon'ble National Company Law Tribunal, Bengaluru Bench, vide Order in C.P. (CAA) No. 13/BB/2024 dated 26th March, 2025, the Authorized Share Capital of the Company stood revised in accordance with Section 232(3)(i) of the Companies Act, 2013. Upon payment of the applicable stamp duty, the Capital Clause (Clause V) of the Memorandum of Association was deemed to have been amended without requiring any separate approval of the shareholders.

Accordingly, Clause V of the Memorandum of Association now reads as follows:

05th The Authorized Share Capital of Company of the Company is Rs. 24,50,00,000 (Rupees Twenty-Four Crores Fifty Lakhs only) divided into 2,45,00,000 (Two Crore Forty Five Lakhs only) equity shares of Rs. 10/- (Rupees Ten Only) each with power to increase or decrease or reclassify and to very, modify or abrogate any such rights , privileges or condition in such manner as provided by resolution of the company. (Amended vide Special Resolution passed by the members on 23.09.2019).

BOARD MEETINGS

The Board of Directors of the Company met Six (6) times during the year under review. The details of these Board Meetings are provided in the Report on Corporate Governance forming part of the Annual Report. The necessary quorum was present for all the meetings. The maximum interval between any two meetings did not exceed 120 days.

COMMITTEES OF THE BOARD

The details of composition, and meetings of the Committees of the Board held during the year are given in the Report on Corporate Governance forming part of the Annual Report

BOARD DIVERSITY:

Your Company believes that a diversified board will bring differences in thought, perspective, knowledge, skill, regional and industry experience, cultural and geographical backgrounds, age, ethnicity, race and gender that will help us retain our competitive advantage and as a collective is equipped to guide the business and strategy of the Company.

At present, your Company has an appropriate mix of Executive, Non-Executive, women and Independent Directors to maintain the independence of the Board, and separate its functions of governance and management. Also, one of the Independent Directors on the Board of the Company is a woman Director.

DIRECTORS AND KEY MANAGERIAL PERSONNEL

As on March 31, 2026, the Board of Directors of your Company comprised of Six Directors, viz., Two Executive Directors, One Non-Executive director and Three Independent Directors including one-woman Independent Director. The Composition of the Board of Directors is in compliance with the applicable provisions of the Act and the Listing Regulations.

Board of the Company comprises of renowned professionals from different walks of life. They bring in diversified competencies, domain knowledge and experience. Right combination of Executive and

Independent Directors draws fine balance of business acumen and independent judgement on Board's decisions. During the year under review, none of the Non-Executive Directors had any pecuniary relationship or transactions with the Company, other than payment of sitting fees, commission and reimbursement of expenses, if any.

Changes in the Board of Directors and KMP:

Appointment of Whole Time Director

Mr. Ravindra Kumar Kothari (DIN: 03418320) was appointed by the Board of Directors as an Additional Director of the Company with effect from 05th May, 2025, based on the recommendation of the Nomination and Remuneration Committee.

Subsequently, the Members of the Company, by way of a Special Resolution passed through Postal Ballot July 25, 2025 approved his appointment as a Non-Executive, Non-Independent Director of the Company for a term of five (5) consecutive years upto 30th July 2030.

Resignation of Whole Time Director

Mr. Kotian Chittanand Damodar (DIN: 09613054), Whole-time Director of the Company, resigned from the office of Director with effect from 16th May, 2025, due to personal reasons.

The Board accepted his resignation and placed on record its sincere appreciation for the valuable contributions and dedicated services rendered by him during his tenure with the Company.

Appointment of Independent Director

Dr. Mukesh Beekamchand (DIN: 11295580) was appointed by the Board of Directors as an Additional Director of the Company with effect from 13th November, 2025, based on the recommendation of the Nomination and Remuneration Committee.

Subsequently, the Members of the Company, by way of a Special Resolution passed through Postal Ballot on 07th February, 2026, approved his appointment as a Non-Executive, Independent Director of the Company for a term of five (5) consecutive years commencing from 07th February, 2026 and ending on 06th February, 2031.

Re-appointment of Independent Director

Based on the recommendation of the Nomination and Remuneration Committee and the approval of the Board of Directors, the Members of the Company, at the 38th Annual General Meeting held on 25th September, 2025, approved the re-appointment of Mr. Jatish Sheth (DIN: 00581963) as an Independent Director of the Company for a second and final term of five (5) consecutive years, commencing from 28th December, 2025 and ending on 27th December, 2030, in accordance with the provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Mr. Jatish Sheth was initially appointed as an Independent Director by the Members at the 34th Annual General Meeting held on 24th September, 2021, for a first term ending on 27th December, 2025.

Completion of tenure

Mr. H. S. Venkatesh (DIN: 01776040), Independent Director of the Company, ceased to be a Director with effect from 30th September, 2025, upon completion of term as an Independent Director. The Board places on record its deep appreciation and gratitude for his invaluable guidance, leadership, and significant contributions during his tenure on the Board.

Retirement by Rotation:

In accordance with the provisions of Section 152 of the Companies Act, 2013 and the Articles of Association of the Company, Mr. Ravindra Kumar Kothari (DIN: 03418320), Director of the Company, retires by rotation at the ensuing Annual General Meeting ("AGM") and, being eligible, has offered himself for re-appointment. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors has recommended his re-appointment for the approval of the Members at the ensuing AGM.

Mr. Himesh Virupakshya (DIN: 08554422), Director of the Company, retired by rotation at the previous Annual General Meeting and was re-appointed by the Members.

Other than what is stated above, there were no changes in the composition of the Board or Key Managerial Personnel of the Company, during the year under review.

Event Subsequent to year-end

Mr. Abdul Basith (M.No. A70640), Company Secretary & Compliance Officer of the Company has tendered his resignation vide his letter dated 2nd March, 2026 and the same has been accepted w.e.f. 11th May, 2026. Mr. Abdul Basith was relieved from the services of the Company w.e.f., close of business hours on Monday, 11th May, 2026.

Mr. Shreepada ML (M. No. A66681), was appointed as Company Secretary and Compliance Officer of the Company pursuant to the approval of the Board of Directors at its meeting held on 27th May 2026 to take the charge and commence his duties as the Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company with effect from 23rd June 2026.

The Composition of the Board and the Committees along with the meeting attendance details are provided in the Report on Corporate Governance.

BOARD EVALUATION

The Company has devised a policy for performance evaluation of the Board, Committees and Individual Directors. The evaluation process among others considers attendance of Directors at the Board and Committee Meetings, acquaintance with business, communication within the Board members, effective participation, domain knowledge, compliance with the internal code of conduct, vision and strategy.

This policy on the nomination and remuneration of Directors, Key Managerial Personnel and Senior Management Personnel has been formulated by the Nomination & Remuneration Committee and approved by the Board of Directors of the Company. The policy is guided by the principles and objectives as enumerated under the provisions of the Companies Act, 2013 and the Listing Regulations, to ensure reasonableness and sufficiency of remuneration to attract, retain and motivate competent resources, a clear relationship of remuneration to performance and a balance between rewarding short and long-term performance of the Company. A copy of the policy is uploaded on the Company's website.

The Board carried out annual performance evaluation of itself, Committees, individual Directors and Chairman at their Meeting held on 11th February 2026.

Report on performance evaluation of the individual Directors, and Committees was reviewed by the Chairman and feedback was given to the Directors. The Board has expressed satisfaction over the overall functioning of the Board Members and their Committees, which are in line with the objectives and goals of the Company.

DECLARATION OF INDEPENDENT DIRECTORS:

Independent Directors of the Company have confirmed that they continue to meet the criteria of independence as laid down under Section 149(6) of the Act and under the Listing Regulations. They have registered their names in the Independent Directors data-base and have passed the proficiency test, if applicable. They have also affirmed compliance to the Code of Conduct for Independent Directors.

Based on disclosures provided by Independent Directors, none of them are disqualified/debarred from being appointed as Director under Section 164 of the Act/SEBI order or any other authority and are independent from the management. The Board is of the opinion that the Independent Directors possess requisite qualifications, experience and expertise in the fields of manufacturing, operations, finance, forex, people management, strategy, sales & marketing, auditing, banking, risk management and they hold high standards of integrity. Skill set, expertise & competencies matrix of all the Directors is provided in the Report on Corporate Governance forming part of this Annual Report.

Familiarization Programmes for Independent Directors

The Company imparts familiarization programmes for its Independent Directors. Objective of these programmes is to familiarize Independent Directors with the business of the Company, industry, operating model, risks, opportunities, challenges etc. The various programmes in place in this regard includes interaction with subject matter experts within the Company, meetings with our business leaders and functional heads on a regular basis. The details of familiarization programmes and other disclosures as specified under the Listing Regulations is available on the Company's website.

AUDITORS AND AUDITORS REPORT

Statutory Auditors:

Messrs. SSJNB & Co, Chartered Accountants (FRN: 013976S) were appointed as Statutory Auditors of the Company from the conclusion of 35th Annual General Meeting held on 19.09.2022 up to the conclusion of 40th Annual General Meeting i.e. for a period of 5 years.

There are no qualifications, reservations or adverse remarks or disclaimers on the audited standalone and consolidated financial statements of the Company by the Statutory Auditors, for the financial year ended 31.03.2026.

Cost Auditors:

Maintenance of Cost Records as prescribed under the provisions of Section 148 of the Act was applicable for the business activities carried out by the Company. The Company as such maintains the Cost Records as specified by the Central Government under Section 148(1) of the Companies Act, 2013 as applicable.

As required by the provisions of Section 148 of the Companies Act, 2013, GNV & Associates, Cost Auditors (Firm Registration No.000150), was appointed as the Cost Auditor of the Company for the financial year 2025-26, to conduct cost audit of the cost records maintained by the Company.

Cost Audit Report for the FY 2024- 2025 has been filed with the Ministry of Corporate Affairs on 08th September 2025.

Secretarial Auditor:

Pursuant to the provisions of Section 204 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors, based on the recommendation of the Audit Committee, appointed Mr. Parameshwar G. Bhat, Practicing Company Secretary (Certificate of Practice No. 11004), as the Secretarial Auditor of the Company for a term of five (5) consecutive financial years, commencing from Financial Year 2025-26 up to Financial Year 2029-30. The said appointment was approved by the Members of the Company at the 38th Annual General Meeting held on 25th September, 2025.

The Secretarial Audit Report for the Financial Year 2025-26 in Form MR-3, issued by the Secretarial Auditor, is annexed to this Report as Annexure – I.

The Secretarial Audit Report for the Financial Year 2025-26 does not contain any qualification, reservation, adverse remark or disclaimer requiring any explanation by the Board, except the observation relating to the composition of the Board and the Audit Committee and Nomination and Remuneration Committee during the third quarter of the financial year (October–December 2025).

The observation pertains to the temporary non-compliance with the requirements of Regulation 17 and the relevant provisions relating to the constitution of the Statutory Committees under the Listing Regulations, arising due to vacancies in the positions of Independent Directors.

The Board would like to clarify that the process of identifying and appointing suitable Independent Directors with the requisite qualifications, experience, expertise and industry knowledge relevant to the Company's business required additional time to ensure the appointment of competent and effective Board members. Consequently, the vacancies could not be filled within the prescribed timeline.

The Company has since appointed the requisite Independent Directors, thereby restoring the composition of the Board of Directors and the Audit Committee in full compliance with the applicable provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The applicable fines levied by BSE Limited and the National Stock Exchange of India Limited in respect of the temporary non-compliance were duly paid. As on 31st March, 2026, the composition of the Board and its Committees was fully compliant with all applicable statutory and regulatory requirements.

Internal Auditors:

Messrs. Murugesh & Co, Chartered Accountants (Firm Registration No: 002233S) were appointed as the Internal Auditors of the Company for the Financial Year 2025-26 and the internal audit reports issued by them were periodically reviewed by the Audit Committee and the Management of the Company is appraised about the observations of the Internal Auditors and on corrective actions, if any, that needs to be taken.

Reporting of fraud by Auditors

During the year, the statutory auditors have not reported to the Audit Committee any fraud on the Company by its officers or employees under Section 143(12) of the Companies Act, 2013, the details of which needs to be provided in this report.

Further, the Cost Auditors, Internal Auditors and Secretarial Auditor have also not reported any instance of fraud involving the Company, its officers or employees during the financial year under review.

RECONCILIATION OF SHARE CAPITAL AUDIT

As per the directive of Securities and Exchange Board of India, Mr. Vijayakrishna K.T, Practicing Company Secretary, undertook the Reconciliation of Share Capital Audit on a quarterly basis and the reconciliation documents, for the year under review, have been duly uploaded on the website of the Stock Exchange.

A qualified practicing Company Secretary carries out reconciliation of share capital to reconcile the total admitted equity share capital with the National Securities Depository Limited (NSDL) and the Central Depository Services (India) Limited (CDSL) and the total issued and listed equity share capital. The reconciliation of share capital audit report confirms that the total issued/paid-up capital is in agreement with the total number of shares in physical form and the total number of dematerialised shares held with NSDL and CDSL.

POLITICAL CONTRIBUTION

Your Company has not made any political contribution to any political parties during the financial year under review.

RISK MANAGEMENT

The Risk Management Committee of the Company comprising of the functional heads of the Company will submit its periodical report to the Board of Directors on the measures to be taken for mitigation of potential risk factors that may affect the business of the Company.

The Risk Management Policy implemented by the Company which is designed to enable risks to be identified, assessed and mitigated appropriately, is available on the website of the Company https://www.balpharma.com

INTERNAL FINANCIAL CONTROL SYSTEM AND ITS ADEQUACY

Your Company has an adequate system of internal controls with clearly defined authority limits. Internal controls ensure that the Company's assets are protected against loss from unauthorized use or disposition and all transactions are authorized, recorded and reported in conformity with generally accepted accounting principles. These systems are designed to ensure accuracy and reliability of accounting data, promotion of operational efficiency and adherence to the prescribed management principles. These policies are periodically reviewed to meet business requirements. The Company has in place adequate internal financial controls with respect to financial statements.

BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT (BRSR)

In terms of the provisions of Regulation 34(2)(f) of the Listing Regulations, submission of the Business Responsibility and Sustainability Report (BRSR) is not applicable to the Company for the financial year under review.

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

In terms of the Listing Regulations, the Management Discussion and Analysis Report is presented in a separate section and forms part of the Annual Report.

DIRECTORS' RESPONSIBILITY STATEMENT

In compliance with the provisions of Section 134(5) of the Companies Act, 2013, your Directors wish to confirm:

a) That in preparing the annual accounts, all the applicable accounting standards had been followed along with proper explanation relating to material departures.

b) That the Directors had selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that period.

c) That the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing / detecting fraud and other irregularities.

d) That the Directors had prepared the annual accounts on a going concern basis.

e) That the Directors had laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively.

f) That the Company had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

SUBSIDIARY, JOINT VENTURE AND ASSOCIATE COMPANIES

During the year under review, the following Companies continued to be the subsidiaries of Bal Pharma Limited. A report on the financial performance of each of the subsidiaries as per Section 129(3) of the Act in the prescribed format AOC-1 is provided in Annexure- 2 to the Board's Report and hence not repeated here, for the sake of brevity:-

NIL

Sl. No.	Name of the Company/LLP	Nature of Business	% of stake held by Bal Pharma Limited, as on 31.03.2026.
1.	Lifezen Healthcare Private Limited.	Marketing of OTC products.	99.40%
2.	Bal Research Foundation	Research and Development.	80%
3.	Balance Clinics LLP.	Diabetic care clinics.	80%
4.	Aurum Research & Analytical Solutions Pvt Ltd	Research and Development	95%

During the year the following changes occurred relating to subsidiaries:

M/s. Golden Drugs Private Limited, wholly owned subsidiary of the Company has been amalgamed with the company pursuant to Hon'ble National Company Law Tribunal, Bengaluru Bench, vide Order in C.P. (CAA) No. 13/BB/2024 dated 26th March, 2025.

RELATED PARTY TRANSACTIONS (RPTs)

All contracts /arrangements / transactions entered by the Company during the financial year with related parties were in ordinary course of business and at arms' length basis and the same were undertaken after receiving omnibus approval of the Audit Committee.

During the year, the Company has not entered into any contract/arrangement/transaction with the related parties that could be considered as material, as per the policy of the Company on materiality of related party transactions.

There were no materially significant related party transactions which could have potential conflict with the interests of the Company at large.

The Company's policy on the related party transactions as approved by the Board can be accessed from the website i.e. www.balpharma.com

Details of disclosures relating to the related party transactions under Section 188 of the Companies Act, 2013, form part of the notes to the financial statements provided in this Annual Report. For Further Details, your attention is drawn to the Related Party disclosures set out in the Financial Statements.

Statement of the related party transactions as approved by the Board, for the financial year 2025-26 in Form AOC-2 is annexed to this report in Annexure- 3.

ACCOUNTING STANDARDS

Your Company has adopted "IndAS" and the financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 (to the extent notified) and guidelines issued by SEBI. The Ind AS are prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

SECRETARIAL STANDARDS

Secretarial Standards i.e. SS1 & SS2 issued by the Institute of Company Secretaries of India (ICSI) relating to the Meetings of Board of Directors and General Meetings, respectively have been duly followed by the Company.

PREVENTION OF INSIDER TRADING

In terms of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has made a Code of practices and procedures for fair disclosure of unpublished price sensitive information and prevention of insider trading to prohibit the insider trading, to govern the fair disclosure of unpublished price sensitive information and to attain equality of access to such information with a view to regulate trading in securities by the Directors and designated employees of the Company. All Directors and the designated employees have confirmed compliance with the Code. The Company has also has complied with the requirement of Structured Digital Database (SDD) pursuant to provisions of Regulation 3(5) and 3(6) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (PIT Regulations) the Company has purchased a software for recording of Name, PAN and email id etc. of the person to whom Unpublished Price Sensitive Information is shared for genuine purpose and the Board confirms that the Company has a system driven Structured Digital Database in place to capture all the UPSI.

DEPOSITORY SYSTEM

As the members are aware, your Company's shares are tradable in electronic form and the Company has established connectivity with both the Depositories i.e., National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). In view of the advantages of the Depository System, the members are requested to avail of the facility of de-materialization of the Company's shares.

DETAILS OF APPLICATION MADE/PROCEEDINGS PENDING UNDER IBC CODE, 2016 DURING THE YEAR AND THEIR STATUS AS AT THE END OF FINANCIAL YEAR 2025-2026

During the Financial Year 2025-26, no application was made against the Company under the provisions of the Insolvency and Bankruptcy Code, 2016. Further, no proceedings under the Insolvency and Bankruptcy Code, 2016 were pending against the Company as on 31st March, 2026.

DETAILS OF DIFFERENCE BETWEEN THE AMOUNT OF VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE AVAILING LOANS FROM BANKS OR FINANCIAL INSTITUTIONS

The requirement to disclose the details of the difference between the amount of valuation done at the time of One Time Settlement (OTS) and the valuation done while availing loans from banks or financial institutions, along with the reasons therefor, is not applicable to the Company during the Financial Year 2025-26, as no One Time Settlement was entered into with any bank or financial institution.

VIGIL MECHANISM

The vigil mechanism of the Company which also incorporates Whistle Blower Policy as prescribed by Listing Regulations, 2015 includes compliance task force comprising of senior executives of the Company.

The policy of whistle blower is available on the Company's website. The policy is reviewed by the Audit Committee from time to time and no concerns and/or irregularities were reported by the employees till date. Please access the Company's website https://www.balpharma.com to refer to the whistle blower policy of the Company.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTFLOW

As per the provisions of Section 134 of the Companies Act, 2013, details relating to the conservation of energy, technology absorption, foreign exchanges earnings and outflow are given as Annexure -4 to this report.

CORPORATE GOVERNANCE

The Board of Directors reaffirm their continued commitment to transparent Corporate Governance & ethical practices. The Company is committed to maintain highest standard of Corporate Governance and elevating the same to the best global practices. Report on Corporate Governance for the year under review, forms part of this report.

A certificate from Mr. Vijayakrishna K.T, Practicing Company Secretary confirming compliance with Corporate Governance requirements as stipulated under the Listing Regulations, forms part of the Corporate Governance Report.

CODE OF CONDUCT

In terms of Regulation 34 read with Schedule V of the Listing Regulations, a declaration signed by Mr. Shailesh Siroya, the Chairman & Managing Director of the Company affirming compliance with the Code of Conduct by the Directors and Senior Management Personnel of the Company for the financial year 2025-26 forms part of the Report on Corporate Governance.

CERTIFICATE PURSUANT TO CLAUSE 10 OF SCHEDULE V OF (LODR), REG, 2015:

In terms of sub clause (i) of clause 10 of Part C of Schedule V of the Listing Regulations, the Company has obtained certificate from Mr. Vijayakrishna K.T, Practicing Company Secretary with respect to disclosure/ declaration/ representation received from the directors and taken on record by the Board of Directors, as on March 31, 2026, none of the Directors of the Company has been debarred or disqualified from being appointed or continuing as director of Companies by the SEBI/ Ministry of Corporate Affairs or any such other statutory authority. The above said Certificate is appended hereto and forms part of the Corporate Governance Report.

CEO & CFO CERTIFICATION:

As per Regulation 17(8) of Listing Regulations, Managing Director and Chief Financial Officer of the Company in their submission to the Board have confirmed that the annual financial statements present a true and fair view of the Company's affairs and do not omit any material facts, which may make the statements or figures contained therein either misleading or false. The above said Certificate is appended hereto and forms part of the Report on Corporate Governance.

PARTICULARS OF LOANS GIVEN, INVESTMENTS MADE, GUARANTEES GIVEN OR SECURITY PROVIDED BY THE COMPANY.

The Company makes investments and trade advances to its subsidiaries for their business purposes. Pursuant to the provisions of Section 134 of the Companies Act, 2013 the particulars of the loans, guarantees and investments made by the Company under Section 186 of the Companies Act, 2013 is detailed in the Notes to Accounts section of the Annual Financial Statements.

MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY BETWEEN THE END OF THE FINANCIAL YEAR AND UP TO THE DATE OF THIS REPORT.

There have been no material changes or commitments affecting the financial position of the Company between the end of the financial year and as on the date of this report. There has been no change in the nature of business or constitution of the Company.

ANNUAL RETURN

In accordance with the provisions of Section 134 of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014, rule 12, sub rule (1) as amended, the extract of the Annual Return (MGT-9) is no longer required to be attached along with Board Report. The copy of the Annual Return for the year 2025-26 can be accessed on the Company's website at the link www.balpharma.com

CORPORATE SOCIAL RESPONSIBILITY (CSR)

Company has dissolved the Corporate Social Responsibility Committee by the Board of Directors in its meeting held on 29.05.2025 as per section 135(9) of Companies Act, 2013 as the amount to be spend towards CSR is below 50 lakhs for the F.Y 2025-26.

Corporate Social Responsibility policy which recommends the social activities to be undertaken by the Company, as specified in Schedule VII of the Companies Act, 2013. A copy of the said policy is available on the Company website.

The Board has recommended CSR budget of Rs 17,50,000 (Rupees Seventeen Lakhs Fifty Thousand Only) for the financial year 2025-26, as per the provisions of Section 135 of the Companies Act, 2013.

The allocated CSR budget is spent on the social welfare activities during the year. Details of CSR activities & the brief outline of the CSR policy of the Company and the initiatives undertaken by the Company on CSR activities during the year are set out in Annexure- 5 of this report in the format prescribed in the Companies (Corporate Social Responsibility Policy) Rules, 2014.

HUMAN RESOURCE, HEALTH AND SAFETY

Human Resources are invaluable assets and Company is committed to provide conducive environment that values their contribution and provides them opportunities to grow. It invests in their training and professional development to equip them with the necessary skills, domain expertise and latest technology in line with the business strategy. The Company is dedicated to the protection of human health, safety, environment and maintains highest standards of health and safety in all its plants and facilities. This commitment forms the basis for our EHS management systems and governance.

REMUNERATION OF DIRECTORS AND KMP

It is confirmed that the remuneration paid to Directors, Key Managerial Personnel and Senior Management Personnel is in accordance with the Company's policy. Statement of Disclosure of Remuneration under Section 197 of Companies Act, 2013 and Rule 5(1) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is attached to this report as "Annexure 6".

MANAGERIAL REMUNERATION AND PARTICULARS OF EMPLOYEES

There were 939 permanent employees of the Company as of 31 March 2026. The information pursuant to Rule (1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is annexed to this report as "Annexure 7". Information pursuant to Rule 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 also forms part of this report pursuant to Section 136(1) of the Act. Any shareholder interested in obtaining a copy of the same may write to the Company Secretary at the registered office address of the Company.

EMPLOYEES STOCK OPTION PLAN (ESOP)

The Company has implemented Bal Pharma Limited Employee Stock Option Plan -2025 (hereinafter after referred to as the 'Scheme') in accordance with the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and applicable provisions of the Companies Act, 2013. The said Scheme has been duly approved by the shareholders of the Company by way of a special resolution at the 38th Annual General Meeting of the Company held on 25th September, 2025. In-principal approvals for the same from both BSE Limited and National Stock Exchange of India Limited were received. Scheme have come into force on the 25.09.2025 and shall continue to be in effect for a term of 10 (Ten) years. The total number of options granted under ESOP 2025 shall not exceed 10,00,000 options convertible into 10,00,000 equity shares of Rs. 10 each, equivalent to 6.28% of the current equity share capital (1,59,20,872 shares) of the Company. The earlier Bal Pharma Limited Employee Stock Option Scheme, 2014 has been successfully completed and no further options remain available for grant under the said scheme.

Further, the Board of Directors at its meeting held on May 27, 2026, based on recommendation of Nomination & Remuneration Committee, approved to grant 5,00,000 Options under the Bal Pharma Limited Employee Stock Option Plan -2025 to some of its senior executives.

Pursuant to the requirements of the SEBI (Share Based Employee Benefit and Sweat Equity) Regulations, 2021, a certificate has been issued by the Secretarial Auditors of the Company confirming that the Plan has been implemented in accordance with the said Regulations and with the resolution passed by the Company in the General Meeting.

The additional details of stock options are provided under Notes to Financial Statements (Standalone).

As required under the SEBI (Share Based Employee Benefit and Sweat Equity) Regulations, 2021, the applicable disclosures as on March 31, 2026, are uploaded on the website of the Company.

Disclosures as per Rule 12(9) of the Companies (Share Capital and Debenture) Rules, 2014 and SEBI (Share Based Employee Benefit and Sweat Equity) Regulations, 2021is attached to this report as "Annexure 08".

LISTING WITH STOCK EXCHANGES

The Equity Shares of the Company continued to be listed on BSE Limited, and National Stock Exchange of India Limited, and the Company has paid the annual listing fees for F.Y 2025-26 to the Exchanges.

INSURANCE COVERAGE

The Company has in place a comprehensive insurance programme commensurate with the nature, scale and risks associated with its business operations. The Management confirms that the Company's movable and immovable properties, plant and machinery, inventories, current assets and other insurable assets are adequately covered under appropriate insurance policies against various operational and business risks.

In addition to asset insurance, the Company has obtained and timely renewed Directors' and Officers' (D&O) Liability Insurance, Public Liability Insurance and other statutory and business-specific insurance policies, as applicable to the pharmaceutical industry. The Company also maintains appropriate employee-related insurance covers and welfare policies, including those mandated under applicable laws, to safeguard the interests of its employees.

The insurance portfolio of the Company is reviewed periodically to ensure that the nature and extent of coverage remain adequate, appropriate and aligned with the Company's risk profile and applicable regulatory requirements.

CREDIT RATING

The discipline with which the Company conducts its financial transactions is reflected in the BBB- rating given by the credit rating agency Acute for the financial year 2025-2026. The Management of the Company aims at further improving its credit rating during the current financial year.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013.

The Company has in place an anti-sexual harassment policy on lines with the requirements of the sexual harassment of women at the workplace (Prevention, Prohibition and Redressal) Act, 2013. All the employees of the Company either they are permanent, contractual, temporary or trainees, are covered by the policy.

The following is the summary of the Complaints regarding sexual harassment, received and redressed during the financial year 2025-26.

Number of Complaints received during the year	: Nil
Number of Complaints resolved	: NA
Number of Complaints pending at the end of the year	: NA

DISCLOSURE UNDER MATERNITY BENEFITS ACT, 1961

Company complies with the provisions of the Maternity Benefit Act, 1961, ensuring eligible women members receive their statutory entitlements, including up to 182 days of fully paid maternity leave. Company also extends additional leave support in cases of medical complications, including leave provisions for miscarriage and medical termination of pregnancy, in line with applicable regulations. These benefits reflect our commitment to creating a compliant, inclusive, and supportive workplace that prioritizes the health, well-being, and diverse needs of expecting and new mothers. There were 91 permanent women employees in the company as of 31st March, 2026.

HUMAN RELATIONS

During the year under review, employee relations at all sites remained cordial. Despite the exceptional challenges faced in past years, the motivated work force aided your Company in maintaining its Industrial Relations at all time.

REVISION OF FINANCIAL STATEMENTS OR BOARDS REPORT:

There was no revision of Financial Statements or Boards Report of the Company that took place in any of the three preceding financial years, under consideration.

GENERAL INFORMATION:

Your Directors confirm that, during the financial year under review, there were no transactions, events or circumstances requiring disclosure or reporting under the applicable provisions of the Companies Act, 2013, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 or any other applicable laws in respect of the following matters:

- Provision of money by the Company for the purchase of its own shares by employees or by trustees for the benefit of employees;
- Suspension of trading in the Company's securities by any Stock Exchange;
- Failure to implement any corporate action; and
- One-time settlement with any bank or financial institution.

Accordingly, no disclosure or reporting on the above matters is required in this Annual Report.

GREEN INITIATIVE

We request all the Members to support the 'Green Initiative' of the Ministry of Corporate Affairs and Bal Pharma continuance towards a greener environment by enabling the service of the Integrated Annual Report, AGM Notice, and other documents electronically to your email address registered with your Depository Participant/ the Registrar and Share Transfer Agent of the Company.

In support of the 'Green Initiative', the Company encourages Members to register their email addresses with their Depository Participant or the Registrar and Share Transfer Agent of the Company to receive soft copies of the Integrated Annual Report, Notices and other information disseminated by the Company, on a real-time basis without any delay.

APPRECIATION:

Your directors place on record earnest appreciation for the contribution made by each and every employee of the Company during the year under review. Company's consistent growth was made possible by their hard work, solidarity, cooperation and dedication. The Directors also wish to express their gratitude to the Investors for the confidence and faith that they continued to repose in the Company. Board takes this opportunity to thank all shareholders, analysts, business partners, government and regulatory authorities, financial institutions, banks, distributors, suppliers, business associates, medical professionals and customers for their continued guidance, encouragement and support.

for and on behalf of the board of directors of
Bal Pharma Limited

Shailesh Siroya	**V Himesh**
Managing Director	Whole Time Director
DIN: 00048109	DIN: 08554422

Place: Bengaluru
Date : 27th May, 2026

Enclosures:

1. Annexures of Board Report

Annexure 1 : Secretarial Audit Report for the Financial Year 2025-26 in Form MR-3

Annexure 2 : AOC-1 , Subsidiary Company details

Annexure 3 : AOC-2 , Related party Transaction details

Annexure 4 : Statement of conservation of energy, technology absorption, foreign exchanges earnings and outflow

Annexure 5 : CSR activities details

Annexure 6: Remuneration of directors and KMPs

Annexure 7 : Top 10 employees Remuneration

Annexure 8 : ESOP details

2. Corporate Governance Report (Integral Part of the Board's Report)

a) Certificate affirming compliance with the Code of Conduct

b) CEO and CFO Certificate

c) Practicing Company Secretary Certificate confirming compliance with Corporate Governance requirements

d) Practicing Company Secretary Certificate confirming on clause 10 of schedule V of (LODR), Reg, 2015

3. Management Discussion and Analysis Report (Integral Part of the Board's Report)

Annexure-I

Form No. MR-3
SECRETARIAL AUDIT REPORT
FOR THE FINANCIAL YEAR ENDED 31.03.2026
[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014]

To,
The Members
Bal Pharma Limited
Bangaluru.

I have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Bal Pharma Limited (CIN: L85110KA1987PLC008368) (hereinafter called 'the Company'). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/ statutory compliances and expressing my opinion thereon.

Based on my verification of the books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, I hereby report that in my opinion, the Company has, during the audit period covering the financial year ended on 31.03.2026 complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31.03.2026 according to the provisions of:

i) The Companies Act, 2013 and the Rules made thereunder;
ii) The Securities Contracts (Regulation) Act, 1956 ("SCRA, 1956") and the Rules made thereunder;
iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
iv) Foreign Exchange Management Act, 1999 and the Rules and Regulations made thereunder to the extent of Foreign Direct Investment, Overseas

Direct Investment and External Commercial Borrowings;

v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 (" SEBI Act, 1992"):-
(a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
(b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
(c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (Not Applicable);
(d) Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021;
(e) The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021 (Not Applicable);
(f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 2025 regarding the Companies Act, 2013 and dealing with client;
(g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021 (Not Applicable);
(h) Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018 (Not Applicable);
(i) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
(j) The Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 and
(k) Circulars/Guidelines issued thereunder;

(vi) The Industry specific laws applicable to the Company are as follows:

a) Pharmacy Act, 1948
b) Drugs and Cosmetics Act, 1940
c) Homoeopathy Central Council Act, 1973
d) Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954
e) Narcotic Drugs and Psychotropic Substances Act, 1985
f) Conservation of Foreign Exchange and Prevention of Smuggling Activities Act, 1974
g) The Medicinal & Toilet Preparations (Excise Duties) Act, 1955
h) Petroleum Act, 1934
I) Poisons Act, 1919
j) Food Safety and Standards Act, 2006
k) Insecticides Act, 1968
l) Biological Diversity Act, 2002
m) The Indian Copyright Act, 1957
n) The Patents Act, 1970
o) The Trade Marks Act, 1999

(vii) The other general laws as may be applicable to the Company including the following:

(1) Employer/Employee Related Laws & Rules:

- The Factories Act, 1948
- The Employees State Insurance Act, 1948
- The Employees' Provident Funds and Miscellaneous Provisions Act, 1952 along with EPF Scheme 1952, EPS Scheme 1995, EFPS Scheme 1971 and EDLI Scheme, 1976
- Contract Labour (Regulation and Abolition) Act, 1970 and Contract Labour (Regulation & Abolition) (Karnataka) Rules, 1974
- The Minimum Wages Act, 1948 and Karnataka Minimum Wages Rules, 1958
- The Payment of Wages Act, 1936 read with Karnataka Payment of Wages Rules, 1963
- The Payment of Gratuity Act, 1972 and Karnataka Payment of Gratuity Rules, 1973 and Karnataka Compulsory Gratuity Insurance Rules, 2024
- The Payment of Bonus Act, 1965
- The Maternity Benefit Act, 1961 read with Karnataka Maternity Benefit Rules, 1966
- The Equal Remuneration Act, 1976 read with Equal Remuneration Rules, 1976
- The Child and Adolescent Labour (Prohibition and Regulation) Act, 1986 and The Child Labour (R&P) (Karnataka) Rules, 1998
- The Employment Exchanges (Compulsory Notification of Vacancies) Act, 1959 read with the Employment Exchanges Rules, 1960
- The Karnataka Labour Welfare Fund Act, 1965 and Rules, 1968
- The Apprentices Act, 1961
- The Industrial Employment Standing Orders Act, 1946 read with Rules of 1961
- The Sexual Harassment of Women at Workplace (Prevention, Prohibition & Redressal) Act, 2013 read with Central Rules, 2013
- The Karnataka Industrial Establishments (National & Festival) Holidays Act, 1963 read with Rules of 1964
- The Karnataka Public Safety (Measures) Enforcement Act, 2017 and Rules of 2018
- Karnataka Shops & Commercial Establishment Act, 1961 and Rules, 1963
- The Rights of Persons with disabilities Act, 2016
- The Kannada Language Comprehensive Development Act, 2022
- The Digital Personal Data Protection Act, 2023 read with Digital Personal Data Protection Rules, 2025

(2) Environment Related Acts & Rules:

- The Environment Protection Act, 1986
- The Water (Prevention & Control of Pollution) Act, 1974
- The Air (Prevention & Control of Pollution) Act, 1981
- Hazardous Wastes (Management, Handling and Transboundary Movement) Rules, 2008.
- The Karnataka Ground Water (Regulation for Protection of Sources of Drinking Water) Act, 1999

I have also examined compliances with the applicable clauses of the Secretarial Standards issued by the Institute of Company Secretaries of India on the Board and General Meetings i.e. SS - 1 and SS – 2 and Listing Agreements entered into by the Company with the BSE Limited and National Stock Exchange of India Limited. Compliances prescribed under Secretarial Standard-1 (Board Meetings) and Secretarial Standard-2 (General Meetings), as issued by the Institute of Company Secretaries of India and notified under Section 118(10) of the Companies Act, 2013 need to be strengthened.

During the period under review, the Company has complied with the provisions of the Acts, Rules, Regulations, Guidelines, Standards, etc. mentioned above as may be applicable during the year under review. Certain non-material findings made during the course of the audit relating to the provisions of Companies Act, 2013, Secretarial Standards, Labour Laws were addressed suitably by the Management.

Following are some of the observations brought before the Stakeholders:

1. The composition of the Board of Directors during Quarter 3 (October–December) of the Financial Year 2025-26 was not in conformity with the requirements prescribed under Regulation 17 (1) of the SEBI (LODR) Regulations for Forty-Three (43) days.
2. The composition of the Audit Committee and Nomination and Remuneration Committee was not in conformity with the requirements prescribed under Regulations 18 (1) and 19 (1)/ 19 (2) of SEBI (LODR) Regulations for three (3) days during Quarter 3 of the Financial Year 2025-26 (October–December).
3. The Company was in receipt of letter NSE/LIST-SOP/COMB/FINES/0215 dated 27/2/2026 from the National Stock Exchange Limited (NSE) imposing fines for non-compliances under Regulations 17 (1), 18 (1), 19 (1)/19 (2). Further, the Company requested for a personal hearing. The personal hearing was scheduled and attended on 21/4/2026. NSE upheld the levy of fines to be paid on or before 15/5/2026. The Company duly paid the referred penalties to both BSE Limited and NSE on 15/5/2026 within the specified due date.

Further, I report that with regard to financial and taxation matters, I have relied on the Audit Report, Limited Review Report and the Internal Audit Report provided by the Statutory/Internal Auditor as the case may be.

I further report that the Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors which took place during the period under review were carried out in compliance with the provisions of the Act except as afore-mentioned.

Adequate notice is given to all Directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the Meeting.

The decisions were carried through majority while the dissenting members' views are captured and recorded as part of the minutes as per the practice followed. However, during the period under report, there was no such case instance.

I further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

Place: Bengaluru
Date: 27.05.2026

Parameshwar G. Bhat
Practising Company Secretary
FCS No.: 8860; CoP No.: 11004
Peer Review Certificate No.: 5508/2024
UDIN: F008860H000502881

Note: This report is to be read with our letter of even date which is annexed as Annexure and forms an integral part of this report 'Annexure'.

Annexure

My report of even date is to be read along with this letter:

1. Maintenance of secretarial records is the responsibility of the management of the Company. My responsibility is to express an opinion on these secretarial records based on our audit.

2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of Secretarial Records. The verification was done on test basis to ensure that correct facts are reflected in the secretarial records. I believe that the processes and practices, I have followed provide a reasonable basis for our opinion.

3. I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company including records under Income Tax Act, Central Excise Act, Customs Act, GST Act.

4. Where ever required, the Company has represented about the compliance of laws, rules and regulations and happening of events etc as applicable from time to time.

5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of Management. My examination was limited to the verification of procedures on test basis.

6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the Management has conducted the affairs of the Company.

Place: Bengaluru
Date: 27.05.2026

Parameshwar G. Bhat
Practising Company Secretary
FCS No.: 8860; CoP No.: 11004

Annexure-2

Form AOC-1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)
Statement containing salient features of the financial statement of subsidiaries/associate companies/joint ventures

Part "A": Subsidiaries

(Amount in Rs)

Particulars	1	2	3	4
Name of the subsidiary	**Lifezen Healthcare Private Ltd.**	**Bal Research Foundation**	**Balance Clinics LLP**	**Aurum Research and Analytical Solutions Private Ltd.**
The date since when subsidiary was acquired	07/11/2014	29/10/2014	15/05/2014	21/08/2023
Reporting period for the subsidiary concerned, if different from the holding company's reporting period	NA	NA	NA	NA
Reporting currency and Exchange rate as on the last date of the relevant Financial year in the case of foreign subsidiaries	NA	NA	NA	NA
Share capital	2,00,00,000	10,00,000	10,00,000	1,00,000
Reserves &surplus	-19,11,94,620	-30,84,920	-2,46,23,230	-77,200
Total assets	1,99,55,200	5,46,880	51,07,770	1,40,160
Total Liabilities	19,11,49,820	26,31,800	2,87,30,930	1,17,360
Investments	0	0	0	0
Turnover	96,97,430	0	60,97,900	0
Profit before taxation	-28,16,130	-4,33,690	-9,87,310	-76,000
Deferred tax	-1,380	0	0	0
Profit after taxation	-28,14,750	-4,33,690	-9,87,310	-76,000
Proposed Dividend	Nil	Nil	Nil	Nil
% of shareholding	Bal Pharma Ltd=99.40 % Bennett, Coleman & Co Ltd=0.1% Shailesh Siroya=0.5 %	Bal Pharma Ltd=80% Shailesh Siroya=20%.	Bal Pharma Ltd=80% Shailesh Siroya=20%.	Bal Pharma Ltd = 95% Shailesh Siroya = 5%

1. Names of subsidiaries which are yet to commence operations - NA
2. Names of subsidiaries which have been liquidated or sold during the year - NA*

** Pursuant to the Scheme of Amalgamation of Golden Drugs Private Limited ("Transferor Company"), a wholly owned subsidiary, with Bal Pharma Limited ("Transferee Company"), sanctioned by the Hon'ble National Company Law Tribunal, Bengaluru Bench, vide Order in C.P. (CAA) No. 13/BB/2024 dated 26th March, 2025, under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, the Scheme became effective upon filing of the certified copy of the said Order with the Registrar of Companies (Date of Filing:28th April 2025) . Consequently, Golden Drugs Private Limited stood amalgamated with Bal Pharma Limited and ceased to be a subsidiary of the Company with effect from the effective date of the Scheme.*

Part "B": Associates and Joint Ventures : NA

For and on behalf of Board of Directors
Bal Pharma Limited

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh Virupakshya
Whole Time Director
DIN: 08554422

Bharath Bhushan D V
Chief Financial Officer

Place: Bengaluru
Date : 27th May, 2026

Annexure-3

Form No AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014.

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

I. Details of contracts or arrangements or transactions not at Arm's length basis: NA
II. Details of contracts or arrangements or transactions at Arm's length basis

(Amount in Lakhs)

Sl. No.	Name (s) of the related party & nature of relationship	Nature of contracts /arrangements/ transaction	Duration of the contracts/ arrangements /transaction	Salient terms of the contracts or arrangements or transaction including the value, if any*	Date of approval by the Board	Amount paid as advances, if any
1	Micro Labs Limited (Promoter group entity)	Supply of Raw Material	Yearly	247.39	29.05.2025	Nil
2	Lifezen Healthcare Private Ltd (Subsidiary of Bal Pharma Ltd)	Supply of Finished Goods	Yearly	20.81	29.05.2025	Nil
3	Lifezen Healthcare Private Ltd (Subsidiary of Bal Pharma Ltd)	Rental Income	Yearly	5.61	29.05.2025	Nil
4	Bal Research Foundation (Subsidiary of Bal Pharma Ltd)	Rental Income	Yearly	2.40	29.05.2025	Nil
5	Lifezen Healthcare Private Ltd (Subsidiary of Bal Pharma Ltd)	Purchase of traded goods/materials	Yearly	18.95	29.05.2025	Nil
6	Shailesh Siroya (Promoter & Director)	Commission on Sales	Yearly	28.66	29.05.2025	Nil
7	M/s Desa Marketing (Mr. Shailesh Siroya is interested as proprietor)	Commission on Purchase	Yearly	94.59	29.05.2025	Nil
8	Shailesh Siroya (Promoter & Director)	Rental Expenses	Yearly	15.00	29.05.2025	Nil
9	Shailesh Siroya (Promoter & Director)	Salary	Yearly	180	29.05.2025	Nil
10	V. Himesh (Director)	Salary	Yearly	19.05	29.05.2025	Nil

(Amount in Lakhs)

Sl. No.	Name (s) of the related party & nature of relationship	Nature of contracts /arrangements/ transaction	Duration of the contracts/ arrangements /transaction	Salient terms of the contracts or arrangements or transaction including the value, if any*	Date of approval by the Board	Amount paid as advances, if any
11	Abdul Basith (Company Secretary)	Salary	Yearly	7.38	29.05.2025	Nil
12	Bharath Bhushan DV(CFO)	Salary	Yearly	34.20	29.05.2025	Nil
13	Ravindrakumar Kothari (Director)	Salary	Yearly	0.78	29.05.2025	Nil
14	Lifezen Healthcare Private Ltd	Deposit for Rendering of Services	Yearly	25	29.05.2025	Nil

*Transactions are ordinary course of business at Arm's length basis

For and on behalf of Board of Directors
Bal Pharma Limited

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh Virupakshya
Whole Time Director
DIN: 08554422

Place: Bengaluru
Date : 27th May, 2026

Annexure-4

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION & FOREIGN EXCHANGE EARNINGS AND OUTFLOW:

As in Financial year 2025-26, the Research and Development department of Bal Pharma has been concentrating on developing and standardizing the methodologies involved in the synthesis of drugs of importance. The projects chosen by R&D for study are directed towards being niche and towards addressing the current needs.

During the FY 2025-26, the following are the products that are being developed by Research and Development department of the Company and are in the process of commercialization.

Dabigatron Etexilate Mesilate:

Dabigatron is an anticoagulant used to treat and prevent blood clots and to prevent stroke in people with atrial fibrillation. Specifically it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. Product development has been completed, and the process of commercialization is underway .

Baclofen:

Baclofen is used for muscle relaxation. It provides relief from rigidity, tension and stiffness in muscles (spasticity) that may occur due to various conditions such as cerebral palsy, multiple sclerosis, motor neuron disease, or injury to the head, brain or spine. Product development has been completed and under commercialization.

Hydrochlorothiazide:

Hydrochlorothiazide is a type of diuretic (water pill). This medicine reduces excess fluid levels in the body and is used to treat edema (fluid overload) associated with heart, liver, kidney, or lung disease. It is also used in treatment of hypertension (high blood pressure) and heart failure. Product development has been completed and R&D samples are under stability study to apply manufacturing license. Commercialization to be started after getting manufacturing license.

Vildagliptin:

It is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Product development has been completed and Product is under commercialization.

Sitagliptin:

Sitagliptin is a medicine used to treat type 2 diabetes mellitus. It is used together with a healthy diet and regular exercise to control blood sugar levels. This helps to prevent serious complications of diabetes like kidney damage and blindness. Product development has been completed and commercialization is pending to be implemented .

Bilastine:

Bilastine is an antihistamine medication and used to treat hives (urticaria), allergic rhinitis and itchy inflamed eyes (allergic conjunctivitis) caused by an allergy. It is a second generation antihistamine and takes effect by selectively inhibiting the histamine H1 receptor preventing the allergic reactions. Product development has been completed and commercialization is pending to follow.

Dapagliflozin Propanediol:

Dapagliflozin Propanediol is the propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Upon administration, dapagliflozin selectively targets and inhibits SGLT2, thereby preventing the reabsorption of glucose by the kidneys. Product development has been completed and R&D samples are under stability study to apply manufacturing license. Commercialization to be started after getting manufacturing license.

Empagliflozin:

Empagliflozin is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. It reduces the kidney's glucose reabsorption and excretes the excess glucose through the urine, thus its place in the treatment of type two diabetes. Product development has been completed and R&D samples are under stability study to apply manufacturing license. Commercialization to be started after obtaining manufacturing license.

Expenditure on R&D during the financial year ended 31-03-2026: **(Amount in Lakhs)**

ii) Revenue Expenditure	426.04
iii) Total Expenditure	426.04
iv) Total R&D expenditure as a percentage of total turnover.	1.38%

Foreign Exchange earnings and outflow: **Amount (In Lakhs)**

	2025-26	**2024-25**
Total Foreign Exchange Earnings	17,267.09	16,517.83
Total Foreign Exchange outflow		
a) Towards purchase of raw materials	6430.65	5887.53
b) Towards purchase of capital goods.	Nil	Nil
c) Towards other foreign currency payments		
i) Travelling Expenses	51.74	132.41
ii) Registration fees	7.17	36.43
iii) Commission on Export Sales	172.48	354.88
iv) Export Promotion Expenses	104.81	62.03
v) Inspection Fees	35.01	9.60
vi)Packing Charges	0	3.98
vii) Lab Chemical	0	1.78
viii)Software and Maintenance	0	25.15

for and on behalf of the board of directors of
Bal Pharma Limited

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh Virupakshya
Whole Time Director
DIN: 08554422

Place: Bengaluru
Date : 27th May, 2026

Annexure-5

Annual Report on Corporate Social Responsibility Activities

1. Brief outline on CSR Policy of the Company

Bal Pharma Limited has always been committed to the cause of social service and has channelized a part of its resources and activities, such that it positively affects the society socially, ethically and also environmentally. The Company formulated a robust CSR Policy which encompasses its philosophy and guides its sustained efforts for undertaking and supporting socially useful programs for the welfare & sustainable development of the society.

The Company is inspired by the principle as enumerated by the father of the nation, Mahatma Gandhi 'quote "I believe it to be perfectly possible for an individual to adopt the way of life of the future.... without having to wait for others to do so" unquote' in drafting its corporate social responsibility policy.

The Company firmly believes that CSR is primarily, the responsibility of the Company in relation to the impact of its decisions and activities on the society and also the environment, through a transparent and ethical behavior which is:

(a) consistent with sustainable development and welfare of society,

(b) takes into account the expectations of stakeholders,

(c) is in compliance with applicable law, and

(d) is uniformly integrated and practiced throughout the Company.

While the Company is eligible to undertake any suitable/rightful activity as specified in Schedule VII of the Act, however, at present, it proposes to undertake the relevant activities on priority basis in the following three Thrust Areas:

1. Community healthcare
2. Education and imparting knowledge
3. Social care and concern

2. Composition of the CSR Committee:

The Corporate Social Responsibility Committee has been dissolved by the Board of Directors in its meeting held on 29.05.2025 as per section 135(9) of Companies Act, 2013 as the amount to be spend is below 50 lakhs for the F.Y 2025-26.

3. Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the Board-Disclosed on the website of the Company

Composition of the CSR committee : NA

CSR policy - https://www.balpharma.com/balpharmacom/pdf/finance/irl/CSR%20Policy%.pdf

CSR projects - https://www.balpharma.com/balpharmacom/pdf/finance/irl/CSR%20Policy%.pdf

4. Average net profit of the company for last three financial years: 8,14,48,942/-

5. Prescribed CSR Expenditure (two percent of the amount as in item 4 above): 16,28,979/-

6. Details of CSR spent during the financial year: 17,50,000.

7. Total amount to be spent for the financial year: NA

8. Amount unspent, if any: NA

9. Manner in which the amount spent during the financial year is detailed

10. Manner in which the amount spent during the financial year is detailed below.

Sl. NO	CSR project or activity identified	Sector in which the Project is covered	Projects or programs (1)Local area or other (2) Specify the State and district where projects or programs was undertaken	Amount outlay (budget) project or programs wise	Amount spent on the projects or Programs Subheads: (1)Direct expenditure on projects or programs (2)Overheads	Cumulative expenditure up to the reporting period	Amount spent: Direct or through implementing agency
1	Dialysis for patients with malfunction of Kidneys.	Health care	Jain Mission Trust, Chikkaballapur, Karnataka state	2,00,000	2,00,000	2,00,000	Through Agency: Jain Mission Trust, Chikkaballapur CSR Registration No.: CSR00004169
2	Various support services for poor and needy patients.	Health care	Local area: Bhagwan Mahaveer Memorial Jain Trust. Bangalore	2,00,000	2,00,000	2,00,000	Through Agency: Bhagwan Mahaveer Memorial Jain Trust. Bangalore CSR Registration number: CSR00003259
3	Financial support to the poor and meritorious students.	Support to education activities	Local area: Swamy Vivekananda Vidya Niketana, Bangalore.	1,00,000	1,00,000	1,00,000	Through agency: Swamy Vivekananda Vidya Niketana, Bangalore. CSR Registration number: CSR00054986
4	Scholarships for poor and needy children studying in Adarsh group of Institutions	Support to education activities	Local area: Adarsh Vidya Sangh, Bangalore.	1,00,000	1,00,000	1,00,000	Through agency: Adarsh Vidya Sangh, Bangalore. CSR Registration number:CSR00000798
5	Donation of medical equipment and consumables to D.R Ranka Dialysis Centre, Bangalore.	Health care	Local area: Karnataka Marwari Youth Federation, Bangalore	1,50,000	1,50,000	1,50,000	Through agency: Karnataka Marwari Youth Federation, Bangalore. CSR Registration number:CSR00003457
6	Donation of medical equipment to Primary health centre's at KSRP 3rd Battalion, Koramangala and Halanayakahalli, Sarjapur Road, Bangalore.	Health care	Local area: Rotary Bangalore Brigades, Bangalore	3,00,000	3,00,000	3,00,000	Through agency: Rotary Bangalore Brigades, Bangalore. CSR Registration number:CSR00018833
7	Various support services for poor and needy patients..	Health care	Local area: Prabhavhem Kamdhenu Girivihar Trust , Bangalore	1,00,000	1,00,000	1,00,000	Through agency: Prabhavhem Kamdhenu Girivihar Trust , Bangalore. CSR Registration number:CSR00010910

Sl. NO	CSR project or activity identified	Sector in which the Project is covered	Projects or programs (1)Local area or other (2) Specify the State and district where projects or programs was undertaken	Amount outlay (budget) project or programs wise	Amount spent on the projects or Programs Subheads: (1)Direct expenditure on projects or programs (2)Overheads	Cumulative expenditure up to the reporting period	Amount spent: Direct or through implementing agency
8	Sponsoring Mid-day meals to government and government aided schools.	Support to education activities	Local area: Akshaya Patra Foundation, Bangalore	1,50,000	1,50,000	1,50,000	Through agency: Akshaya Patra Foundation , Bangalore. CSR Registration number:CSR00000286
9	Supporting various social service activities.	Support to social activities.	Local area: Jain Yuva Sangathan, Bangalore	50,000	50,000	50,000	Through agency: Jain Yuva Sangathan , Bangalore. CSR Registration number:CSR00070380
10	Donating fodder for animals at Dhyan Foundation Gaushala.	Animal welfare Activities.	Local area: Dhyan Foundation, Bangalore	50,000	50,000	50,000	Through agency: Dhyan Foundation, Bangalore. CSR Registration number:CSR00003498
11	Donating for Charitable activity of Parshwanath Charitable Trust	Charitable activities	Local area: Parshwanath Charitable Trust	2,00,000	2,00,000	2,00,000	Through Agency: Parshwanath Charitable Trust CSR Registration number: CSR00091607
12	Donating to Mahaveer Sadhna avam Swadhya Samiti for Social service activities	Social service activities	Local area: Mahaveer Sadhna avam Swadhya Samiti	1,50,000	1,50,000	1,50,000	Through Agency: Mahaveer Sadhna avam Swadhya Samiti CSR Registration number: CSR00105157
	TOTAL			**17,50,000**	**17,50,000**	**17,50,000**	

11. In case the company has failed to spend the two per cent of the average net profit of the last three financial years or any part thereof, the company shall provide the reasons for not spending the amount in its Board report.: NA

12. Corporate Social Responsibility Committee confirms that the implementation and monitoring of CSR Policy is in compliance with CSR objectives and Policy of the company: CFO certificate enclosed

for and on behalf of the board of directors of
Bal Pharma Limited

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh Virupakshya
Whole Time Director
DIN: 08554422

Place: Bengaluru
Date : 27th May, 2026

CHIEF FINANCIAL OFFICER'S CERTIFICATE ON UTILIZATION OF CSR FUNDS

(Pursuant to Rule 4(5) of the Companies (Corporate Social Responsibility Policy) Rules, 2014)

To,
Board of Directors
Bal Pharma Limited
Bangaluru.

I Bharath Bhushan DV Chief Financial Officer of Bal Pharma Limited ("the Company"), hereby certify that

1. Company has disbursed CSR funds aggregating to Rs. 17,50,000 during the financial year 2025-26 towards the Corporate Social Responsibility (CSR) projects/programmes approved as by the Board.
2. The funds disbursed by the Company towards Corporate Social Responsibility (CSR) projects and programmes for the financial year 2025-26 have been utilized for the purposes and in the manner as approved by the Board of Directors of the Company.
3. CSR expenditure has been accounted for in accordance with the applicable provisions of the Companies Act, 2013, the Companies (Corporate Social Responsibility Policy) Rules, 2014, and other applicable laws, to the extent relevant.

for and on behalf of
Bal Pharma Limited

Bharath Bhushan D V
Chief Financial Officer

Date: 27.05.2026
Place: Bangaluru

Annexure-6

Statement of Disclosure of Remuneration under Section 197 of Companies Act, 2013 and Rule 5(1) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

a) The Nomination and Remuneration Committee of the Company fixes the remuneration of whole time Directors and key managerial personnel and is as per the remuneration policy of the Company.

The ratio of the remuneration of each Director and Key Managerial Personnel to the median remuneration of the employees of the Company for the financial year ended March 31, 2026, and percentage increase in remuneration compared to last financial year

Sl. No.	Name and Designation of Director & KMP.	Ratio of remuneration of each Director to the median remuneration of employee of the Company for F.Y 2025-2026.	% Increase / Decrease in remuneration in the F.Y 2024-2025.
1.	Mr. Shailesh Siroya Managing Director	30.1	-
2.	Mr. Virupakshaya Himesh Whole-Time Director	3:1	-
3.	Mr. Ravindra kumar Kothari Director *(From 05.05.2025)*	3:1	-
4.	Mr. Bharath Bhushan D.V. Chief Financial Officer	6:1	6 %
5.	Mr. Abdul Basith Company Secretary	2:1	3 %

Note: *For the purpose of calculation of the median remuneration, an amount of 6,00,000/- per annum as at March 31, 2026, has been considered. The said amount has been arrived at by dividing the total employee benefit expenses by the total number of employees and rounding off the resultant amount to the nearest applicable figure.*

** During the financial year under review, the Company has paid sitting fees to the Independent Directors for attending meetings of the Board of Directors and its Committees, as applicable. The sitting fees paid to the Independent Directors are within the limits prescribed under the applicable provisions of the Companies Act, 2013 and the rules made thereunder, and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time. Except for the sitting fees paid for attending meetings of the Board of Directors and its Committees, no other remuneration has been paid to the Independent Directors during the financial year under review.*

b) % increase in the median remuneration of the employees in the financial year: 10 %.

c) Number of permanent employees on the rolls of the Company: 939

d) Average percentile increase already made in the salaries of the employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in managerial remuneration: Average increase in the remuneration of the employees for the financial year 2025-26 was 10 % and 05 % increase in the remuneration of KMP, There were no increase in remuneration of directors during the year. The percentile increases in the median remuneration and that of managerial personnel does not require any justification.

for and on behalf of the board of directors of
Bal Pharma Limited

Place: Bengaluru
Date : 27th May, 2026

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh
Whole Time Director
DIN: 08554422

Annexure-7

DETAILS OF TOP TEN EMPLOYEES IN TERMS OF REMUNERATION FOR F.Y 2024-25

Statement of particulars of employees pursuant to the provisions of section 197(12) of the Companies Act, 2013 read with rules 5(2) & (3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014 for the Year ended 31st March, 2026

Sl. No.	Name of the Employee	Designation of the Employee	Remune-ration received (Yearly)	Nature of Employment, whether contractual or otherwise	Experience in the company & Qualification of the employee	Date of commencement of employment	Age of Employee	Last employment held by such employee before joining the company	Percentage of equity shares held by the employee in the company	whether any such employee is a relative of any director or manager of the company and if so, name of such director or manager
1.	Shailesh Siroya	Managing Director	1,80,00,000	Permanent	32 Years MBA	01.08.1994	59 Years	NA	17.37%	NA
2.	Archana Dubey	COO	89,92,056	Permanent	23 Years Graduate	01.01.2003	51 Years	NA	NA	NA
3.	Nabajit Sharma	A.V.P, Exports	46,09,740	Permanent	21 Years MBA	03.01.2005	46 Years	NA	NA	NA
4.	Ezaz Kaseem Azmi	Senior GM	37,54,116	Permanent	09Years B.Pharma	21.04 2017	44 Years	NA	NA	NA
5.	Aby Abharam	GM	34,76,748	Permanent	22 Years MBA	05.05.2004	56 Years	NA	NA	NA
6.	Bharath Bhushan D.V.	CFO	34,65,396	Permanent	5 Years CA	22.11.2021	37 Years	NA	NA	NA
7.	Krishna Moorthy UV	A.G.M	29,20,440	Permanent	1 Years MSC	23.01.2025	46 Years	NA	NA	NA
8.	N Subrahma nyeswara Rao	Senior GM,	28,48,716	Permanent	3Year PHD	01.06.2023	51 Years	NA	NA	NA
9.	Bidyut Kumar Bhattacharrya	AVP	28,42,704	Permanent	4Year MBA	24.08 2022	50 Years	NA	NA	NA
10.	Navneet Singh	DGM	27,72,924	Permanent	1 Years B.Pharma	18.06.2025	43 Years	NA	NA	NA

for and on behalf of the board of directors of
Bal Pharma Limited

Place: Bengaluru
Date : 27th May, 2026

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh
Whole Time Director
DIN: 08554422

Annexure-8

A. Disclosure as per Rule 12(9) of the Companies (Share Capital and Debentures) Rules, 2014
Details of Employees Stock Option scheme

Particulars	Bal Pharma Limited Employee Stock Option Scheme, 2025
Number of Options granted for F.Y 2025-26	Nil
Date on which options exercised	NA
Options exercised	NA
Number of shares arising as result of exercise of option	NA
options lapsed	Nil
Variation of terms of option	Nil

Employee wise details of options granted to :

(1) Directors & Key managerial personnel: Nil

(2) Any other employee who receives a grant of options in any one year of option amounting to five percent or more of options granted during that year: Nil

(3) Identified employees who were granted option, during any one year, equal to or exceeding one percent of the issued capital (excluding outstanding warrants and conversions) of the company at the time of grant: Nil

B. Disclosure with respect to Employees Stock Option Schemes of the Company Pursuant to Regulation 14 of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ('SEBI SBEB C SE Regulations')

As on March 31, 2026, your Company has only One employee stock option scheme called "Bal Pharma Limited Employee Stock Option Scheme - 2025" pursuant to special resolution passed at the 38th Annual General Meeting of the Company held on 25th September, 2025, under which stock options are granted to eligible employees of the Company from time to time.

Disclosures pursuant to Regulation 14 of the SEBI SBEB C SE Regulations and the status of compliance are as follows:

SI NO.	Particulars	Bal Pharma Limited Employee Stock Option Scheme, 2025
A	Any material change in the scheme(s) and whether the scheme(s) is / are in compliance with the regulations.	There were no material changes in the schemes during the year and the schemes are in compliance with the SEBI SBEB C SE Regulations.
B	Relevant disclosures in terms of the 'Guidance note on accounting for employee share-based payments' issued by ICAI or any other relevant accounting standards as prescribed from time to time.	Applicable Matters Disclosed in Notes to Accounts of the Standalone Financial Statements for the year ended March 31, 2026.
C	Diluted EPS on issue of shares pursuant to all the schemes covered under the regulations shall be disclosed in accordance with 'Accounting Standard on Earnings Per Share' issued by ICAI or any other relevant accounting standards as prescribed from time to time.	
D	Details related to Employee Stock Option Schemes (ESOS) A description of each ESOS that existed at any time during the year, including the general terms and conditions of each ESOS.	<u>Brief Terms of Bal Pharma Limited Employee Stock Option Scheme – 2025</u> 1.The scheme shall be deemed to have come into force on the 25.09.2025 and shall continue to be in effect for a term of 10 (Ten) years, unless all the options granted under the scheme are exercised or have been extinguished or unless the scheme is terminated 2.Employee means any person employed on a full-time and permanent basis by BAL PHARMA and shall include all its executives , whether whole time or not, but shall exclude (i) an person who is a Promoter or belongs to the Promoter Group and (ii) a Director who either by himself or through his relative or through anybody corporate, directly or indirectly holds more than 10% of the outstanding equity shares of the Company ;& (iii) Independent /nominee Directors of the Company . 3.The total number of options granted under ESOP 2025 shall not exceed 10,00,000 options convertible into 10,00,000 equity shares of Rs. 10 each, equivalent to 6.28% of the current equity share capital (1,59,20,872 shares) of the Company. 4.The maximum number of options granted to any one employee in a year shall not exceed 1% of the issued Equity Share capital of the Company at the time of granting of an option.The maximum quantum of the option per employee shall not exceed 5% of the total paid up capital during the tenure of the Scheme. 5.The Exercise price per share comprised in the options granted under the plan shall be Rs.10/- per equity share of Rs.10/- each.

Note : *The details of the "Bal Pharma Limited Employee Stock Option Scheme - 2025" and the requirement specified under Regulation 14 of the SEBI SBEB C SE Regulations, are also available on the Company website at www.balpharma.com (Refer ESOP Scheme)*

E. Details Related to "Bal Pharma Limited Employee Stock Option Scheme - 2025"

<table>
<tr><th>SI NO.</th><th>Particulars</th><th>Details</th></tr>
<tr><td>1</td><td>Date of shareholders' approval</td><td>September 25, 2025</td></tr>
<tr><td>2</td><td>Total number of options approved under ESOP 2025</td><td>10,00,000</td></tr>
<tr><td>3</td><td>Vesting requirements</td><td>Vesting Period is as follows
<table>
<tr><th>Quantum of options</th><th>Vesting from the date of grant of options</th></tr>
<tr><td>10%</td><td>1 Year</td></tr>
<tr><td>15%</td><td>2 Year</td></tr>
<tr><td>20%</td><td>3 Year</td></tr>
<tr><td>25%</td><td>4 Year</td></tr>
<tr><td>30%</td><td>5 Year</td></tr>
</table>
Note: Options shall vest on the 1st working day of the calendar month following the calendar month during which the respective vesting period gets completed as above</td></tr>
<tr><td>4</td><td>Exercise price or pricing formula</td><td>1. The Exercise Price per shares comprised in the options granted under the plan shall be Rs.10 per equity share of Rs.10 each. However, the exercise price of options shall in no circumstances be less than the face value of the underlying shares;

2. The employee can exercise his right to convert the options into shares either in full or in trenches by addressing a communication, either written or electronic, to the Remuneration Committee as per Format at Annexure 'D' of the Scheme. He has to mention the number of shares that he is willing to subscribe under the ESOP 2025. However, the exercise price in respect of quantum of shares exercised shall be paid by cheque or online bank transfer only;

3. The Options granted under the Scheme and vested in the Employee in accordance with the terms of this Scheme shall be exercisable by the Employee only within the Exercise period. All the Vested Options not exercised within the Exercise Period shall expire;

4. The exercise period shall commence from the date of vesting of options and expire not later than 5 (five) calendar years from the date of vesting of options. The Remuneration Committee may grant an extension upon a specific request made by the employee concerned to this effect, provided such extension is well within the tenure of the scheme;

5. Tax on the perquisite value, if any, shall be paid by the employee concerned on exercise of option or else it shall be deducted from his salary. Perquisite value for payment of tax shall be calculated as provided under the provisions of the Indian Income Tax Act, 1961;

6. The employee shall not have the right to receive any dividend or any other corporate benefits from the Company or to vote in any manner or enjoy the benefit of a shareholder in respect of the options granted to him, till the underlying shares are issued on exercise of options;

7. Option granted to an employee shall not be transferable to any person. It shall not be sold, pledged, assigned, hypothecated, transferred or disposed off in any manner. No person other than the employee to whom the option is granted shall be entitled to exercise the option except as provided under this scheme;

8. Employees who do not want to avail the Options granted to them under this Scheme, may opt out of the scheme any time before the Exercise Period and surrender the Options to the Company for cancellation. Such Options will be available for re – issuance under the Scheme;</td></tr>
</table>

Sl NO.	Particulars	Details
5	Maximum term of options granted	The ESOPs granted under ESOP 2025 shall have a fixed vesting period from the Grant Date of the ESOPs, which shall be inclusive of the minimum Vesting Period of 1 (One) year as required under the Applicable Laws. The exercise period shall commence from the date of vesting of options and expire not later than 5 (five) calendar years from the date of vesting of options. The Remuneration Committee may grant an extension upon a specific request made by the employee concerned to this effect, provided such extension is well within the tenure of the scheme. The scheme shall be deemed to have come into force on the 25.09.2025 and shall continue to be in effect for a term of 10 (Ten) years, unless all the options granted under the scheme are exercised or have been extinguished or unless the scheme is terminated applicable Clause of the scheme. If any options granted under the Scheme lapse / are forfeited, such options shall be available for further grant under the Scheme.
6	Source of shares (primary, secondary or combination)	Primary (Equity Shares)
7	Variation in terms of options	No variation
8	Method used to account for ESOS - Intrinsic or fair value	intrinsic method or Fair Value method
9	Where the company opts for expensing of the options using the intrinsic value of the options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognized if it had used the fair value of the options shall be disclosed. The impact of this difference on profits and on EPS of the company shall also be disclosed.	Not Applicable

10. Option movement during the FY 2025-26

Sl NO.	Particulars	Bal Pharma Limited Employee Stock Option Scheme – 2025
i	No. of Options outstanding at the beginning of the year	Nil. No any Options granted during Fy 2025-26
ii	Options Granted during the year	
iii	Options forfeited during the year	
iv	Options lapsed during the year	
v	Options vested during the year	
vi	Options exercised during the year	
vii	Number of shares arising as a result of exercise of Options	
viii	Money realized by exercise of options if scheme is implemented directly by the Company	
ix	Loan repaid by the Trust during the year from exercise price received	
x	No. of options outstanding at the end of the year	
xi	No. of options exercisable at the end of the year	

11. Other Details

a	Method of Accounting	Fair Value Method
b	Where the company opts for expensing of the options using the intrinsic value of the options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognized if it had used the fair value of the options shall be disclosed. The impact of this difference on profits and on EPS of the company.	Not applicable because the Company has accounted for employee compensation in books using the fair value of options.
c	Weighted-average exercise prices and weighted average fair values of options shall be disclosed separately for options whose exercise price either equals or exceeds or is less than the market price of the stock	Not Applicable
d	Any other employee who received a grant during the year, options amounting to 5% or more of option granted during the year:	Nil
e	Identified employees who were granted options during the year, equal to or exceeding 1% of the issued capital (excluding outstanding warrants and conversions) of the company at the time of grant:	Nil

12. Description of the method and significant assumptions used during the year to estimate the fair value of options including the following information

SI NO.	Particulars	Bal Pharma Limited Employee Stock Option Scheme – 2025
a	Weighted-average values of share price, exercise price, expected volatility, expected option life, expected dividends, the risk-free interest rate and any other inputs to the mode	Not Applicable
b	Method used and the assumptions made to incorporate the effects of expected early exercise	
c	How expected volatility was determined, including an explanation of the extent to which expected volatility was based on historical volatility	
d	Whether and how any other features of the option grant were incorporated into the measurement of fair value, such as a market condition	

13. Disclosures in respect of grants made in three years prior to IPO under each ESOS

Until all options granted in the three years prior to the IPO have been exercised or have lapsed, disclosures of the information specified above in respect of such options shall also be made : Not Applicable

Note: The earlier Bal Pharma Limited Employee Stock Option Scheme, 2014 has been successfully completed and no further options remain available for grant under the said scheme. Under this schemes no any options granted during Fy 2025-26.

14. Details related to ESPS: Not applicable

15. Details related to SAR: Not applicable

16. Details related to GEBS / RBS : Not applicable

17. Details related to Trust : Not applicable

for and on behalf of the board of directors of
Bal Pharma Limited

Place: Bengaluru
Date : 27th May, 2026

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh
Whole Time Director
DIN: 08554422

ESOP COMPLIANCE CERTIFICATE

[Pursuant to Regulation 13 of the Securities Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021]

To,
The Members
Bal Pharma Limited
Bangaluru

I, Parameshwar G Bhat, Practising Company Secretary, with a Peer Review Certificate No. – 5508/2024, have verified the relevant records and documents of Bal Pharma Limited (hereinafter referred to as 'the Company'), with CIN: L85110KA1987PLC008368and having its Registered Office at "21-22, Bommasandra, Industrial Area, Bommasandra Industrial Estate, Bangalore- 560099, Bangalore South, Karnataka, India". This Certificate is issued under the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (hereinafter referred to as "the Regulations"), for the financial year ended 31st March, 2026.

Management Responsibility:

It is the responsibility of the Management of the Company to implement the scheme(s) including designing, maintaining records and devising proper systems and effective internal controls to ensure compliance with the provisions of all applicable laws and regulations and to ensure that the systems are adequate and operate effectively.

Verification:

The Company has implemented Bal Pharma Limited Employee Stock OptionPlan -2025(hereinafter after referred to as the 'Scheme') in accordance with the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and applicable provisions of the Companies Act, 2013. The said Scheme has been duly approved by the shareholders of the Company by way of a special resolution at the 38th Annual General Meeting of the Company held on 25th September, 2025.

In-principle approvals for the same from both BSE Limited and National Stock Exchange of India Limited were received on 8th May, 2026. The Company has not made grants under the referred Scheme until the date of receipt of In-principle approvals from both the Exchanges.

For the purpose of verifying the compliances of the Regulations, I have examined the following documents:

1. ESOP Scheme of the Company;
2. The Articles of Association of the Company;
3. Minutes of the Meetings of the Board of Directors;
4. Minutes of the Meetings of the Shareholders;
5. Minutes of the Meetings of the Nomination and Remuneration Committee;
6. Detailed Terms and Conditions of the scheme as approved by Nomination and Remuneration Committee;
7. Relevant filings, disclosures, and compliances made with the Stock Exchange(s) for obtaining In-principle approvals.
8. In-principle approvals accorded by the BSE Limited and National Stock Exchange of India Limited.

Certification:

In my opinion and to the best of my knowledge and according to the verifications carried out as considered necessary and based on the information and explanations furnished to me by the Company and its Officers, I certify that the Company has implemented the aforesaid Scheme in accordance with the applicable provisions of the Regulations and the resolution passed by the Members of the Company.

Assumptions & Limitation of Scope and Review:

1. Ensuring the authenticity of documents and information furnished is the responsibility of the Board of Directors of the Company.
2. My responsibility is to issue this certificate based upon the examination of relevant documents and informationmade available to me. This engagement does not constitute an audit or an investigation.
3. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.
4. This certificate is issued solely for the purpose of compliance with the applicable Regulations and should not be used, circulated, quoted, or otherwise referred to for any other purpose without my prior written consent.

Parameshwar G Bhat
Practising Company Secretary
FCS: 8860 CP: 11004
Peer Review No.:5508/2024
UDIN: F008860H000428741

Place: Bangaluru
Date: 21.05.2026

CORPORATE GOVERNANCE REPORT FOR THE FINANCIAL YEAR 2025-2026

Company's Philosophy on Code of Governance

Your Company believes that Corporate Governance is an ethical business process that enables the Company to practice sound governance discipline, which enables the Board to direct and control the affairs of the Company in an effective manner and create value for all its stakeholders.

Corporate governance refers to a combination of laws, regulations, procedures, implicit rules and good corporate practices, which ensure that a Company meets its obligations with the objective to optimize shareholders value and fulfil its responsibilities to the shareholders, employees, customers, community, government and other societal segments.

Good Corporate governance is a reflection of its core values and principles, practices, policies and relationship with its stakeholders. The Corporate Governance framework of your Company is based on an effective Board with Non-Executive Directors, separation of the Board's supervisory role from the executive management team and constitution of the Board Committees, as required under law. Our Board is active, well-informed and independent, with clearly defined roles and responsibilities. It ensures that it is aligned with the best governance and sustainability practices. The Board also plays a pivotal role in guiding the evolution of culture and values in line with the changing times and the external environment. Your Company's Board has the right balance and breadth of backgrounds, business experience, skills and expertise in areas vital to its success, given the markets served and the stage of development.

The operations of the Company are conducted under the supervision and directions of the Board within the framework set by the Companies Act, 2013 and the Rules made there under ('the Act'), its Articles of Association, SEBI Guidelines, and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Listing Regulations').

This report is prepared in order to ensure compliance with the requirements stipulated under Regulations 17 to 27 read with Schedule V and clauses (b) to (i) of sub-regulation (2) of Regulation 46 of the Listing Regulations, as applicable, with regard to corporate governance.

1. BOARD OF DIRECTORS:

1.1 Composition:

The Board has an optimum combination of Executive and Independent Directors. The composition of the Board is in conformity with the applicable provisions of the Act and the Listing Regulations.

The Board of Directors of the Company consists of 6 Directors, including the Managing Director, 1 Whole Time Director, 1 Non-Executive Non Independent director , 1 Non-Executive Independent Woman Director and 2 Non-Executive Independent Directors.

Composition of the Board was as follows.

Sl. No.	Name of Director	DIN	Designation	Category
1.	Mr. Shailesh Siroya	00048109	Managing Director	Executive Director
2.	Mr. Himesh Virupakshaya	08554422	Whole Time Director	Executive Director
3.	Mr. Ravindra Kumar Kothari	03418320	Non Executive Director	Non-Executive, Non-Independent
4.	Ms. Nicola Neeladri	01997936	Independent Director	Non-Executive, Independent Director
5.	Mr. Jatish Sheth	00581963	Independent Director	Non-Executive, Independent Director
6.	Mr. Mukesh Bheekamchand	11295580	Independent Director	Non-Executive Independent Director

Particulars of Change in Directors during FY 2025-2026

Name	Date of appointment/ change in designation/ cessation	Designation at the beginning / during the financial year	Nature of change (Appointment/ Change in designation/ Cessation)
Mr. Ravindra Kumar Kothari	05.05.2025	Additional Non-Executive Director	Appointment
	31.07.2025	Non-Executive Director	Regularization (Change in Designation)
Mr. Kotian Chittananda Damodar	16.05.2025	Whole Time Director	Resignation
Mr. H S Venkatesh	30.09.2025	Independent Director	Completion of tenure
Mr. Mukesh Bheekamchand	13.11.2025	Additional Independent Director	Appointment
	07.02.2026	Independent Director	Regularization (Change in Designation)
Mr. Jatish Sheth	28.12.2025	Independent Director	Reappointed for Second Term
Mr. Himesh Virupakshaya	25.09.2025	Whole Time Director	Re-appointment (Retire by Rotate)

All the Independent Directors possess the requisite qualifications and are experienced in their own fields. None of the Directors hold directorship in more than Eight (8) Listed Companies or Ten (10) Public Limited Companies or act as Independent Director in more than Seven (7) Listed Companies. Further, none of the Directors are the members of more than ten committees or Chairperson of more than five Committees in Public Listed Companies in which they are Directors. Necessary disclosures have been obtained from all the Directors regarding their Directorship's and have been taken on record by the Board.

The Board of Directors confirms that all the Independent Directors of the Company fulfill the conditions specified under SEBI (LODR) Regulations, 2015 and are Independent of the Management of the Company.

1.2 Board Meetings:

During the financial year under review, 6 (Six) Board Meetings were held on 29.05.2025 11.08.2025, 12.11.2025 , 04.12.2025 , 11.02.2026 , and 18.03.2026 Composition of the Board, attendance of the members of the Board at the Board meetings and Annual General Meeting along with their Chairmanship/Membership on the Boards/Committees as on 31.03.2026, are as furnished below:

Sl. No.	Name of Director	Category	No. of Board Meeting attended during the year	Whether attended last AGM held on September, 25, 2025	Number of Directorships in other Public Companies as on		Number of Committee positions held in other Public Companies as on		Directorship in other listed entity (Category of Directorship) as on this Report
					As Chairman	As Member	As Chairman	As Member	
1.	Mr. Shailesh Siroya	Managing Director	6/6	Yes	0	0	0	0	0
2.	Mr. Himesh Virupakshya	Whole-Time Director	6/6	Yes	0	0	0	0	0
3.	Mr. H S Venkatesh $	Independent Director	2/2	Yes	0	2	1	2	1.Umiya Buildcon Limited Independent Director
4.	Ms. Nicola Neeladri	Independent Director	4/5	Yes	0	1	0	1	1. Umiya Buildcon Limited: Independent Director
5.	Mr. Jatish Sheth	Independent Director	6/6	Yes	0	0	0	0	0
6.	Mr. Kotian Chittananda Damodar @	Director	0/0	Yes	0	0	0	0	0
7.	Mr. Mukesh Bheekamchand #	Independent Director	2/3	Yes	0	0	0	0	0
8.	Mr. Mr. Ravindra Kumar Kothari *	Independent Director Non Executive Director	6/6	Yes	0	0	0	0	0

$ Retirement due to completion of tenure effect from 30.09.2025

@ Resigned with effect from 16.05.2025

Appointed with effect from 13.11.2025

* Appointment with effective from 05.05.2025

Notes:

1. Other directorships excludes Foreign Companies, Private Limited Companies and alternate Directorships.
2. Only membership in Audit Committee, Nomination and Remuneration Committee and Stakeholders' Relationship Committee have been reckoned for Committee Chairmanships/memberships.
3. All the Directors possess requisite qualifications, experience and expertise in leadership, Mentorship, Business ethics and vision to achieve the goals of the Company, which the Board has identified as key functional areas which a director should possess and which are in sync with the business and operations of the Company.
4. There are no inter-se relationships between the Board Members.

Declaration under Schedule V, Part C, Clause 10(I) of SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018:

All the Directors have confirmed that they are neither debarred nor disqualified from being appointed or continuing as Director by Securities and Exchange Board of India / The Ministry of Corporate Affairs or any such statutory authority. The Company has obtained a Certificate to this effect from Mr. Vijayakrishna K.T, Practicing Company Secretary, Bangalore as mandated under Schedule V, Part C, Clause 10(i) of SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018.

Brief profiles of the Directors are as follows:

i) Mr. Shailesh Siroya, Managing Director

Mr. Shailesh Siroya is the Chief Promoter and Managing Director of the Company and with over 30 years of pharmaceutical Industry experience. He is Post Graduate in Management Sciences from Akron University, Ohio, USA and is heading the Management team of the Company from the beginning.

ii) Mr. Himesh Virupakshaya, Executive Director

Mr. Himesh Virupakshaya is a qualified Chemical Engineer with over 37 years of experience in the field of manufacturing of API and has served several reputed pharmaceutical Companies including Bal Pharma Limited.

iii) Mr. H S Venkatesh, Independent Director #

Mr. H S Venkatesh is a Chartered Accountant by profession with over 40 years of experience in Audit, Finance, Fund Management and Statutory Compliance.

Retired with effect from 30.09.2025

iv) Ms. Nicola Neeladri, Independent Director

Ms. Nicola Neeladri is a graduate in Arts with over 15 years of experience in diverse businesses including the wellness industry.

v) Mr. Jatish Sheth, Independent Director

Mr. Jatish Sheth is a graduate having 30 years of Pharmaceutical Industry experience. He has been very actively associated with KDPMA- Karnataka Drugs and Pharmaceuticals Manufacturers' Association since twenty years, and has the credit of holding posts of Joint Secretary, Secretary and President and currently Managing Committee and Steering Committee member of KDPMA. He is also an Executive Member of the CII National Committee of Pharmaceuticals.

vi) Mr. Kotian Chittananda Damodar **

Mr. Kotian Chittananda Damodar is a graduate with over 34 years of experience in field of API & formulation, administration and Quality assurance in the pharmaceutical industries including Bal Pharma Limited.

** Resigned with effect from 16.05.2025

vii) Dr. Mukesh Bheekamchand (Appointment effective from 13.11.2025)

Dr. Mukesh Bheekamchand is doctor by profession and is associated with product development , commercialization of anti diabetic drugs.

viii) Mr. Ravindra Kumar Kothari (Appointment effective from 05.05.2025)

Mr. Kothari has experience of over 35 years in internal audit, legal and administration. He served in diverse industries across India.

In the Opinion of the Board, all the Independent Directors possess integrity, expertise and experience and are the person's of high repute. They fulfil the conditions specified in the Companies Act, 2013 and the rules made thereunder and are independent of the management.

Detailed Profiles of the Board of Directors of the Company are also uploaded on the website of the Company www.balpharma.com

1.3 Skills / expertise / competencies fundamental for the effective functioning of the Company currently available with the Board:

Based on the recommendation of the Committee, the Board re-affirmed the matrix setting out the skills/expertise/competence required for the Board in the context of the business and sector. The matrix inter-alia included areas such as Global Business, Strategy and Planning, Governance, Pharma Expertise, Finance and Accounts, Research and Development. As on the date of this Report, details of the Directors and their skills/expertise/competencies are following:

Skills/expertise/ competencies	Mr. Shailesh Siroya	Mr. Himesh Virupakshaya	Dr. Ravindra Kumar Kothari	Mr. Mukesh Bheekamchand	Ms. Nicola Neeladri	Mr. Jatish Sheth
Global Business	√	√	√	√	√	√
Strategy and Planning	√	√	√	√	√	√
Governance	√	√	√	√	√	√
Pharma Expertise or Industrial Knowledge	√	√	√	-	-	√
Finance and Accounts	√	-	√	√	√	√
Research and Development	√	-	√	-	-	√

The eligibility of a person to be appointed as a Director of the Company is dependent on whether the person possesses the requisite skill sets identified by the Board as above and whether the person is a proven leader in running a business that is relevant to the Company's business or is a proven academician in the field relevant to the Company's business. The Directors so appointed are from diverse backgrounds and possess special skills with regard to the industries / fields from where they come.

1.4 TRANSACTIONS OF THE BOARD

Board Meetings are governed by structured agenda. The Board, in consultation with the Chairman, may bring up any matter for consideration of the Board. All major agenda items are backed by information to enable the Board to make informed decisions. Agenda and all the supporting information/documents are circulated at least seven working days prior to the Board Meeting date.

The following are, among other things tabled before the Board for its periodic review/information/approval:

- Annual operating plans and budgets and any updates.
- Capital budgets and any updates.
- Quarterly results for the Company and its operating divisions or business segments.
- Minutes of Meetings of the Audit Committee and of Subsidiaries and other Committees of the Board.
- The information on recruitment and remuneration of senior officers just below the Board level, including appointment or removal of Chief Financial Officer and the Company Secretary.
- Show cause, demand, prosecution notices and penalty notices which are materially important.
- Fatal or serious accidents, dangerous occurrences, any material effluent or pollution problems.
- Any material default in financial obligations to and by the Company, or substantial non-payment of goods sold by the Company.
- Any issue, which involves possible public or product liability claims of substantial nature, including any judgement or order which, may have passed strictures on the conduct of the Company or taken an adverse view regarding another enterprise that can have negative implications on the company.
- Details of any joint venture or collaboration agreement.
- Transactions which involve any substantial payment towards goodwill, brand equity or intellectual property.
- Significant labour problems and their proposed solutions. Any significant development in Human Resources/ Industrial Relations front like signing of wage agreement, implementation of Voluntary retirement Scheme etc.
- Sale of investments, subsidiaries, assets which are material in nature and not in normal course of business
- Quarterly details of foreign exchange exposures and the steps taken by management to limit the risk of adverse exchange rate movement, if material.
- Non-Compliance of any regulatory, statutory or listing requirements and Shareholder services such as non-payment of dividend, delay in share transfer etc.

2. AUDIT COMMITTEE:

Audit Committee functions in accordance with Regulation 18 read with Part C of Schedule II of SEBI (LODR) Regulations, 2015 and in accordance with Section 177 of Companies Act, 2013 read with the relevant Rules made thereunder.

2.1 The terms of reference broadly include:

- Review of internal Audit Reports and action taken reports.
- Assessment of the efficiency of internal control systems/ financial reporting systems and reviewing the efficiency of the financial policies and the practices followed by the Company.
- Review of the compliances with the legal and statutory requirements, the quarterly and annual financial statements, audit reports and related party transactions and report its findings to the Board.
- Recommendation for of the appointment of the Chief Financial Officer, Internal Auditor, Statutory Auditor, and Cost Auditor and remuneration thereof.
- Noting of any default in the payments to Creditors and Shareholders.
- Compliances/matters relating to accounting standards, policies, financial statements.
- Such other matters as may be specifically referred to it by the Board.

2.2 The composition and changes in Audit Committee during the financial year ended 31st March, 2026 are as follows:

Sl. No.	Name & Designation of the Member	Category
1.	Mr. Jatish Sheth, Chairman	Independent Director
2.	Mrs. Nicola Neeladri, Member	Independent Director
3.	Dr. Mukesh Bheekamchand, Member	Independent Director

Particulars of Change in Committee Composition during FY 2025-2026

1. Mr. H S Venkatesh was Chairman of the audit Committee Upto 30.09.2025.
2. Dr. Mukesh Bheekamchand Appointed as a Member of the Audit Committee with effect from 24.11.2025
3. Mr. Jatish Sheth appointed as Chairman of audit Committee with effect from 01.10.2025.

   As on 31st March, 2026, the Committee comprised of three Independent Directors all of whom are financially literate and have relevant finance/ audit exposure.

The Company Secretary acts as the Secretary to the Committee.

The composition of the Audit Committee is as per the SEBI (LODR) Regulations, 2015. Chairman of the Audit Committee was present at the previous Annual General Meeting of the Company held on 25th September, 2025.

The Audit Committee met four (4) times during the year on 29.05.2025, 11.08.2025, 12.11.2025 and 11.02.2026. The details are as follows:

Sl. No.	Name of the Member	Number of Meetings entitled to attend	No. of Meetings attended
1	Mr. H S Venkatesh $, Chairman	2	2
2	Mrs. Nicola Neeladri , Member	4	4
3	Dr. Mukesh Bheekamchand # , Member	1	1
4	Mr. Jatish Sheth *, Chairman	4	4

$ Retirement due to completion of tenure effect from 30.09.2025

Member with effect from 24.11.2025

* Chairman with effect from 01.10.2025

3. NOMINATION AND REMUNERATION COMMITTEE:

The Nomination and Remuneration Committee functions in accordance with Regulation 19 read with Part D (A) of Schedule II SEBI (LODR) Regulations, 2015 and in accordance with Section 178 of Companies Act, 2013 read with the relevant Rules made thereunder.

3.1 The terms of reference broadly include:

- To guide the Board in relation to appointment and removal of the Directors, Key Managerial Personnel and Senior Management.
- To evaluate the performance of the Board and provide necessary report to the Board for further evaluation of the Board.
- To recommend to the Board on Remuneration payable to the Directors, Key Managerial Personnel and Senior Management.
- To provide to Key Managerial Personnel and Senior Management reward linked directly to their effort, performance, dedication and commitment relating to the Company's operations.
- To retain, motivate and promote talent and to ensure long term sustainability of talented managerial persons and create competitive advantage.
- To devise a policy on Board diversity.
- To develop a succession plan for the Board and to regularly review the plan.

3.2 The composition and changes in Nomination and Remuneration Committee during the financial year ended 31st March, 2026 are as follows:

Sl. No.	Name & Designation of the Member	Category
1	Mr. Jatish Sheth, Chairman	Independent Director
2.	Mrs. Nicola Neeladri, Member	Independent Director
3.	Dr. Mukesh Bheekamchand, Member	Independent Director
4.	Mr. Ravindra Kumar Kothari , Member	Non-Executive Director

<u>Particulars of Change in Committee Composition during FY 2025-2026</u>

1. Mr. H S Venkatesh was Chairman of the NRC Upto 30.09.2025.
2. Dr. Mukesh Bheekamchand Appointed as a Member of the NRC with effect from 24.11.2025
3. Mr. Ravindra Kumar Kothari Appointed as a Member of the NRC with effect from 01.10.2025
4. Mr. Jatish Sheth appointed as Chairman of NRC with effect from 01.10.2025.

The Nomination and Remuneration Committee met three (3) times during the year on 29.05.2025, 11.08.2025 and 12.11.2025. The details are as follows:

Sl. No.	Name of the Member	Number of Meetings entitled to attend	Number of Meetings attend
1	Mr. H S Venkatesh $	2	2
2	Mrs. Nicola Neeladri	3	3
3	Mr. Ravindra Kumar Kothari @	1	1
4	Mr. Jatish Sheth *	3	3
5	Dr. Mukesh Bheekamchand, #	0	0

$ Retirement due to completion of tenure effect from 30.09.2025

@ Member with effect from 01.10.2025

* Chairman with effect from 01.10.2025

Member with effect from 24.11.2025

3.3 Remuneration Policy:

The Company framed a detailed Remuneration Policy as per the requirements of the Companies Act, 2013.The policy is available on the website of the Company www.balpharma.com.

3.4 The Nomination and Remuneration Committee is also authorized to function as 'Compensation Committee' under the SEBI (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 for Bal Pharma Limited Employee Stock Option Plan -2025.

3.5 The Remuneration paid to Mr. Shailesh Siroya (Managing Director), Mr.V Himesh (Whole Time Director), Mr. Kotian Chittananda Damodar (Whole Time Director), Mr. Ravindra Kumar Kothari (Non-Executive Directors) and sitting fee paid to Independent Directors, during the year are as under:

SL No.	Particulars	Mr. Shailesh Siroya	Mr. Himesh	Mr. Ravindra Kumar Kothari	Mr. H S Venkatesh	Mrs. Nicola Neeladri	Mr. Jatish Sheth	Mr. Kotian C D	Dr. Mukesh Bheekamchand
1.	Salary and Perquisites	₹.1,80,00,000	₹.19,05,000	78,000	NA	NA	NA	₹.1,481,000	NA
2.	Sitting Fees	NA	NA	NA	₹.74,000	₹.61,000	₹.74,000	NA	₹.55,000
	TOTAL	**₹.1,80,00,000**	**₹.19,05,000**	**₹.78,000**	**₹.74,000**	**₹.61,000**	**₹.74,000**	**₹.1,481,000**	**₹.55,000**

Remuneration paid to Whole Time Directors, KMPs and Employees of the Company is based on the Remuneration policy adopted by the Company.

3.6 There were no pecuniary relationships or transactions of the Non-Executive Directors vis-a-vis the Company during the Financial Year ended 31st March, 2026.

3.7 Details of Equity Shares held by Non- Executive Directors as on 31.03.2026

Sl. No.	Director	No. of Equity Shares held
1	Mrs. Nicola Neeladri	NIL
2	Mr. Jatish Sheth	NIL
3	Dr. Mukesh Bheekamchand, Member	NIL
4	Mr. Ravindra Kumar Kothari	2,437

4. STAKE HOLDERS' RELATIONSHIP COMMITTEE:

The Stakeholder's relationship Committee functions in accordance with Regulation 20 read with Part D (B) of Schedule II SEBI (LODR) Regulations, 2015 and in accordance with Section 178 of Companies Act, 2013 read with the relevant Rules made thereunder.

4.1 The composition and changes in Stakeholder's relationship Committee during the financial year ended 31st March, 2026 are as follows::

Sl. No.	Name &Designation of the Member	Category
1	Mrs. Nicola Neeladri, Member	Independent Director
2	Mr. Jatish Sheth, Chairman	Independent Director
3	Mr. Shailesh Siroya, Member	Executive Director
4	Dr. Mukesh Bheekamchand , Member	Independent Director
5	Mr. Ravindra Kumar Kothari, Member	Non-Executive Director

<u>Particulars of Change in Committee Composition during FY 2025-2026</u>

1. Mr. H S Venkatesh was Chairman of the SRC Upto 30.09.2025.
2. Dr. Mukesh Bheekamchand Appointed as a Member of the SRC with effect from 24.11.2025
3. Mr. Ravindra Kumar Kothari Appointed as a Member of the SRC with effect from 01.10.2025
4. Mr. Jatish Sheth appointed as Chairman of SRC with effect from 01.10.2025.

4.2 The Stakeholder's Relationship Committee met once during the year on 11-02-2026.

Sl. No.	Name of the Member	Number of Meetings entitled to attend	No. of Meetings attended
1.	Mr. H S Venkatesh $	0	0
2.	Mr. Shailesh Siroya	1	1
3.	Mr. Jatish Sheth *	1	1
4.	Mrs. Nicola Neeladri	1	1
5.	Dr. Mukesh Bheekamchand #	1	1
6	Mr. Ravindra Kumar Kothari @	1	1

$ Retirement due to completion of tenure effect from 30.09.2025
* Chairman with effect from 01.10.2025
# Member with effect from 24.11.2025
@ Member with effect from 01.10.2025

4.3 Investor Queries/Requests/ Complaints handled:

Year	Outstanding as on 31.03.2025	Received during the FY 2025-2026	Resolved during the FY 2025-2026	Pending as on 31.03.2026
2024-2025	NIL	0	0	0

5. CORPORATE SOCIAL RESPONSIBILITY (CSR) COMMITTEE:

During the Financial year 2025-26, Corporate Social Responsibility Committee has been dissolved by the Board , as per the provisions of section 135(9) of Companies Act, 2013, as the amount to be spent under CSR is below 50 lakhs for the F.Y 2025-26.
Henceforth, the Board of Directors of the Company will decide on the CSR activities and budget allocations for the same.

6. OTHER COMMITTEES:

6.1 Banking Transactions Committee.

Considering the size and the continuous growth of both the Company and its banking transactions, a Sub-Committee of Board, named as Banking Transactions Committee was constituted on 30th April, 2006 for approving specific banking transactions, as below:

- To review periodically the banking transactions of the Company;
- To open new bank accounts for the business purposes of the Company, wherever required;
- To close bank accounts of the Company, where required
- To change signatories to the bank accounts of the Company, where required;
- To borrow funds from various Banks and financial institutions, within the limits prescribed towards working capital and for purchase of movable and immovable assets and to create charge of these assets.

The composition and changes in Banking Transaction Committee during the financial year ended 31st March, 2026 are as follows:

Sl. No.	Name &Designation of the Member	Category
1	Mr. Shailesh Siroya, Chairman	Executive Director
2	Mr. V Himesh , Member	Executive Director
3	Mr. Ravindra Kumar Kothari, Member	Non-Executive Director

Particulars of Change in Committee Composition during FY 2025-2026

1. Mr.Kotian C.D was resigned with effect from 16.05.2025.
2. Mr.Ravindra Kumar Kothari Appointed as a Member of the BTC with effect from 29.05.2025

7. MEETING OF INDEPENDENT DIRECTORS:

The Independent Directors of the Company met on 11.02.2026, to review the performance of Non-Independent Directors and the Board as a whole, to review the performance of the Chairperson of the Company and has assessed the quality, quantity and timeliness of flow of information between the Company Management and the Board.

8. GENERAL MEETINGS:

ANNUAL GENERAL MEETING:

8.1 The details of the last three Annual General Meetings held are as follows:

Financial Year	Date	Time	Location
2024-2025 (38th AGM)	25.09.2025	11.30 A.M	Through Video Conference/Audio Visual Means
2023-2024 (37th AGM)	25.09.2024	11.30 A.M	Through Video Conference/Audio Visual Means
2022-2023 (36th AGM)	25.09.2023	10.30 A.M	Through Video Conference/Audio Visual Means

8.2 The Special Resolutions passed by the Company in its 36th,37th and 38th AGMs are as under

Date of AGM	AGM No.	Business Transacted by Special Resolution
25-09-2025	38th	1.To appoint Mr. Jatish Sheth (DIN# 00581963) as an Independent Director of the Company for second term of Five year. 2.To approve "Bal Pharma Limited – Employee Stock Option Plan – 2025.
25-09-2024	37th	1.To re appoint Mr. Himesh Virupakshya (DIN # 08554422) as Whole-time Director of the Company and to fix his remuneration 2.To re appoint Mr. Shailesh Siroya (DIN # 00048109) as Managing Director of the Company and to fix his remuneration 3. Reclassification of the promoter group
25-09-2023	36th	1.To renew contract with Desa Marketing International.

8.3 E-Voting:

The Company has entered into a tripartite agreement with National Securities Depository Ltd (NSDL) and MUFG Intime India Private Limited, Mumbai (R&T agents) to enable the company's securities to be held and traded in dematerialized (demat) form.

NSDL is appointed as the agency for providing e-voting facility to shareholders at the 39th AGM, as specified in Section 108 of the Companies Act, 2013 and Regulation 44 of the SEBI(LODR) Regulations,2015.

8.4 Postal Ballot:

The Company has passed following resolutions by way of Postal Ballot during the Financial year 2025 -2026.

a. Appointment of Dr. Mukesh Beekamchand (DIN 11295580) as Non-Executive Independent Director of the Company, for a period of 5 (five) years.

b. Appointment of Mr. Ravindra Kumar Kothari (DIN# 03418320) as Non independent and Non-executive Director of the Company for a term of 5 years.

9. SUBSIDIARY /ASSOCIATE COMPANIES:

During the year under review, Lifezen Healthcare Private Limited, Bal Research Foundation, Balance Clinics LLP, Aurum Research & Analytical Solutions Private Limited continued to be the Subsidiaries of the Company.

*With effect from 26.03.2025 pursuant to the final order of Honourable NCLT Bench Bengaluru, Golden Drugs Private Ltd got amalgamated with Bal Pharma Limited and ceased to be a subsidiary of Bal Pharma Limited.

Material Subsidiary

As per Regulation 16(1)© of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a "Material Subsidiary" means a subsidiary whose turnover or net worth exceeds 10% of the consolidated turnover or net worth, respectively, of the listed entity and its subsidiaries in the immediately preceding accounting year.

Based on the above criteria, the Company did not have any Material Subsidiary during the financial year 2025-26. Accordingly, the requirements applicable to Material Subsidiaries under the SEBI (LODR) Regulations, 2015 were not applicable to the Company during the said financial year.

10. WHISTLE BLOWER POLICY:

The Company promotes ethical behavior in all its business activities and has put in place mechanism of reporting illegal or unethical behavior.

As per the requirements of the SEBI (LODR) Regulations, 2015, the Company has issued a circular including its employees, about their right to access the Audit Committee or its Chairman for the purpose of bringing to the Committee's notice any unethical or improper practices in the Company. The Company affirms that no employee has been denied access to the Audit Committee. The Audit Committee, Directors and Management personnel are obliged to maintain confidentiality of such reporting and ensure that the whistle blowers are not subjected to any discrimination.

11. DISCLOSURES:

11.1 Related Party Transactions:

There have been no materially significant related party transactions with the Company's Promoters, Directors, or relatives, the Management, their Subsidiaries, which may have potential conflicts with the interest of the Company at large.

The Company has also formulated a policy for determining the material Related Party Transactions and detail of such policies for dealing with related party and the related party transactions are disseminated in the website of the Company www.balpharma.com

11.2. Compliances:

The Company has complied with all the laws/statutes applicable to it during the year under review.

11.3. Demat suspense Account:

As the Company do not have any outstanding /unclaimed shares, we have not reported the details of the outstanding shares in the demat suspense account.

11.4: Transfer of shares to IEPF Suspense Account:

During the year under review, the Company has transferred 10,915 equity shares of the shareholders, whose dividend is outstanding for 7 years and above, to the IEPF suspense account, as per the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016.

Shareholders holding shares in physical form are advised to encash their Dividend on time to avoid transfer of their shares to IEPF a/c.

11.5 Disclosure under the sexual harassment of Women at workplace (Prevention, Prohibition and Redressal) Act, 2013:

Details are already mentioned in Board Report, forming part of the Annual Report.

12. MEANS OF COMMUNICATION:

The Unaudited quarterly financial results of the Company are published in newspapers such as Financial Express, Bengaluru & Mumbai editions and Sanjivani newspaper, Bengaluru Edition.The financial results are uploaded on the website on periodic intervals for the benefit of shareholders.

The financial results and other information about the Company were disseminated to the Stock Exchanges for its up dation on their respective websites.

Pursuant to the SEBI (LODR) Regulations, 2015, all data related to quarterly financial results, shareholding pattern, etc. are filed in NEAPS within the time frame prescribed in this regard.

No presentations have been made to institutional investors or to analysts during the year under review.

13. RISK MANAGEMENT:

Risk Management is attempting to identify and then manage threats that could severely impact organizational effectiveness. Generally, this involves reviewing operations of the organization, identifying potential threats to the organization and the likelihood of their occurrence, and then taking appropriate actions to address the most likely threats.

The Company has constituted the Risk Management Committee with various functional heads of the Company and the Company Secretary, as its members.

14. GENERAL INFORMATIONS TO SHAREHOLDERS:

Annual General Meeting: (2025 – 2026): 24.09.2026

Date of Incorporation	May 19, 1987.
CIN	L85110KA1987PLC008368
Date and time of the 39thAnnual General meeting.	24-09-2026
Venue of Annual General Meeting	Through Video Conference ("VC") / other Audio Visual Means("OAVM")
Date of Book Closure	Friday, 18th September, 2026 to Thursday, 24th September, 2026 (both days inclusive)
Financial Year	1st April, 2025 - 31st March, 2026.

b) Financial Calendar 2026-27 (tentative):

Financial reporting for the first quarter ended on 30.06.2026	On or before 13th August 2026
Financial reporting for the second quarter ended on 30.09.2026	On or before 14th November 2026
Financial reporting for the third quarter ended on 31.12.2026	On or before 14th February 2027.
Financial reporting for the quarter &year ended on 31.03.2027	On or before 30th May,2027.

c) Particulars of Payment of Dividend for the year ended 31.03.2026:

Date of Declaration (if approved at the General Meeting)	24.09.2026.
Rate of Dividend (proposed)	Rs.1.20 per equity share of Rs.10 each i.e 12%
Book Closure Date	Friday, 18th September, 2026 to Thursday, 24th September,
	2026 (both days inclusive)
Record Date / Cut-off date for Payment of Dividend	17.09.2026
Date of payment of dividend (subject to approval at the general meeting)	on / before 24th October 2026
Amount of dividend to be paid	Rs 1,91,05,046.40
Share Capital (in Rs)	Rs.15,92,08,720.00

d) Listing of Shares:

Name of the Stock Exchange	Stock Code
BSE Ltd (BSE)	524824
National Stock Exchange of India Ltd (NSE)	BALPHARMA
ISIN Number	INE083D01012.

The listing fees for the F.Y ended 2026 have been paid for the above Stock Exchanges.

e) Market Price Data:

Monthly high and low quotations as well as the volume of shares traded at National Stock Exchange of India Limited during F.Y 2025-2026 are as under:

Month	High Price Rs	Low Price Rs	Traded volume of (in Lakhs)	Traded volume of (in Lakhs)
Apr-25	128.74	85.60	39.81	4,655.44
May-25	103.50	91.50	6.89	674.47
Jun-25	111.18	96.50	6.26	643.06
Jul-25	104.50	94.84	3.28	327.50
Aug-25	102.99	84.98	3.33	302.84
Sep-25	93.79	82.46	7.29	635.78
Oct-25	90.30	80.00	3.85	323.10
Nov-25	83.96	73.30	1.71	134.51
Dec-25	79.50	69.00	1.70	124.62
Jan-26	78.10	65.70	1.58	112.01
Feb-26	81.50	66.00	2.66	198.78
Mar-26	75.90	60.00	2.61	178.50

Monthly high and low quotations as well as the volume of shares traded at BSE Limited, during 2025-2026 are as under:

Month	High Price	Low Price	No.of Shares	No. of Trades	Total Turnover (Rs.)	Deliverable Quantity
Apr-25	128.86	88.9	401552	7637	45041860	254586
May-25	104.85	93	52685	3500	5193049	39166
Jun-25	109.9	96.4	50630	2158	5157181	38371
Jul-25	104.3	93.3	30859	1711	3072723	24580
Aug-25	112.97	85.1	65586	2127	5975184	33865
Sep-25	95.4	82	88230	3443	7700834	69197
Oct-25	90.24	76.6	58290	1092	4936231	27482
Nov-25	84.29	74	41227	1261	3240843	33741
Dec-25	79.02	67.15	33009	1162	2394612	28552
Jan-26	76.8	65.01	52139	850	3736236	41831
Feb-26	83.9	64	19251	832	1426611	17175
Mar-26	76.95	59.69	76036	674	5034432	69967

f) Distribution of Shareholding as on 31.03.2026:

SL. NO.	Shares Range			Number of Shareholders	% of Total Shareholders	Total Shares for the Range	% of Issued Capital
1	1	to	500	13935	89.9090	1324283	8.3179
2	501	to	1000	828	5.3423	671269	4.2163
3	1001	to	2000	378	2.4389	579027	3.6369
4	2001	to	3000	107	0.6904	272224	1.7099
5	3001	to	4000	59	0.3807	209553	1.3162
6	4001	to	5000	41	0.2645	192076	1.2064
7	5001	to	10000	74	0.4775	523762	3.2898
8	10001	to	15920872	77	0.4968	12148678	76.3066
			Total	**15499**	**100.0000**	**15920872**	**100.0000**

g) Categories of Shareholders as on 31.03.2026:

Category	Demat Securities	Demat Holders	Physical Securities	Physical Holders	Total Securities	Total Holders	%-Issued Capital
Corporate Bodies (Promoter Co)	2011736	2	0	0	2011736	2	12.6358
Clearing Members	6721	8	0	0	6721	8	0.0422
Other Bodies Corporate	79008	41	101	2	79109	43	0.4969
Escrow Account	0 0	100	1	100	1	0.0006	
Foreign Promoters	655187	3	0	0	655187	3	4.1153
Hindu Undivided Family	415423	267	0	0	415423	267	2.6093
Non Resident Indians	1876994	81	4500	2	1881494	83	11.8178
Non Resident (Non Repatriable)	42835	68	5000	1	47835	69	0.3005
Public	5142921	14521	79420	486	5222341	15007	32.8019
Promoters	5430259	9	0	0	5430259	9	34.1078
Body Corporate - Ltd Liability Partnership	6282	4	0	0	6282	4	0.0395
FPI (Corporate) - I	20661	1	0	0	20661	1	0.1298
Investor Education And Protection Fund	142819	1	0	0	142819	1	0.8971
FPI (Individual) - II	905 1	0	0	905	1	0.0057	
TOTAL :	**15831751**	**15007**	**89121**	**492**	**15920872**	**15499**	**100**

h) Detail of shares held in Demat and Physical form as on 31.03.2026:

Name of the Depository	Number of shares held	% of share held
NSDL	11091950	69.67
CDSL	4739801	29.77
Physical	89121	0.56
Total	15920872	100

i) Share Transfer System:

MUFG Intime India Private Limited Mumbai, is the Share Transfer Agent of the Company for transfer of the Company's shares. Shares are tradable in the electronic form only.

The Demat requests are being processed within 21 days from the date of request. The Shareholder's relationship Committee whose terms of reference include approving physical transfer of shares, meets as and when required.

j) Details of the outstanding amounts in the unpaid Dividend accounts: (As on 31.03.2026)

Year	Outstanding amount in Rs. Lakh
2018-19	2.06
2020-21	1.56
2021-22	1.10
2022-23	0.98
2023-24	1.36
2024-25	1.30
Total	**8.36**

As per Section 125 of the Companies Act, 2013, dividends which remain unclaimed for a period of seven years from the date of declaration are required to be transferred to the Investor Education and Protection Fund (IEPF) administered by the Central Government. Shares pertaining to such unpaid dividends outstanding for 7 consecutive years are also liable for transfer to IEPF a/c.

Shareholders are advised to en-cash their dividend before the due date for transfer of unclaimed dividend amount to IEPF account.

Shareholders holding shares in electronic form are requested to deal only with their Depository Participant in respect of change of address, nomination facility and furnishing bank account number, etc.

k) Request to Shareholders:

Shareholders are requested to follow the general safeguards/ procedures as detailed here under in-order to avoid risks, while dealing in the securities of the Company.

Shareholders are requested to convert their physical holding of share certificates into demat /electronic form through any of the DP's (Depository Participants) to avoid any possibility of the loss, mutilation etc, of physical share certificates and also to ensure safe and speedy transaction in securities. As per the notification of SEBI, transfer of physical shares lodged for transfer will not be processed by the R&T agents from 1st April 2019 onwards. Hence, the shareholders are advised to convert their shareholding into electronic form in order to avoid any possible hurdles in the transfer process.

Shareholders holding shares in physical form should communicate the change of address, if any, directly to the Registrar and Share Transfer Agent of the Company.

It has become mandatory for transferees to furnish a copy of Permanent Account Number for registration of transfer of Shares held in physical mode.

Shareholders holding Shares in physical form who have not availed nomination facility and would like to do so are requested to avail the same, by submitting the Nomination Form SH-13. Those holding shares in electronic form are advised to contact their Dp's.

As required by SEBI, it is advised that the shareholder furnish details of their bank account for incorporating the same in the dividend warrants. This would avoid credits being given to the unauthorized persons.

l) Reconciliation of Share Capital Audit:

Quarterly audit was conducted by a Practicing Company Secretary, reconciling the issued and listed capital of the Company with the aggregate of the number of shares held by investors in the depositories and the said certificate were submitted to the Stock Exchange within the prescribed time limit. As on 31st March, 2026 there was no difference between the issued capital and the listed capital and the aggregate of shares held by investors in both physical and electronic form with the depositories.

m) Details of Credit Ratings obtained by the Company along with any revision.

The discipline with which the Company conducts its financial transactions is reflected in the BBB- stable rating given by the credit rating agency Acute for the financial year 2025-26.

Sl. No.	Bank Limits Rated	Credit Rating assigned
1.	Fund based Limits	BBB- Stable
2.	Non-fund-based limits	A3
3.	Term Loan	BBB- Stable

n) Other Disclosures

Details of total fees for all services paid by the Company to the statutory auditors and all entities in the network firm / network entity of which the statutory auditor have been included in notes to the financial statements which forms part of the Annual Report.

Policy for determining material subsidiary is available on the Company's website https://www.balpharma.com.

o) Details of non-compliance by the listed entity, penalties, structures imposed on the listed entity by stock exchanges or the board or any statutory authority, on any matter related to capital markets, during the last 3 years

The Board acknowledges the observations made by the Practising Company Secretary in Corporate Governance Certificate regarding the temporary non-compliance with the composition requirements under Regulations 17(1), 18(1) and 19(1)/19(2) of the SEBI (LODR) Regulations, 2015 during the third quarter of the Financial Year 2025-26.

The non-compliance related to the composition of the Board for 43 days and the Statutory Committee for 3 days, respectively. The deviation arose due to changes in the composition of the Board during the relevant period. The Company thereafter took necessary corrective measures to ensure compliance with the applicable requirements. The fines imposed by BSE Limited and National Stock Exchange of India Limited in this regard were duly paid on May 15, 2026, within the stipulated timeline. The Board has taken note of the matter and has advised that necessary measures be continued to ensure compliance with the applicable regulatory requirements.

p) Locations of manufacturing Units:

1) Unit 1 (Formulations)
21 & 22, Bommasandra Industrial Area
Bangalore-560099.

2) Unit 2 (API & Intermediates)
61/B, Bommasandra Industrial Area
Bangalore-560099.

3) Unit 3 (Parenterals) (temporarily in-operational)
732/735, Off National Highway No.4
Village Kenjal-412217,
Dist Bhor. Maharashtra.

4) Unit 4 (Formulations)
Plot # 1,2,3 & 69, Sector 4, IIE-Pantnagar
Rudrapur, Udham Singh Nagar-263153
Uttarakhand.

5) Unit 5 (API's and Intermediates)
Thabadewadi Post, KavathaMahankal
Sangli-416405
Maharashtra.

6) Unit 6 (API and Intermediates)
#C-155, Mewar Industrial Area
Madri, Udaipur-313001.
Rajasthan.

q) Address for Correspondence:
Company Secretary & Compliance Officer
Bal Pharma Limited,
Corporate Office:
5th Floor, 'Lakshmi Narayan Complex',
10/1, Palace Road, Bengaluru – 560053.
Tel: 080 - 41379500 Fax: 080 - 22354057
Email: secretarial@balpharma.com.

r) Registrar & Transfer Agents:
MUFG Intime India Private Limited, C 101, Embassy 247,
L.B.S. Marg, Vikhroli (West) MUMBAI - 400 083
Email: rnt.helpdesk@ in.mpms.mufg.com

Shareholders can also contact the branch offices/Agencies of MUFG Intime India Private Limited whose addresses are given below:

MUFG Intime India Private Limited, Surya 35, Mayflower Avenue, Behind Senthil Nagar, Swordplay Road, Coimbatore - 641 028. Phone: +91 422 2314 792 & Email: Coimbatore@ in.mpms.mufg.com.

MUFG Intime India Private Limited, Noble Heights, 1st floor, Plot No NH-2, C-1 Block, LSC, Near Savitri Market, Janakpuri, New Delhi - 110 058. Phone: +91 11 4141 0592/93/94, Telefax: +91 11 4141 0591, Email: Delhi@ in.mpms.mufg.com.

MUFG Intime India Private Limited, Vaishno Chamber,5th Floor, Flat Nos-502 & 503, No. 6, Brabourne Road, Kolkata - 700 001. Phone: +91 33 4004 9728 /+91 33 4073 1698, Telefax: +91 33 4073 1698, Email: kolkata@ in.mpms.mufg.com.

MUFG Intime India Private Limited, Block No. 202,2nd Floor, Akshay Complex, Near Ganesh Temple, Off Dhole Patil Road, Pune - 411 001. Phone: +91 20 4601 4473, Telefax: +91 20 2616 3503, Email: pune@ in.mpms.mufg.com.

MUFG Intime India Private Limited, 5th Floor,506 TO 508, Amarnath Business Centre–I (ABC-1), Beside Gala Business Centre, Nr.St. Xavier's College Corner, Off CG Road, Ellisbridge, Ahmedabad-380 006. Phone: +91 7926465179, Email:Ahmedabad@ in.mpms.mufg.com.

MUFG Intime India Private Limited, Geetakunj,1, Bhakti nagar society, BEHIND ABS TOWER, Old padra road, Vadodara – 390 015. Phone: +91 265 3566 768, Email: vadodara@ in.mpms.mufg.com.

MUFG Intime India Private Limited.' has implemented various investor initiatives given below as part of their constant endeavor to enhance investor servicing:

Investor Service portal:

'SWAYAM' is a secure, user-friendly web-based application developed by our RTA, that empowers investors to effortlessly access various services. Investors are requested to get registered and have first-hand experience of the portal. This application can be accessed at https://swayam.mufg.co.in

Chatbot

'iDIA' is a Chatbot developed by our RTA, that utilizes conversational technology to provide investors with a round-the-clock intuitive platform to ask questions and get information about queries. Talk to iDIA by logging in to www.mufg.co.in

FAQs

The FAQ section on their website has very detailed answers to almost all probable investor queries. Please visit https://liiplweb.linkintime.co.in /faq.html to find answers to your queries related to securities.

Tax Exemption Form submission –

You can submit your Tax exemption forms through online services on their website. Please visit https://liiplweb.mufg.co.in /formsreg/submission-of-form-15g-15h.html.

for and on behalf of the board of directors of
Bal Pharma Limited

Place: Bengaluru
Date : 27th May, 2026

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh Virupakshya
Whole Time Director
DIN: 08554422

CG Report Enclosures: (Integral Part of the Corporate Governance Report)

- CG Report Enclosure A : Certificate affirming compliance with the Code of Conduct
- CG Report Enclosure B : CEO and CFO Certificate
- CG Report Enclosure C : Practicing Company Secretary Certificate confirming compliance with Corporate Governance requirements
- CG Report Enclosure D : Practicing Company Secretary Certificate confirming on clause 10 of schedule V of (LODR), Reg, 2015

CG Report Enclosure A: Certificate affirming compliance with the Code of Conduct

DECLARATION BY MANAGING DIRECTOR ON CODE OF CONDUCT AS PER REGULATION 34(3) OF SEBI (LODR) REGULATIONS, 2013

To,
The Members
Bal Pharma Limited
Bangaluru.

I hereby declare that to the best of my knowledge and information, all the Board Members and Senior Management Personnel have affirmed compliance with the Code of Conduct of Board of Directors and Senior Management for the year ended March 31, 2026.

Shailesh Siroya
Managing Director
Din: 00048109

Place: Bengaluru
Date: 27.05.2026

CG Report Enclosure B : CEO and CFO Certificate

To
The Board of Directors
Bal Pharma Limited
Bangaluru.

SUB: CEO & CFO Certification.
Ref: As per Regulation 17(8) of SEBI (LODR) Regulations.

A. We have reviewed financial statements and cash flow statement for the year ended 31.03.2026 and that to the best of our knowledge and belief:

i) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;

ii)these statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.

B. There are, to the best of our knowledge and belief, no transactions entered into by the listed entity during the year which are fraudulent, illegal or violative of the Company's code of conduct.

C. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the listed entity pertaining to financial reporting and we have disclosed to the auditors and the audit committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.

D. We have indicated to the Aauditors and the Audit Committee:

(1)significant changes in internal control over financial reporting during the year;

(2)significant changes in accounting policies during the year to date and that the same have been disclosed in the notes to the financial statements; and

(3) instances of significant fraud of which we have become aware and involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

Shailesh Siroya
Chief Executive Officer /MD
Din: 00048109

Bharath Bhushan D V
Chief Financial Officer

Date: 27.05.2026
Place: Bangaluru

CG Report Enclosure C : Practicing Company Secretary Certificate confirming compliance with Corporate Governance requirements

CERTIFICATE ON COMPLIANCE WITH THE CONDITIONS OF CORPORATE GOVERNANCE AS REQUIRED UNDER SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To,
The Members
Bal Pharma Limited
Bangaluru

I have examined the compliance of the conditions of Corporate Governance by Bal Pharma Limited ('the Company') for the year ended 31st March, 2026, as stipulated in Regulations 17 to 27, clauses (b) to (i) of Regulation 46 (2) and paragraphs C, D and E of Schedule V of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The compliance of the conditions of Corporate Governance is the responsibility of the Management. My examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In my opinion and to the best of my information and explanations given to me, I certify that the Company has complied with the conditions of Corporate Governance as stipulated in the afore-mentioned Regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 [SEBI (LODR) Regulations] except the following:

1.The composition of the Board of Directors during Quarter 3 (October–December) of the Financial Year 2025-26 was not in conformity with the requirements prescribed under Regulation 17 (1) of the SEBI (LODR) Regulations for Forty-Three (43) days.

2.The composition of the Audit Committee and Nomination and Remuneration Committee were not in conformity with the requirements prescribed under Regulations 18(1) and 19 (1)/ 19 (2) of SEBI (LODR) Regulations for three (3) days during Quarter 3 of the Financial Year 2025-26 (October–December).

3.The Company was in receipt of letter NSE/LIST-SOP/COMB/FINES/0215 dated 27.2.2026 from the National Stock Exchange Limited (NSE) imposing fines for non-compliances under Regulations 17 (1), 18 (1), 19 (1)/19 (2). Further, the Company requested for a personal hearing. The personal hearing was scheduled and attended on 21.4.2026. NSE upheld the levy of fines to be paid on or before 15.5.2026. The Company duly paid the referred penalties to both BSE Limited and NSE on 15.5.2026 within the specified due date.

I further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

Place: Bangalure
Date: 27.05.2026

Vijayakrishna K T
Practising Company Secretary
FCS: 1788 CP: 980
UDIN: F001788H000505478
Peer Review Certificate No. 1883/2022

CG Report Enclosure D : Practicing Company Secretary Certificate confirming on clause 10 of schedule V of (LODR), Reg, 2015

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To
The Members
Bal Pharma Limited
21-22, Bommasandra Industrial Area
Bommasandra Industrial Estate
Bengaluru South, Bengaluru- 560099
Karnataka

I have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Bal Pharma Limited (hereinafter referred to as "the Company") having CIN: L85110KA1987PLC008368 and having Registered Office at 21-22, Bommasandra, Industrial Area, Bommasandra Industrial Estate, Bengaluru South, Bengaluru-560099, Karnataka, produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations,2015 as amended from time to time.

In my opinion and to the best of my information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to me by the Company & its officers, I hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ended as on 31st March, 2026 has been debarred or disqualified from being appointed or continuing as Directors of the Companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority:to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company

Sl. No.	Name of Director	DIN	Date of Appointment in company	Designation
1.	Mr. Shailesh Siroya	00048109	01/08/2004	Managing Director
2.	Mr. Virupakshaya Himesh	08554422	28/09/2019	Executive Director
3.	Mr. Jatish Sheth	00581963	28/12/2020	Non-Executive Independent Director
4.	Ms. Nicola Neeladri	01997936	23/05/2020	Non-Executive Independent Director
5.	Mr. Ravindrakumar Kothari	03418320	05/05/2025	Non-Executive Director
6.	Mr. Bheekamchand Mukesh	11295580	13/11/2025	Non-Executive Independent Director

Ensuring the eligibility for the appointment / continuity of every Director on the Board is the responsibility of the Management of the Company. My responsibility is to express an opinion on these based on my verification.

This Certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the Management has conducted the affairs of the Company..

Place: Bangalure
Date: 27.05.2026

Vijayakrishna K T
Practising Company Secretary
FCS: 1788 CP: 980
UDIN: F001788H000505522
Peer Review Certificate No. 1883/2022

Industry Overview

The global pharmaceutical industry continues to demonstrate resilient long-term growth, supported by increasing healthcare expenditure, ageing populations, rising chronic diseases, and greater access to affordable medicines. While pricing pressure continues in generic APIs due to excess manufacturing capacity, particularly from China, the long-term outlook remains favourable for companies with strong regulatory compliance, diversified product portfolios, and established customer relationships.

India continues to strengthen its position as a preferred global pharmaceutical manufacturing hub, supported by cost competitiveness, technical expertise, regulatory capabilities, and increasing export opportunities. Revised Schedule M requirements are expected to improve industry quality standards and create long-term opportunities for compliant manufacturers.

The Indian pharmaceutical industry continues to remain a key pillar of the healthcare ecosystem and is witnessing steady growth, supported by increasing healthcare awareness, rising demand for quality and affordable medicines, technological advancements and expanding global opportunities.

The industry continues to benefit from India's strong capabilities in generic medicines, active pharmaceutical ingredients (APIs), formulations and pharmaceutical manufacturing. Indian pharmaceutical companies are increasingly diversifying into complex generics, specialty medicines, biosimilars, biologics and other high-value segments, thereby strengthening the country's position in the global pharmaceutical market.

Digital transformation, artificial intelligence and data analytics are emerging as important enablers across pharmaceutical research, drug development, manufacturing, quality management and supply-chain operations. These technologies are expected to improve productivity, accelerate innovation and enhance operational efficiency across the industry.

Domestic pharmaceutical demand continues to be supported by increasing healthcare access, changing disease patterns, greater awareness of preventive healthcare and rising demand for chronic therapies. Growth opportunities remain across branded generics, specialty therapies and other value-added healthcare segments.

Government initiatives aimed at strengthening domestic pharmaceutical manufacturing, promoting self-reliance in APIs and key starting materials, encouraging research and development, and improving manufacturing capabilities are expected to further support the industry's long-term growth.

Overall, the Indian pharmaceutical sector remains well positioned to benefit from growing domestic healthcare requirements and increasing global demand. The industry is expected to continue its focus on innovation, quality, regulatory compliance, technology adoption and sustainable growth

Business Snapshot

The Company maintains a diversified business model across markets and product segments, reducing concentration risk and providing multiple growth opportunities.

Revenue Mix	Contribution (Approx)
Export Markets	63%
Domestic Markets	37%

Revenue Mix	Contribution (Approx)
API Business	50%
Formulations Business	50%

The balanced revenue mix enabled business stability despite temporary operational disruptions and market pricing pressures.

FY 2025-26 Business Performance

FY 2025-26 was a year of strategic investment focused on strengthening manufacturing capabilities and regulatory compliance.

Major Schedule M compliance projects and infrastructure upgrades were undertaken across manufacturing facilities. While these investments significantly enhance long-term competitiveness, they resulted in temporary production interruptions, lower capacity utilisation, and delayed dispatches due to geopolitical and logistical disruptions, particularly during the fourth quarter.

Key Strategic Achievements

During the year, the Company successfully achieved several important milestones:

- Substantial completion of Schedule M compliance and facility upgradation.
- Renewal of European regulatory approvals for Unit II and Unit IV, strengthening export capabilities.
- Continued investment in manufacturing infrastructure and quality systems.
- Maintenance of a diversified revenue profile across geographies and product categories.
- Strong customer retention and healthy order pipeline despite pricing pressures.
- Progress in restructuring OTC healthcare subsidiaries towards digital and e-commerce focused business models.

Internal Controls

An external agency is auditing the Company's internal controls. This results in an unbiased and independent examination of the adequacy and effectiveness of the internal financial control systems in achieving the Company's goal of optimal operation. The activities are safeguarding and protecting the Company's assets from unauthorized use or disposition, keeping proper accounting records, and verifying the authenticity of all transactions.

Bal Pharma has an effective compliance management system that issues preventative warnings in the event of any violations. The independent Audit Committee and the Board of Directors regularly review the Company's performance to ensure that it is by overall corporate policy and in line with predetermined objectives. Company's internal auditors, guiding the smooth operation of risk management policies, raising organizational awareness of risks across businesses and corporate functions, developing formal reporting and monitoring processes, and developing risk management maintenance plans to keep the information updated and refreshed, deploying an Enterprise Risk Management Framework in key business areas and corporate functions, and aligning risk management with the business plan.

Revenue and Net Profits

During the year under review, the Company continued to operate in a challenging and competitive business environment, influenced by volatility in domestic and international markets, pricing pressures and subdued demand in certain export markets. Despite these challenges, the Company maintained its focus on operational efficiency, product diversification and strengthening its market presence.

The Formulations exporting and API business continued to be a key growth driver during the year, supported by steady demand in both domestic and international markets. The Company continued to strengthen its presence across key therapeutic segments, with Anti-Diabetic and Anti-Histamine products remaining significant contributors to its business.

Operational Highlights

The Company maintained a stable financial and operational position during the year, supported by prudent working capital management and continued focus on operational efficiency. The Company remains committed to optimising inventory levels, improving receivables management and maintaining effective management of its working capital cycle.

The Company continued to focus on efficient utilisation of its capital and resources while maintaining a balanced approach towards debt management and financial discipline. The management remains focused on improving operational performance, strengthening profitability and enhancing returns to stakeholders.

For detailed information on the financial and operational ratios of the Company, reference may be made to the relevant notes forming part of the Financial Statements.

Shareholders' Interest

The Company continues to maintain a strong shareholders' funds position, reflecting its sound financial foundation and prudent financial management. The Company remains focused on strengthening shareholder value through sustainable business growth, efficient capital management and consistent financial performance.

The Company has also continued its commitment towards rewarding shareholders through dividend distribution. The proposed dividend reflects the Board's confidence in the Company's financial position and its commitment to enhancing long-term shareholder value

Risk and Concerns

Bal Pharma Limited faces risks and uncertainties typical to that faced by domestic and global pharmaceuticals industry players, which could have a material impact on earnings and the ability to operate in the future. These are determined via robust assessment considering our risk context by the Board of Directors with inputs from the executive management. The Board is satisfied that these risks are being managed appropriately and consistently.

Research and Development

Market research is a critical business catalyst, allowing the Company to develop and market differentiated generics and specialty products globally. Best-in-class technologies support the Company's R&D capabilities, allowing it to deliver affordable products globally. The Company is making proactive investments to build a global pipeline of generics, over-the-counter drugs, and specialty products. Long-term pipeline development investments are expected to continue and expand in scale and scope. The Company is also investing in research and development. It is developing specific products for emerging frontier markets.

The Company has incurred higher expenditure towards Research & Development activities during the current financial year, demonstrating its continued commitment to innovation and product development.

Information Technology

The Company is in the process of automating as many business processes as possible to increase efficiency and accuracy. A framework has been developed within the organization to capitalize on the opportunities presented by the proliferation of new-age digital technologies and transform into a digitally savvy company.

Technologies and platforms have been piloted as part of the plan to provide our customers with a better and more integrated experience.

Cautionary Statement.

The Management Discussion and Analysis statements describing Companies objectives, projections, estimates, and expectations may be "forward-looking statements" within the scope of applicable securities laws and regulations. Actual results could differ from those expressed or implied. Important factors that could make a difference to the Company's operations include economic conditions affecting demand-supply and price conditions in the domestic and overseas markets. The Company operates under various government regulations, tax laws, and other statutes & other incidental factors which might affect the future performance of the Company.

Outlook for FY 2026-27

With completion of major regulatory and infrastructure initiatives, the Company enters FY 2026-27 with enhanced manufacturing capabilities and improved operational readiness.

Management expects:

- Improved production and capacity utilisation following completion of Schedule M projects.
- Better operational efficiencies and fixed cost absorption.
- Growth in regulated export markets supported by renewed European approvals.
- Strengthening of domestic formulations business through focused marketing initiatives.
- Improved working capital management and inventory optimisation.
- Expansion of value-added API products and enhanced export opportunities.

While pricing pressures in certain API segments may persist in the near term, the Management remains confident of the Company's growth prospects, supported by healthy market demand, strengthened regulatory capabilities, a diversified business portfolio and a robust order pipeline. These factors are expected to support sustained revenue growth, improved profitability and stronger cash generation during FY 2026-27.

Key Takeaways for the Members

- Export business contributes 63% of revenue, while domestic business contributes 37%.
- API and Formulations each contribute 50% of total revenue.
- FY 2025-26 performance was temporarily impacted by Schedule M implementation, logistics disruptions, and API pricing pressure.
- European approvals for Unit II and Unit IV have been successfully renewed.
- Major Schedule M compliance initiatives have been substantially completed, strengthening long-term competitiveness.
- Management expects improved capacity utilisation, profitability, working capital efficiency, and overall financial performance in the coming year.

Other Applicable Disclosures

The Management Discussion and Business Analysis Report should be read in conjunction with the Board's Report, Corporate Governance Report, Financial Statements and the Notes forming part thereof, and other relevant sections of this Annual Report. The disclosures contained therein provide further information on matters relating to the Company's business, operations, financial performance, financial position, risks and other statutory and regulatory requirements, as applicable to the Company under the Companies Act, 2013, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable laws, rules and regulations.

Wherever the information required to be disclosed under the applicable statutory or regulatory provisions is already provided in the aforesaid sections of the Annual Report, the same may be read with reference to such disclosures and is not repeated herein.

To the Members of Bal Pharma Limited

Report on the Audit of the Standalone Financial Statements
Opinion

We have audited the standalone financial statements of Bal Pharma Limited ("the Company"), which comprise the balance sheet as at 31st March 2026, and the statement of Profit and Loss (including other comprehensive income), Statement of Changes in Equity and Statement of Cash Flows for the year then ended, and notes to the financial statements, including a summary of material accounting policies and other explanatory information(hereinafter referred to as the "Standalone Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the Indian accounting standards prescribed under section 133 of the act, ("IND AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, and profit (including other comprehensive income), changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Standalone Financial Statements' section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

We draw attention to Note 61 regarding recoverability of outstanding receivables from the subsidiary companies. Our opinion is not modified in respect of this matter.

Key Audit Matters

Key audit matters ('KAM') are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.

Key Audit Matters	How our audit addressed the key audit matter
Related Party Transactions: Identification and disclosures of Related Parties: (as described in Note-56 of the Standalone Ind AS financial statements) • The Company has related party transactions which include, amongst others, sale, and purchase of goods/ services to its subsidiaries and other related parties and lending, investing, and borrowing to it subsidiaries and other related parties. • We focussed on identification and disclosure of related parties in accordance with relevant Indian Accounting Standards and hence considered it as a key audit matter.	Our audit procedures amongst others included the following: • Evaluated the design and tested the operating effectiveness of controls over identification and disclosure ofrelated party transactions. • Obtained a list of related parties from the Company's Management and traced the related parties to declarations given by directors, where applicable, and to Note 56 of the standalone Ind AS financial statements. • Verified the minutes of the meetings of the Board of Directors and Audit Committee • Tested material creditors/debtors, loan outstanding/ loans taken to evaluate existence of any related party relationships: tested transactions based on declaration of related party transactions given to the Board of Directors and Audit Committee • Evaluated the disclosures in the Standalone Ind AS financial statements for compliance with Ind AS 24, compliance with Companies Act 2013 and determining the audit reporting required under CARO.

Key Audit Matters	How our audit addressed the key audit matter
Inventory ● As of 31 March 2026, the Company held inventories of Rs 11,612.85 Lakhs as disclosed in Note 11 to the Standalone financial statements. Inventories mainly consist of raw and packing material, work-in-progress, stock-in-trade, finished goods and stores, spares and consumables. ● We considered the value of the inventory as a key audit matter given the relative size of the balance in the financial statements and significant judgement involved in the consideration of various factors involved in determination of cost or selling prices	● Reviewed the management's process for ensuring that there was no movement of stock during the physical verification of inventory. ● We understood and tested the design and operating effectiveness of controls as established by the management in determination and identification of returned stock nearing expiry, and the stock lying at different locations. ● We Assessed the appropriateness of Company's accounting policy for valuation of stock-in- trade and compliance of the policy with the requirements of the prevailing accounting standards. Weconsidered various factors including the actual selling price prevailing around and subsequent to the year-end. Compared the cost of the finished goods with the estimated net realizable value and checked if the finished goods were recorded at net realizable value where the cost was higher than the net realizable value. For the purpose of determination of cost, the company has considered the prevailing market situation. ● Based on the above procedures performed, by the management for determination of expired stock, the net realizable value of the inventory as at the year end, the methodology adopted for arriving at cost and comparison with cost for valuation of inventory is considered to be reasonable
Contingencies, including litigations and tax ● The Company is involved in disputes, lawsuits, claims, governmental and / or regulatory inspections, inquiries investigations and proceedings, including tax and commercial matters that arise from time to time in the ordinary course of business. Most of the claims involve complex issues. The Company assisted by their external legal counsel assesses the need to disclose a contingency on a case- to case basis considering the underlying facts of each litigation. ● This area is significant to our audit, since the accounting and disclosure for contingent legal and tax liabilities is complex and judgmental (due to the difficulty in predicting the outcome of the matter and estimating the potential impact if the outcome is unfavourable), and the amounts involved are, or can be, material to the standalone financial statements.	● We obtained a list of ongoing litigations from the Company's in house legal counsel. We selected a sample of litigations based onmateriality and performed inquiries with the said counsel on the legal evaluation of these litigations. We compared the evaluation with the provision or disclosure in thestandalone financial statements. We tested the underlying computation of the management inrelation to the measurement of the contingency. ● We inspected relevant communication with tax authorities. ● We also evaluated the disclosures made in the standalone financial statements.

Information Other than the Financial Statements and Auditor's Report Thereon om our examination of those books.

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's annual report but does not include the standalone financial statements and our auditors' report thereon. Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management for the Standalone Financial Statements

The Company's Management and Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, the management and Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(I) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure, and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Standalone Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (I) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. As required by Section 143(3) of the Act, we report that:
   a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

   b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

   c. The Balance Sheet, The Statement of Changes in Equity, the Statement of Profit and Loss (including other comprehensive income), and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.

d. In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act.

e. On the basis of the written representations received from the directors as on 31st March 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March 2026 from being appointed as a director in terms of Section 164 (2) of the Act

f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".

g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company has disclosed the impact of pending litigations on its financial position in its standalone financial statements – Refer Note 39 to the standalone financial statements.

ii. the Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

iv. **(a)** The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person or entity, including foreign entities , with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(b) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person or entity , including foreign entities , with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(c) Based on such audit procedures that the auditor has considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (i) and (ii) contain any material misstatement.

v. (a) The dividend proposed in the previous year, declared, and paid by the company during the year is in accordance with section 123 of the Act.

(b) The Board of Directors have proposed dividend for the current year which is subject to the approval of the members at the Annual General Meeting.

vi. Based on our examination, which included test checks, the Company has used accounting software for maintaining its books of account for the financial year ended March 31, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with and the audit trail has been preserved by the Company as per the statutory requirements for record retention.

3. With respect to the matter to be included in the Auditors' Report under section 197(16):

According to the information & explanations given to us and based on our examination of the records of the Company, the Company has paid / provided for managerial remuneration in accordance with the provisions of section 197 of the Act.

for **S S J N B & CO**
Chartered Accountants
Firm registration number: 013976S

Dhanpal I Sakaria
Partner
Membership No: 213666
UDIN: 26213666MGVPMQ6422

Place: Bengaluru
Date : 27th May, 2026

Annexure A to the Independent Auditor's Report of even date to the members of Bal Pharma Limited, on the standalone financial statements for the year ended 31 March 2026

(Referred to paragraph 1 under 'Report on other Legal and Regulatory requirements' Section of our report to the members of Bal Pharma Limited of even date)

Based on the audit procedures performed for the purpose of reporting a true and fair view on the standalone financial statements of the Company and taking into consideration the information and explanations given to us and the books of account and other records examined by us in the normal course of audit, and to the best of our knowledge and belief, we report that,

(i) a) (A) The Company has maintained proper records showing full, including quantitative details and situation of property, plant, and equipment and relevant details of right-of-use assets.

(B) The Company has maintained proper records showing full particulars of intangible assets.

b) The Company has a program of physical verification of property, plant and equipment and capital work-in-progress so to cover all the assets over a period of five years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the program, certain property, plant and equipment and capital work-in -progress were due for verification during the year and were physically verified by the management during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification.

c) The title deeds of all the immovable properties (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee), as disclosed under Property, Plant and Equipment in the financial statements are held in the name of the Company.

d) The Company has not revalued its Property, Plant and Equipment or Intangible Assets during the year.

e) According to the information and explanations given by the management, no proceedings has been initiated or are pending against the Company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 and the rules made thereunder.

(ii) a) As explained to us, inventory of the company has been physically verified during the year by the management at regular intervals. In our opinion, the frequency of such verification is reasonable. The discrepancies identified on verification were not more than 10% or more in aggregate for each class of inventory. Inventories lying with the third parties have been confirmed by them and no material discrepancies were noticed in respect of such confirmations.

b) According to the information and explanations given to us by the management and based on our examination of the books of accounts in the normal course of audit, the Company has been sanctioned working capital limits in excess of five crores rupees in aggregate, from bank or financial institutions on the basis of security of current assets. On verification of the quarterly returns or statements, as provided to us by the management, filed by the Company with such banks or financial institution, no material discrepancy other than the following has been identified between the books of accounts and the returns/statements submitted to banks.

(Rs. in Lakhs)

Month	Particulars	Nature	Amount as provided in Quarterly Statement	Amount as recorded in Books of accounts	Difference	Remarks
June	Closing Stock	Current Asset	11,175.89	11,175.89	-	-
June	Trade Receivables	Current Asset	8,254.22	8,498.01	-243.79	Trade Receivables in the statement submitted to bank contains only of outstanding for less than 150 Days
June	Trade Payables	Current Liability	5,246.73	5,130.91	115.82	-
September	Closing Stock	Current Asset	11,125.60	11,243.96	-118.36	Closing stock in the statement submitted to bank does not contain stock in transit
September	Trade Receivables	Current Asset	8,988.14	9,334.10	-345.96	Trade Receivables in the statement submitted to bank contains only of outstanding for less than 150 Days
September	Trade Payables	Current Liability	5,762.97	5,762.97	-	-

(Rs. in Lakhs)

Month	Particulars	Nature	Amount as provided in Quarterly Statement	Amount as recorded in Books of accounts	Difference	Remarks
December	Closing Stock	Current Asset	10,986.53	10,986.53	-	-
December	Trade Receivables	Current Asset	8,882.79	9,125.23	-242.44	Trade Receivables in the statement submitted to bank contains only of outstanding for less than 150 Days
December	Trade Payables	Current Liability	5,844.80	5,595.67	249.13	-
March	Closing Stock	Current Asset	11,607.14	11,607.14	-	-
March	Trade Receivables	Current Asset	8,838.88	9,636.24	-797.36	Trade Receivables in the statement submitted to bank contains only of outstanding for less than 150 Days
March	Trade Payables	Current Liability	6,305.40	6,197.29	108.11	-

(iii) According to the information and explanation given to us and based on the audit procedures performed by us, the Company has made investments in, but not provided loans or advances in nature of loans or stood guarantee or provided security to companies, firms, limited liability partnerships or any other parties:

a) According to the information and explanations given to us and based on the audit procedures performed by us, the Company has not provided any loans or advances in the nature of loans or stood guarantee or provided security to any other entity during the year, and hence reporting under clause 3(iii)(a) of the Order is not applicable:

b) According to the information and explanations given to us and based on the audit procedures conducted by us, the investments made, guarantee provided and securities provided are, prima facie, not prejudicial to the company's interest.

c) According to the information and explanation provided to us and based on the audit procedures conducted by us, the Company has not granted any loan or advance in nature of loan to any parties. Hence reporting under paragraph 3(iii)©, 3(iii)(d), 3(iii)(e) and 3(iii)(f) is not applicable to the Company.

(iv) In our opinion and according to the information and explanations given to us the Company has not advanced loans to directors/ to a Company in which the director is interested to which the provisions of Section 185 of the Companies Act, 2013 ('Act') apply and hence not commented upon. However, in respect of loans given, investments made and guarantees given to subsidiary, associates, or joint ventures the Company is in compliance with provisions of Section 186 of the Act.

(v) The Company has not accepted any deposits or has any amounts which are deemed to be deposits to which the provisions of Section 73 to 76 or any other relevant provisions of the Companies Act rules framed thereunder and the directions issued by the RBI are applicable. Hence paragraph 3 (v) of CARO is not applicable to the company.

(vi) We have broadly reviewed the cost records maintained by the company pursuant to the Companies (Cost Accounting Records) Rules, as amended, specified by the Central Government under section 148(1) of the Companies Act and are of the opinion that prima facie the prescribed cost records have been maintained. We have, however, not made a detailed examination of the cost records with a view to determine whether they are accurate or complete.

(vii) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/accrued in the books of account in respect of undisputed statutory dues including Provident Fund, Employees' State Insurance, Income-tax, Duty of Customs, Goods and Services tax, Cess and other material statutory dues have been regularly deposited by the company with the appropriate authorities.

(b) According to the information and explanations given to us and based on the audit procedures conducted by us, there are no dues of income tax, Goods and Service Tax, custom duty, and cess which have not been deposited on account of any dispute other than that stated below:

Statement of Disputed Dues					
Name of the statute	**Nature of Dues**	**Amount (in lakhs)**	**Period to which the amount relates**	**Forum where the. dispute is pending**	**Remarks, if any**
Chapter V of Finance Act, 1994	Service Tax and equivalent penalty	31.70	Nov 2007 to March 2012	Assistant Commissioner of Service Tax.	-
Chapter V of Finance Act, 1994	Service Tax and equivalent penalty	27.34	FY 2012-13 to FY 2016-17	Audit Commissioner of Central Excise	-
Chapter V of Finance Act, 1994	Service Tax and equivalent penalty	15.51	FY 2012-13 to FY 2015-16	Audit Commissioner of Central Excise	-
Income tax Act, 1961	Income tax	99.10	FY 2016-17 (AY 2017-18)	Commissioner of Income Tax (Appeals)	-
Income tax Act, 1961	Income tax	32.56	FY 2018-19 (AY 2019-20)	Commissioner of Income Tax (Appeals)	-
Income tax Act, 1961	Income tax	147.25	FY 2017-18 (AY 2018-19)	Commissioner of Income Tax (Appeals)	-
Income tax Act, 1961	Income tax	19.30	FY 2022-23 (AY 2023-24)	Deputy Commissioner /Assistant Commissioner of Income Tax	-
Goods & Service Tax	GST	36.47	September 2023	Jt Commissioner, State Tax, Udaipur.	-

The Company has received show cause notices under the Central Excise laws and Service Tax laws for the years 2007-08 onwards which in various stages of assessment as of 31 March 2026. The assessments are in progress and the Company has not received the assessment order in respect of the same. In certain cases, the Company has preferred an appeal which has been remanded back to the original authority for reassessment.

(viii) Based on our audit procedure and on the information and explanation given to us by the management, no transaction has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

(ix) a) Based on our audit procedure and on the information and explanation given by the management, we are of the opinion that the company has not defaulted in repayment of loans or other borrowing to its lender .

b) According to the information and explanation given to us by the management, the Company is not declared as willful defaulter by any bank or Financial Institution or other lenders.

c) In our opinion and according to the information and explanations given to us, the Company has utilized the money obtained by way of term loans during the year for the purposes for which they were obtained.

d) According to the information and explanations given to us and on an overall examination of the balance sheet of the company, we report that no funds raised on short-term basis have been used for long-term purposes by the company.

e) According to the information and explanations given to us and on an overall examination of the balance sheet of the company/ examination of the cash flow statement of the Company, we report that the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures as defined under Companies Act, 2013.

f) According to the information and explanations given to us and procedures performed by us, we report that the company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures, or associate companies.

(x) (a) According to the information and explanation given to us and based on audit procedure performed, no money was raised by the way of public issue/follow-on-offer (including debt instruments).

(b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause 3(x)(b) of the Order is not applicable.

(xi) (a) Based upon audit procedure performed and information and explanation given by the management, we report that no fraud by the company or any fraud on the company has been noticed or reported during the year.

(b) No report under sub-section (12) of section 143 of the Companies Act has been filed by us or by other auditors of the Company.

(c) As represented to us by the management, there are no whistle blower complaints received by the company during the year.

(xii) The company is not a Nidhi Co. and therefore clause 3(ix) of the order is not applicable to the company.

(xiii) In our opinion, all transactions with the related parties entered into by the Company during the year are in compliance with section 188 of the Companies Act of 2013 and the details thereof have been disclosed in the Financial Statement as required by the Accounting Standards and Companies Act, 2013. Further, the company has complied with the provisions of Sec 177 subject to certain exceptions.

(xiv) (a) In our opinion, the Company has an internal audit system commensurate with the size and nature of its business.
(b) We have considered the Internal Audit reports of the Company issued till date, for the period under audit.

(xv) Based on the information and explanations given to us, in our opinion during the year the company has not entered into any non-cash transactions with its directors or persons connected with its directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.

(xvi) (a) According to the information and explanation given to us and in our opinion, the Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause 3(xvi)(a), (b) and (c) of the Order is not applicable.
(b) In our opinion, there is no core investment company within the Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016) and accordingly reporting under clause 3(xvi)(d) of the Order is not applicable.

(xvii) The Company has not incurred any cash losses in the financial year and in the preceding financial year.

(xviii) There has been no resignation of the statutory auditors during the year and accordingly clause is not applicable.

(xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans, we are of the opinion that no material uncertainty exists as on the date of the audit report that company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.

(xx) (a) In respect of other than ongoing projects, as at balance sheet date, the Company does not have any amount remaining unspent under Section 135(5) of the Act. Accordingly, reporting under clause 3(xx)(a) of the Order is not applicable.
(b) There is no amount remaining unspent under sub-section (5) of section 135 of the Companies Act, pursuant to any ongoing project. Accordingly, reporting under clause 3(xx)(b) of the Order is not applicable for the year.

(xxi) The reporting under clause 3(xxi) of the Order is not applicable in respect of audit of Standalone Financial Statements. Accordingly, no comment in respect of the said clause has been included in this report.

for **S S J N B & CO**
Chartered Accountants
Firm registration number: 013976S

Dhanpal I Sakaria
Partner
Membership No: 213666
UDIN: 26213666MGVPMQ6422

Place: Bengaluru
Date : 27th May, 2026

Annexure B to the Independent Auditors' Report

on the standalone financial statements of Bal Pharma Limited for the period ended 31 March 2026

Report on the Internal Financial Controls with reference to the aforesaid standalone financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')

(Referred to clause (f) of paragraph 2 under 'Report on other Legal and Regulatory requirements' Section of our report to the members of Bal Pharma Limited of even date)

We have audited the internal financial controls with reference to standalone financial statements of Bal Pharma Limited ("the Company") as of 31 March 2026 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (hereinafter referred to as "the Act").

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to standalone financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to standalone financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to standalone financial statements were established and maintained and whether such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to standalone financial statements and their operating effectiveness. Our audit of internal financial controls with reference to standalone financial statements included obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk.The

procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to standalone financial statements.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial controls with reference to standalone financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of standalone financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to standalone financial statements include those policies and procedures that:
(1)pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company.

(2)provide reasonable assurance that transactions are recorded as necessary to permit preparation of standalone financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

(3)provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the standalone financial statements.

Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system with reference to standalone financial statements and such internal financial controls with reference to standalone financial statements were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by ICAI.

for **S S J N B & CO**
Chartered Accountants
Firm registration number: 013976S

Dhanpal I Sakaria
Partner
Membership No: 213666
UDIN: 26213666MGVPMQ6422

Place: Bengaluru
Date : 27th May, 2026

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Audited Standalone Balance Sheet
(all amounts in Rs. lakhs unless otherwise stated)

Particulars	Note No	As at 31 March 2026	As at 31 March 2025
ASSETS			
Non-current assets			
Property, Plant and Equipment	4	7,672.89	7,094.80
Capital work-in-progress	5	742.42	278.58
Goodwill	6A	382.69	382.69
Other Intangible Assets	6B	1,342.24	1,199.75
Intangible assets under development			-
Financial assets			-
- Investments	7	215.86	215.86
- Loans		-	-
- Other financial assets	8	807.08	712.24
Deferred tax Asset (Net)	9	78.14	39.53
Other non-current assets	10	300.62	367.74
		11,541.94	**10,291.19**
Current assets			
Inventories	11	11,612.85	10,277.80
Financial assets			-
- Investments	12	208.17	246.80
- Trade receivable	13	9,636.25	9,484.78
- Loans	14	116.57	113.28
- Cash and cash equivalents	15	219.49	163.95
- Other bank balances	16	490.89	629.89
- Other financial assets	17	164.91	127.63
Current tax assets (Net)	18	13.43	98.84
Other current assets	19	5,101.00	3,622.22
		27,563.56	**24,765.19**
		39,105.50	**35,056.38**

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Audited Standalone Balance Sheet
(all amounts in Rs. lakhs unless otherwise stated)

Particulars	Note No	As at 31 March 2026	As at 31 March 2025
EQUITY & LIABILITIES			
Equity			
Equity share capital	20	1,592.09	1,592.09
Other equity	21	8,817.80	8,290.37
		10,409.89	**9,882.46**
LIABILITIES			
Non-current liabilites			
Financial liabilities			
- Borrowings	22	3,188.48	3,140.02
- Other financial liabilities	23	561.21	127.65
Provisions	24	615.77	560.43
		4,365.46	**3,828.10**
Current liabilities			
Financial liabilities			
- Borrowings	25	12,186.31	11,321.14
- Trade payables	26		
Due to Micro and Small Enterprises		39.26	461.66
Due to Other than Micro and Small Enterprises		8,877.97	7,723.13
- Other financial liabilities	27	2,463.05	1,075.15
Other current liabilities	28	686.41	648.58
Provisions	29	77.15	116.16
		24,330.15	**21,345.82**
		39,105.50	**35,056.38**

The accompanying notes referred to above form an integral part of these standalone financial statements.
As per our report of even date attached

for **S S J N B & CO**
Chartered Accountants
Firm registration number: 013976S

Dhanpal I Sakaria
Partner
Membership No: 213666
UDIN: 26213666MGVPMQ6422

Place: Bengaluru
Date : 27th May, 2026

for and on behalf of the board of directors of
Bal Pharma Limited

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh
Whole Time Director
DIN: 08554422

Bharath Bhushan D V
Chief Financial Officer

Place: Bengaluru
Date : 27th May, 2026

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Standalone Statement of Profit and Loss

(all amounts in Rs. lakhs unless otherwise stated)

Particulars	Note No	For the year ended 31 March 2026	For the year ended 31 March 2025
Income			
Revenue from operations	30	31,079.70	30,249.64
Other income	31	200.29	214.93
Total Income		**31,279.99**	**30,464.57**
Expenses			
Cost of materials consumed	32	16,096.75	14,988.61
Purchase of traded goods	33	912.94	1,496.68
(Increase)/decrease in inventories of finished goods and work-in-progress	34	-1,224.63	-708.12
Employee Benefit expense	35	6,592.41	6,182.88
Finance costs	36	1,681.03	1,684.51
Depreciation and amortisation	37	1,105.91	964.87
Other expenses	38	5,479.11	5,281.87
Total expenses		**30,643.48**	**29,891.34**
Profit before exceptional items and tax		**636.51**	**573.23**
Profit before tax		**636.51**	**573.23**
Less: Tax expense:			
Current tax	49	-	-
Excess/Short provision of tax written back			(14.06)
Tax adjustments relating to previous year		-	-
Deferred tax charge/ (credit)	49	(38.61)	(192.66)
Tax expenses		-38.61	-206.72
Profit / (Loss) for the year		**675.12**	**779.95**
Other Comprehensive Income (OCI)			
A (i) Items that will not be reclassified to statement of profit or loss			
Remeasurements of post-employment benefit obligations	58	43.37	(4.33)
(ii) Income tax relating to items that will not be reclassified to statement profit or loss			-
Total other comprehensive income		43.37	(4.33)
Total Comprehensive Income for the year		**718.50**	**775.62**
Earning per share (face value per equity share Rs. 10)			
- Basic		4.51	4.89
- Diluted		4.51	4.89

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Standalone Statement of Profit and Loss
(all amounts in Rs. lakhs unless otherwise stated)

The accompanying notes referred to above form an integral part of these standalone financial statements.
As per our report of even date attached

As per our report of even date attached
for **S S J N B & CO**
Chartered Accountants
Firm registration number: 013976S

Dhanpal I Sakaria
Partner
Membership No: 213666

Place: Bengaluru
Date : 27th May, 2026

UDIN: 26213666MGVPMQ6422

for and on behalf of the board of directors of
Bal Pharma Limited

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh
Whole Time Director
DIN: 08554422

Bharath Bhushan D V
Chief Financial Officer

Place: Bengaluru
Date: 27th May, 2026

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Standalone Statement of Cash Flows

(all amounts in Rs. lakhs unless otherwise stated)

Cash flow from operating activities:	For the year ended 31 March 2026	For the year ended 31 March 2025
Profit / (Loss) before tax	636.51	573.23
Adjustment for :		
- Interest income	(84.68)	(73.64)
- (Gain)/Loss on sale of Property, Plant and Equipment	(5.61)	-
- Balances written off as no more payable	-	(14.20)
- Unrealised Foreign (Gain)/Loss	61.84	20.68
- Finance cost (including effect of amortisation of processing fees)	1,681.03	1,684.51
- Rental Expense(IND AS 116)	(153.38)	(116.66)
- Balances written off as no more receivable	0.02	-
- Depreciation and amortisation	1,105.91	964.87
- Expected Credit Losses	2.81	-
- Imairment on investment write back	-	(0.01)
- Other comprehensive income	43.37	(4.33)
Operating cash flow before working capital changes	**3,287.83**	**3,034.46**
Changes in		
- Decrease/(Increase) in Inventories	(1,335.05)	(1,524.38)
- Decrease/(Increase) in Trade receivables	(216.14)	679.53
- Decrease/(Increase) in Loans	(3.29)	3.56
- Decrease/(Increase) in Financial Assets (Current and Non current)	(32.81)	(64.97)
- Decrease/(Increase) in Other Assets (Current and Non current)	(1,378.58)	(351.80)
- Increase/ (Decrease) in Trade payables	732.43	436.91
- Increase/ (Decrease) in Other Financial liabilities (Current and Non current)	1,974.83	247.20
- Increase/ (Decrease) in Other liabilities (Current and Non current)	37.84	(300.62)
- Increase/ (Decrease) in Provisions	16.33	79.22
Cash (used in)/ generated from operations	**3,083.39**	**2,239.12**
Income taxes (paid)/ refund	0.00	(207.71)
Net cash generated (used in) operating activities	**3,083.39**	**2,031.41**
Cash flow from investing activities:		
Purchase of Property,Plant & Equipment including intangible assets and capital work-in-progress	(1,855.49)	(1,677.14)
Intercorporate Deposit to Subsidiary	-	0.10
Right to Use of Asset as per IND AS	(382.51)	(199.84)
Proceeds from sale of fixed assets	5.61	-
Decrease/ (increase) in fixed deposits/Liquid Funds	78.32	313.25
Interest received	84.68	73.64
Net cash generated/ (used in) investing activities	**(2,069.39)**	**(1,489.98)**

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Standalone Statement of Cash Flows
(all amounts in Rs. lakhs unless otherwise stated)

Cash flow from operating activities:	For the year ended 31 March 2026	For the year ended 31 March 2025
Cash flow from financing activities:		
Proceeds from/(Repayment) of long term borrowings	341.18	(76.74)
Proceeds from / (repayment) of short term borrowings	572.43	1,154.86
Dividend Paid including unpaid dividends of preceding years	(191.05)	(191.05)
Money received on issue of Equity shares	(0.01)	80.69
Share based payment reserve	0.00	(66.57)
Interest Paid (Gross)	(1,681.03)	(1,684.51)
Net cash arising/ (used in) from financing activities	**(958.47)**	**(783.31)**
Net (decrease)/ increase in cash and cash equivalents	55.54	(241.87)
Cash and cash equivalents at the beginning of the year	163.94	405.83
Cash and cash equivalents at the end of the year	**219.48**	**163.94**
Cash and cash equivalents comprise of:		
Cash on hand	1.83	2.43
Balances with banks		
- in current accounts	131.13	67.35
- in deposits with original maturity of less than 3 months	86.52	94.16
	219.48	**163.94**

The accompanying notes referred to above form an integral part of these standalone financial statements.
As per our report of even date attached

As per our report of even date attached
for **S S J N B & CO**
Chartered Accountants
Firm registration number: 013976S

Dhanpal I Sakaria
Partner
Membership No: 213666

Place: Bengaluru
Date : 27th May, 2026

UDIN: 26213666MGVPMQ6422

for and on behalf of the board of directors of
Bal Pharma Limited

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh
Whole Time Director
DIN: 08554422

Bharath Bhushan D V
Chief Financial Officer

Place: Bengaluru
Date: 27th May, 2026

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Standalone Statement of changes in equity
(all amounts in Rs. lakhs unless otherwise stated)

A. Equity share Capital

Particulars	Numbers in 0.000
Equity shares of Rs 10 each issued, subscribed and fully paid	
Balance as at 1 April 2024	**1,580.44**
Add: Issue of shares	11.65
Balance as at 31 March 2025	**1,592.09**
Balance as at 1 April 2025	**1,592.09**
Add: Issue of shares	
Balance as at 31 March 2026	**1,592.09**

B. Other Equity

	Reserves & Surplus					OCI	
	Share based payment reserve	Securities premium	General Reserve	Capital Reserve	Retained earnings	Remeasurements of the net defined benefit plans	Total Other Equity
Balance as at 1 April 2024	**66.57**	**3,128.74**	**245.15**	**44.06**	**4,289.70**	**-70.90**	**7,703.32**
Profit/(Loss) for the year	-	-	-	-	779.95	-	779.95
Less:Appropriations for dividend and tax on same	-	-	-	-	-191.05	-	(191.05)
Other Comprehensive income	-		-	-	-	-4.32	(4.32)
Issue of shares during the year		69.04					69.04
Transer to OCI			-		-4.65	4.65	-
Share based payment reserve	-66.57	-	-	-	-	-	(66.57)
Balance as at 31 March 2025	**(0.00)**	**3,197.78**	**245.15**	**44.06**	**4,873.95**	**(70.57)**	**8,290.37**
Balance as at 1 April 2025	**(0.00)**	**3,197.78**	**245.15**	**44.06**	**4,873.95**	**(70.57)**	**8,290.37**
Profit/(Loss) for the year					675.12		675.12
Less:Appropriations for dividend and tax on same					(191.05)		(191.05)
Other Comprehensive income/Additions						43.37	43.37
Balance as at 31 March 2026	**-**	**3,197.78**	**245.15**	**44.06**	**5,358.02**	**(27.19)**	**8,817.80**

Significant accounting policies (refer note 3)

The accompanying notes referred to above form an integral part of these standalone financial statements.

As per our report of even date attached
for **S S J N B & CO**
Chartered Accountants
Firm registration number: 013976S

Dhanpal I Sakaria
Partner
Membership No: 213666

Place: Bengaluru
Date : 27th May, 2026

UDIN: 26213666MGVPMQ6422

for and on behalf of the board of directors of
Bal Pharma Limited

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh
Whole Time Director
DIN: 08554422

Bharath Bhushan D V
Chief Financial Officer

Place: Bengaluru
Date: 27th May, 2026

BAL PHARMA LIMITED

CIN: L85110KA1987PLC008368

Notes to standalone financials statements

1. Company Overview

Bal Pharma Limited (the Company) is a Public Limited Company domiciled in India and incorporated under provisions of the Companies Act,1956. Its shares are listed on two recognized stock exchanges in India.

The Company is engaged in the manufacturing and selling of pharmaceutical products. The Company caters to both domestic and international markets.

2. Basis for preparation of Standalone Financial Statements

2.01 Statement of compliance

These standalone financial statements as of and for the year ended March 31,2026 comply in all material aspects with the Indian Accounting Standards ("Ind AS") notified under the Companies(Indian Accounting Standards) Rules, 2015, and presentation requirements of Division II of Schedule III to the Companies Act, 2013, and as amended from time to time.

These standalone financial statements have been prepared by the Company as a going concern on the basis of relevant Ind AS that are effective at the Company's annual reporting date, March 31, 2026.These standalone financial statements were authorised for issuance by the Company's Board of Directors on May 27,2026.

2.02 Functional and presentation currency

These standalone financial statements are presented in Indian Rupees, which is the Company's functional currency and the currency of the primary economic environment in which the Company operates. All financial information presented in Indian Rupees has been rounded off to nearest lakhs, unless otherwise indicated.

2.03 Basis of measurement

"The standalone financial statements have been prepared on a historical cost basis and on an accrual basis except for the following:

- certain financial assets and financial liabilities that are measured at fair value (refer accounting policies regarding financial instrument).
- employee defined benefit assets / liability recognised as the net total of the fair value of plan assets, and actuarial losses/gains, and the present value of defined benefit obligation
- equity-settled and cash-settled share-based payments are measured at fair value on the grant date and the reporting date, respectively."

2.04 Use of judgements,Assumptions and estimates

In preparing these standalone financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

These estimates are reviewed on an ongoing basis. Subsequent revisions to accounting estimates are recognised prospectively.

Judgements

Information about judgements in applying accounting policies that have the most significant effect on the amounts recognised in the standalone financial statements is included in the following notes:

- Note 3.01 : whether the Company acts as an agent rather than as a principal in a transaction.
- Note 63(j) - contingent liabilities : measurement and likelihood of occurrence of provisions and contingencies
- Note 63(g) - leases : whether an arrangement contains a lease; lease classification

Assumptions and estimations

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment in the year ended 31 March 2026 or subsequent year/ years is included in the following notes:

- Note 3.02: Useful lives of various of Property, Plant and Equipment
- Note 58: Fair Value of Financial Instruments
- Note 57: Accounting for Defined Benefit Plan - measurement of defined benefit obligation - key actuarial assumptions.
- Note 63(b): Expected Credit Losses associated with its assets carried at amortized cost

2.05 Current vs Non-Current Classification

The Company presents assets and liabilities in the balance sheet based on current/ non-current classification. An asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle
- Held primarily for the purpose of trading
- Expected to be realised within twelve months after the reporting period, or
- Cash or cash equivalents unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when:
- It is expected to be settled in normal operating cycle
- It is held primarily for the purpose of trading
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

The Company classifies all other liabilities as non-current.
Deferred tax assets and liabilities are classified as non-current assets and liabilities.
The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents.The Company has identified twelve months as its operating cycle.

2.06 Measurement of fair values

Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows.

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e.as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The management regularly reviews significant unobservable inputs and valuation adjustments.
Measurement of fair values
When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.
The Company recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.
Further information about the assumptions made in measuring fair values is included in the following notes:
Financial Instruments - Refer Note 58 and 59

2.07 New and amended standards adopted by the Company

The Ministry of Corporate Affairs vide notifications dated 7 May 2025 and 13 August 2025 notified the Companies (Indian Accounting Standards)Amendment Rules, 2025 and Companies (Indian Accounting Standards) Second Amendment Rules, 2025, respectively, amended certain accounting standards listed below, effective from annual reporting periods beginning on or after 1 April 2025:

- Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants – Amendments to Ind AS 1
- Supplier Finance Arrangements – Amendments to Ind AS 7 and Ind AS 107
- International Tax Reform – Pillar Two Model Rules – Amendments to Ind AS 12
- Lack of Exchangeability – Amendments to Ind AS 21

These amendments did not have any material impact on the amounts recognised in prior periods and are not expected to significantly affect the current or future period.

New standards or amendments not yet adopted

The amendment to Ind AS 1 includes specific provisions that will take effect for reporting periods beginning on or after 1 April 2026, as outlined below:

- Classification of Liabilities as Current or Noncurrent and Non-current Liabilities with Covenants – Amendments to Ind AS 1 - Lender waivers for breach of material provision of a long-term loan arrangement.

The Company does not expect this amendment to have an impact on its operations or financial statements.

3. Material Accounting Policies Information

3.01 Revenue Recognition

Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government.

Sale of Goods:

"Revenue from contracts with customers is recognised when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In the Company's case, the obligation of the Company is said to be completed on movement of the goods from the factory gate.The Company has generally concluded that it is the principal in its revenue arrangements, since it is the primary obligor in all of its revenue arrangement, as it has pricing latitude and is exposed to inventory and credit risks. Revenue is stated net of goods and service tax and net of returns, chargebacks, rebates and other similar allowances. These are calculated on the basis of historical experience and the specific terms in the individual contracts. In determining the transaction price, the Company considers the effects of variable consideration, the existence of significant financing components, noncash consideration, and consideration payable to the customer (if any). The Company estimates variable consideration at contract inception until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognised will not occur when the associated uncertainty with the variable consideration is subsequently resolved.

Other Operating revenue is recognised on accrual basis."

"Government grants and incentives:

The Company recognizes government grants only when there is reasonable assurance that the conditions attached to them will be complied with, and the grants will be received. Grants related to income and other incentives are deducted in reporting the related expense in the standalone statement of Profit and Loss.

Export entitlements under the Duty Drawback ('DBK'), Remission of duties & taxes on export of goods (RoDTEP)are recognized as income when the right to receive credit as per the terms of the scheme is established in respect of the exports made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds. As the Company derives a substantial portion of its revenue from export of goods, such incentives is recognised as ""Other Operating Income""."

Rendering of Services:

Revenue from services rendered is recognised in the profit or loss as the underlying services are performed and is recognised net of service tax and goods and service tax (provided that it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably).

Interest Income:

Interest income from a financial asset is recognized when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principle outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Dividend Income

Dividend income from investments is recognized when the right to receive payment has been established, provided that it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably.

Rental Income

Rental income is recognised on a straight-line basis over the term of the lease

3.02 Property, Plant & Equipment, Intangible Assets and Work -in - Progress

Recognition and Measurement

All items of property, plant and equipment, including freehold land, are initially recorded at cost. Cost of property, plant and equipment comprises purchase price, non refundable taxes, levies and any directly attributable cost of bringing the asset to its working condition for the intended use. Expenses directly attributable to new manufacturing facility during its construction period are capitalized if the recognition criteria is met. Freehold land has an unlimited useful life and therefore is not depreciated.

The cost of an item of property, plant and equipment is recognized as an asset if, and only if, it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The cost includes the cost of replacing part of the property, plant and equipment and borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying property, plant and equipment. The accounting policy for borrowing costs is set out in note below.

Items such as spare parts, stand-by equipment and servicing equipment that meet the definition of property, plant and equipment are capitalized at cost and depreciated over their useful life. Costs in nature of repairs and maintenance are recognized in the Statement of Profit and Loss as and when incurred.

When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognized in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied.

Subsequent Measurement

Subsequent to initial recognition, property, plant and equipment other than freehold land are measured at cost less accumulated depreciation and any accumulated impairment losses. The carrying values of property, plant and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable.

Disposal/Write-off

An item of property, plant and equipment is derecognized on disposal, or when no future economic benefits are expected from use or disposal. Gains or losses arising from derecognition of property, plant and equipment, measured as the difference between the net disposal proceeds and the carrying amount of the asset, are recognized in profit or loss when the asset is derecognized.

Capital Work-in-Progress

Capital work-in-progress includes cost of property, plant and equipment that are not ready for their intended use. Capital work-in-progress included property, plant and equipment are not depreciated as these assets are not yet available for use.

Depreciation

Depreciable amount for assets in the cost of an asset, or other amount substituted for cost, less its estimated residual value. Depreciation on the property, plant and equipment is provided on straight line method, over the useful life of the assets, as specified in schedule II to the companies Act, 2013 and is recognised in the statement of profit and loss except for the below mentioned assets:

Particulars	Useful life as per schedule II of Companies Act, 2013	Useful life as technically assessed
Motor buses, motor lorries and motor cars other than those used in a business of running them on hire	8	10

Property, plant and equipment which are added / disposed off during the year, depreciation is provided on pro-rata basis. Building constructed on leasehold land is depreciated based on the useful life specified in schedule II to the companies Act, 2013 where the lease period of the land is beyond the life of the building. In other cases, building constructed on leasehold lands are amortised over the primary lease period of the lands.

Depreciation method, useful lives and residual values are reviewed at each financial year-end and adjusted if appropriate.

3.03 Inventories:

Inventories are valued at the lower of cost and net realisable value. Costs incurred in bringing each product to its present location and condition are accounted for as follows:

Raw materials and accessories:

Cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Cost is determined on first in, first out basis.

Finished goods and work in progress:

Cost includes cost of direct materials and labour and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs. Cost is determined on first in, first out basis.

Trading Goods:

Cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Notes to the standalone financial statements (continued)
(all amounts in Rs. lakhs unless otherwise stated)

4. Tangible Assets

Particulars	Building (Right-Of-Use assets)	Freehold land	Leasehold land	Building	Plant and machinery	Furniture and fixtures	Office equipment	Motor vehicles	Total
Gross Block (Deemed Cost)									
Balance as at 01 April 2024	473.37	1,216.16	273.12	2,332.13	5,962.63	134.34	266.61	328.43	10,986.79
Additions	66.55	-	237.85	61.71	825.57	32.91	44.03	14.83	1,283.44
Disposals	-	-	-	-	-	-	-	-	-
									-
Balance as at 31 March 2025	**539.92**	**1,216.16**	**510.97**	**2,393.84**	**6,788.20**	**167.25**	**310.63**	**343.26**	**12,270.24**
Balance as at 01 April 2025	539.92	1,216.16	510.97	2,393.84	6,788.20	167.25	310.63	343.26	12,270.24
Additions	667.25		40.84	94.98	356.73	3.61	30.27	81.30	1,274.97
Disposals					(2.39)			(31.39)	(33.78)
Classification Realignment	1.47	(1.47)	(13.37)	(19.63)	18.63	11.71	3.51	0.87	
Balance as at 31 March 2026	**1,207.17**	**1,217.63**	**550.34**	**2,475.45**	**7,122.92**	**189.49**	**352.61**	**396.68**	**13,512.29**
Accumulated Depreciation									
Balance as at 01 April 2024	**230.43**	**-**	**17.02**	**731.38**	**3,158.27**	**91.54**	**221.25**	**120.60**	**4,570.49**
Additions	133.29	-	1.37	84.43	321.30	12.03	25.98	26.51	604.90
Disposals							-		
Merger Pooling of Interest							-		
Balance as at 31 March 2025	**363.73**	**-**	**18.39**	**815.81**	**3,479.57**	**103.57**	**247.23**	**147.11**	**5,175.40**
Balance as at 01 April 2025	**363.73**	**-**	**18.39**	**815.81**	**3,479.57**	**103.57**	**247.23**	**147.11**	**5,175.40**
Additions	182.37		5.59	87.20	347.54	12.87	28.05	30.48	694.10
Disposals			(0.28)			(29.81)	(30.09)		
Balance as at 31 March 2026	**546.10**	**-**	**23.98**	**903.01**	**3,826.82**	**116.44**	**275.28**	**147.78**	**5,839.41**
Carry Amount (Net)									
Balance as at 31 March 2025	**176.19**	**1,216.16**	**492.58**	**1,578.04**	**3,308.64**	**63.68**	**63.41**	**196.15**	**7,094.84**
Balance as at 31 March 2026	**661.07**	**1,217.63**	**526.36**	**1,572.44**	**3,296.10**	**73.05**	**77.33**	**248.90**	**7,672.84**

1. The assets are owned by the Company except as stated otherwise

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Notes to the standalone financial statements (continued)
(all amounts in Rs. lakhs unless otherwise stated)

5. Capital work-in-progress

Particulars	As at 31 March 2026	As at 31 March 2025
Capital work-in-progress	742.42	278.58
	742.42	**278.58**

Capital work-in-progress ageing schedule

Capital work-in-progress	Amount in Capital work-in-progress for a period of				Total
	Less than 1 Year	1 - 2 Years	2 - 3 Years	More than 3 Years	
Projects in progress Project 1	742.42	-	-	-	742.42
	742.42	**-**	**-**	**-**	**742.42**

6. Intangible Assets

Particulars	Computer software	Development Expenses	Trade Licence	Total Inangible assets
Gross Block (Deemed Cost)				
Balance as at 01 April 2024	**108.54**	**2,312.93**	**198.55**	**2,620.02**
Additions	25.15	325.03	70.73	420.91
Disposals	-	-	-	-
	-	-	-	
Balance as at 31 March 2025	**133.69**	**2,637.96**	**269.28**	**3,040.93**
Additions	26.62	426.04	102.60	555.26
Disposals	-		-	-
Classification Realignment	0.77	-1.40	-0.36	-0.98
Balance as at 31 March 2026	**161.08**	**3,062.61**	**371.53**	**3,595.22**
Accumulated Depreciation				
Balance as at 01 April 2024	**56.59**	**1,299.73**	**125.57**	**1,481.89**
Additions	30.07	236.41	92.81	359.29
Disposals	-		-	-
		-	-	
Balance as at 31 March 2025	**86.66**	**1,536.14**	**218.38**	**1,841.18**
Additions	27.16	283.22	101.41	411.79
Disposals	-	-	-	-
Balance as at 31 March 2026	**113.82**	**1,819.36**	**319.79**	**2,252.97**
Carry Amount (Net)				
Balance as at 31 March 2025	**47.03**	**1,101.82**	**50.90**	**1,199.75**
Balance as at 31 March 2026	**47.26**	**1,243.25**	**51.74**	**1,342.25**

Non-current financial assets

7. Investments

Particulars	As at 31 March 2026	As at 31 March 2025
Investment in equity instruments - Quoted		
" 31 Mar 2026: 19,89,000 (31 Mar 2025: 19,89,000)		
Equity shares of Rs 10 each fully paid in Lifezen Healthcare Private Limited "	198.91	198.91
" 31 Mar 2026: 80,000 (31 Mar 2025 : 80,000)		
Equity shares of Rs 10 each fully paid in Bal Research Foundation "	8.00	8.00
" 31 Mar 2026: 80% (31 Mar 2025 : 80%)		
Percentage of share in Balanace Clinic LLP "	8.00	8.00
" 31 Mar 2026: 9500 (31 Mar 2025: 9500)		
Equity shares of Rs.10 each fully paid 9500 shares in Aurum Res & Antyl soln pvt ltd "	0.95	0.95
- -		
Less: Impairment in value of Investments	-	-
	-	
	215.86	**215.86**
Aggregate Amount of Quoted Investments and market value thereof	-	-
Aggregate Amount of Unquoted Investments	215.86	215.86
Aggregate Amount of Impairment in Value of Investments	-	-

Financial Assets

8. Other financial assets

Particulars	As at 31 March 2026	As at 31 March 2025
Bank Deposits (original maturity of more than 12 months)	522.77	423.47
Earnest Money - Non current	19.35	16.53
Others	-	
Security deposit	264.96	272.24
	807.08	**712.24**

9. Deferred tax Asset (Net)

Particulars	As at 31 March 2026	As at 31 March 2025
Deferred tax Asset (Net)	78.14	39.53
	78.14	**39.53**

Non-financial assets

10. Other non-current assets

Particulars	As at 31 March 2025	As at 31 March 2024
Capital Advances	106.66	158.98
Other Non Current Assets	17.11	17.11
Balances with Statutory/Government Authorities	176.86	191.64
	300.62	**367.74**

Current assets

11. Inventories (valued at lower of cost and net realisable value)

Particulars	As at 31 March 2026	As at 31 March 2025
Raw materials	3,331.31	3,271.35
Packing material	641.27	589.80
Work-in progress	4,410.29	3,350.73
Finished goods	3,224.25	3,059.18
Fuel	5.74	6.74
	11,612.85	**10,277.80**

12. Current Investments

Particulars	As at 31 March 2026	As at 31 March 2025
Investment in Mutual Fund	208.17	246.80
		-
	208.17	**246.80**

Current financial assets

13. Trade Receivables

Particulars	As at 31 March 2026	As at 31 March 2025
Trade Receivables considered good - secured		
Trade Receivables considered good - unsecured	9,636.24	9,484.78
Trade Receivables which have significant increase in credit risk	157.04	154.22
Trade Receivables - credit risk	-	-
	9,793.28	**9,639.00**
Loss Allowance	-157.04	-154.22
	9,636.24	**9,484.78**

Debts due by firms or private companies in which any director is a partner or a director or a member as at 31 March 2026 - Rs380.39 lakhs (31 March 2025 - Rs. 370.68lakhs)

Trade Receivables ageing schedule for the year ended 31 March 2026

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 6 Months	6 Months - 1 Year	1 - 2 Years	2 - 3 Years	
(i) Undisputed Trade Receivables – considered good	9,101.87	204.88	217.48	112.01	9,636.24
(ii) Undisputed Trade Receivables – considered doubtful	-	-	-	-	-
(iii) Disputed Trade Receivables – considered good	-	-	-	-	-
(iv) Disputed Trade Receivables – considered doubtful	-	-	-	-	-
Total	**9,101.87**	**204.88**	**217.48**	**112.01**	**9,636.24**

Trade Receivables ageing schedule for the year ended 31 March 2025

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 6 Months	6 Months - 1 Year	1 - 2 Years	2 - 3 Years	
(i) Undisputed Trade Receivables – considered good	8,532.41	484.38	341.77	126.22	9,484.78
(ii) Undisputed Trade Receivables – considered doubtful	-	-	-	-	-
(iii) Disputed Trade Receivables – considered good	-	-	-	-	-
(iv) Disputed Trade Receivables – considered doubtful	-	-	-	-	-
Total	**8,532.41**	**484.38**	**341.77**	**126.22**	**9,484.78**

14. Loans

Particulars	As at 31 March 2026	As at 31 March 2025
Unsecured-Considered good		
Loan receivables considered good - unsecured	-	-
- Loans/advances to employees	116.56	113.27
	116.57	**113.28**

15. Cash and cash equivalents

Particulars	As at 31 March 2026	As at 31 March 2025
Cash on hand	1.83	2.43
Balance with bank	-	-
- On current Account	131.13	67.35
Deposits with original maturity of less than 3 months	86.52	94.16
	219.49	**163.95**

16. Other Bank balances

Particulars	As at 31 March 2026	As at 31 March 2025
Bank Deposits (maturity between 3 months to 12 months)	482.48	619.06
Balance earmarked for Unclaimed Dividends	8.40	10.83
	490.89	**629.89**

17. Other financial assets

Particulars	As at31 March 2026	As at31 March 2025
Security deposits	33.69	24.35
Unsecured, considered good -	-	
Earnest Money	131.22	103.29
	-	-
	164.91	**127.63**

18. Current tax assets (Net)

Particulars	As at 31 March 2026	As at 31 March 2025
Advance Tax (net of provision)	13.43	98.84
	13.43	**98.84**

Non-financial assets

19. Other Current Assets

Particulars	As at 31 March 2026	As at 31 March 2025
Balances with statutory/government authorities	1,981.49	1,500.54
Govt Incentives Receivable	952.65	231.31
Security Deposit	-	-
- from related parties	978.00	953.00
Advances recoverable in Cash or Kind	-	-
- from related parties	160.91	158.11
Advance to suppliers	538.97	412.80
Insurance claim receivable	79.35	79.35
Prepayments	203.34	134.37
Other curent assets	-	-
- from related parties	-	-
- from others	206.27	152.73
	5,101.00	**3,622.23**

20. Equity

Particulars	As at 31 March 2026	As at 31 March 2025
Authorised Share capital		
31 March 2026: 2,45,00,000 equity shares of Rs.10 each	2,450.00	2,450.00
31 March 2025 : 2,45,00,000 equity shares of Rs.10 each		-
-		
Issued, subscribed and paid-up share capital		-
31 March 2026: 15920872 equity shares of Rs.10 each	1,592.09	1,592.09
31 March 2025 :15920872 equity shares of Rs.10 each		-
	1,592.09	**1,592.09**

a) Reconciliation of the shares outstanding at the beginning and at the end of the period

Particulars	As at 31 March 2025	As at 31 March 2024
Authorised Share capital		
Opening Balance (Number of shares in Lakhs)	159.21	158.05
Add :Shares Issued during the year (Number of shares in Lakhs)		1.16
Closing Balance	**159.21**	**159.21**

b. Rights, preferences and restrictions attached to equity shares:

(i) The Company has only one class of shares referred to as equity shares having par value of Rs 10 each.

(ii) Each holder of the equity share,as reflected in the records of the Company as of the date of the shareholders' meeting,is entitled to one vote in respect of each share held for all matters submitted to vote in the shareholders' meeting.

(iii) The Company declares and pays dividends in Indian Rupees.The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing General Meeting.

(iv) In the event of liquidation of the Company,the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts.The distribution will be in proportion to the number of equity shares held by the shareholders.

(v) Each Share holder has a right to inspect the statutory registers of the company as per the provisions of the companies act,2013.

(vi) Each and every share holder has a right to participate in the share holders's meetings as and when called by the company subject to provisions of the Companies Act,2013.

c) Equity shareholders holding more than 5 percent shares in the Company:

Name of the shareholder	As at31 March 2026 No. of shares(in Lakhs)		As at31 March 2025 No. of shares(in Lakhs)	
	No. of shares	Percentage	No. of shares	Percentage
Shailesh Siroya	27.45	17.24%	27.45	17.24%
Micro Labs Limited	20.11	12.63%	20.11	12.64%
Anita Siroya	10.49	6.59%	10.49	6.59%

(d) Shares reserved for issue under options & contracts/commitments for sale of shares /disinvestment,including the terms & amounts - NIL

(e) For period of 5 years immediately preceding the balance sheet date.

- Alloted as fully paid up by way of bonus shares - NIL
- Bought back - NIL
- For consideration other than cash - NIL

(f) Securities convertible into equity /preference shares issued - NIL

(g) No Calls Unpaid

(h) Issue of securities made for a specific purpose at balance sheet date - Nill

21. Other Equity

Particulars	As at 31 March 2026	As at 31 March 2025
(i) Retained Earnings	-	
Balance as at beginning of the reporting period	4,873.94	4,289.70
Transferred to OCI		-4.65
Add: Net profit/(loss) for the period	675.12	779.95
Less: Dividend payable	-191.05	-191.05
	5,358.01	4,873.94
(ii) Other Reserves*		
Securities premium	3,197.79	3,197.79
General reserve	245.15	245.15
Capital Reserve	44.06	44.06
	3,486.99	3,487.00
(iii) Other comprehensive income		-
Others (acturial gain/ (Loss))	-70.57	-70.90
Add : Transferred from retained earnings		4.65
Add: Net gain/(loss) for the period	43.37	-4.33
	(27.19)	(70.57)
	8,817.81	**8,290.37**

*Refer Statement of changes in equity for detailed movement in other equity balances.

Nature and purpose of reserves

Retained Earnings:
Retained earnings are the profits that the Company has earned till date, less any transfers to general reserve, dividends or other distribution to share holders.

Securities premium:
The amount received in excess of face value of the equity shares is recognised in securities premium. This reserve will be utilised in accordance with provisions of Section 52 of the Companies Act, 2013.

General reserve:
The Company has transferred a portion of its net profit before declaring dividend to general reserve pursuant to the earlier provisions of the Companies Act, 1956. Mandatory transfer to general reserve is not required under the Companies Act, 2013

Other Comprehensive Income (OCI):
Re-measurement of defined employee benefit plans
Difference between the interest income on plan assets and the return actually achieved, any changes in the liabilities over the year due to changes in actuarial assumptions or experience adjustments with in the plans, are recognised in other comprehensive income and subsequently not reclassified into standalone statement of profit and loss

Financial liabilities

22. Borrowings

Particulars	As at 31 March 2026	As at 31 March 2025
Terms loans		
- from banks	2,464.46	686.92
- from others	156.53	1,751.93
GECL Loan	500.00	639.29
Other Loans	-	-
- vehicle loans	67.50	61.89
	-	
	3,188.48	**3,140.03**

The above amount includes		
Secured Barrowings (includes vehicle loans)	**2,567.98**	**2,470.42**
Unsecured Barrowings		
Loan Under guaranteed emergency credit line & Bank Loan	**620.50**	**669.60**

I) A **Term loans (including current maturities of non-current borrowings) from South Indian Bank Limited -Term Loan I**

As at 31 March 2026 :Rs.286.13 lakhs (31 March 2025 :Rs.325.42 lakhs)

Security

i. All the property bearing municipal no 6/3 situated at Vasanthnagar, new ward number 63, Bengaluru consisting of 6825 square feet land owned by the Company

Repayment and interest

ii. The loan was repayable in 154 monthly instalments starting from March 2018.

iii. The loan carried interest rate equal to the lender's 12 month's MCLR rate Date of Maturity : 19.06.2031

B **Term loans (including current maturities of non-current borrowings) from South Indian Bank Limited -Term Loan 2**

As at 31 March 2026 :Rs.232.67 lakhs (31 March 2025 :Rs.253.08 lakhs)

Security

i. All the property bearing municipal no 6/3 situated at Vasanth Nagar, new ward number 63, Bengaluru consisting of 6825 square feet land owned by the Company

Repayment and interest

ii. The loan was repayable in 180 monthly instalments starting from April 2018.

iii. The loan carried interest rate equal to the applicable 12 month's MCLR rate Date of Maturity :31.12.2035

C **Term loans (including current maturities of non-current borrowings) from Canara Bank.**

As at 31 March 2026 :Rs 00.00 lakhs (31 March 2025 : Rs.90.89 lakhs)

Security

i. Hypothecation of Plant and Machinery which were funded from the term loan. For all the limits sanctioned by bank including term loan, charge on current assets of the Company along with HDFC Bank limited and Canara Bank and first charge on the property located in Plot 61B, Bommasandra, Bengaluru and personal guarantee of Mr Shailesh Siroya (managing director)

Repayment and interest

i. The disbursed loan to be repayable in 84 months with 5 months of moratorium and 1 month for project implementation

ii. The loan carried interest rate equal to the applicable RLLR(presently 6.90%)+2.80%+0.8% (Liquidity Premium) - **Date of Maturity : 21.01.2029**

iii. Loan take over by the Federal Bank on 27.03.2026.

D **Term loans (including current maturities of non-current borrowings) from Canara Bank.**

As at 31 March 2026 :Rs 00.00 lakhs (31 March 2025 : Rs.205.36)

Security

i. The assets created out of the credit facility so extended, that is, paripassu first charge on the entire current assets of the Company

Repayment and interest

i. The disbursed loan to be repayable in 72 months with 24 months of moratorium

ii. The loan carried interest rate equal to the applicable RLLR(presently 6.90%)+0.60%= 7.5% Date of Maturity : 29.02.2028

iii. Loan take over by the Federal Bank on 27.03.2026.

ii) Details of securities, repayment and interest of secured term loans from others (including current maturities of long-term debt):

A Term loans (including current maturities of non-current borrowings) from STCI Finance Limited

As at 31 March 2026 : Rs 000.00 lakhs (31 March 2025 : Rs.1900.00)

Security

i. Exclusive Charge by way of mortgage of Plot No.C-155, Mewar Industrial Area, Udaipur, Rajasthan - 313003, presently mortgaged in favour of TFSL towards Term loan which has taken over by STCI Finance Limited

ii. First and Exclusive charge on entire present and future Fixed Assets (both movable and Immovable of Golden Drugs Pvt Ltd.

"Repayment and interest

i. The loan is repayable in 60 monthly instalments shall comments from the end of the 12th month succeding the month of first disbursement. Starting from Jan'25 with an initial moratorium of 12 months"

ii. The loan carried interest rate equal to the lender's long term lending rate @ 12.50% p.a payable monthly. Date of Maturity : 22.12.2029

iii. Loan take over by the Union Bank on 07.07.2025

B Term loans (including current maturities of non-current borrowings) from Small Industries Development Bank of India (SIDBI)

As at 31 March 2026 : Rs 251.93 lakhs (31 March 2025 : Rs.347.33 lakhs)

Security

i. First Charge by way of hypothecation of Plant and Machinery pertaining to the project of Rs.429 Lakhs, ii.Collateral Security FDR of Rs. 129 lakh lien mark with SIDBI in favour of Borrower and unconditional joint and several personal guarantee of Mr Shailesh Siroya (Managing director) and Mr.V.Himesh, Executive Director

Repayment and interest

ii. The loan is repayable in 54 monthly instalments starting from June 2024 with a initial moratorium of 6 months

iii. The loan carried interest rate equal to the lender's long term lending rate less 8.90% Date of Maturity : 10.11.2028

ii) Details of securities, repayment and interest of Working Capital Term Loan under GECL scheme (including current maturities of long-term debt):

C Working Capital Term Loans (including current maturities of non-current borrowings) from Canara Bank limited - 01

Current Maturities as at 31 March 2025 : Rs.00.00 lakhs (31 March 2025 : Rs.91.67 lakhs)

Security

i. The Loan is secured by all assets created out of credit facility

ii. The Loan is further secured by extending the charges created over existing loan.

iii. The facility is to be covered under Emergency Credit Line Guarantee Scheme (ECLGS) administered by National Credit Guarantee Trustee Company (NCGTC) Limited

Repayment and interest

i. Initial moratorium of 12 months and thereafter repayable in 48 months as Rs 8.35 lakhs per month for 47 months and Rs 7.55 lakh per month for 1 month

ii. The loan carried interest rate equal to the lender's long term lending rate less 7.50% p.a Date of Maturity : 15.02.2026

iii. The Loan closed on 15.02.2026

B Working Capital Term Loans (including current maturities of non-current borrowings) from HDFC Bank Limited-02

As at 31 March 2026 : Rs.162.50 lakhs (31 March 2025 : Rs.325.00 lakhs)

Security

i. The Loan is secured by all assets created out of credit facility

ii. The Loan is further secured by extending the charges created over existing loan.

iii. The facility is to be covered under Emergency Credit Line Guarantee Scheme (ECLGS) administered by National Credit Guarantee Trustee Company (NCGTC) Limited

Repayment and interest

i. Total tenor of 60 months with 12 months moratorium period .

ii. The loan carried interest rate equal to 7.5%.p.a Date of Maturity : 26.03.2027

C Working Capital Term Loans (including current maturities of non-current borrowings) from HDFC Bank Limited-03

As at 31 March 2026 : Rs 500 lakhs (31 March 2025 : Rs.700 lakhs)

Security

i. The Loan is secured by all assets created out of credit facility

ii. The Loan is further secured by extending the charges created over existing loan.

iii. The facility is to be covered under Emergency Credit Line Guarantee Scheme (ECLGS) administered by National Credit Guarantee Trustee Company (NCGTC) Limited

Repayment and interest

i.Total tenor of 48 months with 24 months moratorium period .

ii.The loan carried interest rate equal to 8%.p.a Date of Maturity : 28.09.2028

iv) Details of securities, repayment and interest of Term Loan / W C D L (including current maturities of long-term debt):

A Term loans (including current maturities of non-current borrowings) from South Indian Bank Limited - Term Loan 3

As at 31 March 2026 : Rs.268.73 lakhs (31 March 2025 : Rs.000.00 lakhs)

Security

i. All the property bearing municipal no 6/3 situated at Vasanth Nagar, new ward number 63, Bengaluru consisting of 6825 square feet land owned by the Company

Repayment and interest

ii. The loan was repayable in 48 monthly instalments starting from 1st Sept'2025

ii. The loan carried interest rate equal to the applicable 12 month's MCLR rate (Bench Mark + Spread) 10.25% Date of Maturity : 05.10.29

iii. Fresh Loan sanctioned by South Indian Bank Mortgage Loan - TL - 300.00 lakhs

B Term loans (including current maturities of non-current borrowings) from Federal Bank - TL 1

As at 31 March 2026 : Rs .67.69 lakhs (31 March 2025 : Rs.00.00 lakhs)

Security

i. Exclusive charge on the assets acquired out of term Loan valued at 9.03 Cr.

Repayment and interest

i. The disbursed loan to be repayable in 12 months with Nil moratorium- Equal monthly repayment.

ii. The loan carried interest rate equal to the applicable Bench Mark + Spread (5.25+3.75 =9 %) - Date of Maturity : 21.01.2029

iii. Loan take over from Canara Bank on 27.03.2026.

C Term loans (including current maturities of non-current borrowings) from Federal Bank.-TL 2

As at 31 March 2026 : Rs 136.72 lakhs (31 March 2025 : Rs.00.00)

Security

i. First paripasur charge along with HDFC Bank on current assets including stocks and book debts (Present and Future of the company)

Repayment and interest

i. The disbursed loan to be repayable in 12 months with Nil moratorium- Equal monthly repayment.

ii. The loan carried interest rate equal to the applicable Bench Mark + Spread (5.25+ 3.75 = 9%) Date of Maturity : 29.02.2028

iii. Loan take over from Canara Bank on 27.03.2026.

D Term loans (including current maturities of non-current borrowings) from UNION BANK - TLSUV - 1

As at 31 March 2026 : Rs 1552.64 lakhs (31 March 2025 : Rs.000.00)

Security

i. Exclusive Charge by way of mortgage of Plot No.C-155, Mewar Industrial Area, Udaipur, Rajasthan - 313003, presently mortgaged in favour of Union Bank towards Term loan which has taken over by Union Bank from STCI Finance Limited.

ii. First and Exclusive charge on entire present and future Fixed Assets (both movable and Immovable) of Unit 6, Situated at Udaipur, presently owned by Bal Pharma Limited.

Repayment and interest

i. The loan is repayable in 54 monthly instalments shall comments from 25th Sept'25 with Nil moratorium.

ii. The loan carried interest rate equal to the EBLR @ 8.25% p.a payable monthly. Date of Maturity : 25.02.2030

iii. The Loan taken over from STCI Finance Limited

E Term loans (including current maturities of non-current borrowings) from UNION BANK -TLSUV - 2

As at 31 March 2026 : Rs 168.00 lakhs (31 March 2025 : Rs.000.00)

Security

i. Exclusive Charge by way of mortgage of Plot No.C-155, Mewar Industrial Area, Udaipur, Rajasthan - 313003, presently mortgaged in favour of Union Bank towards Term loan which has taken over by Union Bank from STCI Finance Limited.

ii. First and Exclusive charge on entire present and future Fixed Assets (both movable and Immovable) of Unit 6, Situated at Udaipur, presently owned by Bal Pharma Limited.

Repayment and interest

i. The loan is repayable in 60 monthly instalments shall comments from 24th July'26 with Nil moratorium.

ii. The loan carried interest rate equal to the EBLR @ 8.25% p.a payable monthly. Date of Maturity : 24.06.2031

iii. Fresh Loan sanctioned by Union Bank for Capex at Unit -6 for 400.00 lakhs Disbursed so far 168.00 lakhs

F Working Capital Demand Loans (including current maturities of non-current borrowings) from HDFC Bank Limited

As at 31 March 2026 : Rs 458.33 lakhs (31 March 2025 : Rs.00.00 lakhs)

Security

i. The Loan is secured by way of Equitable mortgage of Unit I located at Plot no.21 and 22, sy No270,298 and 328,and Unit -2 API Division Locted at #61/B, Bommasandra Industrial area, Bangalore 560 099, Karnataka

ii. The Loan is further secured by personal Guarantee of Mr. Shailesh Siroya

Repayment and interest

i. Total tenor to be repaid 60 equal monthly instalments.

ii. The loan carried interest rate equal to 8.5% linked to Repo Rate 3M (Repo Rate + 3%) Date of Maturity : 14.10.2030

iii. Fresh Loan sanctioned by HDFC Bank Limited for Capex at Unit -I & II for 500.00 lakhs

v) Details of Vehicle loans (including current maturities of long-term debt):

A Vehicle Loans (including current maturities of non-current borrowings) from HDFC Bank Limited - INNOVA HYCROSS HYBRIDE

As at 31 March 2026 : Rs.15.07 lakhs (31 March 2025 : Rs.21.14 lakhs)

(i) Secured by hypothecation of motor vehicles.

(ii) These loans carry an interest rate of 8.50%

(iii) The principal amount has to be repaid in 60 equated monthly instalments Date of Maturity : 05.05.2028

B Vehicle Loans (including current maturities of non-current borrowings) from HDFC Bank Limited - MAHINDRA XUV700 AX7AWD

As at 31 March 2026 : 16.12 Rs.lakhs (31 March 2025 : Rs.22.34)

(i) Secured by hypothecation of motor vehicles.

(ii) These loans carry an interest rate of 9 %

(iii) The principal amount has to be repaid in 60 equated monthly instalments Date of Maturity : 05.06.2028

C Vehicle Loans (including current maturities of non-current borrowings) from HDFC Bank Limited - GLANZA 1.2 G P MT

As at 31 March 2026 : Rs.3.91 lakhs (31 March 2025 : Rs.5.46 lakhs)

(i) Secured by hypothecation of motor vehicles.

(ii) These loans carry an interest rate of 9 %

(iii) The principal amount has to be repaid in 60 equated monthly instalments Date of Maturity: 05.05.2028

D Vehicle Loans (including current maturities of non-current borrowings) from HDFC Bank Limited - EECO AMBULANCE

As at 31 March 2026 : Rs.2.05 lakhs (31 March 2025 : Rs.3.76 lakhs)

(i) Secured by hypothecation of motor vehicles.
(ii) These loans carry an interest rate of 10%
(iii) The principal amount has to be repaid in 39 equated monthly instalments.- Date of Maturity :05.04.2027

E Vehicle Loans (including current maturities of non-current borrowings) from Mercedes- Benz Financial Services India Pvt Lrd
As at 31 March 2026 :Rs.19.66 lakhs (31 March 2025: Rs.34.16 lakhs)
(i) Secured by hypothecation of motor vehicles.
(ii) These loans carry an interest rate of 7.27%
(iii) The principal amount has to be repaid in 60 equated monthly instalments. Date of Maturity :04.06.2027

F Vehicle Loans (including current maturities of non-current borrowings) from Union Bank of india - EECO -CAR
As at 31 March 2026 :Rs.1.57 lakhs (31st March 2025 : Rs.2.53 lakhs)
(i) Secured by hypothecation of motor vehicles.
(ii)These loans carry an interest rate of 9.45%
(iii)The principal amount has to be repaid in 60 equated monthly instalments.Date of Maturity :05.09.2027

G Vehicle Loans (including current maturities of non-current borrowings) from HDFC BANK LTD - RUDRAPUR - GLANZA
As at 31 March 2026 :Rs.3.82 lakhs (31 March 2025: Rs 5.84 lakhs)
(i) Secured by hypothecation of motor vehicles.
(ii) These loans carry an interest rate of 9.53%
(iii) The principal amount has to be repaid in 36 equated monthly instalments.Date of Maturity 05.11.2027

vi) Details of Unsecured loans (including current maturities of long-term debt) from Kotak Mahindra Bank Limited:
A Kotak Mahindra Bank Limited-Jaldi Loan-Personal Loan-01
As at 31 March 2026 :Rs.00.00 lakhs (31 March 2025 : Rs.11.91 lakhs)
i. The Loan is Not secured and sanctioned loan under Jaldi Loan credit facility offered by Kotak Mahindra Bank Limited
Repayment and interest
i. Total tenor of 24 months without any moratorium period .
ii. The loan carried interest rate equal to 14.17 %.p.a Date of Maturity : 10.05.2025
iii. The Loan closed on 10.05.2026

B Kotak Mahindra Bank Limited-Jaldi Loan-Personal Loan-02
As at 31 March 2026 :Rs.00.00 lakhs (31 March 2025 : Rs.18.40 lakhs)
i.The Loan is Not secured and sanctioned loan under Jaldi Loan credit facility offered by Kotak Mahindra Bank Limited
Repayment and interest
i.Total tenor of 24 months without any moratorium period .
ii.The loan carried interest rate equal to 14.50%.p.a Date of maturity : 10.11.2025
iii.The Loan closed on 10.11.2025

vii) Details of Unsecured loans (including current maturities of long-term debt) from Kotak Mahindra Bank Limited: [New Loan]
A Kotak Mahindra Bank Limited-Jaldi Loan-Personal Loan-03
As at 31 March 2026 : 122.73 Rs. lakhs (31 March 2025 : Rs.00.00 lakhs)
i. The Loan is Not secured and sanctioned loan under Term Loan offered by Kotak Mahindra Bank Limited
Repayment and interest
i. Total tenor of 24 months without any moratorium period .
ii. The loan carried interest rate equal to 14 %.p.a Date of Maturity : 10.10.2027
iii. Fresh Loan sanctioned by Kotak Mahindra Bank Limited for 150.00 lakhs.

viii) Details ofVehicle loans (including current maturities of long-term debt): [New Loans]

A Vehicle Loans (including current maturities of non-current borrowings) from AXIS BANK - INNOVA HYCROSS

As at 31 March 2026 : Rs.30.15 lakhs (31 March 2025 : Rs.0.00 lakhs)

(i) Secured by hypothecation of motor vehicles.

(ii) These loans carry an interest rate of 8.50%

(iii) The principal amount has to be repaid in 39 equated monthly instalments Date of Maturity : 01.11.2028

B Vehicle Loans (including current maturities of non-current borrowings) from BANK OF BARODA - HONDA CITY

As at 31 March 2026 : Rs.12.74 lakhs (31 March 2025 : Rs.0.00 lakhs)

(i) Secured by hypothecation of motor vehicles.

(ii) These loans carry an interest rate of 8.50%

(iii) The principal amount has to be repaid in 36 equated monthly instalments Date of Maturity : 10.03.2028

C Vehicle Loans (including current maturities of non-current borrowings) from HDFC Bank Limited - MAHINDRA XEV

As at 31 March 2026 : Rs.20.08 lakhs (31 March 2025 : Rs.0.00 lakhs)

(i) Secured by hypothecation of motor vehicles.

(ii) These loans carry an interest rate of 8.38 %

(iii) The principal amount has to be repaid in 39 equated monthly instalments Date of Maturity : 07.01.2029

ix) There are no defaults in repayment of principal or interest to lenders as at the balance sheet date, however, in certain cases based on information available as on date, there exists delay in repayment of loan as mentioned below.

A The following are delay in repayments towards loan for the year ended March 31, 2025

In case of vehicle loans taken from HDFC Bank Limited, the terms of which is stipulated in (iv) above, there is a delay in repayment for 7 days in the month of April 24 where auto debit was linked is rejected due to signature mismatch.

In case of Unsecured loans taken from Kotak Mahindra Bank Limited-02, the terms of which is stipulated in (v) above, there is a delay in repayment for 2 days in the month of April 24 where auto debit was linked is rejected due to signature mismatch in ECS form.

In case of Unsecured loans taken from Kotak Mahindra Bank Limited-02, the terms of which is stipulated in (v) above, there is a delay in repayment for 1 day in the month of Feb 25 due to bank server error.

B There are no delays in repayment towards loan for the year ended 31st March, 2026.

23 Other financial liabilities

Particulars	As at 31 March 2026	As at 31 March 2025
Lease Liability (Ind AS 116)	561.21	127.65
	561.21	**127.65**

24. Provisions

Particulars	As at 31 March 2026	As at 31 March 2025
Provision for employee benefits		-
Gratuity	495.10	469.84
Leave benefits	120.68	90.59
	-	
	615.77	**560.43**

Current financial liabilities

25. Borrowings

Particulars	As at 31 March 2026	As at 31 March 2025
Secured:		
- Cash Credit	6,182.34	5,808.72
- Packing Credit	4,340.75	4,273.55
- Buyers Credit	203.50	71.89
Current maturities of long-term debt *		-
- term loan from banks	1,142.17	161.20
- term loan from others	95.40	495.40
- vehicle loans	59.67	33.01
- GECL loan	162.49	477.37
- others	-	-
	12,186.31	**11,321.14**

A) All secured loans payable on demand and secured short term loans from banks are secured by first charge by way of hypothecation of all the stocks, book debts and other current assets (both present and future) and carries interest rate @ 9.75% to 13.15%

26. Trade Payables

Particulars	As at 31 March 2026	As at 31 March 2025
Due to Micro, Small and Medium Enterprises*	39.26	461.66
Due to Other than Micro, small and Medium Enterprises		-
- Due to Related Parties	161.20	63.47
- Due to Others	8,716.77	7,659.66
	8,917.22	**8,184.79**

Trade Payable ageing schedule for year ended March 2026

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1 - 2 Years	2 - 3 Years	More than 3 Years	
(I) Micro, Small and Medium Enterprises (MSME)	39.26				39.26
(ii) Others	8,503.09	61.37	48.29	265.21	8,877.96
(iii) Disputed Dues - Micro, Small and Medium Enterprises (MSME)				-	
(iii) Disputed Dues - Others				-	
Total	**8,542.35**	**61.37**	**48.29**	**265.21**	**8,917.22**

Trade Payable ageing schedule for year ended March 2025

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1 - 2 Years	2 - 3 Years	More than 3 Years	
(I) Micro, Small and Medium Enterprises (MSME)	461.66				461.66
(ii) Others	7,322.49	53.27	52.91	294.47	7,723.13
(iii) Disputed Dues - Micro, Small and Medium Enterprises (MSME)				-	
(iii) Disputed Dues - Others				-	
Total	**7,784.14**	**53.27**	**52.91**	**294.46**	**8,184.79**

27. Other Financial Liabilities

Particulars	As at 31 March 2026	As at 31 March 2025
Interest accrued but not due	27.17	32.70
Interest accrued and due	-	-
Security deposits	149.88	148.88
Payable towards purchase of PPE & Outsourcing	1,263.81	206.93
Accrued Payroll	522.03	496.49
Unclaimed Dividends	8.36	10.79
Payable towards Dividend Distribution Tax	-0.00	-0.00
Lease Liability (IND AS 116)	146.81	61.76
Rental Deposits	-	-
Rental Deposits from Related Party	4.00	4.00
Other current liabilities	-	-
- Due to Others	340.99	113.63
	-	
	2,463.05	**1,075.15**

* For details of terms of loan, refer note no. 22

28. Other Current Liabilities

Particulars	As at 31 March 2026	As at 31 March 2025
Advance received from Customers	623.00	552.24
Statutory dues	63.41	84.67
Other Current Liabilities	-0.00	11.67
	686.42	**648.58**

29. Provision

Particulars	As at 31 March 2025	As at 31 March 2024
Provision for employee benefits		
Gratuity	57.01	82.17
Leave Encashment	20.14	34.00
	77.15	**116.16**

30. Revenue from operations

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Sale of Product	30,211.48	29,368.62
Other operating revenue	868.22	881.02
	31,079.70	**30,249.64**

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Sale of Product		
API		
- Domestic	5,780.08	6,415.95
- Exports	9,182.20	6,819.52
Formulations		
- Domestic	5,427.77	4,627.76
- Exports	9,821.43	11,505.39
	30,211.48	**29,368.62**
Other operating revenue		
Scrap Sales	14.18	44.40
Govt Incentives	854.04	836.62

31. Other income

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Interest income		
- on fixed deposits with bank	84.68	73.64
- Others	10.61	26.34
	-	-
Net gain on foreign currency translation and transactions	42.82	29.11
Profit on sale of Property, Plant and Equipment	5.61	-
Rental Income	19.56	19.56
Insurance Claim	5.69	1.35
Balances/Advances No More Payable	-	14.20
Reverseal of expected Credit Loss	-	11.28
Other Non -Operating revenue	31.32	39.46
	200.29	**214.93**

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Notes to the standalone financial statements (continued)
(all amounts in Rs. lakhs unless otherwise stated)

32. Cost of materials consumed

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Raw materials		
Opening stock	3,271.35	2,495.27
Add: Purchases - Raw Material	14,543.73	14,286.08
Less: Closing stock	-3,331.31	-3,271.35
	14,483.77	**13,510.00**
Packing Materials		
Opening Stock	589.80	549.02
Add: Purchases - Packing Material	1,664.43	1,519.39
Less: Closing stock	-641.27	-589.80
	1,612.97	**1,478.61**
	16,096.74	**14,988.61**

33. Purchases of traded goods

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Purchase of traded goods	912.94	1,496.68
	912.94	**1,496.68**

34. (Increase)/decrease in Inventories of finished goods and work in progress

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Inventories at the end of the year		
Work-in-progress	4,410.29	3,350.73
Finished goods	3,224.25	3,059.18
	7,634.54	**6,409.91**
Inventories at the beginning of the year		
Work-in-progress	3,350.73	3,091.65
Finished goods	3,059.18	2,610.14
	6,409.91	**5,701.79**
	(1,224.63)	**(708.12)**

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Notes to the standalone financial statements (continued)
(all amounts in Rs. lakhs unless otherwise stated)

35. Employee benefits expense

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Salary and wages	5,922.39	5,543.26
Contribution to provident and other funds	224.21	221.83
Staff welfare expenses	313.52	296.98
Share based payment Expense	-	2.47
Gratuity Expenses	97.68	96.76
Leave Encashment Expense	34.59	21.58
	6,592.40	**6,182.89**

36. Finance Cost

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Interest Expenses on Term Loan	391.32	446.19
Interest Expenses on Working Capital	860.98	833.53
Interest Expenses GECL	26.39	51.37
Interest Expenses - others	152.57	101.04
Interest Expenses on Lease Liability (Ind AS 116)	57.00	20.76
Other Finance Cost	192.76	231.63
	1,681.02	**1,684.5**

37. Depreciation and Amortisation

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Depreciation on Property, Plant and Equipment	694.10	605.59
Amortisation on Intangible Assets	411.80	359.29
	1,105.90	**964.88**

38. Other expenses

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Consumption of stores and spares	65.27	37.72
Power and fuel		
Fuel - Opening Balance	6.74	7.36
Add: Fuel/Spares Purchases	353.08	300.18
Less: Closing Stock of Fuel/Spares	-5.74	-6.74
Cost of fuel consumption	354.09	300.80
Electricity charges	12.21	13.79
Power charges	539.11	478.12
Water Charges	53.84	36.41
Laboratory and Testing Charges	336.48	311.39
Sub contracting expenses	366.75	213.47
Repairs & Maintenance		
- Plant and machinery	330.46	279.94
- Building	95.90	98.12
- Others	108.86	148.87
Commission on sales & Others	404.43	660.99
Commission on Import	94.59	76.28
Freight and forwarding charges	842.72	783.01
Net loss on foreign currency translation and transactions	188.60	-
Travelling Expenses	244.60	335.32
Advertisement and selling expenses	445.64	465.10
Legal and professional charges	241.39	254.43
Rent	86.13	103.20
Rates & Taxes	121.42	210.68
Communication Cost	70.74	52.59
Registeration fees	-	0.00
Liquidated damages	15.95	28.31
Security Charges	90.39	85.03
Donation	2.55	6.46
Corporate Social Responsibility	17.86	19.00
Seminar, Conference & Exhibition Expenses	75.95	22.69
Insurance	157.12	150.43
Printing & Stationary	48.72	41.27
Subscription & Membership	25.62	29.94
Bank charges	20.65	19.92
Expected Credit Losses	2.81	-
Balances/Advances No More Recoverable	0.02	-
Director Sitting fee	2.16	2.22
Miscellaneous Expenses	16.08	16.39
	5,479.10	**5,281.89**

39. Contingent liabilities and commitments

Particulars	As at 31 March 2026	As at 31 March 2025
Contingent liabilities		
- Income tax	298.22	326.22
- Excise & Customs and Service Tax (refer note 1 below)	223.04	223.04
- GST	36.47	1,160.39
Capital commitments		
- Estimated amount of contracts remaining to be executed on capital account (net of advances) and not provided for	-	-

Note 1 : The Company has received show cause notices under the Central Excise laws and Service Tax laws in for the years 2007-08 onwards which in various stages of assessment as at 31 March 2026.The assessments are in progress and the Company has not received the assessment order in respect of the same. In certain cases, the Company has preferred an appeal which has been remanded back to the original authority for reassessment.

Other Disputes

The Company is also involved in other lawsuits, claims, investigations and proceedings, which arise in the ordinary course of business, however, there are no such matters pending that the company expects to be material in relation to its business.

40. Auditors' remuneration excluding tax (included in Legal and Professional Charges)

Particulars	As at 31 March 2025	As at 31 March 2024
As auditor		
- for Statutory audit	12.50	12.50
- for Taxation matters	2.00	2.00
- for Limited Review	0.40	0.40
- for Internal Financial Controls & Reporting	1.50	1.50
In other capacity		
Other services (certification fees)	2.75	2.85
	19.15	**19.25**

41. Disclosure with respect to Micro and Small Enterprises

The Company has certain dues to Micro and small enterprises registered (suppliers) under Micro, Small, and medium Enterprises Development Act, 2006(MSMED Act) .The disclousure pursuant to the said MSMED Act, to the extent the information is available with company are as below:

(Rs. in Lakhs)

a)	Principal amounts due to suppliers remaining unpaid as at the year end	39.26
b)	Interest due to the suppllier as at the year and	

42. Confirmations

Balances of Trade Receivables, Trade Payables, Loans and Advances, Receivables and Payables are subject to confirmation / reconciliation, if any

43. Earnings per share

Basic EPS amounts are calculated by dividing the income for the year attributable to equity holders by the weighted average number of equity shares outstanding during the year.The Company has no potentially dilutive instruments.

(i) Reconciliation of earnings used in calculating earnings per share:

Particulars	As at 31 March 2026	As at 31 March 2025
From continuing operations: Total Profit / (Loss) for the period attributable to Equity shareholders	718.50	775.62
Net profit/(loss) for basic and diluted earnings	**718.50**	**775.62**

(ii) Reconciliation of basic and diluted shares used in computing earnings per share

Particulars	As at 31 March 2026	As at 31 March 2025
Number of equity shares at the beginning of the year (in Lakhs)	159.20	158.05
Add: Weighted average number of equity shares issued during the year	-	0.49
Number of weighted average equity shares considered for calculation of basic and diluted earnings per share (in lakhs)	159.20	158.53

(iii) Earnings per share:

Particulars	As at 31 March 2026	As at 31 March 2025
Basic	4.51	4.89
Diluted	4.51	4.89

(All share warrants issued at average market price)
*The Company has no potential dilutive instrument

44. Unclaimed Dividends on Equity Shares

Particulars	As at 31 March 2026	As at 31 March 2025
2017 - 2018		2.48
2018 - 2019	2.06	2.60
2020 - 2021	1.56	1.66
2021 - 2022	1.10	1.40
2022 - 2023	0.98	1.22
2023 - 2024	1.36	1.43
2024 - 2025	1.30	
	8.36	**10.79**

45. Expenditure on corporate social responsibility activities

Particulars	As at 31 March 2026	As at 31 March 2025
(a) Amount required to be spent by the Company during the year*	16.28	19.00
(b) Amount spent during the year	17.86	19.00

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Notes to the standalone financial statements (continued)

(all amounts in Rs. lakhs unless otherwise stated)

Particulars	As at 31 March 2026	As at 31 March 2025
Where the company covered under section 135 of the companies act, the following shall be disclosed with regard to CSR activities:-		
(a) amount required to be spent by the company during the year,	16.28	19.00
(b) amount of expenditure incurred,	17.86	19.00
(I) Construction/acquisition of any asset		
(ii) On purposes other than (i) above	17.86	19.00
(c) shortfall at the end of the year,	-	-
(d) total of previous years shortfall,	-	-
(e) reason for shortfall,		
(f) nature of CSR activities,	Education to socially and financially underprivileged children & Financial assistance to health care institutions, Food & Nutrition	Education to socially and financially underprivileged children & Financial assistance to health care institutions
(g) details of related party transactions		
(h) Provision made in respect of a Liability incurred due to a Contractual Obligation		

46. Leases

(a) Company as a lessee

The Company adopted Ind-AS 116, on all lease contracts, except for the leases with a term of twelve month or less (short term leases) and low value leases using the modified retrospective method with Right-of-use assets recognised at an amount equal to the lease liabilities in the balance sheet. The Right-of-use assets as on March 31, 2025 and March 31, 2026 have been presented as part of Property, plant and equipment. For these short term leases, the Company recognises the lease payments as an operating expense on a straight line basis over the period of lease.

Changes in Lease Liabilities

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Opening Balance	189.42	260.20
On account of adoption of Ind AS 116		
Additions	667.25	66.55
Finance Cost	57.00	20.76
Payment of Lease Liabilities	-205.65	-158.08
Closing Balance	708.02	189.42
Current Lease Liabilities	146.81	61.76
Non-current Lease Liabilities	561.21	127.66

48.Leases (continued)

Contractual Maturities of Lease Liability

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Less than one year	146.81	61.76
1 to 5 years	527.48	77.56
above 5 years	33.72	50.10

47. Export Benefit Incentives

Export benefit Incentives includes Duty Drawback ('DBK'), Focus Marketing incentive scheme(FMS), Focus product scheme (FPS), Market Linked Product Scheme (MLPS), Incremental Exports incentive scheme, Merchandise Export India Scheme, Service tax rebate scheme (STR) and Remission of Duties or Taxes on Export Products Scheme .The Company has accounted an amount of Rs. 254.03 lakhs (31 March 2025 : Rs. 236.62 lakhs) under "other operating revenue", being the net amount of credit under various export incentive schemes as announced under Foreign trade Policy.The same will be either be sold or utilized for off-setting customs duty on future imports.The accumulated amount outstanding on this account as on 31 March 2026 is Rs. 352.65 lakhs (31 March 2025 is Rs. 231.31 lakhs) and the same is reflected under Export Incentives Receivable.

48. Segment reporting

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses and for which discrete financial information is available.The operating segments' operating results are reviewed by the Chief Operating Decision Maker (Board of Directors) to make decisions about resources to be allocated to the segments and assess their performance. The Company's business activities fall within one component namely, "manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients". Accordingly, separate disclosures per the requirements of Ind AS 108, Operating Segments, are not considering necessary.

In accordance with Ind AS-108 "Operating Segments", information about geographical areas has been given in the Consolidated Financial Statements of Bal Pharma Limited and therefore, no separate disclosure on geographical areas is given in these financial statements

49. Income tax

A. Amounts recognised in statement of profit and loss

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Current income tax:		
Current income tax charge	-	-
Excess/Short provision of tax written back	-	(14.06)
Previous Year's Tax Adjustment	-	-
	-	(14.06)
Deferred tax:		
Attributable to -		
Origination and reversal of temporary differences	(38.61)	(192.66)
	(38.61)	(192.66)
Minimum Alternate Tax credit entitlement		
Excess of tax liability under Minimum Alternate Tax over Normal Provisions as per Income Tax Act, 1961	-	-
	-	-
Income tax (credit) / expense reported in the Statement of profit or loss	**(38.61)**	**(206.72)**

B. Income tax recognised in other comprehensive income

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Net (gain)/loss on remeasurement of defined benefit liability/ (assets)	-	-
Income tax charged to OCI	**-**	**-**

C. Reconciliation of tax expense and the accounting profit multiplied by India's domestic tax rate:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Profit before income tax	636.51	573.23
Domestic tax rate *	27.82%	27.82%
Tax using the Company's domestic tax rate	177.08	159.47
Impact of Non-taxable items due to Ind AS adjustments	20.00	8.72
Weighted Deductions and Exemptions	(118.53)	(90.42)
Impact of non-deductible expenses for tax purposes	8.00	16.37
Impact of deductible expenses for tax purposes	(66.40)	(54.26)
Impact of disallowance for non payment and non deduction of TDS	0.67	-
Impact of allowability of certain expenditure on payment basis	5.88	16.77
Impact of Depreciation on Property, Plant and Equipment and others	114.72	70.02
Impact of tax losses on tax expense	(141.42)	(126.67)
Excess/Short provision of tax written back	-	(14.06)
Previous Year's Tax Adjustment	-	-
Others	-	-
Current tax Expense	**0.00**	**(14.06)**
Effective Tax Rate	0.00%	-2.45%

* Including applicable surcharge rate and cess

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Notes to the standalone financial statements (continued)
(all amounts in Rs. lakhs unless otherwise stated)

49. Income tax (continued)

D. Deferred Tax

Deferred tax relates to the following:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Deferred Tax Liability		
Property, Plant and Equipment	(528.90)	(552.80)
Borrowings	(18.74)	(15.84)
Deferred tax Asset		
Allowability of certain expenditure on payment basis	203.35	203.01
Disallowance under sec 40(a)(ia)	-	-
Impairment of Investments	-	-
Lease Liability and ROU Asset	196.97	52.70
Provision for Doubtful debts	43.69	42.91
Carried forward loss	181.77	309.56
Deferred tax Asset Reflected in Balance Sheet	**78.14**	**39.53**

50. Expenditure on Research and Development

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Total Expenditure		
Raw material consumed	1.00	4.02
Power and Fuel	82.47	66.06
Water Charges	4.77	4.54
Laboratory and testing	1.50	17.56
Employee benefit expense	209.32	191.37
Others	126.99	41.47
Total Expenditure towards Research and Development	**426.04**	**325.03**
Amount Capitalised (refer note 6)		
Development Expenses	-426.04	-325.03

51. Note on Suspended Activities in Unit located at Pune

"The Management of the Company has decided to suspend the operations of its IV fluids and parenterals manufacturing facility at Pune as this unit has been consistently incurring operational losses due to various reasons such as higher costs of raw materials, escalation in production cost, employee cost, lack of adequate orders and thin margins on products manufactured.The above have led to a situation wherein any further efforts to restore the profitability of the unit will be futile.

This decision was taken as part of the restructuring exercise undertaken by the Company to streamline its operations and to exit from its noncore businesses, so that further deterioration of its noncore business revenues can be plugged. The management is considering both avenues of disinvestment of the Unit or partnering with an outside party, whichever is beneficial."

52. Value of Imports calculated on CIF basis

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Raw Materials	5,142.87	5,770.38
Capital goods (Including spares and components)	-	-
	5,142.87	**5,770.38**

53. Details of consumption of imported and indigenous raw materials, components and spare parts:

Particulars	31 March 2026		31 March 2025	
	Value in Rs	% of total consumption	Value in Rs	% of total consumption
Raw Material				
Imported	6,430.65	39.95%	5,887.53	39.28%
Indigenous	9,666.09	60.05%	9,101.09	60.72%
16,096.74	**100%**	**14,988.61**	**100%**	
Stores and Spares				
Imported	-	-	-	-
Indigenous	-	-	-	-
	-	-	-	-
	16,096.74		**14,988.61**	

54. Earnings in Foreign Currency

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
FOB value of Exports	17,267.09	16,517.83
	17,267.09	**16,517.83**

55. Expenditure in Foreign Currency

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Lab Chemical		1.78
Traveling expenditure	51.74	132.41
Registration fee	7.17	36.43
Commission on export sales	172.48	354.88
Sales promotion expenses	104.81	62.03
Inspection Fees	35.01	9.60
Packing charges	-	3.98
software and Maintaince	-	25.15
Total	**371.21**	**626.26**

56. Related Party Transactions

A	**Subsidiaries**	
	Subsidiary Entity	Balance Clinics LLP
	Subsidiary Company	Bal Research Foundation
	Subsidiary Company	Lifezen Healthcare Private Limited
	Subsidiary Company	Aurum Research & Analytical Solutions Pvt Ltd
B	**Enterprise owned by the Managing Director of the company**	Desa Marketing International
C	**Enterprise over which the Managing Director of the Company exercises joint control with other relatives**	Siroya Construction Siroya Wellness
D	**Enterprise over which the Managing Director of the Company exercises control**	Siroya Properties & Holdings
E	**Significant Interest Entities**	Micro Labs Limited
F	**Key management personnel**	Shailesh D. Siroya - Managing Director Himesh Virupakshaya - Whole-Time Director C. D. Kotian - Whole-time Director (Resigned on May 16, 2025) Bharath Bhushan D.V. - CFO Abdul Basith - CS & Compliance Officer (Date of relieving: 11 May 2026)Ravindra Kumar Kothari - Non-Executive Director (Date of Appointment: 18 March 2026)

(ii) Particulars of Related Party Transactions

Particulars	Category	For the year ended 31 March 2026	For the year ended 31 March 2025
Revenue from Operations			
- Micro Labs Limited	E	247.39	328.90
-Lifezen Healthcare Private Limited	A	20.81	7.99
- Balance Clinics LLP	A		17.05
		268.20	353.94
Other Income - Rental Income			
- Lifezen Healthcare Private Limited	A	5.16	5.16
- Bal Research Foundation	A	2.40	2.40
		7.56	7.56
Purchase of traded goods/Material			
- Lifezen Healthcare Private Limited	A	18.95	21.46
		18.95	21.46
Commission on sales			
- Shailesh D Siroya	F	28.66	51.35
- Desa Marketing International	B	94.59	72.34
		123.25	123.69
Rental Expenses			
- Shailesh D Siroya	F	15.00	15.00
		15.00	15.00

56. Related Party Transactions (continued)

(ii) Particulars of Related Party Transactions

Particulars	Category	For the year ended 31 March 2026	For the year ended 31 March 2025
Key Managerial Personnel Compensation			
-Shailesh D Siroya	F	180.00	183.33
- HimeshVirupakshaya	F	19.05	37.13
-Abdul Basith	F	7.38	7.63
- Bharath Bhushan DV	F	34.20	33.71
- Ravindra Kumar Kothari	F	0.78	
- Chittanand Damodar Kotian (resigned on 16 May 2025)	F	-	14.81
		241.41	**276.61**
Deposit Provided for rendering of services			
-Lifezen Healthcare Private Limited	A	25.00	37.00
		25.00	37.00

iii. Amount outstanding as at the balance sheet date

Particulars	Category	For the year ended 31 March 2026	For the year ended 31 March 2025
Capital advances			
- Siroya Properties & Holdings Private Limited	D	18.89	74.51
		18.89	**74.51**
Trade Receivables			
- Lifezen Healthcare Private Limited	A	280.04	273.16
- Balance Clinics LLP	A	78.08	78.08
- Micro Labs Limited	E	124.02	215.58
- Bal Research Foundation	A	22.27	19.44
		504.41	**586.26**
Security Deposit			
-Lifezen Healthcare Private Limited	A	978	953.00
		978	**953.00**
Advances recoverable in Cash or Kind			
- Balance Clinics LLP	A	156.92	154.83
- Bal Research Foundation	A	2.51	2.18
- Siroya Wellness	C	0.98	0.98
- Aurum Research & Analytical Solutions Pvt Ltd	C	0.50	0.11
		160.91	**158.11**
Other current assets			
- Siroya Constructions	C	1.44	1.44
- Himesh Virupakshaya	F	-	0.25
		1.44	**1.69**

iii. Amount outstanding as at the balance sheet date (continued)

Particulars	Category	For the year ended 31 March 2025	For the year ended 31 March 2024
Trade Payables			
- Desa Marketing International	B	151.67	53.94
- Balance Clinics LLP	A	9.53	9.53
		161.20	**63.47**
Payable towards Capital Goods			
- Siroya Constructions	C	1.85	-
		1.85	-
Other financial liabilities - Rental Deposits			
- Bal Research Foundation	A	1.00	1.00
- Lifezen Healthcare Private Limited	A	3.00	3.00
		4.00	**4.00**
Other Current Liabilities			
Shailesh D Siroya	F	73.52	58.93
		73.52	**58.93**

57. Employee benefits

(a) Defined Contribution Plans

Employees receive benefits from a provident fund and employee state insurance funds. The employer and employees each make periodic contributions to the plan as per local regulations.The following table discloses the employers contribution to the funds:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Provident Fund Contribution	213.76	206.12
Contribution to Employee State Insurance	9.72	15.42
Labour Welfare Fund	0.73	0.29

(b) Defined Benefit Plans and other Long term plans

In accordance with applicable Indian laws, the Company provides for gratuity, a defined benefit retirement plan (Gratuity Plan). The Gratuity Plan provides a lump sum payment to vested employees, at retirement or termination of employment, an amount based on the respective employee's last drawn salary and the number of years of employment with the Company.

Actuarial Valuation for compensated absences is done as at the year end and the provision is made as per Company policy with corresponding (gain)/charge to the statement of profit and loss and it covers all regular employees. Obligation in respect of earned leave policy are actuarially determined as at the year end using the 'Projected Unit Credit' method.

The following tables summarise the components of net benefit expense recognised in the statement of profit and loss and the funded status and amounts recognised in the balance sheet for gratuity benefit and leave encashment

(b) Defined Benefit Plans and other Long term plans (continued)

Particulars	Gratuity		Leave Encashment	
	As at 31 March 2026	As at 31 March 2025	As at 31 March 2026	As at 31 March 2025
Changes in present value of defined benefit obligations during the year				
Present Value of Defined Benefits at the beginning of the year	552.00	483.83	124.58	113.55
Service cost	62.41	63.12	34.59	21.56
Past Service Cost	-		-	
Interest on defined benefit obligation	35.27	33.63	-	-
Benefits settled	(54.21)	(32.91)	(18.36)	(10.52)
Actuarial (gain) / loss (	43.37)	4.33		-
	552.10	**552.00**	**140.81**	**124.59**
Reconciliation of present value of the obligation and the fair value of the plan assets:				
Present Value of Defined Benefits at the end of the year	552.10	552.00	140.81	124.59
Fair value of plan assets at the end of the year				
	552.10	**552.00**	140.81	124.59
Net Liability - Current (Refer Note No.29)	57.01	82.16	20.14	34.00
Net Liability - Non Current (Refer Note No.24)	495.10	469.84	120.68	90.59
Expenses recognised in Statement of Profit or Loss during the year		0		
Current Service cost 62.41	63.12	34.59	21.56	
Past Service Cost	-			
Interest cost on defined benefit (net)	35.27	33.63	-	-
Expected return on plan assets				
Others				
	97.68	96.75	34.59	21.56

(b) Defined Benefit Plans and other Long term plans (continued)

Particulars	Gratuity		Leave Encashment	
	As at 31 March 2026	As at 31 March 2025	As at 31 March 2026	As at 31 March 2025
Actuarial (gain) / loss				
Remeasurements - Due to Demographic Assumptions	-	-		-
Remeasurements - Due to Financial Assumptions	(17.18)	16.56	-	-
Remeasurements - Due to Experience Adjustments	(26.20)	(12.23)	-	-
(Return) on Plan Assets (Excluding Interest Income)	-			-
(Return) on Reimbursement Rights	-			-
Changes in Asset Ceiling / Onerous Liability	-			
	(43.38)	**4.33**	**-**	**-**
Maturity Profile of Defined Benefit Plan				
Within the next 12 months	65.14	81.71	16.19	20.33
Between 2 and 5 years	235.20	161.59	47.81	35.47
Between 6 and 9 years	230.06	142.03	32.57	27.87
For 10 years and above	391.18	166.67	44.24	40.92
Sensitivy Analysis for significant assumptions				
Salary Escalation - Up by 1%	5.45%	9.74%	6.45%	9.02%
Salary Escalation - Down by 1%	-4.99%	-8.35%	-5.78%	-7.66%
Attrition Rates - Up by 1%	-0.34%	-1.14%	-0.25%	-0.49%
Attrition Rates - Down by 1%	0.36%	1.23%	0.28%	0.54%
Discount Rates - Up by 1%	-5.34%	-8.63%	-6.20%	-8.06%
Discount Rates - Down by 1%	5.95%	10.23%	7.02%	9.65%
Assumptions				
Discount rate	7.30%	6.85%	7.30%	6.85%
Estimated rate of return on plan assets	0.00%	0.00%	0.00%	0.00%
Salary increase	7.00%	7.00%	7.00%	7.00%
Attrition Rate	15.00%	12.50%	15.00%	12.50%
Retirement age	58.00%	58 years	58 years	58 years

58. Financial Instruments - Fair Value Disclosure

The carrying value and fair value of financial instruments by categories for year ended 31 March, 2026

Particulars	Note No	Carrying value	Amortized Cost	Fair Value
Financial Asset at Amortised Cost (Current and Non-Current)				
Investments *	7 & 12	424.03	424.03	-
Loans	14	116.57	116.57	-
Trade receivable	13	9,636.24	9,636.24	-
Cash and cash equivalents	15	219.49	219.49	-
Other bank balances	16	490.89	490.89	-
Other financial assets	8 & 17	971.99	971.99	-
Total Financial Assets		**11,859.20**	**11,859.20**	-

58. Financial Instruments - Fair Value Disclosure (Continue)

The carrying value and fair value of financial instruments by categories for year ended 31 March, 2026

Particulars	Note No	Carrying value	Amortized Cost	Fair Value
Financial Liabilities at Amortised Cost (Current and Non-Current)				
Borrowings (including current maturities)	22 & 26	15,374.79	15,374.79	-
Trade payables	27	8,917.22	8,917.22	-
Other financial liabilities	23 & 28	3,024.26	3,024.26	-
Total Financial Liabilities		**27,316.27**	**27,316.27**	-
		(15,457.07)	**(15,457.07)**	**-**

*The Company has opted to account for investments in subsidiaries at cost as per Ind-AS 27 'Separate financial statements'

The carrying value and fair value of financial instruments by categories for year ended 31 March, 2025

Particulars	Note No	Carrying value	Amortized Cost	Fair Value
Financial Asset at Amortised Cost (Current and Non-Current)				
Investments *	7 & 12	462.66	462.66	-
Loans	14	113.28	113.28	-
Trade receivable	13	9,484.78	9,484.78	-
Cash and cash equivalents	15	163.95	163.95	-
Other bank balances	16	629.89	629.89	-
Other financial assets	8 & 17	839.87	839.87	-
Total Financial Assets		**11,694.43**	**11,694.43**	**-**
Financial Liabilities at Amortised Cost (Current and Non-Current)				
Borrowings (including current maturities)	22 & 26	14,461.17	14,461.17	-
Trade payables	27	8,184.79	8,184.79	-
Other financial liabilities	23 & 28	1,202.81	1,202.81	-
Total Financial Liabilities		**23,848.76**	**23,848.76**	**-**
		(12,154.33)	**(12,154.33)**	**-**

59. Financial Instruments - Financial risk management

The Company has exposure to following risks arising from financial instruments-
- Market Risk
- Credit Risk
- Liquidity Risk

The Company's board of directors has overall responsibility for the establishment and oversight of the Company's risk management framework. The Company's risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities.

The Company's audit committee oversees how management monitors compliance with the Company's risk management policies and procedures and reviews the adequacy of the risk management framework in relations to the risks faced by the Company.

A Market Risk

1) Currency Risk

The Company operates internationally and a major portion of the business is transacted in several currencies and consequently the Company is exposed to foreign exchange risk to the extent that there is mismatch between the currencies in which its sales and services and purchases from overseas suppliers in various foreign currencies. However as the Company exports as well as imports goods and services, the Company has a natural hedging due to its operations. Market Risk is the risk that changes in market prices such as foreign exchange rates will effect company's income or value of its holding financial assets/ instruments.The exchange rate between the Rupee and foreign currencies has changed substantially in recent years and may fluctuate substantially in the future. Consequently, the results of the Company's operations are adversely affected as the Rupee appreciates/ depreciates against US dollar (USD), Euro (EUR), Dhirams (AED) and Others.

(a) Foreign Exchange Exposures outstanding at the year end

Nature Of Instrument	As at 31 March 2026	As at 31 March 2025
Unhedged Foreign Exchange Exposures		
Trade Receivables		4,369.07 4,845.62
Cash and Cash Equivalents		- -
	4,369.07	4,845.62
Trade Payables	(881.28)	(1,801.75)
Current Borrowings	(203.50)	(71.89)
Others		- -
	(1,084.77)	(1,873.64)
	3,284.29	**2,971.98**

(b) Foreign Currency Risk from Financial Instrument as at 31 March 2026

Nature Of Instrument	USD	EUR	AED	Others	Total
Trade Receivables	3,809.36	559.31	0.40		4,369.07
Cash and Cash Equivalents					-
Trade Payables	(881.28)				(881.28)
Current Borrowings	(203.50)				(203.50)
Others					-
Net Assets/(Liabilities)	**2,724.59**	**559.31**	**0.40**	**-**	**3,284.29**

(b) Foreign Currency Risk from Financial Instrument as at 31 March 2025

Nature Of Instrument	USD	EUR	AED	Others	Total
Trade Receivables	4,366.19	342.06	137.37		4,845.62
Cash and Cash Equivalents					-
Trade Payables	(1,799.24)	(2.52)			(1,801.75)
Current Borrowings	(71.89)				(71.89)
Others				-	
Net Assets/(Liabilities)	**2,495.07**	**339.54**	**137.37**	**-**	**2,971.98**

(c) Sensitivity Analysis

A reasonably possible change in foreign exchange rates by 5% would have increased/ (decreased) equity and profit or loss by the amounts shown below. This analysis assumes that all other variables in particular interest rates remain constant

Particulars	USD	EUR	AED
Impact on Statement of Profit and Loss			
Increase by 5%			
As at 31 March 2026	136.23	27.97	0.02
As at 31 March 2025	124.75	16.98	6.87
Decrease by 5%			
As at 31 March 2026	(136.23)	(27.97)	(0.02)
As at 31 March 2025	(124.75)	(16.98)	(6.87)
Impact on Equity (Net of Tax)			
Increase by 5%			
As at 31 March 2026	100.81	20.69	0.01
As at 31 March 2025	92.32	12.56	5.08
Decrease by 5%			
As at 31 March 2026	100.81)	(20.69)	(0.01)
As at 31 March 2025	(92.32)	(12.56)	(5.08)

2 Interest rate Risk

Interest rate risk can be either fair value interest rate risk or cash flow interest rate risk. Fair value interest rate risk is the risk of changes in fair values of fixed interest bearing investments because of fluctuations in the interest rates, in cases where the borrowings are measured at fair value through profit or loss. Cash flow interest rate risk is the risk that the future cash flows of floating interest bearing investments will fluctuate because of fluctuations in the interest rates.

a) Exposure to Interest Rate Risk

The interest rate profile of the Company's interest-bearing financial instruments as reported :

Nature Of Instrument	For the year ended As at 31 March 2026	For the year ended As at 31 March 2025
Fixed Rate Instruments		
Financial Assets	1,091.78	1,136.69
- Fixed Deposits	1,091.78	1,136.69
- Loans	-	-
Financial Liabilities	(15,524.66)	(14,610.04)
- Received from Customers	(149.88)	(148.88)
- Other Borrowings	(15,374.79)	(14,461.17)
Variable Rate Instruments		
Financial Assets	-	-
Financial Liabilities	-	-
	(14,432.89)	**(13,473.35)**

(b) Fair value sensitivity analysis for fixed-rate instruments

The Company's fixed rate instruments are carried at amortised cost. They are therefore not subject to interest rate risk as defined as per Ind AS 107, since neither the carrying amount nor future cash flows will fluctuate because of change in market interest rates.

(c) Cash flow sensitivity analysis for variable-rate instruments

A reasonable possible change of 2% (200 basis points) in interest rates at the reporting date would have increased/ (decreased) equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular foreign currency exchange rates, remain constant.

Particulars	For the year ended As at 31 March 2026	For the year ended As at 31 March 2025
Impact on Statement of Profit and Loss		
Increase by 2%	-	-
Decrease by 2%	-	-
Impact on Equity (Net of Tax)		
Increase by 2%	-	-
Decrease by 2%	-	-

B Liquidity Risk

Liquidity risk refers to the risk that the Company cannot meet its financial obligations. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements. Prudent liquidity risk management implies maintaining sufficient cash and marketable securities and the availability of funding through an adequate amount of committed credit facilities to meet obligations when due. Due to the nature of the business, the Company maintains flexibility in funding by maintaining availability under committed facilities.

The Company manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities.

Maturities of financial liabilities:

The table below analyse the Company's financial liabilities into relevant maturity groupings based on their contractual maturities for all non-derivative financial liabilities. The amounts disclosed in the table are the contractual undiscounted cash flows.

Particulars	Contractual cash Flows				
	Carrying Amount	< 12 Months	1 to 5 years	> 5 years	Total
31 March, 2026					
Borrowings (Incl Current Maturities)*	4,648.20	1,459.72	3,188.48	-	4,648.20
Trade and other payables	8,917.22	8,542.35	374.87	-	8,917.22
Short Term Borrowings	10,726.59	10,726.59	-	-	10,726.59
Other Financial Liabilities	3,024.26	2,874.38	149.88	-	3,024.26
31 March, 2025					
Borrowings (Incl Current Maturities)*	4,307.02	1,166.99	3,140.03	-	4,307.02
Trade and other payables	8,184.79	7,784.14	400.65	-	8,184.79
Short Term Borrowings	10,154.16	10,154.16	-	-	10,154.16
Other Financial Liabilities	1,202.81	1,053.93	148.88	-	1,202.81

*indicates actual outflow

C Credit Risk

Credit risk arises from the possibility that counter party may not be able to settle their obligations as agreed. The Company's exposure to credit risk is limited to the carrying amount of financial assets recognised at the date of the balance sheet, as summarised in the table below. The Company periodically assesses the financial reliability of the counter party taking into account the financial condition, current economic trends, analysis of historical bad debts and ageing of accounts receivable. Individual customer limits are set accordingly.

Particulars	As at 31 March 2026	As at 31 March 2025
Cash and Cash Equivalents	219.49	163.95
Other Bank Balances	490.89	629.89
Trade Receivables	9,636.24	9,484.78
Short Term Financial Assets	281.47	240.91
Long Term Financial Assets	807.08	712.24
	11,435.17	**11,231.76**

Credit risk on cash and cash equivalents is limited as they are generally invested in deposits with banks and financial institutions with high credit ratings assigned by international and domestic credit rating agencies. Advances to Related Parties are for business purposes and the Company assesses the credit risk on the these advances on a regular basis and does not forsee any event of default.

Trade receivables are typically unsecured and are derived from revenue earned from customers. Credit risk has always been managed through credit approvals, establishing credit limits and continuously monitoring the credit worthiness of customers to which the Company grants credit terms in the normal course of business. On account of adoption of Ind AS 109, the Company uses expected credit loss model to assess the impairment loss or gain. The Company is exposed to credit risk in the event of non-payment by customers. Credit risk concentration with respect to trade receivables is mitigated by the Company's large customer base. Adequate expected credit losses are recognized as per the assessments and as such has provided for a expected credit loss of Rs.157.04lakhs.(31 March 2025: 154.22 lakhs)

Ageing of Trade Receivable

Particulars	0-180 Days	Above 180 Days	Total
As on 31 March, 2026	9,101.87	534.37	9,636.24
As on 31 March, 2025	8,532.41	952.37	9,484.78
	17,634.28	**1,486.74**	**19,121.02**

Reconciliation of Loss Allowance

Particulars	As at 31 March 2026	As at 31 March 2025
Loss allowance in the beginning of the year	154.22	165.50
Add: Changes in allowance	2.82	(11.28)
Loss allowance at the end of the year	**157.04**	**154.22**

60 Capital Management

For the purpose of the Company's capital management, capital includes issued equity capital, share premium and all other equity reserves attributable to the equity shareholders of the Company. The primary objective of the Company's capital management is to maximise the shareholder value.

The Company manages its capital structure and makes adjustments in light of changes in economic conditions, annual operating plans and long term and other strategic investment plans. In order to maintain or adjust its capital structure, the Company may adjust the amount of dividends paid, return the capital to shareholders, issue new shares or adjust its short term borrowings. The current capital structure of the Company is equity based backed with borrowings.

Particulars	As at 31 March 2026	As at 31 March 2025
Long Term Borrowings (incl Current Maturities)*	4,648.20	4,307.02
Short Term Borrowings	10,726.59	10,154.16
Total Borrowings (A)	15,374.79	14,461.18
As a percentage of total equity	59.63%	59.40%
Total equity (B)	10,409.89	9,882.46
As a percentage of total equity	40.37%	40.60%
Total Capital (A+B)	**25,784.68**	**24,343.65**

*Taken Borrowings at amortised cost

61 Recoverability from Subsidiary Companies

The Company has an outstanding recoverability of Rs.978.00 lakhs and Rs.156.92 lakhs from it subsidiaries Lifezen Healthcare Private Limited and Balance Clinic LLP respectively. The said subsidiaries have incurred losses and have a negative net worth. However the management is confident that with infusion of additional funds, introduction of new brands and renewed marketing, the companies can be revived and the amounts recovered.

62. Ratio Analysis

Particulars	Numerator	Denomitor	As at 31 March 2026	As at 31 March 2025
Current ratio	Current Assets	Current Liabilities	1.13	1.16
Debt-equity ratio	Total Debt	Total Equity	1.48	1.46
Debt service coverage ratio	Earnings for debt service = Net profit after taxes + Non-cash operating expenses + Finance Cost	Debt service = Interest Payments + Principal Repayments	1.60	1.81
Return on equity (%)	Net Profits after taxes – Preference Dividend	Average Shareholder's Equity	6.65%	8.14%
Inventory turnover ratio	Cost of goods sold OR sales	Average Inventory	1.65	1.66
Trade receivables turnover ratio	Net credit sales = Gross credit sales - sales return	Average Trade Receivable	3.25	3.08
Trade payables turnover ratio	Net credit purchases = Gross credit purchases - purchase return	Average Trade Payables	2.00	2.17
Net capital turnover ratio	Net sales	Working capital	9.61	8.85
Net profit (%)	Net Profit	Net sales = Total sales - sales return	2.17%	2.58%
Return on capital employed (%)	Earnings before interest and taxes	Capital Employed = Tangible Net Worth + Total Debt + Deferred Tax	17.04%	17.34%

Particulars	As at 31 March 2026	As at 31 March 2025
Revenue	31,079.70	30,249.64
Current Assets	27,563.56	24,765.20
Current Liabilities	24,330.15	21,345.82
EBIT (Earnings before Interest and Tax)	2,317.54	2,257.74
Profit After Tax (PAT)	675.12	779.95
EBITDA	3,423.45	3,222.62
COGS	15,785.06	15,777.17
Purchases	17,121.11	17,302.15
Working Capital	3,233.41	3,419.38
Total expenses	30,643.48	29,891.34
Total Borrowings	15,374.79	14,461.17
Total Equity	10,409.89	9,882.46
Average Shareholders' Equity	10,146.17	9,583.11
Average Value of Inventory	9,560.51	9,515.62
Average Accounts Receivable	9,560.51	9,834.88
Average Accounts Payable	8,551.01	7,973.43
Capital Employed	13,598.38	13,022.49

62. Ratio Analysis (Continued)

Particulars	As at 31 March 2026 % of Variance	Reason
Current ratio	-2.35%	
Debt-equity ratio	0.93%	
Debt service coverage ratio	-11.60%	
Return on equity (%)	-18.24%	
Inventory turnover ratio	-0.42%	Due to increase in Net working capital for the end of the year
Trade receivables turnover ratio	5.69%	
Trade payables turnover ratio	-7.73%	
Net capital turnover ratio	8.65%	
Net profit (%)	-15.75%	
Return on capital employed (%)	-1.70%	

66. Other Accounting Policies Information

a) Intangible Asset

Recognition and Measurement

Te items of intangible assets, with finite life, are measured at cost less accumulated amortisation and impairment losses, if any. Cost of an item of intangible assets comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any cost directly attributable to bringing the asset to its working condition for its intended use.

Subsequent expenditure

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure on internally generated goodwill and brands, is recognised in profit or loss when incurred.

Research and Development

Expenditure on research activities undertaken with the prospect of gaining new scientific or technical knowledge and understanding are recognised as an expense when incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. An internally-generated intangible asset arising from development is recognised if following have been demonstrated by the Company.

development costs can be measured reliably;

- the product or process is technically and commercially feasible
- future economic benefits are probable; and
- the Company intends to and has sufficient resources to complete development and to use or sell the asset.

As such, expenditure on projects which have become unsuccessful are charged off as an expense in the year in which they are abandoned. Capital expenditure incurred on research and development is capitalized as Property, Plant and Equipment and depreciated in accordance with the depreciation policy of the company.

Disposal/Write-off

An intangible asset is derecognized on disposal, or when no future economic benefits are expected from use or disposal. Gains or losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, are recognized in profit or loss when the asset is derecognized.

Amortisation

Amortisation is calculated to write-off the cost of intangible assets less their estimated residual values over their estimated useful lives using the straight-line method, and is included in depreciation and amortisation in the statement of profit and loss. The estimated useful life of intangibles are as follows:

Asset	Management estimate of useful life (years)
Computer software	3
Research and Development	10

The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.

b) Impairment

i. Impairment of financial instruments

The Company recognises loss allowances for expected credit losses on:

- financial assets measured at amortised cost; and

- financial assets measured at FVOCI- debt investments.

At each reporting date, the Company assesses whether financial assets carried at amortised cost and debt securities at FVOCI are credit-impaired. A financial asset is 'credit-impaired' when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

Evidence that a financial asset is credit-impaired includes the following observable data:

- significant financial difficulty of the borrower or issuer;
- a breach of contract such as a default or being past due for 180 days or more;
- the restructuring of a loan or advance by the Company on terms that the Company would not consider otherwise;
- it is probable that the borrower will enter bankruptcy or other financial reorganisation; or
- the disappearance of an active market for a security because of financial difficulties.

The Company measures loss allowances at an amount equal to lifetime expected credit losses, except for the following, which are measured as 12 month expected credit losses:

- debt securities that are determined to have low credit risk at the reporting date; and
- other debt securities and bank balances for which credit risk (i.e. the risk of default occurring over the expected life of the financial instrument) has not increased significantly since initial recognition.

Loss allowances for trade receivables are always measured at an amount equal to lifetime expected credit losses. Lifetime expected credit losses are the expected credit losses that result from all possible default events over the expected life of a financial instrument. 12-month expected credit losses are the portion of expected credit losses that result from default events that are possible within 12 months after the reporting date (or a shorter period if the expected life of the instrument is less than 12 months).

In all cases, the maximum period considered when estimating expected credit losses is the maximum contractual period over which the Company is exposed to credit risk.

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating expected credit losses, the Company considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis, based on the Company's historical experience and informed credit assessment and including forward-looking information.

The Company assumes that the credit risk on a financial asset has increased significantly if it is more than 180 days past due.

The Company considers a financial asset to be in default when:

- the borrower is unlikely to pay its credit obligations to the Company in full, without recourse by the Company to actions such as realising security (if any is held); or
- the financial asset is 180 days or more past due.

***A.* Measurement of expected credit losses**

"Expected credit losses are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (i.e. the difference between the cash flows due to the Company in accordance with the contract and the cash flows that the Company expects to receive).

As a practical expedient, the Company uses a provision matrix to determine impairment loss allowance on portfolio of its trade receivables. The provision matrix is based on its historically observed default rates over the expected life of the trade receivables and is adjusted for forward-looking estimates. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed."

B. Presentation of allowance for expected credit losses in the balance sheet

Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount of the assets.

C. Write-off

The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Company determines that the debtor does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write-off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Company's procedures for recovery of amounts due.

ii. Impairment of non-financial assets

The Company's non-financial assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset).

The Company's corporate assets do not generate independent cash inflows. To determine impairment of a corporate asset, recoverable amount is determined for the CGUs to which the corporate asset belongs.

An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its estimated recoverable amount. Impairment losses are recognised in the Statement of profit and loss. Impairment loss recognised in respect of a CGU is allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets of the CGU (or group of CGUs) on a pro rata basis.

In respect of other assets for which impairment loss has been recognised in prior periods, the Company reviews at each reporting date whether there is any indication that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. Such a reversal is made only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

c) Financial Instruments

i. Recognition and initial measurement

Trade receivables and debt securities issued are initially recognised when they are originated. All other financial assets and financial liabilities are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

A financial asset or financial liability is initially measured at fair value plus, for an item not at fair value through profit and loss (FVTPL), transaction costs that are directly attributable to its acquisition or issue.

ii. Classification and subsequent measurement

A. Financial assets

On initial recognition, a financial asset is classified as measured at

- amortised cost
- Fair value through other comprehensive income (FVOCI) - debt investment;
- Fair value through other comprehensive income (FVOCI) - equity investment; or
- Fair value through profit & loss- (FVTPL)

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Company changes its business model for managing financial assets.

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at FVTPL:

he asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and

- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

A debt investment is measured at FVOCI if it meets both of the following conditions and is not designated as at FVTPL:

- the asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and Interest on the principal amount outstanding.

On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment's fair value in OCI (designated as FVOCI – equity investment). This election is made on an investment-by-investment basis.

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. This includes all derivative financial assets. On initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost or at FVOCI as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

B. Financial assets : Business model assessment

The Company makes an assessment of the objective of the business model in which a financial asset is held at a portfolio level because this best reflects the way the business is managed and information is provided to management.The information considered includes:

- the stated policies and objectives for the portfolio and the operation of those policies in practice.These include whether management's strategy focuses on earning contractual interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities or expected cash outflows or realising cash flows through the sale of the assets;
- how the performance of the portfolio is evaluated and reported to the Company's management;
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;
- how managers of the business are compensated – e.g. whether compensation is based on the fair value of the assets managed or the contractual cash flows collected; and
- the frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about future sales activity.

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, consistent with the Company's continuing recognition of the assets.

Financial assets that are held for trading or are managed and whose performance is evaluated on a fair value basis are measured at FVTPL.

C. Financial assets:Assessment whether contractual cash flows are solely payments of principal and interest.

For the purposes of this assessment, 'principal' is defined as the fair value of the financial asset on initial recognition. 'Interest' is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative costs), as well as a profit margin.

In assessing whether the contractual cash flows are solely payments of principal and interest, the Company considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows such that it would not meet this condition. In making this assessment, the Company considers:

- contingent events that would change the amount or timing of cash flows;
- terms that may adjust the contractual coupon rate, including variable interest rate features;
- prepayment and extension features; and
- terms that limit the Company's claim to cash flows from specified assets (e.g. non-recourse features).

A prepayment feature is consistent with the solely payments of principal and interest criterion if the prepayment amount substantially represents unpaid amounts of principal and interest on the principal amount outstanding, which may include reasonable additional compensation for early termination of the contract. Additionally, for a financial asset acquired at a significant discount or premium to its contractual par amount, a feature that permits or requires prepayment at an amount that substantially represents the contractual par amount plus accrued (but unpaid) contractual interest (which may also include reasonable additional compensation for early termination) is treated as consistent with this criterion if the fair value of the prepayment feature is insignificant at initial recognition.

D. Financial assets: Subsequent measurement and gains and losses

Financial assets at FVTPL	These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in profit or loss.
Financial assets at amortised cost	These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in profit or loss. Any gain or loss on derecognition is recognised in profit or loss.

D.1 Financial assets: Subsequent measurement and gains and losses

Debt investments at FVOCI	These assets are subsequently measured at fair value. Interest income under the effective interest method, foreign exchange gains and losses and impairment are recognised in profit or loss. Other net gains and losses are recognised in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss.
Equity investments at FVOCI	These assets are subsequently measured at fair value. Dividends are recognised as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognised in OCI and are not reclassified to profit or loss.

E. Financial liabilities: Classification, subsequent measurement and gains and losses

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held-for-trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in profit or loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in profit or loss. Any gain or loss on derecognition is also recognised in profit or loss.

iii Derecognition

A. Financial assets

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

If the Company enters into transactions whereby it transfers assets recognised on its balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets, the transferred assets are not derecognised.

B. Financial liabilities

The Company derecognises a financial liability when its contractual obligations are discharged or cancelled, or expire.

The Company also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in profit or loss.

iv Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

d) Foreign Currency Transactions:

"Initial recognition:

Transactions in foreign currencies entered into by the Company are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction."

"Measurement of foreign currency monetary items at the Balance Sheet date:

Foreign currency monetary items (other than derivative contracts) of the Company and its net investment in non-integral foreign operations outstanding at the Balance Sheet date are restated at the year-end rates."

"Treatment of exchange differences:

Exchange differences arising on settlement / restatement of short-term foreign currency monetary assets and liabilities of the Company are recognized as income or expense in the Statement of Profit and Loss."

e) Employee Benefits

a) Short Term Employee Benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are recorded as expense as the related service is provided. Benefits such as salaries, short term compensated absences etc., and the expected cost of bonus is recognized in the period in which the employee renders the related services. A liability is recognized for benefits accruing to employees in respect of wages and salaries, annual leave and sick leave in the period the related service is rendered at the undiscounted amount of the benefits expected to be paid in exchange for the related service

b) Post-Employment Benefits

The Company participates in various employee benefit plans. Pensions and other post-employment benefits are classified as either defined contribution plans or defined benefit plans. Under a defined contribution plan, the Company's only obligation is to pay a fixed amount with no obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits. The related actuarial and investment risks are borne by the employee. The expenditure for defined contribution plans is recognised as an expense during the period when the employee provides service. Under a defined benefit plan, it is the Company's obligation to provide agreed benefits to the employees. The related actuarial and investment risks are borne by the Company. The present value of the defined benefit obligations is calculated by an independent actuary using the projected unit credit method.

Defined contribution plans

Defined contribution plans

Employees receive benefits from a provident fund and employee state insurance funds. The employer and employees each make periodic contributions to the plan as per local regulations. The Company has no further payment obligations once the contributions have been paid. The contributions are accounted for as defined contribution plans and the contributions are recognised as employee benefit expenses in the Statement of Profit and Loss as they fall due based on the amount of contribution required to be made.

Defined Benefit plans

In accordance with the Payment of Gratuity Act, 1972, applicable for Indian companies, the Company provides for a lump sum payment to eligible employees, at retirement or termination of employment based on the last drawn salary and years of employment with the Company. Company's liability towards Gratuity are actuarially determined at each balance sheet date using the projected unit credit method. Actuarial gains and losses are recognized in the Statement of Profit and Loss in the period of occurrence.

Other Long Term Benefit plan

Actuarial Valuation for compensated absences is done as at the year end and the provision is made as per Company policy with corresponding (gain)/charge to the statement of profit and loss and it covers all regular employees. Obligation in respect of earned leave policy are actuarially determined as at the year end using the 'Projected Unit Credit' method.

f) Borrowing Cost

Borrowing costs consists of interest, ancillary costs and other costs in connection with the borrowing of funds and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to interest costs.

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets are capitalised as part of the cost of such assets up to the assets are substantially ready for their intended use or sale.

The loan origination costs directly attributable to the acquisition of borrowings (e.g. loan processing fee, upfront fee) are amortised on the basis of the Effective Interest Rate (EIR) method over the term of the loan.

Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalization. All other borrowing costs are recognised in the statement of profit and loss in the period in which they are incurred.

g) Leases

The company assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange of consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Company assesses whether

a. the Contract involves the use of an identified asset

b. the Company has substantially all of the economic benefits from use of the asset through the period of lease

c. the Company has the right to direct the use of asset

The Company determines the lease term as the noncancellable period of a lease, together with both periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option; and periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option. The discount rate is generally based on the incremental borrowing rate specific to the lease being evaluated or for a portfolio of leases with similar characteristics

Leases as Lessor

Leases for which the Company is a lessor is classified as a finance or operating lease. When ever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee, the contract is classified as a finance lease. All other leases are classified as operating leases. The Company recognises lease payments received under operating leases as income on a straight-line basis over the lease term. In case of a finance lease, finance income is recognised over the lease term based on a pattern reflecting a constant periodic rate of return on the lessor's net investment in the lease. When the Company is an intermediate lessor it accounts for its interests in the head lease and the sub-lease separately. It assesses the lease classification of a sub-lease with reference to the right-of-use asset arising from the head lease, not with reference to the underlying asset. If a head lease is a short term lease to which the Company applies the exemption described above, then it classifies the sub-lease as an operating lease

Leases as Lessee

As at the date of commencement of the lease, the Company recognises a right of use asset("ROU") and a corresponding lease liability for all lease arrangements in which it is a lessee, except for the leases with a term of twelve month or less (short term leases) and low value leases. For these short term leases, the Company recognises the lease payments as an operating expense on a straight line basis over the period of lease.

Certain lease arrangements include the options to extend or terminate the lease before the end of the lease term. ROU assets and lease liabilities include these options when it is reasonably certain that they will be exercised. ROU assets are initially recognized at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or prior to the commencement date of the lease and related prepaid amount plus any initial direct costs less any lease incentives.They are subsequently measured at cost less accumulated depreciation and impairment losses

ROU assets are initially recognized at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or prior to the commencement date of the lease plus any initial direct costs less any lease incentives. They are subsequently measured at cost less accumulated depreciation and impairment losses. ROU assets are depreciated from the commencement date on a straight-line basis over the shorter of the lease term and useful life of the underlying asset. ROU assets are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the purpose of impairment testing, the recoverable amount (i.e. the higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the Cash Generating Unit (CGU) to which the asset belongs.

"The lease liability is initially measured at amortized cost at the present value of the future lease payments. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, using the market . Lease liabilities are remeasured with a corresponding adjustment to the related right of use asset if the Company changes its assessment if whether it will exercise an extension or a termination option.

The Right-of-Use asset has been disclosed within the same line item as that within which the corresponding underlying asset would be presented. Where the Right-of-Use asset meets the definition of Investment Property such items has been presented in Balance sheet as Investment Property. Lease liability have been separately presented in the Balance Sheet and lease payments have been classified as financing cash flows"

h) Earnings per Share

Basic earnings per share is computed by dividing the profit / (loss) after tax (including the post-tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year.

Diluted earnings per share is computed by dividing the profit / (loss) after tax (including the post-tax effect of extraordinary items, if any) as adjusted for dividend, interest and other charges to expense or income relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share from continuing ordinary operations. Potential dilutive equity shares are deemed to be converted as at the beginning of the period, unless they have been issued at a later date. The dilutive potential equity shares are adjusted for the proceeds receivable had the shares been actually issued at fair value (i.e. average market value of the outstanding shares). Dilutive potential equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for share splits / reverse share splits and bonus shares, as appropriate.

i) Income Tax

a. Current Tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from 'profit before tax' as reported in the statement of profit and loss because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company's current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

b. Minimum Alternate Tax ('MAT')

Minimum Alternate Tax ('MAT') under the provisions of the Income-tax Act, 1961 is recognised as current tax in the Statement of Profit and Loss. The credit available under the Income-tax Act, 1961 in respect of MAT paid is recognised as an asset only when and to the extent there is convincing evidence that the Company will pay normal income tax during the period for which the MAT credit can be carried forward for set-off against the normal tax liability. MAT credit recognised as an asset is reviewed at each Balance Sheet date and written down to the extent the aforesaid convincing evidence no longer exists.

c. Deferred Tax

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the standalone financial statements and corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. Such deferred tax assets and liabilities not recognised if the temporary differences arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit not the accounting profit. In addition, deferred tax liabilities are not recognised if the temporary difference arises from the initial recognition of goodwill.

Income Tax (continued)

c. Deferred Tax (continued)

Deferred tax liabilities are recognised for taxable temporary differences associated with investments in subsidiaries and associates, and interests in joint ventures, except where the Company is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences associated with such investments and interest are only recognised to the extent that it is probable that there will be sufficient taxable profits against which to utilize the benefits of the temporary differences and they are expected to reverse in the foreseeable future.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset is realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

j) Provisions and Contingencies

a. Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, itis probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognised as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the statement of profit and loss net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

b. Contingent Liabilities and Contingent Assets

A contingent liability is a possible obligation that arises from a past event, with the resolution of the contingency dependent on uncertain future events, or a present obligation where no outflow is probable. Major contingent liabilities are disclosed in the financial statements unless the possibility of an outflow of economic resources is remote. Contingent assets are not recognized in the standalone financial statements but disclosed, where an inflow of economic benefit is probable.

k) Cash and cash equivalents

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

l) Statement of cash flows

Cash flows are reported using the indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated.

66 Additional Regulatory Information

(i) The title deeds of all the immovable properties (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee), as disclosed under Property, Plant and Equipment in the financial statements are held in the name of the Company.

(ii) There are no proceedings that have been initiated or pending against the Company for holding any any benami property under the Benami Transactions (Prohibitions) Act, 1988 (45 of 1988) and the Rules made thereunder.

(iii) The Company has not been declared as a wilful defaulter by any bank or financial institution or any other lender

(iv) The Company has no transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956.

(v) The details of charges and satisfaction of charges have been registered with Registrar of Companies within the statutory period

(vi) Utilisation of Borrowed Funds and Share premium

(A) The Company has not advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries).

(B) The Company has not received any fund from any party(s) (Funding Party) with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(vii) The Company declares that the Relevant Provisions of the FEMA Act ,1999 and Companies Act have been Complied with and are not in violation of the Prevention of Money-Laundering Act ,2002.

(viii) The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961

(ix) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.

As per our report of even date attached
for **S S J N B & CO**
Chartered Accountants
Firm registration number: 013976S

Dhanpal I Sakaria
Partner
Membership No: 213666

Place: Bengaluru
Date : 27th May, 2026

UDIN: 26213666MGVPMQ6422

for and on behalf of the board of directors of
Bal Pharma Limited

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh
Whole Time Director
DIN: 08554422

Bharath Bhushan D V
Chief Financial Officer

Place: Bengaluru
Date: 27th May, 2026

To the Members of Bal Pharma Limited

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of Bal Pharma Limited (hereinafter referred to as the "the Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), which comprise the consolidated balance sheet as at 31st March 2026, and the consolidated statement of Profit and Loss (including other comprehensive income), consolidated Statement of Changes in Equity and consolidated Statement of Cash Flows for the year then ended, and notes to the financial statements, including a summary of material accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Company as at March 31, 2026, and consolidated profit (including other comprehensive income), consolidated changes in equity and its consolidated cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters ('KAM') are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key Audit Matters	How our audit addressed the key audit matter
Related Party Transactions: Identification and disclosures of Related Parties: (as described in Note-55 of the Consolidated Ind AS financial statements) ● The Group has related party transactions which include, amongst others, sale, and purchase of goods/ services to its subsidiaries and other related parties and lending and borrowing to its subsidiaries and other related parties. ● We focused on identification and disclosure of related parties in accordance with relevant accounting standards as a key audit matter.	Our audit procedures amongst others included the following: ● Evaluated the design and tested the operating effectiveness of controls over identification and disclosure of related party transactions. ● Obtained a list of related parties from the Group's Management and traced the related parties to declarations given by directors, where applicable, and to Note 55 of the consolidated Ind AS financial statements. ● Verified the minutes of the meetings of the Board of Directors and Audit Committee ● Tested material creditors/debtors, loan outstanding/ loans taken to evaluate existence of any related party relationships: tested transactions based on declaration of related party transactions given to the Board of Directors and Audit Committee ● Evaluated the disclosures in the consolidated Ind AS financial statements for compliance with Ind AS 24, compliance with Companies Act 2013 and determining the audit reporting required under CARO.

Key Audit Matters	How our audit addressed the key audit matter
Inventory ● As of 31 March 2026, the Group held inventories of Rs 11,635.53 Lakhs as disclosed in Note 10 to the Consolidated financial statements. Inventories mainly consist of raw and packing material, work-in-progress, stock-in-trade, finished goods and stores, spares and consumables. ● We considered the value of the inventory as a key audit matter given the relative size of the balance in the financial statements and significant judgement involved in the consideration of various factors involved in determination of cost or selling prices	● Reviewed the management's process for ensuring that there was no movement of stock during the physical verification of inventory. ● We understood and tested the design and operating effectiveness of controls as established by the management in determination and identification of returned stock nearing expiry, and the stock lying at different locations. ● We Assessed the appropriateness of Group's accounting policy for valuation of stock-in- trade and compliance of the policy with the requirements of the prevailing accounting standards. We considered various factors including the actual selling price prevailing around and subsequent to the year-end. Compared the cost of the finished goods with the estimated net realizable value and checked if the finished goods were recorded at net realizable value where the cost was higher than the net realizable value. For the purpose of determination of cost, the Group has considered the prevailing market situation. ● Based on the above procedures performed, by the management for determination of expired stock, the net realizable value of the inventory as at the year end, the methodology adopted for arriving at cost and comparison with cost for valuation of inventory is considered to be reasonable
Contingencies, including litigations and tax ● The Group is involved in disputes, lawsuits, claims, governmental and / or regulatory inspections, inquiries investigations and proceedings, including tax and commercial matters that arise from time to time in the ordinary course of business. The Group assisted by their external legal counsel assesses to disclose a contingency on a case-to case basis considering the underlying facts of each litigation. ● This area is significant to our audit, since the accounting and disclosure for contingent legal and tax liabilities is complex and judgmental (due to the difficulty in predicting the outcome of the matter and estimating the potential impact if the outcome is unfavorable), and the amounts involved are, or can be, material to the consolidated financial statements.	● We obtained a list of ongoing litigations from the Group's in-house legal counsel. We selected a sample of litigations based on materiality and performed inquiries with the said counsel on the legal evaluation of these litigations. We compared the evaluation with the disclosure in the consolidated financial statements. We tested the underlying computation of the management in relation to the measurement of the contingency. ● We inspected relevant communication with tax authorities. ● We also evaluated the disclosures made in the consolidated financial statements.

Information Other than the Financial Statements and Auditor's Report Thereon

The Holding Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual report but does not include the consolidated Ind AS financial statements and our auditor's report thereon.

Our opinion on the consolidated Ind AS financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the consolidated Ind AS financial statements, our responsibility is to read the other information and in doing so consider whether such other information is materially inconsistent with the consolidated Ind AS financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the preparation and presentation of these consolidated financial statements in term of the requirements of the Companies Act, 2013 that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We are also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(I) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the Group has adequate internal financial controls system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of the consolidated financial statements of such entities included in the consolidated financial statements of which we are the independent auditors. For the other entities included in the consolidated financial statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Consolidated Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

The consolidated financial statement include the audited financial information of four subsidiaries, whose Financial Statements and financial information reflect total assets (before consolidation adjustments) of Rs. 257.50 lakhs as at 31 March 2026, total income (before consolidation adjustments) of Rs. 157.95 lakhs for year ended, total net profit/(loss) after tax (before consolidation adjustments) of Rs. (43.12) lakhs for year ended 31 March, 2026 and net cash flow inflows/(outflows) (before consolidation adjustments) of Rs. (0.59) lakhs for the year ended on that date as considered in the consolidated Financial Results, which have been audited by us.

Our opinion on the consolidated financial statements is not modified in respect of the above matters.

Report on Other Legal and Regulatory Requirements

As required by Section 143(3) of the Act, based on our audit and on the consideration of report of the other auditors on separate financial statements and the other financial information of subsidiaries, as noted in the 'other matter' paragraph we report, to the extent applicable, that:

1.As required by Section 143(3) of the Act, we report that:

(a) We have relied upon, have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated Ind AS financial statements.

(b) in our opinion, proper books of account as required by law relating to preparation of the financial statements have been kept so far as it appears from our examination of those books and reports of the other auditors.

(c) the Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss including the Consolidated Statement of Other Comprehensive Income, the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flows dealt with by this Report are in agreement with the books of account.

(d) in our opinion, the aforesaid consolidated financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act, read with Companies (Indian Accounting Standard) Rules, 2015 as amended.

(e) on the basis of the written representations received from the directors of the Holding as on 31 March 2026 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors who are appointed under section 139 of the Act of its subsidiary companies, none of the directors of the Group is disqualified as on 31 March 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

(f) with respect to the adequacy of the internal financial controls over financial reporting of the Holding Company and its subsidiaries and the operating effectiveness of such controls, refer to our separate report in Annexure A, and

(g) with respect to the other matters to be included in the Auditors' Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the of the report of the other auditors on separate financial statements as also the other financial information of the subsidiaries as notes in 'Other Matter' paragraph.

I. The consolidated Ind AS financial statements has disclosed the impact of pending litigations on its consolidated financial position– Refer Note 38 to the Consolidated Ind AS financial statements.

ii. The Group did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses; and

iii. There has been no delay in transferring amounts required to be transferred to the Investor Education and Protection Fund by the Group.

iv.

(i) The respective managements of the Company and its subsidiaries whose financial statements have been audited under the Act have represented to us that, to the best of their knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company or any subsidiaries/ associates to or in any other person or entity, including foreign entities , with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Group or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(ii) The respective management of the Company and its subsidiaries/ associates whose financials have been audited under the Act have represented to us that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the Group from any person or entity , including foreign entities , with the understanding, whether recorded in writing or otherwise, that the Group shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries

(iii) Based on such audit procedures that the auditor has considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (i) and (ii) contain any material misstatement.

v.

(i) The dividend proposed in the previous year, declared, and paid by the Holding Company during the year is in accordance with section 123 of the Act.

(ii) The Board of Directors have proposed dividend for the current year which is subject to the approval of the members at the Annual General Meeting.

vi. Based on our examination, which included test checks, the Group has used accounting software for maintaining its books of accounts for the financial year ended March 31, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with and the audit trail has been preserved by the Group as per the statutory requirements for record retention.

2. With respect to the matter to be included in the Auditors' Report under section 197(16):

According to the information & explanations given to us and based on our examination of the records of the Holding Company, the Holding Company has paid / provided for managerial remuneration in accordance with the provisions of section 197 of the Act.

3. With respect to the matters specified in paragraphs 3(xxi) and 4 of the Companies (Auditor's Report) Order, 2020 ("CARO") issued by the Central Government in terms of Section 143(11) of the Act, to be included in the Auditor's report, according to the information and explanations given to us, and based on the CARO reports issued by us for the Company, to which reporting under CARO is applicable, we would like to draw your attention to the following qualification/adverse remarks in the CARO reports of the below mentioned holding/subsidiary/ associates of the Company.

Sr No	Name	CIN	Holding/ Subsidiary/ Associate/ Joint Venture	Clause Number of CARO
1	Bal Pharma Limited	L85110KA1987PLC008368	Holding Company	Point(ix)(a)

*for **S S J N B & Co***
Chartered Accountants
Firm registration number: 013976S

Dhanpal I Sakaria
Partner
Membership No: 213666
UDIN : 26213666JVZIHB9169
Place : Bengaluru
Date : 27th May, 2026

Annexure A to the Independent Auditors' Report

on the consolidated financial statements of Bal Pharma Limited for the period ended 31 March 2026

Report on the Internal Financial Controls with reference to the aforesaid consolidated financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')

(Referred to paragraph 1(f) under 'Report on other regulatory requirements' Section of our report to the members of Bal Pharma Limited of even date)

Opinion

In conjunction with our audit of the consolidated financial statements of the Group as of and for the year ended 31 March 2026, we have audited the internal financial controls with reference to consolidated financial statements of Bal Pharma Limited (hereinafter referred to as "the Holding Company") and such companies which are its subsidiary companies as of that date (Holding Company and its subsidiaries together referred to as "the Group").

In our opinion, to the best of information and according to the explanations given to us, the Holding Company and its subsidiaries have in all material aspects, an adequate internal financial control system over financial reporting as at March 31, 2026, based on the internal control over financial reporting criteria established by the Holding company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India.

Management's Responsibility for Internal Financial Controls

The respective Board of Directors of the Holding Company and its subsidiaries is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the 'Guidance Note') issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Group based on our audit. We conducted our audit in accordance with the Guidance Note on audit of internal financial controls and the Standards on Auditing, issued by Institute of Chartered Accountants of India, and deemed to be prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, and the audit evidence obtained by the other auditors in terms of their reports referred to in the Other Matter Paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that:

(1)pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company.

(2)provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

(3)provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Holding Company and its subsidiaries have, in all material respects, an adequate internal financial controls system with reference to consolidated financial statements and such internal financial controls with reference to consolidated financial statements were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Group considering the essential components of internal control stated in the Guidance Note issued by ICAI.

*for **S S J N B & Co***
Chartered Accountants
Firm registration number: 013976S

Dhanpal I Sakaria
Partner
Membership No: 213666
UDIN : 26213666JVZIHB9169
Place : Bengaluru
Date : 27th May, 2026

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Audited Consolidated Balance Sheet

(all amounts in Rs. lakhs unless otherwise stated)

Particulars	Note	As at 31 March 2026	As at 31 March 2025
ASSETS			
Non-current assets			
Property, Plant and Equipment	4	7,675.15	7,099.05
Capital work-in-progress	5	742.42	278.58
Goodwill	6A	382.69	382.69
Other Intangible Assets	6B	1,342.24	1,199.75
Financial assets		-	-
- Other financial assets	7	807.09	713.04
Deferred tax assets (Net)	8	80.41	40.98
Other non-current assets	9	300.63	367.74
		11,330.63	**10,081.83**
Current assets			
Inventories	10	11,635.53	10,302.22
Financial assets			
- Investments	11	208.17	246.80
- Trade receivable	12	9,363.26	9,244.35
- Loans	13	116.57	113.28
- Cash and cash equivalents	14	230.11	175.16
- Other bank balances	15	490.89	629.89
- Other financial assets	16	164.01	127.74
Current tax assets (Net)	17	13.43	98.84
Other current assets	18	4,001.38	2,548.92
		26,223.35	**23,487.20**
		37,553.98	**33,569.03**

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Audited Consolidated Balance Sheet
(all amounts in Rs. lakhs unless otherwise stated)

Particulars	Note	As at 31 March 2026	As at 31 March 2025
EQUITY & LIABILITIES			
Equity			
Equity share capital	19	1,592.09	1,592.09
Other equity	20A	6,630.65	6,149.50
Non Controlling Interest	20B	2.50	-1.15
		8,225.24	**7,740.44**
LIABILITIES			
Non-current liabilites			
Financial liabilities			
- Borrowings	21	3,188.48	3,140.03
- Other financial liabilities	22	597.31	174.07
Provisions	23	620.16	564.46
		4,405.95	**3,878.56**
Current liabilities			
Financial liabilities			
- Borrowings	24	12,763.16	11,897.99
- Trade payables	25	-	-
Due to Micro and Small Enterprises		39.26	461.66
Due to Other than Micro and Small Enterprises		8,857.58	7,706.92
- Other financial liabilities	26	2,462.44	1,074.09
Other current liabilities	27	722.72	692.66
Provisions	28	77.63	116.71
		24,922.79	**21,950.03**
		37,553.98	**33,569.03**

The accompanying notes referred to above form an integral part of these consalidated financial statements.

As per our report of even date attached

*for **S S J N B & CO***
Chartered Accountants
Firm's registration number: 013976S

Dhanpal I Sakaria
Partner
Membership number: 213666
Place: Bengaluru
Date: 27th May 2026
UDIN:*26213666JVZIHB9169*

for and on behalf of the board of directors of
Bal Pharma Limited

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh
Whole Time Director
DIN: 08554422

Bharath Bhushan D.V
Chief Financial Officer

Place: Bengaluru
Date: 27th May 2026

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Consolidated Statement of Profit and Loss

(all amounts in Rs. lakhs unless otherwise stated)

Particulars	Note	For the year ended 31 March 2026	For the year ended 31 March 2025
Income			
Revenue from operations	29	31,166.13	30,308.33
Other income	30	192.78	220.29
Total Income		**31,358.91**	**30,528.62**
Expenses			
Cost of materials consumed	31	16,096.75	14,988.62
Purchase of traded goods	32	922.66	1,505.57
(Increase)/decrease in inventories of finished goods and work-in-progress	33	-1,222.89	-704.83
Employee Benefit expense	34	6,646.48	6,240.05
Finance costs	35	1,681.77	1,685.45
Depreciation and amortisation		36	1,107.93 977.10
Other expenses	37	5,532.84	5,322.96
Total expenses		**30,765.52**	**30,014.88**
Profit before exceptional items and tax		**593.39**	**513.74**
Profit before tax		**593.39**	**513.74**
Less: Tax expense:			
Current tax	48	-	-
Excess/Shortprovision of tax writeen back		-	-14.06
Tax adjustments relating to previous year		-	-
Deferred tax charge/ (credit)	48	-38.62	-195.87
Tax expenses		**(38.62)**	**(209.92)**
Profit / (Loss) for the year		**632.01**	**723.67**
Profit / (Loss) attributable to :			
Equity holders of the parent company		628.36	721.53
Non controlling interest		3.65	2.13

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Audited Consolidated Statement of Profit and Loss

(all amounts in Rs. lakhs unless otherwise stated)

Particulars	Note	For the year ended 31 March 2026	For the year ended 31 March 2025
Other Comprehensive Income (OCI)			
A (i) Items that will not be reclassified to statement of profit or loss		-	-
Remeasurements of post-employment benefit obligations		43.85	-3.46
(ii) Income tax relating to items that will not be reclassified to statement profit or loss		-	-
Total other comprehensive income		43.85	-3.46
Total Comprehensive Income for the year		**675.86**	**720.21**
Profit / (Loss) attributable to :			
Equity holders of the parent company		628.36	721.53
Non controlling interest		3.65	2.13
Earning per share (face value per equity share Rs. 10)			
- Basic	42	3.95	4.56
- Diluted		3.95	4.56

The accompanying notes referred to above form an integral part of these consalidated financial statements.

As per our report of even date attached

*for **S S J N B & CO***
Chartered Accountants
Firm's registration number: 013976S

Dhanpal I Sakaria
Partner
Membership number: 213666
Place: Bengaluru
Date: 27th May 2026
UDIN:*26213666JVZIHB9169*

for and on behalf of the board of directors of
Bal Pharma Limited

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh
Whole Time Director
DIN: 08554422

Bharath Bhushan D.V
Chief Financial Officer

Place: Bengaluru
Date: 27th May 2026

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Audited Consolidated Statement of Cash Flows

(all amounts in Rs. lakhs unless otherwise stated)

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Cash flow from operating activities:		
Profit / (Loss) before tax	593.39	513.74
Adjustment for :		
- Interest income	(84.68)	(73.64)
- (Gain)/Loss on sale of Property, Plant and Equipment	(5.61)	-
- Balances written off as no more payable	-	(14.20)
- Unrealised Foreign (Gain)/Loss	61.84	20.68
- Finance cost (including effect of amortisation of processing fees)	1,681.76	1,685.44
- Rental Expense(IND AS 116)	(153.38)	(116.66)
- Balances written off as no more receivable	0.02	-
- Depreciation and amortisation	1,107.93	977.09
- Expected Credit Losses	2.81	-
- Imairment on investment write back	-	(0.01)
-Other Comprehensive income	43.37	(4.33)
Operating cash flow before working capital changes	**3,247.46**	**2,988.14**
Changes in		
- Decrease/(Increase) in Inventories	(1,333.32)	(1,521.09)
- Decrease/(Increase) in Trade receivables	(215.85)	714.92
- Decrease/(Increase) in Loans	(3.32)	3.52
- Decrease/(Increase) in Financial Assets (Current and Non current)	(32.81)	(64.97)
- Decrease/(Increase) in Other Assets (Current and Non current)	(1,351.28)	(315.96)
- Increase/ (Decrease) in Trade payables	749.93	416.66
- Increase/ (Decrease) in Other Financial liabilities (Current and Non current)	1,965.83	247.21
- Increase/ (Decrease) in Other liabilities (Current and Non current)	40.55	(308.44)
- Increase/ (Decrease) in Provisions	16.33	79.22
Cash (used in)/ generated from operations	**3,083.54**	**2,239.21**
Income taxes (paid)/ refund	-	(207.71)
Net cash generated (used in) operating activities	**3,083.54**	**2,031.51**
Cash flow from investing activities:		
Purchase of Property,Plant & Equipment including intangible assets and capital work-in-progress	(1,855.49)	(1,678.84)
Intercorporate Deposit to Subsidiary	-	0.10
Right to Use of Asset as per IND AS	(382.51)	(199.84)
Proceeds from sale of fixed assets	5.61	-
Decrease/ (increase) in fixed deposits/Liquid Funds	78.33	313.25
Interest received	84.12	73.64
Net cash generated/ (used in) investing activities	**(2,069.94)**	**(1,491.69)**

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Audited Consolidated Statement of Cash Flows
(all amounts in Rs. lakhs unless otherwise stated)

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Cash flow from financing activities:		
Proceeds from/(Repayment) of long term borrowings	341.18	(76.74)
Proceeds from / (repayment) of short term borrowings	572.43	1,154.86
Dividend Paid including unpaid dividends of preceding years	(191.05)	(191.05)
Money received on issue of Equity shares	(0.01)	80.69
Share based payment reserve		0.00 (66.57)
Interest Paid (Gross)	(1,681.20)	(1,685.44)
Net cash arising/ (used in) from financing activities	**-958.64**	**-784.24**
Net (decrease)/ increase in cash and cash equivalents	54.95	(244.44)
Cash and cash equivalents at the beginning of the year	175.16	419.58
Cash and cash equivalents at the end of the year	**230.11**	**175.16**
Cash and cash equivalents comprise of:		
Cash on hand	1.95	3.04
Balances with banks	-	-
- in current accounts	141.63	77.96
- in deposits with original maturity of less than 3 months	86.53	94.16
	230.11	**175.16**

The accompanying notes referred to above form an integral part of these consalidated financial statements.

As per our report of even date attached

*for **S S J N B & CO***
Chartered Accountants
Firm's registration number: 013976S

Dhanpal I Sakaria
Partner
Membership number: 213666
Place: Bengaluru
Date: 27th May 2026
UDIN:*26213666JVZIHB9169*

for and on behalf of the board of directors of
Bal Pharma Limited

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh
Whole Time Director
DIN: 08554422

Bharath Bhushan D.V
Chief Financial Officer

Place: Bengaluru
Date: 27th May 2026

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Consolidated Statement of changes in equity
(all amounts in Rs. lakhs unless otherwise stated)

A. Equity share Capital

Particulars	Numbers(in 0,000)
Equity shares of Rs 10 each issued, subscribed and fully paid	
Balance as at 1 April 2024	1,580.44
Add: Issue of shares	11.65
Balance as at 31 March 2025	**1,592.09**
Balance as at 1 April 2025	1,592.09
Add: Issue of shares	
Balance as at 31 March 2026	**1,592.09**

B. Other Equity

B. Other Equity	Reserves & Surplus				OCI		
	Securities premium	General Reserve	Capital Reserve	Retained earnings	Remeasurements of the net defined benefit plans	Non Controlling Interest	Total Other Equity
Balance as at 1 April 2024	**3,195.32**	**245.15**	**44.06**	**2,205.21**	**(69.73)**	**(3.29)**	**5,616.71**
Profit for the year	-	-	-	721.53	-	2.13	723.67
Appropriations for dividend and tax on same	-	-	-	(191.05)	-	-	(191.05)
Impairment of investement reversal	-	-	-		-		-
Transferred to OCI				(4.65)	4.65		-
Issue of share warrants during the year	-	-	-	-	-	-	-
Other Comprehensive income/Additions	-	-	-	-	(3.46)	-	(3.46)
Issue of shares during the year	69.04						69.04
Share based payment reserve	(66.57)						(66.57)
							-
							-
Balance as at 31 March 2025	**3,197.79**	**245.15**	**44.06**	**2,731.04**	**(68.54)**	**(1.15)**	**6,148.35**
Balance as at 1 April 2025	**3,197.79**	**245.15**	**44.06**	**2,731.04**	**(68.54)**	**(1.15)**	**6,148.35**
Profit for the year				628.36		3.65	632.01
Appropriations for dividend and tax on same				(191.05)			(191.05)
Impairment of investement reversal							-
Transferred to OCI					43.85		
Issue of share warrants during the year							**-**
							-
Balance as at 31 March 2026	**3,197.79**	**245.15**	**44.06**	**3,168.35**	**(24.69)**	**2.49**	**6,589.30**

The accompanying notes referred to above form an integral part of these consalidated financial statements.

As per our report of even date attached

for ***S S J N B & CO***
Chartered Accountants
Firm's registration number: 013976S

Dhanpal I Sakaria
Partner
Membership number: 213666
Place: Bengaluru

Date: 27th May 2026
UDIN:*26213666JVZIHB9169*

for and on behalf of the board of directors of **Bal Pharma Limited**

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh
Whole Time Director
DIN: 08554422

Bharath Bhushan D.V
Chief Financial Officer

Place: Bengaluru
Date: 27th May 2026

BAL PHARMA LIMITED

CIN: L85110KA1987PLC008368

Notes to consolidated financials statements

1. Group Overview

The consolidated financial statements comprise financial statements of Bal Pharma Limited ('the Parent Group' or 'Holding Group' or 'the Group') together with its subsidiaries (collectively termed as 'the Group' or 'the Consolidated Entities') for the year ended March 31, 2026. Bal Pharma Limited is a public Group domiciled in India and was incorporated under the provisions of the Companies Act applicable in India. Its shares are listed on two recognized stock exchanges in India. The Group is primarily engaged in the manufacturing and selling of pharmaceutical products and related services. The Group caters to both domestic and international markets.

2. Basis for preparation of Consolidated Financial Statements

2.01 Statement of compliance

These financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) as per the Companies (Indian Accounting Standards) Rules, 2015 notified under Section 133 of Companies Act, 2013, (the 'Act') and other relevant provisions of the Act.

The financial statements were authorised for issue by the Holding Group's Board of Directors on 27th May, 2026

2.02 Historical Cost Convention

The consolidated financial statements have been prepared on a historical cost basis, except for the following assets and liabilities which have been measured at fair value or revalued amount

- Certain financial assets and liabilities measured at fair value (refer accounting policy regarding financial instruments),

- employee defined benefit assets / liability recognised as the net total of the fair value of plan assets, and actuarial losses/gains, and the present value of defined benefit obligation

The consolidated financial statements are presented in Lakhs unless otherwise stated

2.03 Principles for consolidation

The Consolidated Financial Statements relate to Bal Pharma Limited and its subsidiaries. Subsidiaries are all entities over which Bal Pharma Limited exercises control. The Holding Group exercises control if and only if it has the following:

- Power over the entity

- exposure, or rights, to variable returns from its involvement with the entity; and

- the ability to use its power over the entity to affect the amount of its returns.

The Consolidated Financial Statements have been prepared on the following basis:

- The Financial Statements of the Group have been combined on a line-by-line basis by adding together the book values of like items of assets, liabilities, income and expenses, after fully eliminating intra-Group balances and intra-group transactions and resulting unrealised profits. Unrealised losses resulting from intra-group transactions are eliminated unless cost cannot be recovered.

- The Group treats transactions with non-controlling interests that do not result in a loss of control as transactions with equity owners of the Group. A change in ownership interest results in an adjustment between the carrying amounts of the controlling and non-controlling interests to reflect their relative interests in the subsidiary. Any difference between the amount of the adjustment to non-controlling interests and any consideration paid or received is recognised within equity.

- The Financial Statements of the subsidiaries used for the purpose of consolidation are drawn up to the same reporting date as of the Group.

- The Consolidated Financial Statements have been prepared using uniform accounting policies for like transactions and other events in similar circumstance and are presented to the extent possible, in the same manner, as the Group's Financial Statements.

Group Information

The Consolidated Financial Statements have been prepared on the basis of the financial statements of the following subsidiaries:

Name of the Entity	Country of Incorporation	% of interest As at 31 March 2026	As at 31 March 2026
1 Lifezen Healthcare Private Limited	India	99.46	99.46
2 Balance Clinic LLP	India	80.00	80.00
3 Bal Research Foundation	India	80.00	80.00
4 Aurum Research & Analytical Solutions Pvt Ltd	India	95.00	95.00

2.04 Use of judgements, Assumptions and estimates

In preparing these consolidated financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

These estimates are reviewed on an ongoing basis. Subsequent revisions to accounting estimates are recognised prospectively.

Judgements

The Consolidated Financial Statements have been prepared on the basis of the financial statements of the following subsidiaries:
Information about judgements in applying accounting policies that have the most significant effect on the amounts recognised in the standalone financial statements is included in the following notes:
- Note 3.01 : whether the Group acts as an agent rather than as a principal in a transaction.
- Note 62(j) - contingent liabilities : measurement and likelihood of occurrence of provisions and contingencies
- Note 62(g) - leases : whether an arrangement contains a lease; lease classification

Assumptions and estimations

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment in the year ended 31 March 2026 or subsequent year/ years is included in the following notes:
- Note 3.02: Useful lives of various of Property, Plant and Equipment
- Note 57: Fair Value of Financial Instruments
- Note 56: Accounting for Defined Benefit Plan - measurement of defined benefit obligation - key actuarial assumptions.
- Note 62(b): Expected Credit Losses associated with its assets carried at amortized cost

2.05 Current vs Non-Current Classification

The Group presents assets and liabilities in the balance sheet based on current/ non-current classification. An asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle
- Held primarily for the purpose of trading
- Expected to be realised within twelve months after the reporting period, or
- Cash or cash equivalents unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

  All other assets are classified as non-current.

  A liability is current when:
- It is expected to be settled in normal operating cycle
- It is held primarily for the purpose of trading
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

The Group classifies all other liabilities as non-current.
Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Group has identified twelve months as its operating cycle.

2.06 Measurement of fair values

Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows.

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The management regularly reviews significant unobservable inputs and valuation adjustments.

Measurement of fair values

When measuring the fair value of an asset or a liability, the Group uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Group recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred. Further information about the assumptions made in measuring fair values is included in the following notes:

- Financial Instruments - Refer Note 57 & 58

2.07 New and amended standards adopted by

The Ministry of Corporate Affairs vide notifications dated 7 May 2025 and 13 August 2025 notified the Companies (Indian Accounting Standards)Amendment Rules, 2025 and Companies (Indian Accounting Standards) Second Amendment Rules, 2025, respectively, amended certain accounting standards listed below, effective from annual reporting periods beginning on or after 1 April 2025:

- Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants – Amendments to Ind AS 1
- Supplier Finance Arrangements – Amendments to Ind AS 7 and Ind AS 107
- International Tax Reform – Pillar Two Model Rules – Amendments to Ind AS 12
- Lack of Exchangeability – Amendments to Ind AS 21

These amendments did not have any material impact on the amounts recognised in prior periods and are not expected to significantly affect the current or future period. New standards or amendments not yet adopted

The amendment to Ind AS 1 includes specific provisions that will take effect for reporting periods beginning on or after 1 April 2026, as outlined below:

- Classification of Liabilities as Current or Noncurrent and Non-current Liabilities with Covenants – Amendments to Ind AS 1- Lender waivers for breach of material provision of a long-term loan arrangement.

The Group does not expect this amendment to have an impact on its operations or financial statements.

3. Material Accounting Policies Information

3.01 Revenue Recognition

Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government.

Sale of Goods:

Revenue from contracts with customers is recognised when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Group expects to be entitled in exchange for those goods or services. In the Group's case, the obligation of the Group is said to be completed on movement of the goods from the factory gate. The Group has generally concluded that it is the principal in its revenue arrangements, since it is the primary obligor in all of its revenue arrangement, as it has pricing latitude and is exposed to inventory and credit risks. Revenue is stated net of goods and service tax and net of returns, chargebacks, rebates and other similar allowances. These are calculated on the basis of historical experience and the specific terms in the individual contracts. In determining the transaction price, the Group considers the effects of variable consideration, the existence of significant financing components, noncash consideration, and consideration payable to the customer (if any). The Group estimates variable consideration at contract inception until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognised will not occur when the associated uncertainty with the variable consideration is subsequently resolved.

Other Operating revenue is recognised on accrual basis.

Government grants and incentives:

The Group recognizes government grants only when there is reasonable assurance that the conditions attached to them will be complied with, and the grants will be received. Grants related to income and other incentives are deducted in reporting the related expense in the standalone statement of Profit and Loss.

Export entitlements under the Duty Drawback ('DBK'), Remission of duties & taxes on export of goods (RoDTEP)are recognized as income when the right to receive credit as per the terms of the scheme is established in respect of the exports made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.As the Group derives a substantial portion of its revenue from export of goods, such incentives is recognised as "Other Operating Income".

Rendering of Services:

Revenue from services rendered is recognised in the profit or loss as the underlying services are performed and is recognised net of service tax and goods and service tax (provided that it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably).

Interest Income:

Interest income from a financial asset is recognized when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principle outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Dividend Income

Dividend income from investments is recognized when the right to receive payment has been established, provided that it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably.

Rental Income

Rental income is recognised on a straight-line basis over the term of the lease

3.02 Property, Plant & Equipment, Intangible Assets and Work - in - Progress

Recognition and Measurement

All items of property, plant and equipment, including freehold land, are initially recorded at cost. Cost of property, plant and equipment comprises purchase price, non refundable taxes, levies and any directly attributable cost of bringing the asset to its working condition for the intended use. Expenses directly attributable to new manufacturing facility during its construction period are capitalized if the recognition criteria is met. Freehold land has an unlimited useful life and therefore is not depreciated.

The cost of an item of property, plant and equipment is recognized as an asset if, and only if, it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably.The cost includes the cost of replacing part of the property, plant and equipment and borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying property, plant and equipment. The accounting policy for borrowing costs is set out in note below.

Items such as spare parts, stand-by equipment and servicing equipment that meet the definition of property, plant and equipment are capitalized at cost and depreciated over their useful life. Costs in nature of repairs and maintenance are recognized in the Statement of Profit and Loss as and when incurred.

When significant parts of plant and equipment are required to be replaced at intervals, the Group depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognized in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied.

Subsequent Measurement

Subsequent to initial recognition, property, plant and equipment other than freehold land are measured at cost less accumulated depreciation and any accumulated impairment losses. The carrying values of property, plant and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable.

Disposal / Write-off

An item of property, plant and equipment is derecognized on disposal, or when no future economic benefits are expected from use or disposal. Gains or losses arising from derecognition of property, plant and equipment, measured as the difference between the net disposal proceeds and the carrying amount of the asset, are recognized in profit or loss when the asset is derecognized.

Capital Work-in-Progress

Capital work-in-progress includes cost of property, plant and equipment that are not ready for their intended use. Capital work-in-progress included property, plant and equipment are not depreciated as these assets are not yet available for use.

Depreciation

Depreciable amount for assets in the cost of an asset, or other amount substituted for cost, less its estimated residual value. Depreciation on the property, plant and equipment is provided on straight line method, over the useful life of the assets, as specified in schedule II to the companies Act, 2013 and is recognised in the statement of profit and loss except for the below mentioned assets:

Particulars	Useful life as per schedule II of Companies Act, 2013	Useful life as technically assessed
Motor buses, motor lorries and motor cars other than those used in a business of running them on hire	8	10

Property, plant and equipment which are added / disposed off during the year, depreciation is provided on pro-rata basis. Building constructed on leasehold land is depreciated Depreciation method, useful lives and residual values are reviewed at each financial year-end and adjusted if appropriate.

3.03 Inventories:

Inventories are valued at the lower of cost and net realisable value. Costs incurred in bringing each product to its present location and condition are accounted for as follows:

Raw materials and accessories:

Cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Cost is determined on first in, first out basis.

Finished goods and work in progress:

Cost includes cost of direct materials and labour and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs. Cost is determined on first in, first out basis.

Trading Goods:

Cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion a

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Notes to the consolidated financial statements (continued)
(all amounts in Rs. lakhs unless otherwise stated)

4. TANGIBLE ASSETS

	Building (Right-Of-Use assets)	Free holdland	Lease holdland	Building	Plant and machinery	Furniture and fixtures	Office equipment	Motor vehicles	Total
Gross Block (Deemed Cost)									
Balance as at 01 April 2024	**478.92**	**1,216.16**	**273.12**	**2,332.13**	**5,977.12**	**142.51**	**269.28**	**328.43**	**11,017.68**
Additions	66.55	-	237.85	61.71	825.57	32.91	45.72	14.83	1,285.13
Disposals									-
Merger Pooling of Interest									-
Balance as at 31 March 2025	**545.47**	**1,216.16**	**510.97**	**2,393.84**	**6,802.69**	**175.42**	**314.99**	**343.26**	**12,302.81**
Balance as at 01 April 2025	**545.47**	**1,216.16**	**510.97**	**2,393.84**	**6,802.69**	**175.42**	**314.99**	**343.26**	**12,302.81**
Additions	667.25		40.84	94.98	356.73	3.61	30.27	81.30	1,274.97
Disposals					(2.39)			(31.39)	(33.78)
Classification Realignment		1.47	(1.47)	(13.37)	(19.63)	18.63	11.71	3.51	0.87
Balance as at 31 March 2026	**1,212.72**	**1,217.63**	**550.34**	**2,475.45**	**7,137.41**	**197.66**	**356.97**	**396.68**	**13,544.86**
Accumulated Depreciation									
Balance as at 01 April 2024	**231.21**	**-**	**17.02**	**731.38**	**3,165.40**	**97.12**	**223.92**	**120.60**	**4,586.63**
Additions	135.14	-	1.37	84.43	328.66	14.62	26.35	26.51	617.08
Disposals							-		
Merger Pooling of Interest							-		
Balance as at 31 March 2025	**366.35**	**-**	**18.39**	**815.81**	**3,494.05**	**111.74**	**250.27**	**147.11**	**5,203.71**
Balance as at 01 April 2025	**366.35**	**-**	**18.39**	**815.81**	**3,494.05**	**111.74**	**250.27**	**147.11**	**5,203.71**
Additions	184.22		5.59	87.20	347.54	12.87	28.19	30.48	696.09
Disposals					(0.28)			(29.81)	(30.09)
Balance as at 31 March 2026	**550.57**	**-**	**23.98**	**903.01**	**3,841.31**	**124.61**	**278.46**	**147.78**	**5,869.71**
Carry Amount (Net)									
Balance as at 31 March 2025	**179.12**	**1,216.16**	**492.58**	**1,578.04**	**3,309.28**	**63.68**	**64.73**	**196.15**	**7,099.73**
Balance as at 31 March 2026	**662.15**	**1,217.63**	**526.36**	**1,572.44**	**3,296.10**	**73.05**	**78.51**	**248.90**	**7,675.11**

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Notes to the consolidated financial statements (continued)
(all amounts in Rs. lakhs unless otherwise stated)

5. Capital work-in-progress

Particulars	As at 31 March 2026	As at 31 March 2025
Capital work-in-progress	742.42	278.58
	742.42	**278.58**

Capital work-in-progress ageing schedule

Capital work-in-progress	Amount in Capital work-in-progress for a period of				
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
Projects in progress					
Project I	742.42	-	-	-	742.42
	742.42	**-**	**-**	**-**	**742.42**

6A. Goodwill

Particulars	As at 31 March 2026	As at 31 March 2025
Goodwill	382.69	382.69
	382.69	**382.69**

6B. Intangible Assets

Particulars	Computer software	Development Expenses	Trade Licence	Total Inangible assets
Gross Block (Deemed Cost)				
Balance as at 01 April 2024	108.54	2,312.93	198.55	2,187.67
Additions	25.15	325.03	70.73	429.35
Disposals				-
Merger Pooling of Interest				-
Balance as at 31 March 2025	**133.69**	**2,637.96**	**269.28**	**2,617.02**
Additions	26.62	426.04	102.60	555.26
Disposals	-	-	-	-
Classification Realignment	0.77	-1.40	-0.36	-0.98
Balance as at 31 March 2026	**161.08**	**3,062.61**	**371.53**	**3,171.31**
Accumulated Depreciation				
Balance as at 01 April 2024	**56.59**	**1,299.73**	**125.57**	**1,142.54**
Additions	30.07	236.41	92.81	359.29
Disposals				-
Merger Pooling of Interest				
Balance as at 31 March 2025	**86.66**	**1,536.14**	**218.38**	**1,501.83**
Additions	27.16	283.22	101.41	411.79
Disposals	-	-	-	-
Balance as at 31 March 2026	**113.82**	**1,819.36**	**319.79**	**1,913.62**
Carry Amount (Net)				
Balance as at 31 March 2025	**47.03**	**1,101.82**	**50.90**	**1,199.75**
Balance as at 31 March 2026	**47.26**	**1,243.25**	**51.74**	**1,342.25**

Non-current financial assets

7. Other financial assets

Particulars	As at 31 March 2026	As at 31 March 2025
Bank Deposits (original maturity of more than 12 months)	522.77	423.47
Earnest Money - Non current	19.35	16.53
Others		-
Prepayments	-	0.05
Security deposit	264.96	272.99
	807.08	**713.04**

8. Deferred tax assets (Net)

Particulars	As at 31 March 2026	As at 31 March 2025
Deferred tax assets (Net)	80.40	40.98
	80.40	**40.98**

Non-financial assets

9. Other non-current assets

Particulars	As at 31 March 2026	As at 31 March 2025
Capital Advances	106.66	158.98
Other Non Current Assets	17.11	17.11
Balances with Statutory/Government Authorities	176.86	191.64
	300.62	**367.74**

Current assets

10. Inventories (valued at lower of cost and net realisable value)

Particulars	As at 31 March 2026	As at 31 March 2025
Raw materials	3,331.31	3,271.35
Packing material	641.27	589.80
Work-in progress	4,410.29	3,350.73
Finished goods	3,246.93	3,083.60
Fuel	5.74	6.74
	11,635.53	**10,302.22**

11. Current Investments

Particulars	As at 31 March 2026	As at 31 March 2025
Investment in Mutual Fund	208.17	246.80
		-
	208.17	**246.80**

Current financial assets

12. Trade receivables

Particulars	As at31 March 2026	As at31 March 2025
Trade Receivables considered good - secured		
Trade Receivables considered good - unsecured	9,363.26	9,244.35
Trade Receivables which have significant increase in credit risk	157.04	154.22
Trade Receivables - credit risk	-	-
	9,520.30	**9,398.58**
Loss Allowance	-157.04	-154.22
	9,363.26	**9,244.35**

Trade Receivables ageing schedule for the year ended 31 March 2026

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 6 months	6 months-1 Year	1-2 Years	2-3 Years	
(i) Undisputed Trade Receivables -considered good	9,035.90	118.38	137.44	71.54	9,363.26
(ii) Undisputed Trade Receivables -considered doubtful			-		-
(iii) Disputed Trade Receivables considered good					-
(iv) Disputed Trade Receivables considered doubtful					-
Total	**9,035.90**	**118.38**	**137.44**	**71.54**	**9,363.26**

Trade Receivables ageing schedule for the year ended 31 March 2025

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 6 months	6 months-1 Year	1-2 Years	2-3 Years	
(i) Undisputed Trade Receivables -considered good	8,519.20	457.20	166.08	101.88	9,244.35
(ii) Undisputed Trade Receivables -considered doubtful			-		-
(iii) Disputed Trade Receivables considered good					-
(iv) Disputed Trade Receivables considered doubtful					-
Total	**8,519.20**	**457.20**	**166.08**	**101.88**	**9,244.35**

Current financial assets

13. Loans

Particulars	As at31 March 2026	As at31 March 2025
Unsecured-Considered good		
Loan receivables considered good - unsecured	-	-
- Security deposit	-	-
- Loans/advances to employees	116.56	113.27
- Inter-Corporate Loan to related party	-	-
- Interest receivable on Inter-Corporate Loan to related party	-	-
	116.57	**113.28**

14. Cash and cash equivalents

Particulars	As at 31 March 2026	As at 31 March 2025
Cash on hand	1.95	3.04
Balance with bank	-	-
- On current Account	141.63	77.96
Deposits with original maturity of less than 3 months	86.52	94.16
	230.11	**175.16**

15. Other Bank balances

Particulars	As at 31 March 2026	As at 31 March 2025
Bank Deposits (maturity between 3 months to 12 months)	482.48	619.06
Balance earmarked for Unclaimed Dividends	8.40	10.83
	490.89	**629.89**

16. Other financial assets

Particulars	As at 31 March 2026	As at 31 March 2025
Security deposits	32.79	24.45
Unsecured, considered good	-	-
Earnest Money	131.22	103.29
	-	-
	164.01	**127.73**

17. Non current tax assets (Net)

Particulars	As at 31 March 2026	As at 31 March 2025
Advance Tax (net of provision)	13.43	98.84
	13.43	**98.84**

Non-financial assets

18. Other current assets

Particulars	As at 31 March 2026	As at 31 March 2025
Balances with statutory/government authorities	1,996.64	1,515.73
Govt Incentives Receivable	952.65	231.31
Advances recoverable in Cash or Kind	-	-
- from related parties	0.98	0.98
Advance to suppliers	559.50	431.79
Insurance claim receivable	79.35	79.35
Prepayments	203.34	134.37
Other curent assets	-	-
- from others	208.90	155.38
	4,001.38	**2,548.91**

19. Equity

Particulars	As at 31 March 2026	As at 31 March 2025
Authorised Share capital		
31 March 2026: 2,45,00,000 equity shares of Rs.10 each	2,450.00	2,450.00
31 March 2025 : 2,45,00,000 equity shares of Rs.10 each		-
-		
Issued, subscribed and paid-up share capital		-
31 March 2026: 15920872 equity shares of Rs.10 each	1,592.09	1,592.09
31 March 2025 :15920872 equity shares of Rs.10 each		-
	1,592.09	**1,592.09**

a) Equity shareholders holding more than 5 percent shares in the Company:

Name of the shareholder	As at 31 March 2026 No. of shares(in Lakhs)		As at 31 March 2025 No. of shares(in Lakhs)	
	No. of shares	Percentage	No. of shares	Percentage
Shailesh Siroya	27.45	17.24%	27.45	17.24%
Micro Labs Limited	20.11	12.63%	20.11	12.64%
Anita Siroya	10.49	6.59%	10.49	6.59%

b) Details of shares held by promoters at the end of the year

Name of the Promoter	As at 31 March 2026	Percentage of holding.
Shailesh Siroya	2745459	17.49%
Anita Siroya	1049220	6.68%
Micro Labs Limited	2011736	12.83%
Dilip Surana	474994	3.00%
Archana Surana	284996	1.81%
Anand Surana	525686	3.35%
Monica Surana	179909	1.14%
Dilip Surana (HUF)	169995	1.08%
Chandraprakash Dheerajmal Siroya	486420	3.10%
Anita Chandraprakash Siroya	122687	0.78%
Jivi Dheerajmal Siroya	46,080	0.29%
	80,97,182	**51.60%**

Non-financial assets

c) Reconciliation of the shares outstanding at the beginning and at the end of the period

Particulars	As at 31 March 2026	As at 31 March 2025
Opening Balance (Number of shares in Lakhs)	159.21	158.05
Add : Shares Issued during the year (Number of shares in Lakhs)		1.16
Closing Balance	**159.21**	**159.21**

d) Rights, preferences and restrictions attached to equity shares:

(i) The Company has only one class of shares referred to as equity shares having par value of Rs 10 each.

(ii) Each holder of the equity share, as reflected in the records of the Company as of the date of the shareholders' meeting, is entitled to one vote in respect of each share held for all matters submitted to vote in the shareholders' meeting.

(iii) The Company declares and pays dividends in Indian Rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing General Meeting.

(iv) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

(v) Each Share holder has a right to inspect the statutory registers of the company as per the provisions of the companies act, 2013.

(vi) Each and every share holder has a right to participate in the share holders's meetings as and when called by the company subject to provisions of the Companies Act, 2013.

(e) Shares reserved for issue under options & contracts/commitments for sale of shares /disinvestment, including the terms & amounts - NIL

(f) FFor period of 5 years immediately preceding the balance sheet date.

- Alloted as fully paid up by way of bonus shares NIL
- Bought back NIL
- For consideration other than cash- NIL

(g) Securities convertible into equity /preference shares issued - NIL

(h) No Calls Unpaid

(I) Issue of securities made for a specific purpose at the balance sheet date - NIL

20A. Other Equity

Particulars	As at 31 March 2026	As at 31 March 2025
(i) Retained Earnings		-
Balance as at beginning of the reporting period	2,731.03	2,205.21
Transferred to OCI	-	-4.65
Add: Net profit/(loss) for the period	628.36	721.53
Less: Dividend payable	-191.05	-191.05
	3,168.35	**2,731.03**
(ii) Other Reserves*		
Securities premium	3,197.79	3,197.79
General reserve	245.15	245.15
Capital Reserve	44.06	44.06
	3,486.99	**3,487.00**
(iii) Other comprehensive income		-
Others (acturial gain/ (Loss))	-68.53	-69.73
Add : Transferred from retained earnings	-	4.65
Add: Net gain/(loss) for the period	43.85	-3.46
	(24.69)	**(68.53)**
	-	-
	6,630.65	**6,149.50**

*Refer Statement of changes in equity for detailed movement in other equity balances.

Nature and purpose of reserves

Retained Earnings:

Retained earnings are the profits that the Company has earned till date, less any transfers to general reserve, dividends or other distribution to share holders.

Securities premium:

The amount received in excess of face value of the equity shares is recognised in securities premium. This reserve will be utilised in accordance with provisions of Section 52 of the Companies Act, 2013.

General reserve:

The Company has transferred a portion of its net profit before declaring dividend to general reserve pursuant to the earlier provisions of the Companies Act, 1956. Mandatory transfer to general reserve is not required under the Companies Act, 2013

Other Comprehensive Income (OCI):

Re-measurement of defined employee benefit plans

Difference between the interest income on plan assets and the return actually achieved, any changes in the liabilities over the year due to changes in actuarial assumptions or experience adjustments with in the plans, are recognised in other comprehensive income and subsequently not reclassified into standalone statement of profit and loss

20 B. Non- Controlling Interest

Particulars	As at 31 March 2026	As at 31 March 2025
Lifezen Healthcare Private Limited	(695.50)	(695.21)
Bal Research Foundation	(0.50)	(0.12)
Balance Clinic LLP	8.74	4.37
Aurum research & Analytical solution pvt ltd	(0.04)	-
Less: Reduction in Minority Interest	689.81	689.81
	2.50	**(1.15)**

Financial liabilities

21. Borrowings

Particulars	As at 31 March 2025	As at 31 March 2024
Terms loans		
- from banks	2,464.46	686.92
- from others	156.53	1,751.93
GECL Loan	500.00	639.29
Other Loans	-	-
- vehicle loans	67.50	61.89
		-
	3,188.48	**3,140.03**

The above amount includes		
Secured Borrowings (includes vehicle loans)	2,567.98	**2,470.42**
Unsecured Borrowings	-	
Loan Under guaranteed emergency credit line & Bank Loan	620.50	**669.60**

i) A Term loans (including current maturities of non-current borrowings) from South Indian Bank Limited -Term Loan 1

As at 31 March 2026 : Rs. 286.13 lakhs (31 March 2025 : Rs.325.42 lakhs)

Security

i.All the property bearing municipal no 6/3 situated at Vasanthnagar, new ward number 63, Bengaluru consisting of 6825 square feet land owned by the Company

Repayment and interest

ii.The loan was repayable in 154 monthly instalments starting from March 2018.

iii.The loan carried interest rate equal to the lender's 12 month's MCLR rate Date of Maturity : 19.06.2031

B Term loans (including current maturities of non-current borrowings) from South Indian Bank Limited -Term Loan 2

As at 31 March 2026 : Rs.232.67 lakhs (31 March 2025 : Rs. 253.08 lakhs)

Security

i.All the property bearing municipal no 6/3 situated at Vasanth Nagar, new ward number 63, Bengaluru consisting of 6825 square feet land owned by the Company

Repayment and interest

ii.The loan was repayable in 180 monthly instalments starting from April 2018.

iii.The loan carried interest rate equal to the applicable 12 month's MCLR rate Date of Maturity : 31.12.2035

C Term loans (including current maturities of non-current borrowings) from Canara Bank.

As at 31 March 2026 : Rs 00.00 lakhs (31 March 2025 : Rs. 90.89 lakhs)

Security

i. Hypothecation of Plant and Machinery which were funded from the term loan. For all the limits sanctioned by bank including term loan, charge on current assets of the Company along with HDFC Bank limited and Canara Bank and first charge on the property located in Plot 61B, Bommasandra, Bengaluru and personal guarantee of Mr Shailesh Siroya (managing director)

Repayment and interest

i.The disbursed loan to be repayable in 84 months with 5 months of moratorium and 1 month for project implementation

ii.The loan carried interest rate equal to the applicable RLLR(presently 6.90%)+2.80%+0.8% (Liquidity Premium) - Date of Maturity : 21.01.2029

iii. Loan take over by the Federal Bank on 27.03.2026.

D Term loans (including current maturities of non-current borrowings) from Canara Bank.

As at 31 March 2026 : Rs 00.00 lakhs (31 March 2025 : Rs.205.36)

Security

i.The assets created out of the credit facility so extended, that is, paripassu first charge on the entire current assets of the Company

Repayment and interest

i.The disbursed loan to be repayable in 72 months with 24 months of moratorium

ii.The loan carried interest rate equal to the applicable RLLR(presently 6.90%)+0.60%= 7.5% Date of Maturity : 29.02.2028

iii. Loan take over by the Federal Bank on 27.03.2026.

ii) Details of securities, repayment and interest of secured term loans from others (including current maturities of long-term debt):

A Term loans (including current maturities of non-current borrowings) from STCI Finance Limited

As at 31 March 2026 : Rs 000.00 lakhs (31 March 2025 : Rs.1900.00)

Security

i. Exclusive Charge by way of mortgage of Plot No.C-155, Mewar Industrial Area, Udaipur, Rajasthan - 313003, presently mortgaged in favour of TFSL towards Term loan which has taken over by STCI Finance Limited

ii. First and Exclusive charge on entire present and future Fixed Assets (both movable and Immovable of Golden Drugs Pvt Ltd.

Repayment and interest

i.The loan is repayable in 60 monthly instalments shall comments from the end of the 12th month succeding the month of first disbursement. Starting from Jan'25 with an initial moratorium of 12 months"

ii.The loan carried interest rate equal to the lender's long term lending rate @ 12.50% p.a payable monthly. Date of Maturity : 22.12.2029

iii. Loan take over by the Union Bank on 07.07.2025

B Term loans (including current maturities of non-current borrowings) from Small Industries Development Bank of India (SIDBI)

As at 31 March 2026 : Rs 251.93 lakhs (31 March 2025 : Rs.347.33 lakhs)

Security

i. First Charge by way of hypothecation of Plant and Machinery pertaining to the project of Rs.429 Lakhs, ii. Collateral Security FDR of Rs. 129 lakh lien mark with SIDBI in favour of Borrower and unconditional joint and several personal guarantee of Mr Shailesh Siroya (Managing director) and Mr. V. Himesh, Executive Director

Repayment and interest

ii.The loan is repayable in 54 monthly instalments starting from June 2024 with a initial moratorium of 6 months

iii.The loan carried interest rate equal to the lender's long term lending rate less 8.90% Date of Maturity : 10.11.2028

iii) Details of securities, repayment and interest of Working Capital Term Loan under GECL scheme (including current maturities of long-term debt):

A Working Capital Term Loans (including current maturities of non-current borrowings) from Canara Bank limited - 01

Current Maturities as at 31 March 2025 : Rs.00.00 lakhs (31 March 2025 : Rs.91.67 lakhs)

Security

i.The Loan is secured by all assets created out of credit facility

ii.The Loan is further secured by extending the charges created over existing loan.

iii.The facility is to be covered under Emergency Credit Line Guarantee Scheme (ECLGS) administered by National Credit Guarantee Trustee Company (NCGTC) Limited

Repayment and interest

i. Initial moratorium of 12 months and thereafter repayable in 48 months as Rs 8.35 lakhs per month for 47 months and Rs 7.55 lakh per month for 1 month

ii.The loan carried interest rate equal to the lender's long term lending rate less 7.50% p.a Date of Maturity : 15.02.2026

iii.The Loan closed on 15.02.2026

B Working Capital Term Loans (including current maturities of non-current borrowings) from HDFC Bank Limited-02

As at 31 March 2026 : Rs.162.50 lakhs (31 March 2025 : Rs.325.00 lakhs)

Security

i.The Loan is secured by all assets created out of credit facility

ii.The Loan is further secured by extending the charges created over existing loan.

iii.The facility is to be covered under Emergency Credit Line Guarantee Scheme (ECLGS) administered by National Credit Guarantee Trustee Company (NCGTC) Limited

Repayment and interest

i.Total tenor of 60 months with 12 months moratorium period .

ii.The loan carried interest rate equal to 7.5%.p.a Date of Maturity : 26.03.2027

C Working Capital Term Loans (including current maturities of non-current borrowings) from HDFC Bank Limited-03

As at 31 March 2026 : Rs 500 lakhs (31 March 2025 : Rs.700 lakhs)

Security

i.The Loan is secured by all assets created out of credit facility

ii.The Loan is further secured by extending the charges created over existing loan.

iii.The facility is to be covered under Emergency Credit Line Guarantee Scheme (ECLGS) administered by National Credit Guarantee Trustee Company (NCGTC) Limited

Repayment and interest

i.Total tenor of 48 months with 24 months moratorium period .

ii.The loan carried interest rate equal to 8%.p.a Date of Maturity : 28.09.2028

iv) Details of securities, repayment and interest of Term Loan / W C D L (including current maturities of long-term debt):

A Term loans (including current maturities of non-current borrowings) from South Indian Bank Limited - Term Loan 3

As at 31 March 2026 : Rs.268.73 lakhs (31 March 2025 : Rs.000.00 lakhs)

Security

i.All the property bearing municipal no 6/3 situated at Vasanth Nagar, new ward number 63, Bengaluru consisting of 6825 square feet land owned by the Company

Repayment and interest

ii.The loan was repayable in 48 monthly instalments starting from 1st Sept'2025

ii.The loan carried interest rate equal to the applicable 12 month's MCLR rate (Bench Mark + Spread) 10.25% Date of Maturity : 05.10.29

iii. Fresh Loan sanctioned by South Indian Bank Mortgage Loan - TL - 300.00 lakhs

B Term loans (including current maturities of non-current borrowings) from Federal Bank - TL 1

As at 31 March 2026 : Rs .67.69 lakhs (31 March 2025 : Rs.00.00 lakhs)

Security

i. Exclusive charge on the assets acquired out of term Loan valued at 9.03 Cr.

Repayment and interest

i.The disbursed loan to be repayable in 12 months with Nil moratorium- Equal monthly repayment.

ii.The loan carried interest rate equal to the applicable Bench Mark + Spread (5.25+3.75 =9 %) - Date of Maturity : 21.01.2029

iii. Loan take over from Canara Bank on 27.03.2026.

C Term loans (including current maturities of non-current borrowings) from Federal Bank.-TL 2

As at 31 March 2026 : Rs 136.72 lakhs (31 March 2025 : Rs.00.00)

Security

i. First paripasur charge along with HDFC Bank on current assets including stocks and book debts (Present and Future of the company)

Repayment and interest

i.The disbursed loan to be repayable in 12 months with Nil moratorium- Equal monthly repayment.

ii.The loan carried interest rate equal to the applicable Bench Mark + Spread (5.25+ 3.75 = 9%) Date of Maturity : 29.02.2028

iii. Loan take over from Canara Bank on 27.03.2026.

D Term loans (including current maturities of non-current borrowings) from UNION BANK - TLSUV - 1

As at 31 March 2026 : Rs 1552.64 lakhs (31 March 2025 : Rs.000.00)

Security

i. Exclusive Charge by way of mortgage of Plot No.C-155, Mewar Industrial Area, Udaipur, Rajasthan - 313003, presently mortgaged in favour of Union Bank towards Term loan which has taken over by Union Bank from STCI Finance Limited.

ii. First and Exclusive charge on entire present and future Fixed Assets (both movable and Immovable) of Unit 6, Situated at Udaipur, presently owned by Bal Pharma Limited.

Repayment and interest

i.The loan is repayable in 54 monthly instalments shall comments from 25th Sept'25 with Nil moratorium.

ii.The loan carried interest rate equal to the EBLR @ 8.25% p.a payable monthly. Date of Maturity : 25.02.2030

iii.The Loan taken over from STCI Finance Limited

E Term loans (including current maturities of non-current borrowings) from UNION BANK - TLSUV - 2

As at 31 March 2026 : Rs 168.00 lakhs (31 March 2025 : Rs.000.00)

Security

i. Exclusive Charge by way of mortgage of Plot No.C-155, Mewar Industrial Area, Udaipur, Rajasthan - 313003, presently mortgaged in favour of Union Bank towards Term loan which has taken over by Union Bank from STCI Finance Limited.

ii. First and Exclusive charge on entire present and future Fixed Assets (both movable and Immovable) of Unit 6, Situated at Udaipur, presently owned by Bal Pharma Limited.

Repayment and interest

i.The loan is repayable in 60 monthly instalments shall comments from 24th July'26 with Nil moratorium.

ii.The loan carried interest rate equal to the EBLR @ 8.25% p.a payable monthly. Date of Maturity : 24.06.2031

iii. Fresh Loan sanctioned by Union Bank for Capex at Unit -6 for 400.00 lakhs Disbursed so far 168.00 lakhs

F Working Capital Demand Loans (including current maturities of non-current borrowings) from HDFC Bank Limited

As at 31 March 2026 : Rs 458.33 lakhs (31 March 2025 : Rs.00.00 lakhs)

Security

i.The Loan is secured by way of Equitable mortgage of Unit I located at Plot no.21 and 22, sy No270,298 and 328,and Unit -2 API Division Locted at #61/B, Bommasandra Industrial area, Bangalore 560 099, Karnataka

ii.The Loan is further secured by personal Guarantee of Mr..

Shailesh Siroya

Repayment and interest

i.Total tenor to be repaid 60 equal monthly instalments.

ii.The loan carried interest rate equal to 8.5% linked to Repo Rate 3M (Repo Rate + 3%) Date of Maturity : 14.10.2030

iii. Fresh Loan sanctioned by HDFC Bank Limited for Capex at Unit -I & II for 500.00 lakhs

v) Details ofVehicle loans (including current maturities of long-term debt):

A Vehicle Loans (including current maturities of non-current borrowings) from HDFC Bank Limited - INNOVA HYCROSS HYBRIDE

As at 31 March 2026 : Rs.15.07 lakhs (31 March 2025 : Rs.21.14 lakhs)

(i) Secured by hypothecation of motor vehicles.

(ii) These loans carry an interest rate of 8.50%

(iii) The principal amount has to be repaid in 60 equated monthly instalments Date of Maturity : 05.05.2028

B Vehicle Loans (including current maturities of non-current borrowings) from HDFC Bank Limited - MAHINDRA XUV700 AX7 AWD

As at 31 March 2026 : 16.12 Rs. lakhs (31 March 2025 : Rs.22.34)

(i) Secured by hypothecation of motor vehicles.

(ii) These loans carry an interest rate of 9 %

(iii) The principal amount has to be repaid in 60 equated monthly instalments Date of Maturity : 05.06.2028

C Vehicle Loans (including current maturities of non-current borrowings) from HDFC Bank Limited - GLANZA 1.2 G P MT

As at 31 March 2026 : Rs.3.91 lakhs (31 March 2025 : Rs.5.46 lakhs)

(i) Secured by hypothecation of motor vehicles.

(ii) These loans carry an interest rate of 9 %

(iii) The principal amount has to be repaid in 60 equated monthly instalments Date of Maturity: 05.05.2028

D Vehicle Loans (including current maturities of non-current borrowings) from HDFC Bank Limited - EECO AMBULANCE

As at 31 March 2026 : Rs.2.05 lakhs (31 March 2025 : Rs.3.76 lakhs)

(i) Secured by hypothecation of motor vehicles.

(ii) These loans carry an interest rate of 10%

(iii) The principal amount has to be repaid in 39 equated monthly instalments. - Date of Maturity : 05.04.2027

E Vehicle Loans (including current maturities of non-current borrowings) from Mercedes- Benz Financial Services India Pvt Lrd

As at 31 March 2026 :Rs.19.66 lakhs (31 March 2025: Rs.34.16 lakhs)

(i) Secured by hypothecation of motor vehicles.

(ii) These loans carry an interest rate of 7.27%

(iii) The principal amount has to be repaid in 60 equated monthly instalments. Date of Maturity :04.06.2027

F Vehicle Loans (including current maturities of non-current borrowings) from Union Bank of india - EECO -CAR

As at 31 March 2026 :Rs.1.57 lakhs (31st March 2025 : Rs.2.53 lakhs)

(i) Secured by hypothecation of motor vehicles.

(ii) These loans carry an interest rate of 9.45%

(iii) The principal amount has to be repaid in 60 equated monthly instalments. Date of Maturity :05.09.2027

G Vehicle Loans (including current maturities of non-current borrowings) from HDFC BANK LTD - RUDRAPUR - GLANZA

As at 31 March 2026 :Rs.3.82 lakhs (31 March 2025: Rs 5.84 lakhs)

(i) Secured by hypothecation of motor vehicles.

(ii) These loans carry an interest rate of 9.53%

(iii) The principal amount has to be repaid in 36 equated monthly instalments. Date of Maturity 05.11.2027

vi) Details of Unsecured loans (including current maturities of long-term debt) from Kotak Mahindra Bank Limited:

A Kotak Mahindra Bank Limited-Jaldi Loan-Personal Loan-01

As at 31 March 2026 :Rs.00.00 lakhs (31 March 2025 : Rs.11.91 lakhs)

i.The Loan is Not secured and sanctioned loan under Jaldi Loan credit facility offered by Kotak Mahindra Bank Limited

Repayment and interest

i.Total tenor of 24 months without any moratorium period .

ii.The loan carried interest rate equal to 14.17 %.p.a Date of Maturity : 10.05.2025

iii.The Loan closed on 10.05.2026

B Kotak Mahindra Bank Limited-Jaldi Loan-Personal Loan-02

As at 31 March 2026 :Rs.00.00 lakhs (31 March 2025 : Rs.18.40 lakhs)

i.The Loan is Not secured and sanctioned loan under Jaldi Loan credit facility offered by Kotak Mahindra Bank Limited

Repayment and interest

i.Total tenor of 24 months without any moratorium period .

ii.The loan carried interest rate equal to 14.50%.p.a Date of maturity : 10.11.2025

iii.The Loan closed on 10.11.2025

vii) Details of Unsecured loans (including current maturities of long-term debt) from Kotak Mahindra Bank Limited: [New Loan]

A Kotak Mahindra Bank Limited-Jaldi Loan-Personal Loan-03

As at 31 March 2026 : 122.73 Rs.lakhs (31 March 2025 : Rs.00.00 lakhs)

i.The Loan is Not secured and sanctioned loan under Term Loan offered by Kotak Mahindra Bank Limited

Repayment and interest

i.Total tenor of 24 months without any moratorium period .

ii.The loan carried interest rate equal to 14 %.p.a Date of Maturity : 10.10.2027

iii. Fresh Loan sanctioned by Kotak Mahindra Bank Limited for 150.00 lakhs.

viii) Details ofVehicle loans (including current maturities of long-term debt): [New Loans]

A Vehicle Loans (including current maturities of non-current borrowings) from AXIS BANK - INNOVA HYCROSS

As at 31 March 2026 :Rs.30.15 lakhs (31 March 2025 : Rs.0.00 lakhs)

(i) Secured by hypothecation of motor vehicles.

(ii) These loans carry an interest rate of 8.50%

(iii) The principal amount has to be repaid in 39 equated monthly instalments   Date of Maturity : 01.11.2028

B Vehicle Loans (including current maturities of non-current borrowings) from BANK OF BARODA - HONDA CITY

As at 31 March 2026 : Rs.12.74 lakhs (31 March 2025 : Rs.0.00 lakhs)

(i) Secured by hypothecation of motor vehicles.

(ii) These loans carry an interest rate of 8.50%

(iii) The principal amount has to be repaid in 36 equated monthly instalments   Date of Maturity : 10.03.2028

C Vehicle Loans (including current maturities of non-current borrowings) from HDFC Bank Limited - MAHINDRA XEV

As at 31 March 2026 : Rs.20.08 lakhs (31 March 2025 : Rs.0.00 lakhs)

(i) Secured by hypothecation of motor vehicles.

(ii) These loans carry an interest rate of 8.38 %

(iii) The principal amount has to be repaid in 39 equated monthly instalments   Date of Maturity : 07.01.2029

ix) There are no defaults in repayment of principal or interest to lenders as at the balance sheet date, however, in certain cases based on information available as on date, there exists delay in repayment of loan as mentioned below.

a The following are delay in repayments towards loan for the year ended March 31, 2025

In case of vehicle loans taken from HDFC Bank Limited, the terms of which is stipulated in (iv) above, there is a delay in repayment for 7 days in the month of April 24 where auto debit was linked is rejected due to signature mismatch.

In case of Unsecured loans taken from Kotak Mahindra Bank Limited-02, the terms of which is stipulated in (v) above, there is a delay in repayment for 2 days in the month of April 24 where auto debit was linked is rejected due to signature mismatch in ECS form.

In case of Unsecured loans taken from Kotak Mahindra Bank Limited-02, the terms of which is stipulated in (v) above, there is a delay in repayment for 1 day in the month of Feb 25 due to bank server error.

b There are no delays in repayments towards loan for the year ended Mar 31, 2026

22. Other financial liabilities

Particulars	As at 31 March 2026	As at 31 March 2025
Deposits received from customers	36.11	45.11
Lease Liability (Ind AS 116)	561.21	128.97
	597.32	**174.07**

23. Provisions

Particulars	As at 31 March 2026	As at 31 March 2025
Provision for employee benefits		-
Gratuity	498.76	473.21
Leave benefits	121.40	91.26
		-
	620.16	**564.46**

Current financial liabilities

24. Borrowings

Particulars	As at 31 March 2026	As at 31 March 2025
Secured: -		
- Cash Credit	6,182.34	5,808.72
- Packing Credit	4,340.75	4,273.55
- Buyers Credit	203.50	71.89
		-
Unsecured:		-
Convertible Zero Coupon Debenture	576.85	576.85
Current maturities of long-term debt *		-
- term loan from banks	1,142.17	161.20
- term loan from others	95.40	495.40
- vehicle loans	59.67	33.01
- GECL loan	162.49	477.37
	12,763.16	**11,897.99**

All secured loans payable on demand and secured short term loans from banks are secured by first charge by way of hypothecation of all the stocks, book debts and other current assets (both present and future) and carries interest rate @ 9.75% to 13.15%

25. Trade Payables

Particulars	As at 31 March 2025	As at 31 March 2024
Due to Micro, Small and Medium Enterprises*	39.26	461.66
Due to Other than Micro, small and Medium Enterprises	-	-
- Due to Related Parties	151.57	55.78
- Due to Others	8,705.91	7,651.14
	8,896.73	**8,168.58**

Trade Payable ageing schedule for year ended March 2026

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 years	
(i) Micro, Small and Medium Enterprises (MSME)	39.26	-	-	-	39.26
(ii) Others	7,452.45	102.35	83.31	219.46	8857.57
(iii) Disputed Dues Micro Small and Medium Enterprises (MSME)	-	-	-	-	-
(iv) Disputed Dues Others	-	-	-	-	-
Total	**8,491.71**	**102.35**	**83.31**	**219.46**	**8,896.83**

Trade Payable ageing schedule for year ended March 2025					
Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 years	
(i) Micro Small and Medium Enterprises (MSME)	461.66	-		-	461.66
(ii) Others	7,311.08	61.47	85.46	248.90	7,706.97
(iii) Disputed Dues Micro Small and Medium Enterprises (MSME)	-	-	-	-	-
(iii) Disputed Dues Others -	-	-	-	-	-
Total	**7,772.74**	**61.47**	**85.46**	**248.90**	**8,168.57**

26. Other Financial Liabilities

Particulars	As at 31 March 2026	As at 31 March 2025
Interest accrued but not due	27.17	32.70
Interest accrued and due	-	-
Security deposits	149.88	148.88
Payable towards purchase of PPE & Outsourcing	1,263.81	206.93
Accrued Payroll	522.03	496.49
Unclaimed Dividends	8.36	10.79
Payable towards Dividend Distribution Tax	-0.00	-0.00
Lease Liability (IND AS 116)	148.13	63.75
Other current liabilities	-	-
- Due to Others	343.08	114.58
		-
	2,462.45	**1,074.09**

* For details of terms of loan, refer note no. 21

27. Other Current Liabilities

Particulars	As at 31 March 2026	As at 31 March 2025
Advance received from Customers	623.00	562.81
Statutory dues	64.35	85.52
Other Current Liabilities	35.37	44.32
	722.72	**692.66**

28. Provision

Particulars	As at 31 March 2025	As at 31 March 2024
Provision for employee benefits		-
Gratuity	57.34	82.48
Leave Encashment	20.29	34.22
	77.63	**116.71**

29. Revenue from operations

Particulars	For the period ended 31 Mar 2026	For the period ended 31 Mar 2025
Sale of Product	30,297.91	29,427.31
Other operating revenue	868.22	881.02
	31,166.13	**30,308.33**

30. Other income

Particulars	For the period ended 31 Mar 2026	For the period ended 31 Mar 2025
Interest income		
- on fixed deposits with bank	84.68	73.64
- Others	10.65	26.39
	-	-
Net gain on foreign currency translation and transactions	42.82	29.11
Profit on sale of Property, Plant and Equipment	5.61	-
Rental Income	12.00	12.00
Insurance Claim	5.69	1.35
Balances/Advances No More Payable	-	26.82
Reverseal of expected Credit Loss	-	11.28
Other Non -Operating revenue	31.34	39.71
	192.78	**220.29**

31. Cost of materials consumed

Particulars	For the period ended 31 Mar 2026	For the period ended 31 Mar 2025
Raw materials		
Opening stock	3,271.35	2,495.27
Add: Purchases - Raw Material	14,543.73	14,286.08
Less: Closing stock	-3,331.31	-3,271.35
	14,483.77	**13,510.00**
Packing Materials		
Opening Stock	589.80	549.02
Add: Purchases - Packing Material	1,664.43	1,519.39
Less: Closing stock	-641.27	-589.80
	1,612.97	**1,478.61**
	16,096.74	**14,988.61**

32. Purchases of traded goods

Particulars	For the period ended 31 Mar 2026	For the period ended 31 Mar 2025
Purchase of traded goods	922.66	1,505.56
	922.66	**1,505.56**

33. (Increase)/decrease in Inventories of finished goods and work in progress

Particulars	For the period ended 31 Mar 2026	For the period ended 31 Mar 2025
Inventories at the end of the year		
Work-in-progress	4,410.29	3,350.73
Finished goods	3,246.93	3,083.60
	7,657.22	**6,434.32**
Inventories at the beginning of the year		
Work-in-progress	3,350.73	3,091.65
Finished goods	3,083.59	2,637.85
	6,434.32	**5,729.49**
	(1,222.89)	**(704.83)**

34. Employee benefits expenses

Particulars	For the period ended 31 Mar 2026	For the period ended 31 Mar 2025
Salary and wages	5,972.77	5,597.33
Contribution to provident and other funds	225.78	223.77
Staff welfare expenses	313.86	297.26
Share based payment Expense	-	2.47
Gratuity Expenses	98.47	97.64
Leave Encashment Expense	34.59	21.58
	6,645.47	**6,240.05**

35. Finance Cost

Particulars	For the period ended 31 Mar 2026	For the period ended 31 Mar 2025
Interest Expenses on Term Loan	391.32	446.19
Interest Expenses on Working Capital	860.98	833.53
Interest Expenses GECL	26.39	51.37
Interest Expenses - others	152.57	101.97
Interest Expenses on Lease Liability (Ind AS 116)	57.00	20.76
Other Finance Cost	193.50	231.63
	1,681.76	**1,685.44**

36. Depreciation and Amortisation

Particulars	For the period ended 31 Mar 2026	For the period ended 31 Mar 2025
Depreciation on Property, Plant and Equipment	696.10	617.80
Amortisation on Intangible Assets	411.83	359.29
	1,107.93	**977.09**

37. Other expenses

Particulars	For the period ended 31 Mar 2026	For the period ended 31 Mar 2025
Consumption of stores and spares	65.27	37.72
Power and fuel		
Fuel - Opening Balance	6.74	7.36
Add: Fuel/Spares Purchases	353.08	300.18
Less: Closing Stock of Fuel/Spares	-5.74	-6.74
Cost of fuel consumption	354.09	300.80
Electricity charges	12.26	13.82
Power charges	539.11	478.12
Water Charges	53.84	36.41
Laboratory and Testing Charges	336.48	311.39
Sub contracting expenses	366.75	213.47
Repairs & Maintenance	-	
- Plant and machinery	330.46	279.94
- Building	95.90	98.12
- Others	110.02	149.85
	-	
Commission on sales & Others	415.17	669.51
Commission on Import	94.59	76.28
Freight and forwarding charges	845.20	787.39
Net loss on foreign currency translation and transactions	188.60	-
Travelling Expenses	245.86	336.20
Advertisement and selling expenses	463.13	482.40
Legal and professional charges	250.92	257.58
Rent	83.73	100.80
Rates & Taxes	128.54	214.18
Communication Cost	70.84	53.92
Registeration fees	-	0.20
Liquidated damages	15.95	28.31
Security Charges	90.39	85.03
Donation	2.55	6.46
Corporate Social Responsibility	17.86	19.00
Seminar, Conference & Exhibition Expenses	75.95	22.69
Insurance	157.14	150.46
Printing & Stationary	49.34	41.63
Subscription & Membership	25.74	30.12
Bank charges	20.69	19.99
Expected Credit Losses	2.81	-
Balances/Advances No More Recoverable	0.02	0.91
Director Sitting fee	2.16	2.22
Discount Paid	5.12	1.57
Miscellaneous Expenses	16.40	16.45
	5,532.85	**5,322.96**

BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
Notes to the Consolidated financial statements for the year ended 31 Mar 2026
(all amounts in Rs. lakhs unless otherwise stated)

38. Contingent liabilities and commitments

Particulars	As at 31 March 2026	As at 31 March 2025
Contingent liabilities		
- Income tax	298.22	326.22
- Excise & Customs and Service Tax (refer note 1 below)	223.04	223.04
- GST	36.47	1,160.39
Capital commitments		
-Estimated amount of contracts remaining to be executed on capital account (net of advances) and not provided for	-	-

Note 1 :The Company has received show cause notices under the Central Excise laws and Service Tax laws in for the years 2007-08 onwards which in various stages of assessment as at 31 March 2026.The assessments are in progress and the Company has not received the assessment order in respect of the same. In certain cases, the Company has preferred an appeal which has been remanded back to the original authority for reassessment.

Other Disputes

The Company is also involved in other lawsuits, claims, investigations and proceedings, which arise in the ordinary course of business, however, there are no such matters pending that the company expects to be material in relation to its business.

39. Auditors' remuneration excluding tax (included in Legal and Professional Charges)

Particulars	As at 31 March 2026	As at 31 March 2025
As auditor		
- for Statutory audit	12.50	12.50
- for Taxation matters	2.00	2.00
- for Limited Review	0.40	0.40
- for Internal Financial Controls & Reporting	1.50	1.50
In other capacity		
Other services (certification fees)	2.75	2.85
	19.15	**19.25**

40. Disclosure with respect to Micro, Small and Medium Enterprises

The Company has certain dues to Micro and small enterprises registered (suppliers) under Micro, Small, and medium Enterprises Development Act, 2006(MSMED Act) .The disclousure pursuant to the said MSMED Act, to the extent the information is available with company are as below:

		(in Lakhs)
a)	Principal amounts due to suppliers remaining unpaid as at the year end	39.26
b)	Interest due to the suppllier as at the year and	

41. Confirmations

Balances of Trade Receivables, Trade Payables, Loans and Advances, Receivables and Payables are subject to confirmation / reconciliation, if any

42. Earnings per share

Basic EPS amounts are calculated by dividing the income for the year attributable to equity holders by the weighted average number of equity shares outstanding during the year. The Company has no potentially dilutive instruments.

(i) Reconciliation of earnings used in calculating earnings per share:

Particulars	As at 31 March 2026	As at 31 March 2025
From continuing operations:		
Total Profit / (Loss) for the period attributable to Equity shareholders	675.86	720.20
Net profit/(loss) for basic and diluted earnings	**675.86**	**720.20**

(ii) Reconciliation of basic and diluted shares used in computing earnings per share

Particulars	As at 31 March 2026	As at 31 March 2025
Number of equity shares at the beginning of the year (in Lakhs)	159.20	158.05
Add: Weighted average number of equity shares issued during the year	-	0.49
Number of weighted average equity shares considered for calculation of basic and diluted earnings per share (in lakhs)	**159.20**	**158.53**

(iii) Earnings per share:

Particulars	As at 31 March 2026	As at 31 March 2025
Basic	3.95	4.54
Diluted	3.95	4.54
(All share warrants issued at average market price)		

* The Company has no potential dilutive instruments

43. Unclaimed Dividends on Equity Shares

Particulars	As at 31 March 2026	As at 31 March 2025
2017 - 2018		2.48
2018 - 2019	2.06	2.60
2020 - 2021	1.56	1.66
2021 - 2022	1.10	1.40
2022 - 2023	0.98	1.22
2023 - 2024	1.36	1.43
2024 - 2025	1.30	
	8.36	**10.79**

44. Expenditure on corporate social responsibility activities

Particulars	As at 31 March 2026	As at 31 March 2025
(a) Amount required to be spent by the Company during the year*	16.28	19.00
(b) Amount spent during the year	17.86	19.00

Particulars	As at 31 March 2026	As at 31 March 2025
Where the company covered under section 135 of the companies act, the following shall be disclosed with regard to CSR activities:-		
(a) amount required to be spent by the company during the year,	16.28	19.00
(b) amount of expenditure incurred,	17.86	19.00
(i) Construction/acquisition of any asset		
(ii) On purposes other than (i) above	17.86	19.00
(c) shortfall at the end of the year,	-	-
(d) total of previous years shortfall,	-	-
(e) reason for shortfall		

Particulars	As at 31 March 2026	As at 31 March 2025
(f) nature of CSR activities,	Education to socially and financially underprivileged children & Financial assistance to health care institutions, Food & Nutrition	Education to socially and financially underprivileged children & Financial assistance to health care institutions
(g) details of related party transactions		
(h) Provision made in respect of a Liability incurred due to a Contractual Obligation		

45. Leases

(a) Company as a lessee

The Company adopted Ind-AS 116, on all lease contracts, except for the leases with a term of twelve month or less (short term leases) and low value leases using the modified retrospective method with Right-of-use assets recognised at an amount equal to the lease liabilities in the balance sheet. The Right-of-use assets as on March 31, 2025 and March 31, 2026 have been presented as part of Property, plant and equipment. For these short term leases, the Company recognises the lease payments as an operating expense on a straight line basis over the period of lease.

Changes in Lease Liabilities

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Opening Balance	192.72	265.14
On account of adoption of Ind AS 116		
Additions	667.25	66.55
Finance Cost	57.18	21.09
Payment of Lease Liabilities	-207.82	-160.06
Closing Balance	709.33	192.72
Current Lease Liabilities	148.13	63.75
Non-current Lease Liabilities	561.21	128.97

Contractual Maturities of Lease Liability

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Less than one year	148.13	63.75
1 to 5 years	527.48	78.87
above 5 years	33.72	50.10

46. Export Benefit Incentives

Export benefit Incentives includes Duty Drawback ('DBK'), Focus Marketing incentive scheme(FMS), Focus product scheme (FPS), Market Linked Product Scheme (MLPS), Incremental Exports incentive scheme, Merchandise Export India Scheme, Service tax rebate scheme (STR) and Remission of Duties or Taxes on Export Products Scheme . The Company has accounted an amount of Rs. 254.03 lakhs (31 March 2025 : Rs. 236.62 lakhs) under "other operating revenue", being the net amount of credit under various export incentive schemes as announced under Foreign trade Policy. The same will be either be sold or utilized for off-setting customs duty on future imports. The accumulated amount outstanding on this account as on 31 March 2026 is Rs. 352.65 lakhs (31 March 2025 is Rs. 231.31 lakhs) and the same is reflected under Export Incentives Receivable.

47. Segment reporting

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses and for which discrete financial information is available. The operating segments' operating results are reviewed by the Chief Operating Decision Maker (Board of Directors) to make decisions about resources to be allocated to the segments and assess their performance. The Company's business activities fall within one component namely, "manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients". Accordingly, separate disclosures per the requirements of Ind AS 108, Operating Segments, are not considering necessary.

In accordance with Ind AS-108 "Operating Segments", information about geographical areas has been given in the Consolidated Financial Statements of Bal Pharma Limited and therefore, no separate disclosure on geographical areas is given in these financial statements

48. Income tax

A. Amounts recognised in statement of profit and loss

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Current income tax:		
Current income tax charge	-	-
Excess/Short provision of tax written back		(14.06)
Previous Year's Tax Adjustment	-	-
	-	**(14.06)**
Deferred tax:		
Attributable to -		
Origination and reversal of temporary differences	(38.61)	(195.87)
	(38.61)	**(195.87)**
Minimum Alternate Tax credit entitlement		
Excess of tax liability under Minimum Alternate Tax over Normal Provisions as per Income Tax Act, 1961	-	-
	-	-
Income tax (credit) / expense reported in the Statement of profit or loss	**(38.61)**	**(209.92)**

B. Income tax recognised in other comprehensive income

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Net (gain)/loss on remeasurement of defined benefit liability/ (assets)	-	-
Income tax charged to OCI	-	-

C. Reconciliation of tax expense and the accounting profit multiplied by India's domestic tax rate:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Profit before income tax(Consolidated Profit of Group)	593.39	513.73
Add: Losses of Subsidiaries		-43.12 (59.49)
	636.51	573.22
Domestic tax rate *	27.82%	27.82%
Tax using the Company's domestic tax rate	177.08	159.47

C. Reconciliation of tax expense and the accounting profit multiplied by India's domestic tax rate: (continued)

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Impact of Non-taxable items due to Ind AS adjustments	20.00	8.72
Weighted Deductions and Exemptions	(118.53)	(90.42)
Impact of non-deductible expenses for tax purposes	8.00	16.37
Impact of deductible expenses for tax purposes	(66.40)	(54.26)
Impact of disallowance for non payment and non deduction of TDS	0.67	-
Impact of allowability of certain expenditure on payment basis	5.88	16.77
Impact of Depreciation on Property, Plant and Equipment and others	114.72	70.02
Impact of tax losses on tax expense	(141.42)	(126.67)
Excess/Short provision of tax written back	-	(14.06)
Others	-	-
Previous Year Tax Adjustment	-	-
Current tax Expense	**0.00**	**(14.06)**
Effective Tax Rate	0.00%	-2.74%

* Including applicable surcharge rate and cess

D. Deferred Tax

Deferred tax relates to the following:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Deferred Tax Liability		
Property, Plant and Equipment	-526.63	-551.35
Borrowings	-18.74	-15.84
Deferred tax Asset		
Allowability of certain expenditure on payment basis	203.35	203.01
Disallownce under sec 40(a)(ia)	-	-
Impairment of Investments	-	-
Lease Liability and ROU Asset	196.97	52.70
Provision for Doubtful debts	43.69	42.91
Income Tax Losses	181.77	309.56
Deferred tax Asset Reflected in Balance Sheet	**80.41**	**40.98**

49. Expenditure on Research and Development

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Revenue Expenditure		
Raw material consumed	1.00	4.02
Power and Fuel	82.47	66.06
Water Charges	4.77	4.54
Laboratory and testing	1.50	17.56
Employee benefit expense	209.32	191.37
Others	126.99	41.47
Total Expenditure towards Research and Development	**426.04**	**325.03**
Amount Capitalised (refer note 6B)		
Development Expenses	426.04	325.03

50. Note on Suspended Activities in Unit located at Pune

"The Management of the Holding Company has decided to suspend the operations of its IV fluids and parenterals manufacturing facility at Pune as this unit has been consistently incurring operational losses due to various reasons such as higher costs of raw materials, escalation in production cost, employee cost, lack of adequate orders and thin margins on products manufactured. The above have led to a situation wherein any further efforts to restore the profitability of the unit will be futile.
This decision was taken as part of the restructuring exercise undertaken by the Group to streamline its operations and to exit from its noncore businesses, so that further deterioration of its noncore business revenues can be plugged. The management is considering both avenues of disinvestment of the Unit or partnering with an outside party, whichever is beneficial. "

51. Value of Imports calculated on CIF basis

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Raw Materials	5,142.87	5,770.38
Capital goods (Including spares and components)	-	-
	5,142.87	**5,770.38**

52. Details of consumption of imported and indigenous raw materials, components and spare parts:

Particulars	31 March 2025		31 March 2024	
	Value in Rs	% of total consumption	Value in Rs	% of total consumption
Raw Material				
Imported	6,430.65	39.95%	5,887.53	39.28%
Indigenous	9,666.09	60.05%	9,101.09	60.72%
	16,096.74	**100%**	**14,988.61**	**100%**
Stores and Spares				
Imported	-	-	-	-
Indigenous	-	-	-	-
	-	-	-	-
	16,096.74		**14,988.61**	

53. Earnings in Foreign Currency

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
FOB value of Exports	17,267.09	16,517.83
	17,267.09	**16,517.83**

54. Expenditure in Foreign Currency

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Lab Chemical		1.78
Traveling expenditure	51.74	132.41
Registration fee	7.17	36.43
Commission on export sales	172.48	354.88
Sales promotion expenses	104.81	62.03
Inspection Fees	35.01	9.60
Packing charges	-	3.98
Professional Fee	-	-
software and Maintenance	-	25.15
Total	**371.21**	**626.26**

55. Related Party Transactions

A	**Enterprise owned by the Managing Director of the company**	Desa Marketing International
B	**Enterprise over which the Managing Director of the Company exercises joint control with other relatives**	Siroya Construction Siroya Wellness
C	**Enterprise over which the Managing Director of the Company exercises control**	Siroya Properties & Holdings Siroya Developers
D	**Significant Interest Entities**	Micro Labs Limited
E	**Key management personnel**	Shailesh D. Siroya - Managing Director Himesh Virupakshaya - Whole-Time Director C. D. Kotian - Whole-time Director (Resigned on May 16, 2025) Bharath Bhushan D.V. - CFO Abdul Basith - CS & Compliance Officer (Date of relieving: 11 May 2026) Ravindra Kumar Kothari - Non-Executive Director (Date of Appointment: 18 March 2026)

(ii) Particulars of Related Party Transactions

Particulars	Category	For the year ended 31 March 2026	For the year ended 31 March 2025
Revenue from Operations			
- Micro Labs Limited	D	247.39	328.90
		247.39	328.90
Commission on sales			
- Desa Marketing International	A	94.59	76.28
- Shailesh Siroya	E	28.66	51.35
		123.25	**127.63**
Sales promotion expenses			
- Siroya & Company	E	-	-
		-	-
Rental Expenses			
- Shailesh D Siroya	E	15.00	15.00
		15.00	**15.00**
Key Managerial Personnel Compensation			
- Shailesh D Siroya	E	180.00	183.33
- Himesh Virupakshaya	E	19.05	37.13
- Bharath Bhushan D V	E	34.20	33.71
- Chittanand Damodar Kotian	E	-	14.81
- Abdul Basith	E	7.38	7.63
- Ravindra Kumar Kothari	E	0.78	
		240.63	**276.61**

(ii) Particulars of Related Party Transactions (continued)

Particulars	Category	For the year ended 31 March 2026	For the year ended 31 March 2025
Expenses incurred on behalf of			
- Siroya Properties & Holdings Private Limited	C	-	-
		-	-
Loan received from Director (Net)			
- Shailesh D Siroya	E	-	-
		-	-

(iii) Amount outstanding as at the balance sheet date

Particulars	Category	For the year ended 31 March 2026	For the year ended 31 March 2025
Capital advances			
- Siroya Properties & Holdings Private Limited	C	18.89	74.51
		18.89	**74.51**
Trade Receivables			
- Micro Labs Limited	D	124.02	215.58
		124.02	**215.58**
Advances recoverable in Cash or Kind			
- Siroya Wellness	B	0.98	0.98
- Siroya Properties & Holdings Private Limited	C	-	-
		0.98	**0.98**
Other current assets			
- Siroya Constructions		1.44	1.44
- Siroya Properties & Holdings Private Limited	C	-	-
		-	-
Loans/advances to employees			
- Himesh Virupakshaya	E	-	0.25
		-	0.25
Trade Payables			
- Desa Marketing International	A	151.67	53.94
- Siroya Constructions	B		1.84
- Siroya Sunshine	E	-	-
- Shailesh Siroya	E	-	-
		151.67	**55.78**
Payable towards Capital Goods			
- Siroya Constructions	B	1.85	0.00
		1.85	-
Other financial liabilities - Rental Deposits			
		-	-
Other Current Liabilities			
Shailesh D Siroya	E	80.69	67.10
Himesh Virupakshaya	E	-	-
		80.69	**67.10**

* Managerial remuneration does not include provision for gratuity and leave encashment, which is determined for the Company as a whole

56. Employee benefits

(a) Defined Contribution Plans

Employees receive benefits from a provident fund and employee state insurance funds. The employer and employees each make periodic contributions to the plan as per local regulations. The following table discloses the employers contribution to the funds:

Particulars	Category	For the year ended 31 March 2026	For the year ended 31 March 2025
Provident Fund Contribution		215.33	208.06
Contribution to Employee State Insurance		15.42	15.42
Labour Welfare Fund		0.29	0.29

(b) Defined Benefit Plans and other Long term plans

In accordance with applicable Indian laws, the Company provides for gratuity, a defined benefit retirement plan (Gratuity Plan). The Gratuity Plan provides a lump sum payment to vested employees, at retirement or termination of employment, an amount based on the respective employee's last drawn salary and the number of years of employment with the Company. Actuarial Valuation for compensated absences is done as at the year end and the provision is made as per Company policy with corresponding (gain)/charge to the statement of profit and loss and it covers all regular employees. Obligation in respect of earned leave policy are actuarially determined as at the year end using the 'Projected Unit Credit' method.

The following tables summarise the components of net benefit expense recognised in the statement of profit and loss and the funded status and amounts recognised in the balance sheet for gratuity benefit and leave encashment

Particulars	Gratuity		Leave Encashment	
	As at 31 March 2026	As at 31 March 2025	As at 31 March 2026	As at 31 March 2025
Changes in present value of defined benefit obligations during the year				
Present Value of Defined Benefits at the beginning of the year	555.68	488.52	125.47	114.96
Service cost	62.93	63.69	34.57	21.31
Past Service Cost	-	-	-	-
Interest on defined benefit obligation	35.54	33.93	-	-
Benefits settled	(54.21)	(33.93)	(18.36)	(10.79)
Actuarial (gain) / loss	(43.84)	3.46		
	556.10	**555.68**	**141.68**	**125.48**
Reconciliation of present value of the obligation and the fair value of the plan assets:				
Present Value of Defined Benefits at the end of the year	556.10	555.68	141.69	125.49
Fair value of plan assets at the end of the year	-	-	-	-
	556.10	**555.68**	**141.69**	**125.49**
Net Liability - Current (Refer Note No. 30)	57.35	82.47	20.29	34.23
Net Liability - Non Current (Refer Note No. 25)	498.75	473.21	121.39	91.25

(b) Defined Benefit Plans and other Long term plans (continued)

Particulars	Gratuity		Leave Encashment	
	As at 31 March 2026	As at 31 March 2025	As at 31 March 2026	As at 31 March 2025
Expenses recognised in Statement of Profit or Loss during the year				
Current Service cost	62.93	63.69	34.57	21.31
Past Service Cost	-	-	-	-
Interest cost on defined benefit (net)	35.54	33.93	-	-
Expected return on plan assets	-	-	-	-
Others	-	-	-	-
	98.47	**97.63**	**34.57**	**21.31**
Actuarial (gain) / loss				
Remeasurements - Due to Demographic Assumptions	-	-	-	-
Remeasurements - Due to Financial Assumptions	(17.18)	16.56	-	-
Remeasurements - Due to Experience Adjustments	(26.67)	(13.10)	-	-
(Return) on Plan Assets (Excluding Interest Income)	-	-	-	-
(Return) on Reimbursement Rights	-	-	-	-
Changes in Asset Ceiling / Onerous Liability	-	-	-	-
	(43.85)	**3.46**	-	-
Maturity Profile of Defined Benefit Plan				
Within the next 12 months	65.47	82.03	16.29	20.42
Between 2 and 5 years	236.02	162.42	48.05	35.72
Between 6 and 9 years	230.89	142.79	32.78	28.05
For 10 years and above	393.19	168.44	44.56	41.29
Sensitivy Analysis for significant assumptions				
Salary Escalation - Up by 1%	7.48%	9.56%	7.64%	8.55%
Salary Escalation - Down by 1%	-6.68%	-8.25%	-6.72%	-7.30%
Attrition Rates - Up by 1%	0.24%	-0.51%	0.54%	0.08%
Attrition Rates - Down by 1%	0.15%	0.53%	-0.60%	-0.09%
Discount Rates - Up by 1%	-6.89%	-8.49%	-7.10%	-7.69%
Discount Rates - Down by 1%	7.83%	9.97%	8.18%	9.14%
Assumptions				
Discount rate	7.26%	6.97%	7.26%	6.97%
Estimated rate of return on plan assets	0.00%	0.00%	0.00%	0.00%
Salary increase	6.00%	6.33%	6.00%	6.33%
Attrition Rate	13.41%	12.27%	13.41%	12.27%
Retirement age	58 years	58 years	58 years	58 years

57. Financial Instruments - Fair Value Disclosure

The carrying value and fair value of financial instruments by categories for year ended 31 March, 2026

Particulars	Note No	Carrying value	Amortized Cost	Fair Value
Financial Asset at Amortised Cost (Current and Non-Current)				
Investments *	7 & 12	208.17	208.17	-
Loans	14	116.57	116.57	-
Trade receivable	13	9,363.26	9,363.26	-
Cash and cash equivalents	15	230.11	230.11	-
Other bank balances	16	490.89	490.89	-
Other financial assets	8 & 17	971.09	971.09	-
Total Financial Assets		**11,380.07**	**11,380.07**	**-**
Financial Liabilities at Amortised Cost (Current and Non-Current)				
Borrowings (including current maturities)	22 & 26	15,951.64	15,951.64	-
Trade payables	27	8,896.73	8,896.73	-
Other financial liabilities	23 & 28	3,059.76	3,059.76	-
Total Financial Liabilities		**27908.13**	**27908.13**	**-**
		(16528.06)	**(16528.06)**	-

*The Company has opted to account for investments in subsidiaries at cost as per Ind-AS 27 'Separate financial statements'

The carrying value and fair value of financial instruments by categories for year ended 31 March, 2025

Particulars	Note No	Carrying value	Amortized Cost	Fair Value
Financial Asset at Amortised Cost (Current and Non-Current)				
Investments *	7 & 12	246.80	246.80	-
Loans	14	113.28	113.28	-
Trade receivable	13	9,244.35	9,244.35	-
Cash and cash equivalents	15	175.16	175.16	-
Other bank balances	16	629.89	629.89	-
Other financial assets	8 & 17	840.77	840.77	-
Total Financial Assets		**11,250.25**	**11,250.25**	**-**
Financial Liabilities at Amortised Cost (Current and Non-Current)				
Borrowings (including current maturities)	22 & 26	15,038.02	15,038.02	-
Trade payables	27	8,168.58	8,168.58	-
Other financial liabilities	23 & 28	1,248.16	1,248.16	-
Total Financial Liabilities		**24,454.76**	**24,454.76**	**-**
		(13,204.50)	**(13,204.50)**	-

58 Financial Instruments - Financial risk management

The Company has exposure to following risks arising from financial instruments-

- Market Risk
- Credit Risk
- Liquidity Risk

The Company's board of directors has overall responsibility for the establishment and oversight of the Company's risk management framework.The Company's risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities.

The Company's audit committee oversees how management monitors compliance with the Company's risk management policies and procedures and reviews the adequacy of the risk management framework in relations to the risks faced by the Company.

A Market Risk

1) Currency Risk

The Company operates internationally and a major portion of the business is transacted in several currencies and consequently the Company is exposed to foreign exchange risk to the extent that there is mismatch between the currencies in which its sales and services and purchases from overseas suppliers in various foreign currencies. However as the Company exports as well as imports goods and services, the Company has a natural hedging due to its operations. Market Risk is the risk that changes in market prices such as foreign exchange rates will effect company's income or value of its holding financial assets/ instruments. The exchange rate between the Rupee and foreign currencies has changed substantially in recent years and may fluctuate substantially in the future. Consequently, the results of the Company's operations are adversely affected as the Rupee appreciates/ depreciates against US dollar (USD), Euro (EUR), Dhirams (AED) and Others.

(a) Foreign Exchange Exposures outstanding at the year end

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Unhedged Foreign Exchange Exposures		
Trade Receivables	4,369.07	4,845.62
Cash and Cash Equivalents	-	-
	4,369.07	4,845.62
Trade Payables	(881.28)	(1,909.15)
Current Borrowings	(203.50)	(71.89)
Others	-	-
	(1,084.77)	(1,981.04)
	3,284.29	**2,864.58**

(b) Foreign Currency Risk from Financial Instrument as at 31 March 2026

Nature Of Instrument	USD	EUR	AED	Others	Total
Trade Receivables	3,809.36	559.31	0.40		4,369.07
Cash and Cash Equivalents					-
Trade Payables	(881.28)				(881.28)
Current Borrowings	(203.50)				(203.50)
Others					-
Net Assets/(Liabilities)	**2,724.59**	**559.31**	**0.40**	**-**	**3,284.29**

(b) Foreign Currency Risk from Financial Instrument as at 31 March 2025

Nature Of Instrument	USD	EUR	AED	Others	Total
Trade Receivables	4,366.19	342.06	137.37		4,845.62
Cash and Cash Equivalents					-
Trade Payables	(1,906.64)	(2.52)			(1,909.15)
Current Borrowings	(71.89)				(71.89)
Others					-
Net Assets/(Liabilities)	**2,387.67**	**339.54**	**137.37**	**-**	**2,864.58**

(c) Sensitivity Analysis

A reasonably possible change in foreign exchange rates by 5% would have increased/ (decreased) equity and profit or loss by the amounts shown below. This analysis assumes that all other variables in particular interest rates remain constant

Particulars	USD	EURO	AED
Impact on Statement of Profit and Loss			
Increase by 5%			
As at 31 March 2026	136.23	27.97	0.02
As at 31 March 2025	119.38	16.98	6.87
Decrease by 5%			
As at 31 March 2026	(136.23)	(27.97)	(0.02)
As at 31 March 2025	(119.38)	(16.98)	(6.87)
Impact on Equity (Net of Tax)			
Increase by 5%			
As at 31 March 2026	100.81	20.69	0.01
As at 31 March 2025	88.34	12.56	5.08
Decrease by 5%			
As at 31 March 2026	(100.81)	(20.69)	(0.01)
As at 31 March 2025	(88.34)	(12.56)	(5.08)

2) Interest rate Risk

Interest rate risk can be either fair value interest rate risk or cash flow interest rate risk. Fair value interest rate risk is the risk of changes in fair values of fixed interest bearing investments because of fluctuations in the interest rates, in cases where the borrowings are measured at fair value through profit or loss. Cash flow interest rate risk is the risk that the future cash flows of floating interest bearing investments will fluctuate because of fluctuations in the interest rates.

a) Exposure to Interest Rate Risk

The interest rate profile of the Company's interest-bearing financial instruments as reported :

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Fixed Rate Instruments		
Financial Assets	1,091.78	1,136.69
- Fixed Deposits	1,091.78	1,136.69
- Loans	-	-
Financial Liabilities	(16101.51)	(15,232.00)
- Received from Customers	(149.88)	(193.98)
- Other Borrowings	(15951.64)	(15,038.02)
Variable Rate Instruments		
Financial Assets	-	-
Financial Liabilities	-	-
	(15009.74)	**(14,095.30)**

(b) Fair value sensitivity analysis for fixed-rate instruments

The Company's fixed rate instruments are carried at amortised cost. They are therefore not subject to interest rate risk as defined as per Ind AS 107, since neither the carrying amount nor future cash flows will fluctuate because of change in market interest rates.

(c) Cash flow sensitivity analysis for variable-rate instruments

A reasonable possible change of 2% (200 basis points) in interest rates at the reporting date would have increased/ (decreased) equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular foreign currency exchange rates, remain constant.

(c) Cash flow sensitivity analysis for variable-rate instruments (continued)

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Impact on Statement of Profit and Loss		
Increase by 2%	-	-
Decrease by 2%	-	-
Impact on Equity (Net of Tax)		
Increase by 2%	-	-
Decrease by 2%	-	-

B Liquidity Risk

Liquidity risk refers to the risk that the Company cannot meet its financial obligations. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements. Prudent liquidity risk management implies maintaining sufficient cash and marketable securities and the availability of funding through an adequate amount of committed credit facilities to meet obligations when due. Due to the nature of the business, the Company maintains flexibility in funding by maintaining availability under committed facilities.

The Company manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities.

Maturities of financial liabilities:

The table below analyse the Company's financial liabilities into relevant maturity groupings based on their contractual maturities for all non-derivative financial liabilities. The amounts disclosed in the table are the contractual undiscounted cash flows.

		Contractual cash Flows			
	Carrying Amount	< 12 Months	1 to 5 years	> 5 years	Total
31 March, 2026					
Borrowings (Incl Current Maturities)*	4,648.20	1,459.72	3,188.48	-	4,648.20
Trade and other payables	8,896.73	8,146.86	749.87	-	8,896.73
Short Term Borrowings	10,726.59	10,726.59	-	-	10,726.59
Other Financial Liabilities	3,059.76	2,909.89	149.88	-	3,059.76
31 March, 2025					
Borrowings (Incl Current Maturities)*	4,307.02	1,166.99	3,140.03	-	4,307.02
Trade and other payables	8,168.58	7,398.02	770.56	-	8,168.58
Short Term Borrowings	10,154.16	10,154.16	-	-	10,154.16
Other Financial Liabilities	1,248.16	1,099.28	148.88	-	1,248.16

*indicates actual outflow

C Credit Risk

Credit risk arises from the possibility that counter party may not be able to settle their obligations as agreed. The Company's exposure to credit risk is limited to the carrying amount of financial assets recognised at the date of the balance sheet, as summarised in the table below. The Company periodically assesses the financial reliability of the counter party taking into account the financial condition, current economic trends, analysis of historical bad debts and ageing of accounts receivable. Individual customer limits are set accordingly.

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Cash and Cash Equivalents	230.11	175.16
Other Bank Balances	490.89	629.89
Trade Receivables	9,363.26	9,244.35
Short Term Financial Assets	280.57	241.01
Long Term Financial Assets	807.08	713.04
	11,171.91	**11,003.45**

C Credit Risk (continued)

Credit risk on cash and cash equivalents is limited as they are generally invested in deposits with banks and financial institutions with high credit ratings assigned by international and domestic credit rating agencies.Advances to Related Parties are for business purposes and the Company assesses the credit risk on the these advances on a regular basis and does not forsee any event of default.

Trade receivables are typically unsecured and are derived from revenue earned from customers. Credit risk has always been managed through credit approvals, establishing credit limits and continuously monitoring the credit worthiness of customers to which the Company grants credit terms in the normal course of business. On account of adoption of Ind AS 109, the Company uses expected credit loss model to assess the impairment loss or gain. The Company is exposed to credit risk in the event of non-payment by customers. Credit risk concentration with respect to trade receivables is mitigated by the Company's large customer base. Adequate expected credit losses are recognized as per the assessments and as such has provided for a expected credit loss of Rs.157.04lakhs.(31 March 2025: 154.22 lakhs)

Reconciliation of Loss Allowance

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Loss allowance in the beginning of the year	154.22	165.50
Add: Changes in allowance	2.82	(11.28)
Loss allowance at the end of the year	**157.04**	**154.22**

59. Capital Management

For the purpose of the Company's capital management, capital includes issued equity capital, share premium and all other equity reserves attributable to the equity shareholders of the Company. The primary objective of the Company's capital management is to maximise the shareholder value.

The Company manages its capital structure and makes adjustments in light of changes in economic conditions, annual operating plans and long term and other strategic investment plans. In order to maintain or adjust its capital structure, the Company may adjust the amount of dividends paid, return the capital to shareholders, issue new shares or adjust its short term borrowings. The current capital structure of the Company is equity based backed with borrowings.

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Long Term Borrowings (incl Current Maturities)*	4,648.20	4,307.02
Short Term Borrowings	10,726.59	10,154.16
Total Borrowings (A)	15,374.79	14,461.18
As a percentage of total equity	65.15%	65.14%
Total equity (B)	8,225.24	7,740.44
As a percentage of total equity	34.85%	34.86%
Total Capital (A+B)	**23,600.03**	**22,201.63**

* Taken Borrowings at amortised cost

60. Recoverability from Subsidiary Companies

The Holding Company has an outstanding recoverability of Rs.978.00 lakhs and Rs.156.92 lakhs from it subsidiaries Lifezen Healthcare Private Limited and Balance Clinic LLP respectively. The said subsidiaries have incurred losses and have a negative net worth. However the management is confident that with infusion of additional funds, introduction of new brands and renewed marketing, the companies can be revived and the amounts recovered.

61. Financial Ratios Consolidated F.Y.2025-2026

Particulars	Numerator	Denomitor	As at 31 March 2026	As at 31 March 2025
Current ratio	Current Assets	Current Liabilities	1.05	1.07
Debt-equity ratio	Total Debt	Total Equity	1.94	1.94

61. Financial Ratios Consolidated F.Y.2025-2026 (continued)

Particulars	Numerator	Denomitor	As at 31 March 2026	As at 31 March 2025
Debt service coverage ratio	Earnings for debt service = Net profit after taxes + Non-cash operating expenses+Finance cost	Debt service = Interest & Lease Payments + Principal Repayments	1.58	1.58
Return on equity (%)	Net Profits after taxes – Preference Dividend	Average Shareholder's Equity	7.92%	9.69%
Inventory turnover ratio	Cost of goods sold OR sales	Average Inventory	1.44	1.65
Trade receivables turnover ratio	Net credit sales = Gross credit sales - sales return	Average Trade Receivable	3.35	3.16
Trade payables turnover ratio	Net credit purchases = Gross credit purchases - purchase return	Average Trade Payables	2.06	2.18
Net capital turnover ratio	Net sales	Working capital	23.96	19.72
Net profit (%)	Net Profit	Net sales = Total sales - sales return	2.03%	2.39%
Return on capital employed (%)	Earnings before interest and taxes	Capital Employed = Tangible Net Worth + Total Debt + Deferred Tax"	19.93%	20.21%

Particulars	As at 31 March 2026	As at 31 March 2025
Revenue	31,166.13	30,308.33
Current Assets	26,223.35	23,487.18
Current Liabilities	24,922.79	21,950.01
EBIT (Earnings before Interest and Tax)	2,275.15	2,199.18
Profit After Tax (PAT)	632.01	723.66
EBITDA	3,383.09	3,176.27
COGS 15,796.52	15,789.34	
Purchases	17,130.83	17,311.04
Working Capital	1,300.56	1,537.17
Total expenses	30,765.52	30,014.89
Total Borrowings	15,951.64	15,038.02
Total Equity	8,225.24	7,740.44
Average Shareholders' Equity	7,982.84	7,468.80
Average Value of Inventory	10,968.88	9,541.68
Average Accounts Receivable	9,303.81	9,603.26
Average Accounts Payable	8,301.88	7,957.50
Capital Employed	11,413.72	10,880.46

Particulars	As at 31 March 2025 % of Variance	Reason
Current ratio	-1.67%	
Debt-equity ratio	-0.18%	
Debt service coverage ratio	0.00%	
Return on equity (%)	-18.29%	
Inventory turnover ratio	-12.97%	
Trade receivables turnover ratio	6.14%	
Trade payables turnover ratio	-5.15%	
Net capital turnover ratio	21.54%	Due to increase in Net working capital for the end of the year .
Net profit (%)	-15.07%	
Return on capital employed (%)	-1.38%	

62. Other Accounting Policies Information

a) Intangible Asset

Recognition and Measurement

The items of intangible assets, with finite life, are measured at cost less accumulated amortisation and impairment losses, if any. Cost of an item of intangible assets comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any cost directly attributable to bringing the asset to its working condition for its intended use.

Subsequent expenditure

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure on internally generated goodwill and brands, is recognised in profit or loss when incurred.

Research and Development

Expenditure on research activities undertaken with the prospect of gaining new scientific or technical knowledge and understanding are recognised as an expense when incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. An internally-generated intangible asset arising from development is recognised if following have been demonstrated by the Company.

- development costs can be measured reliably;
- the product or process is technically and commercially feasible
- future economic benefits are probable; and
- the Company intends to and has sufficient resources to complete development and to use or sell the asset.

As such, expenditure on projects which have become unsuccessful are charged off as an expense in the year in which they are abandoned. Capital expenditure incurred on research and development is capitalized as Property, Plant and Equipment and depreciated in accordance with the depreciation policy of the company.

Disposal/Write-off

An intangible asset is derecognized on disposal, or when no future economic benefits are expected from use or disposal. Gains or losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, are recognized in profit or loss when the asset is derecognized.

Amortisation

Amortisation is calculated to write-off the cost of intangible assets less their estimated residual values over their estimated useful lives using the straight-line method, and is included in depreciation and amortisation in the statement of profit and loss. The estimated useful life of intangibles are as follows:

Asset	Management estimate of useful life (years)
Computer software	3
Research and Development	10

The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.

b) Impairment

i. Impairment of financial instruments

The Company recognises loss allowances for expected credit losses on:

- financial assets measured at amortised cost; and
- financial assets measured at FVOCI- debt investments.

At each reporting date, the Company assesses whether financial assets carried at amortised cost and debt securities at FVOCI are credit-impaired. A financial asset is 'credit-impaired' when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

Evidence that a financial asset is credit-impaired includes the following observable data:

- significant financial difficulty of the borrower or issuer;
- a breach of contract such as a default or being past due for 180 days or more;
- the restructuring of a loan or advance by the Company on terms that the Company would not consider otherwise;
- it is probable that the borrower will enter bankruptcy or other financial reorganisation; or

B) Impairment (continued)

- the disappearance of an active market for a security because of financial difficulties.

The Company measures loss allowances at an amount equal to lifetime expected credit losses, except for the following, which are measured as 12 month expected credit losses:

- debt securities that are determined to have low credit risk at the reporting date; and

- other debt securities and bank balances for which credit risk (i.e. the risk of default occurring over the expected life of the financial instrument) has not increased significantly since initial recognition.

Loss allowances for trade receivables are always measured at an amount equal to lifetime expected credit losses. Lifetime expected credit losses are the expected credit losses that result from all possible default events over the expected life of a financial instrument.12-month expected credit losses are the portion of expected credit losses that result from default events that are possible within 12 months after the reporting date (or a shorter period if the expected life of the instrument is less than 12 months).

In all cases, the maximum period considered when estimating expected credit losses is the maximum contractual period over which the Company is exposed to credit risk.

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating expected credit losses, the Company considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis, based on the Company's historical experience and informed credit assessment and including forward-looking information.

The Company assumes that the credit risk on a financial asset has increased significantly if it is more than 180 days past due.

The Company considers a financial asset to be in default when:

- the borrower is unlikely to pay its credit obligations to the Company in full, without recourse by the Company to actions such as realising security (if any is held); or
- the financial asset is 180 days or more past due.

A. Measurement of expected credit losses

"Expected credit losses are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (i.e. the difference between the cash flows due to the Company in accordance with the contract and the cash flows that the Company expects to receive).

As a practical expedient, the Company uses a provision matrix to determine impairment loss allowance on portfolio of its trade receivables. The provision matrix is based on its historically observed default rates over the expected life of the trade receivables and is adjusted for forward-looking estimates. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed."

B. Presentation of allowance for expected credit losses in the balance sheet

Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount of the assets.

C. Write-off

The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Company determines that the debtor does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write-off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Company's procedures for recovery of amounts due.

ii. Impairment of non-financial assets

The Company's non-financial assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset).

The Company's corporate assets do not generate independent cash inflows. To determine impairment of a corporate asset, recoverable amount is determined for the CGUs to which the corporate asset belongs.

B) Impairment (continued)

An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its estimated recoverable amount. Impairment losses are recognised in the Statement of profit and loss. Impairment loss recognised in respect of a CGU is allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets of the CGU (or group of CGUs) on a pro rata basis.

In respect of other assets for which impairment loss has been recognised in prior periods, the Company reviews at each reporting date whether there is any indication that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. Such a reversal is made only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

c) Financial Instruments

i. Recognition and initial measurement

Trade receivables and debt securities issued are initially recognised when they are originated. All other financial assets and financial liabilities are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

A financial asset or financial liability is initially measured at fair value plus, for an item not at fair value through profit and loss (FVTPL), transaction costs that are directly attributable to its acquisition or issue.

ii. Classification and subsequent measurement

A. Financial assets

On initial recognition, a financial asset is classified as measured at

- amortised cost
- Fair value through other comprehensive income (FVOCI) - debt investment;
- Fair value through other comprehensive income (FVOCI) - equity investment; or
- Fair value through profit & loss- (FVTPL)

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Company changes its business model for managing financial assets.

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at FVTPL:

- the asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

A debt investment is measured at FVOCI if it meets both of the following conditions and is not designated as at FVTPL:

- the asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and Interest on the principal amount outstanding.

On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment's fair value in OCI (designated as FVOCI – equity investment). This election is made on an investment-by-investment basis.

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. This includes all derivative financial assets. On initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost or at FVOCI as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

B. Financial assets: Business model assessment

The Company makes an assessment of the objective of the business model in which a financial asset is held at a portfolio level because this best reflects the way the business is managed and information is provided to management. The information considered includes:

- the stated policies and objectives for the portfolio and the operation of those policies in practice. These include whether management's strategy focuses on earning contractual interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities or expected cash outflows or realising cash flows through the sale of the assets;
- how the performance of the portfolio is evaluated and reported to the Company's management;
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;

C) Financial Instruments (continued)

- how managers of the business are compensated – e.g. whether compensation is based on the fair value of the assets managed or the contractual cash flows collected; and
- the frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about future sales activity.

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, consistent with the Company's continuing recognition of the assets.

Financial assets that are held for trading or are managed and whose performance is evaluated on a fair value basis are measured at FVTPL.

C. Financial assets: Assessment whether contractual cash flows are solely payments of principal and interest.

For the purposes of this assessment, 'principal' is defined as the fair value of the financial asset on initial recognition. 'Interest' is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative costs), as well as a profit margin.

In assessing whether the contractual cash flows are solely payments of principal and interest, the Company considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows such that it would not meet this condition. In making this assessment, the Company considers:

- contingent events that would change the amount or timing of cash flows;
- terms that may adjust the contractual coupon rate, including variable interest rate features;
- prepayment and extension features; and
- terms that limit the Company's claim to cash flows from specified assets (e.g. non-recourse features).

A prepayment feature is consistent with the solely payments of principal and interest criterion if the prepayment amount substantially represents unpaid amounts of principal and interest on the principal amount outstanding, which may include reasonable additional compensation for early termination of the contract. Additionally, for a financial asset acquired at a significant discount or premium to its contractual par amount, a feature that permits or requires prepayment at an amount that substantially represents the contractual par amount plus accrued (but unpaid) contractual interest (which may also include reasonable additional compensation for early termination) is treated as consistent with this criterion if the fair value of the prepayment feature is insignificant at initial recognition.

D. Financial assets: Subsequent measurement and gains and losses

Financial assets at FVTPLThese assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in profit or loss.

Financial assets at amortised costThese assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in profit or loss. Any gain or loss on derecognition is recognised in profit or loss.

Financial assets at FVTPL	These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in profit or loss.
Financial assets at amortised cost	These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in profit or loss. Any gain or loss on derecognition is recognised in profit or loss.

D.1 Financial assets: Subsequent measurement and gains and losses

Debt investments at FVOCI	These assets are subsequently measured at fair value. Interest income under the effective interest method, foreign exchange gains and losses and impairment are recognised in profit or loss. Other net gains and losses are recognised in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss.
Equity investments at FVOCI	These assets are subsequently measured at fair value. Dividends are recognised as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognised in OCI and are not reclassified to profit or loss.

E. Financial liabilities: Classification, subsequent measurement and gains and losses

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held-for-trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net

C) Financial Instruments (continued)

gains and losses, including any interest expense, are recognised in profit or loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in profit or loss. Any gain or loss on derecognition is also recognised in profit or loss.

iii Derecognition

A. Financial assets

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

If the Company enters into transactions whereby it transfers assets recognised on its balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets, the transferred assets are not derecognised.

B. Financial liabilities

The Company derecognises a financial liability when its contractual obligations are discharged or cancelled, or expire.

The Company also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in profit or loss.

iv Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

d) Foreign Currency Transactions:

Initial recognition:

Transactions in foreign currencies entered into by the Company are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction."

Measurement of foreign currency monetary items at the Balance Sheet date:

Foreign currency monetary items (other than derivative contracts) of the Company and its net investment in non-integral foreign operations outstanding at the Balance Sheet date are restated at the year-end rates."

Treatment of exchange differences:

Exchange differences arising on settlement / restatement of short-term foreign currency monetary assets and liabilities of the Company are recognized as income or expense in the Statement of Profit and Loss."

e) Employee Benefits

a) Short Term Employee Benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are recorded as expense as the related service is provided. Benefits such as salaries, short term compensated absences etc., and the expected cost of bonus is recognized in the period in which the employee renders the related services. A liability is recognized for benefits accruing to employees in respect of wages and salaries, annual leave and sick leave in the period the related service is rendered at the undiscounted amount of the benefits expected to be paid in exchange for the related service

b) Post-Employment Benefits

The Company participates in various employee benefit plans. Pensions and other post-employment benefits are classified as either defined contribution plans or defined benefit plans. Under a defined contribution plan, the Company's only obligation is to pay a fixed amount with no obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits. The related actuarial and investment risks are borne by the employee. The expenditure for defined contribution plans is recognised as an expense during the period when the employee provides service. Under a defined benefit plan, it is the Company's obligation to provide agreed benefits to the employees. The related actuarial and investment risks are borne by the Company. The present value of the defined benefit obligations is calculated by an independent actuary using the projected unit credit method.

Defined contribution plans

Employees receive benefits from a provident fund and employee state insurance funds. The employer and employees each make periodic contributions to the plan as per local regulations. The Company has no further payment obligations once the contributions have been paid. The contributions are accounted for as defined contribution plans and the contributions are recognised as employee benefit expenses in the

Statement of Profit and Loss as they fall due based on the amount of contribution required to be made.

Defined Benefit plans

In accordance with the Payment of Gratuity Act, 1972, applicable for Indian companies, the Company provides for a lump sum payment to eligible employees, at retirement or termination of employment based on the last drawn salary and years of employment with the Company. Company's liability towards Gratuity are actuarially determined at each balance sheet date using the projected unit credit method. Actuarial gains and losses are recognized in the Statement of Profit and Loss in the period of occurrence.

Other Long Term Benefit plan

Actuarial Valuation for compensated absences is done as at the year end and the provision is made as per Company policy with corresponding (gain)/charge to the statement of profit and loss and it covers all regular employees. Obligation in respect of earned leave policy are actuarially determined as at the year end using the 'Projected Unit Credit' method.

f) Borrowing Cost

Borrowing costs consists of interest, ancillary costs and other costs in connection with the borrowing of funds and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to interest costs.

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets are capitalised as part of the cost of such assets up to the assets are substantially ready for their intended use or sale.

The loan origination costs directly attributable to the acquisition of borrowings (e.g. loan processing fee, upfront fee) are amortised on the basis of the Effective Interest Rate (EIR) method over the term of the loan.

Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalization. All other borrowing costs are recognised in the statement of profit and loss in the period in which they are incurred.

g) Leases

The company assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange of consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Company assesses whether

a. the Contract involves the use of an identified asset

b. the Company has substantially all of the economic benefits from use of the asset through the period of lease

c. the Company has the right to direct the use of asset

The Company determines the lease term as the noncancellable period of a lease, together with both periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option; and periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option. The discount rate is generally based on the incremental borrowing rate specific to the lease being evaluated or for a portfolio of leases with similar characteristics

Leases as Lessor

Leases for which the Company is a lessor is classified as a finance or operating lease. When ever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee, the contract is classified as a finance lease. All other leases are classified as operating leases. The Company recognises lease payments received under operating leases as income on a straight-line basis over the lease term. In case of a finance lease, finance income is recognised over the lease term based on a pattern reflecting a constant periodic rate of return on the lessor's net investment in the lease. When the Company is an intermediate lessor it accounts for its interests in the head lease and the sub-lease separately. It assesses the lease classification of a sub-lease with reference to the right-of-use asset arising from the head lease, not with reference to the underlying asset. If a head lease is a short term lease to which the Company applies the exemption described above, then it classifies the sub-lease as an operating lease

Leases as Lessee

As at the date of commencement of the lease, the Company recognises a right of use asset("ROU") and a corresponding lease liability for all lease arrangements in which it is a lessee, except for the leases with a term of twelve month or less (short term leases) and low value leases. For these short term leases, the Company recognises the lease payments as an operating expense on a straight line basis over the period of lease.

Certain lease arrangements include the options to extend or terminate the lease before the end of the lease term. ROU assets and lease liabilities include these options when it is reasonably certain that they will be exercised. ROU assets are initially recognized at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or prior to the commencement date of the lease and related prepaid amount plus any initial direct costs less any lease incentives. They are subsequently measured at cost less accumulated depreciation and

g) Leases (continued)

impairment losses

ROU assets are initially recognized at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or prior to the commencement date of the lease plus any initial direct costs less any lease incentives. They are subsequently measured at cost less accumulated depreciation and impairment losses. ROU assets are depreciated from the commencement date on a straight-line basis over the shorter of the lease term and useful life of the underlying asset. ROU assets are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the purpose of impairment testing, the recoverable amount (i.e. the higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the Cash Generating Unit (CGU) to which the asset belongs.

The lease liability is initially measured at amortized cost at the present value of the future lease payments. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, using the market . Lease liabilities are remeasured with a corresponding adjustment to the related right of use asset if the Company changes its assessment if whether it will exercise an extension or a termination option.

The Right-of-Use asset has been disclosed within the same line item as that within which the corresponding underlying asset would be presented. Where the Right-of-Use asset meets the definition of Investment Property such items has been presented in Balance sheet as Investment Property. Lease liability have been separately presented in the Balance Sheet and lease payments have been classified as financing cash flows"

h) Earnings per Share

Basic earnings per share is computed by dividing the profit / (loss) after tax (including the post-tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year.

Diluted earnings per share is computed by dividing the profit / (loss) after tax (including the post-tax effect of extraordinary items, if any) as adjusted for dividend, interest and other charges to expense or income relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share from continuing ordinary operations. Potential dilutive equity shares are deemed to be converted as at the beginning of the period, unless they have been issued at a later date. The dilutive potential equity shares are adjusted for the proceeds receivable had the shares been actually issued at fair value (i.e. average market value of the outstanding shares). Dilutive potential equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for share splits / reverse share splits and bonus shares, as appropriate.

i) Income Tax

a. Current Tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from 'profit before tax' as reported in the statement of profit and loss because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company's current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

b. Minimum Alternate Tax ('MAT')

Minimum Alternate Tax ('MAT') under the provisions of the Income-tax Act, 1961 is recognised as current tax in the Statement of Profit and Loss. The credit available under the Income-tax Act, 1961 in respect of MAT paid is recognised as an asset only when and to the extent there is convincing evidence that the Company will pay normal income tax during the period for which the MAT credit can be carried forward for set-off against the normal tax liability. MAT credit recognised as an asset is reviewed at each Balance Sheet date and written down to the extent the aforesaid convincing evidence no longer exists.

c. Deferred Tax

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the standalone financial statements and corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. Such deferred tax assets and liabilities not recognised if the temporary differences arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit not the accounting profit. In addition, deferred tax liabilities are not recognised if the temporary difference arises from the initial recognition of goodwill.

Deferred tax liabilities are recognised for taxable temporary differences associated with investments in subsidiaries and associates, and interests in joint ventures, except where the Company is able to control the reversal of the temporary difference and it is probable that the temporary

I) Income Tax (continued)

difference will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences associated with such investments and interest are only recognised to the extent that it is probable that there will be sufficient taxable profits against which to utilize the benefits of the temporary differences and they are expected to reverse in the foreseeable future.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset is realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities."

j) Provisions and Contingencies

a. Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, itis probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognised as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the statement of profit and loss net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

b. Contingent Liabilities and Contingent Assets

A contingent liability is a possible obligation that arises from a past event, with the resolution of the contingency dependent on uncertain future events, or a present obligation where no outflow is probable. Major contingent liabilities are disclosed in the financial statements unless the possibility of an outflow of economic resources is remote. Contingent assets are not recognized in the standalone financial statements but disclosed, where an inflow of economic benefit is probable.

k) Cash and cash equivalents

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

l) Statement of cash flows

Cash flows are reported using the indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated.

63 Additional Regulatory Information

(i) "The title deeds of all the immovable properties (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee),

as disclosed under Property, Plant and Equipment in the financial statements are held in the name of the Company."

(ii) There are no proceedings that have been initiated or pending against the Company for holding any any benami property under the Benami Transactions (Prohibitions) Act, 1988 (45 of 1988) and the Rules made thereunder.

(iii) The Company has not been declared as a wilful defaulter by any bank or financial institution or any other lender

(iv) The Company has no transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956.

(v) The details of charges and satisfaction of charges have been registered with Registrar of Companies within the statutory period

(vi) Utilisation of Borrowed Funds and Share premium

(A) The Company has not advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries).

(B) The Company has not received any fund from any party(s) (Funding Party) with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(vii) The Company declares that the Relevant Provisions of the FEMA Act ,1999 and Companies Act have been Complied with and are not in violation of the Prevention of Money-Laundering Act ,2002.

(viii) The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961

(ix) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.

As per our report of even date attached

*for **S S J N B & CO***
Chartered Accountants
Firm's registration number: 013976S

Dhanpal I Sakaria
Partner
Membership number: 213666
Place: Bengaluru
Date: 27th May 2026
UDIN:*26213666JVZIHB9169*

for and on behalf of the board of directors of
Bal Pharma Limited

Shailesh Siroya
Managing Director
DIN: 00048109

V Himesh
Whole Time Director
DIN: 08554422

Bharath Bhushan D.V
Chief Financial Officer

Place: Bengaluru
Date: 27th May 2026

FINANCIAL SUMMARY - LAST 10 YEARS AT A GLANCE

(Rs In Lakhs)

	2025-26	2024-25	2023-24	2022-23	2021-22	2020-21	2019-20	2018-19	2017-18	2016-17
A. Sales and Earnings										
Turnover	31279.99	30464.57	34189.19	30525.38	28685.57	25200.08	17430.13	22582.53	21152.08	23201.45
Profit Before Tax	636.51	573.23	1210.58	854.97	1205.59	979.61	-907.62	441.07	845.46	806.97
Tax	-38.61	-206.72	183.35	242.33	347.75	69.93	-17.44	-234.95	251.63	310.38
Profit After Tax	675.12	779.95	1027.24	612.63	857.84	909.69	-920.6	676.02	593.83	496.59
"Retained Earning										
(Non Cumulative)"	675.12	779.95	1027.24	612.63	857.23	918.53	-920.6	633.4	564.74	328.51
B. Assets and Liabilities										
Tangible Fixed Assets (Net)	7672.89	7094.8	5317.99	5261.99	4491.95	4542.41	4974.44	5126.98	5381.59	5688.79
Intangible Assets (Net)	1342.24	1199.75	1137.83	1045.15	97.86	722.74	639.09	567.1	446.87	466.41
Investments	424.03	462.66	957.55	839.61	839.6	839.6	741.69	744.19	744.19	117.5
Net Current Assets	3233.4	3419.37	7198.39	5779.48	5596.06	4632.7	3251.92	4431.67	4814.67	2747.67
Share Capital	1592.09	1592.09	1580.44	1568.99	1482.24	1482.24	1417.24	1417.24	1417.24	1417.24
Reserves	8817.8	8290.37	8977.73	8034.35	7249.82	6449.52	5177.24	6268.7	5806.16	6127.47
C. Ratios										
Earning Per share	4.51	4.89	6.72	3.9	5.79	6.41	-6.28	4.77	4.19	3.51
Dividend Per Equity Shares (%)	12	12	12	10	10	10	-	10	10	10
Book Value Per Equity (in Rs)	65	62	67	61	59	54	47	54	51	47.75

Our Mission

A full fledged global player catering to the needs of medical fraternity and pharmaceutical industry

UNIT - 4 RUDRAPUR

- State of the art plant designed for regulated markets in excise free zone
- API manufacturing facility for Tablets, Capsules and Ointments

The manufacturing facility is approved by MCAZ Zimbabwe, PMPB Malawi, NDA Uganda, PPB Kenya, TFDA Tanzania, FMHACA Ethiopia, NAFDAC Nigeria, Republic of Yemen & Malta Medicines Authority (EUGMP), Malta.

The products are exported to South East Asia, Middle East, Latin America, and African markets. The plant also caters to contract manufacturing needs, both in India and abroad.

UNIT - 1 BANGALORE

- Plant commissioned in the year 1992
- WHO - GMP certified & ISO 9001:2000 approved
- Manufacture of finished dosage forms

The manufacturing plant is cGMP approved and has obtained the ISO 9001:2008, ISO 14001:2015, ISO 45001:2018 accreditation..

The products are exported to Africa, South East Asia, Middle East, and Latin American markets. The plant also caters to the needs of companies for Contract Manufacturing, both in India and Abroad.

UNIT - 5 SANGLI

- Multi Purpose API manufacturing facility approved as per WHO-GMP guidelines
- Specializes in manufacture of Intermediates, which supplements Unit 2 production requirements

is an intermediate manufacturing facility qualified by international customers.

UNIT - 2 BANGALORE

- Plant commissioned in the year 1996
- Multi purpose API facility approved as per WHO-GMP guidelines
- Manufacture R&D lab approved Department of Science & Technology

The manufacturing facility is approved by EDQM, TGA Australia, PMDA Japan, MOH Canada, KFDA Korea and COFEPERIS Mexico.

The products are being exported to Europe, Australia, Far East, Middle East, South East Asia, Africa, South America & North America.

UNIT - 6 UDAIPUR

- WHO-GMP certified API manufacturing facility expected to commence production shortly

The manufacturing facility is approved by WHO GMP and possesses CEP for Glicazide and Ebastine.

The products are being exported to Europe, Middle East, South Asia, Africa, Latin America.

Quality Excellence

BAL PHARMA

BAL PHARMA LIMITED

CIN# L85110KA1987PLC008368

Corporate Office:
5th Floor, Lakshmi Narayan Complex, 10/1,
Palace Road, Bangalore - 560 052, India.
Ph : +91-80-4137 9500
Fax : +91-80-2235 4057 / 2235 4058.
Email : secretarial@balpharma.com / info@balpharma.com

www.balpharma.com